/*! For license information please see main.bac5b26c.js.LICENSE.txt */
!function(){var e={76:function(e,t,n){"use strict";n.d(t,{Z:function(){return ae}});var r=function(){function e(e){var t=this;this._insertTag=function(e){var n;n=0===t.tags.length?t.insertionPoint?t.insertionPoint.nextSibling:t.prepend?t.container.firstChild:t.before:t.tags[t.tags.length-1].nextSibling,t.container.insertBefore(e,n),t.tags.push(e)},this.isSpeedy=void 0===e.speedy||e.speedy,this.tags=[],this.ctr=0,this.nonce=e.nonce,this.key=e.key,this.container=e.container,this.prepend=e.prepend,this.insertionPoint=e.insertionPoint,this.before=null}var t=e.prototype;return t.hydrate=function(e){e.forEach(this._insertTag)},t.insert=function(e){this.ctr%(this.isSpeedy?65e3:1)===0&&this._insertTag(function(e){var t=document.createElement("style");return t.setAttribute("data-emotion",e.key),void 0!==e.nonce&&t.setAttribute("nonce",e.nonce),t.appendChild(document.createTextNode("")),t.setAttribute("data-s",""),t}(this));var t=this.tags[this.tags.length-1];if(this.isSpeedy){var n=function(e){if(e.sheet)return e.sheet;for(var t=0;t<document.styleSheets.length;t++)if(document.styleSheets[t].ownerNode===e)return document.styleSheets[t]}(t);try{n.insertRule(e,n.cssRules.length)}catch(r){0}}else t.appendChild(document.createTextNode(e));this.ctr++},t.flush=function(){this.tags.forEach((function(e){return e.parentNode&&e.parentNode.removeChild(e)})),this.tags=[],this.ctr=0},e}(),a=Math.abs,o=String.fromCharCode,i=Object.assign;function s(e){return e.trim()}function l(e,t,n){return e.replace(t,n)}function c(e,t){return e.indexOf(t)}function u(e,t){return 0|e.charCodeAt(t)}function d(e,t,n){return e.slice(t,n)}function f(e){return e.length}function p(e){return e.length}function m(e,t){return t.push(e),e}var h=1,v=1,y=0,b=0,g=0,_="";function w(e,t,n,r,a,o,i){return{value:e,root:t,parent:n,type:r,props:a,children:o,line:h,column:v,length:i,return:""}}function S(e,t){return i(w("",null,null,"",null,null,0),e,{length:-e.length},t)}function k(){return g=b>0?u(_,--b):0,v--,10===g&&(v=1,h--),g}function T(){return g=b<y?u(_,b++):0,v++,10===g&&(v=1,h++),g}function F(){return u(_,b)}function C(){return b}function x(e,t){return d(_,e,t)}function A(e){switch(e){case 0:case 9:case 10:case 13:case 32:return 5;case 33:case 43:case 44:case 47:case 62:case 64:case 126:case 59:case 123:case 125:return 4;case 58:return 3;case 34:case 39:case 40:case 91:return 2;case 41:case 93:return 1}return 0}function E(e){return h=v=1,y=f(_=e),b=0,[]}function D(e){return _="",e}function P(e){return s(x(b-1,N(91===e?e+2:40===e?e+1:e)))}function R(e){for(;(g=F())&&g<33;)T();return A(e)>2||A(g)>3?"":" "}function M(e,t){for(;--t&&T()&&!(g<48||g>102||g>57&&g<65||g>70&&g<97););return x(e,C()+(t<6&&32==F()&&32==T()))}function N(e){for(;T();)switch(g){case e:return b;case 34:case 39:34!==e&&39!==e&&N(g);break;case 40:41===e&&N(e);break;case 92:T()}return b}function O(e,t){for(;T()&&e+g!==57&&(e+g!==84||47!==F()););return"/*"+x(t,b-1)+"*"+o(47===e?e:T())}function z(e){for(;!A(F());)T();return x(e,b)}var I="-ms-",L="-moz-",Z="-webkit-",j="comm",B="rule",W="decl",U="@keyframes";function V(e,t){for(var n="",r=p(e),a=0;a<r;a++)n+=t(e[a],a,e,t)||"";return n}function G(e,t,n,r){switch(e.type){case"@import":case W:return e.return=e.return||e.value;case j:return"";case U:return e.return=e.value+"{"+V(e.children,r)+"}";case B:e.value=e.props.join(",")}return f(n=V(e.children,r))?e.return=e.value+"{"+n+"}":""}function J(e,t){switch(function(e,t){return(((t<<2^u(e,0))<<2^u(e,1))<<2^u(e,2))<<2^u(e,3)}(e,t)){case 5103:return Z+"print-"+e+e;case 5737:case 4201:case 3177:case 3433:case 1641:case 4457:case 2921:case 5572:case 6356:case 5844:case 3191:case 6645:case 3005:case 6391:case 5879:case 5623:case 6135:case 4599:case 4855:case 4215:case 6389:case 5109:case 5365:case 5621:case 3829:return Z+e+e;case 5349:case 4246:case 4810:case 6968:case 2756:return Z+e+L+e+I+e+e;case 6828:case 4268:return Z+e+I+e+e;case 6165:return Z+e+I+"flex-"+e+e;case 5187:return Z+e+l(e,/(\w+).+(:[^]+)/,"-webkit-box-$1$2-ms-flex-$1$2")+e;case 5443:return Z+e+I+"flex-item-"+l(e,/flex-|-self/,"")+e;case 4675:return Z+e+I+"flex-line-pack"+l(e,/align-content|flex-|-self/,"")+e;case 5548:return Z+e+I+l(e,"shrink","negative")+e;case 5292:return Z+e+I+l(e,"basis","preferred-size")+e;case 6060:return Z+"box-"+l(e,"-grow","")+Z+e+I+l(e,"grow","positive")+e;case 4554:return Z+l(e,/([^-])(transform)/g,"$1-webkit-$2")+e;case 6187:return l(l(l(e,/(zoom-|grab)/,Z+"$1"),/(image-set)/,Z+"$1"),e,"")+e;case 5495:case 3959:return l(e,/(image-set\([^]*)/,Z+"$1$`$1");case 4968:return l(l(e,/(.+:)(flex-)?(.*)/,"-webkit-box-pack:$3-ms-flex-pack:$3"),/s.+-b[^;]+/,"justify")+Z+e+e;case 4095:case 3583:case 4068:case 2532:return l(e,/(.+)-inline(.+)/,Z+"$1$2")+e;case 8116:case 7059:case 5753:case 5535:case 5445:case 5701:case 4933:case 4677:case 5533:case 5789:case 5021:case 4765:if(f(e)-1-t>6)switch(u(e,t+1)){case 109:if(45!==u(e,t+4))break;case 102:return l(e,/(.+:)(.+)-([^]+)/,"$1-webkit-$2-$3$1"+L+(108==u(e,t+3)?"$3":"$2-$3"))+e;case 115:return~c(e,"stretch")?J(l(e,"stretch","fill-available"),t)+e:e}break;case 4949:if(115!==u(e,t+1))break;case 6444:switch(u(e,f(e)-3-(~c(e,"!important")&&10))){case 107:return l(e,":",":"+Z)+e;case 101:return l(e,/(.+:)([^;!]+)(;|!.+)?/,"$1"+Z+(45===u(e,14)?"inline-":"")+"box$3$1"+Z+"$2$3$1"+I+"$2box$3")+e}break;case 5936:switch(u(e,t+11)){case 114:return Z+e+I+l(e,/[svh]\w+-[tblr]{2}/,"tb")+e;case 108:return Z+e+I+l(e,/[svh]\w+-[tblr]{2}/,"tb-rl")+e;case 45:return Z+e+I+l(e,/[svh]\w+-[tblr]{2}/,"lr")+e}return Z+e+I+e+e}return e}function $(e){return D(H("",null,null,null,[""],e=E(e),0,[0],e))}function H(e,t,n,r,a,i,s,u,d){for(var p=0,h=0,v=s,y=0,b=0,g=0,_=1,w=1,S=1,x=0,A="",E=a,D=i,N=r,I=A;w;)switch(g=x,x=T()){case 40:if(108!=g&&58==I.charCodeAt(v-1)){-1!=c(I+=l(P(x),"&","&\f"),"&\f")&&(S=-1);break}case 34:case 39:case 91:I+=P(x);break;case 9:case 10:case 13:case 32:I+=R(g);break;case 92:I+=M(C()-1,7);continue;case 47:switch(F()){case 42:case 47:m(K(O(T(),C()),t,n),d);break;default:I+="/"}break;case 123*_:u[p++]=f(I)*S;case 125*_:case 59:case 0:switch(x){case 0:case 125:w=0;case 59+h:b>0&&f(I)-v&&m(b>32?Y(I+";",r,n,v-1):Y(l(I," ","")+";",r,n,v-2),d);break;case 59:I+=";";default:if(m(N=q(I,t,n,p,h,a,u,A,E=[],D=[],v),i),123===x)if(0===h)H(I,t,N,N,E,i,v,u,D);else switch(y){case 100:case 109:case 115:H(e,N,N,r&&m(q(e,N,N,0,0,a,u,A,a,E=[],v),D),a,D,v,u,r?E:D);break;default:H(I,N,N,N,[""],D,0,u,D)}}p=h=b=0,_=S=1,A=I="",v=s;break;case 58:v=1+f(I),b=g;default:if(_<1)if(123==x)--_;else if(125==x&&0==_++&&125==k())continue;switch(I+=o(x),x*_){case 38:S=h>0?1:(I+="\f",-1);break;case 44:u[p++]=(f(I)-1)*S,S=1;break;case 64:45===F()&&(I+=P(T())),y=F(),h=v=f(A=I+=z(C())),x++;break;case 45:45===g&&2==f(I)&&(_=0)}}return i}function q(e,t,n,r,o,i,c,u,f,m,h){for(var v=o-1,y=0===o?i:[""],b=p(y),g=0,_=0,S=0;g<r;++g)for(var k=0,T=d(e,v+1,v=a(_=c[g])),F=e;k<b;++k)(F=s(_>0?y[k]+" "+T:l(T,/&\f/g,y[k])))&&(f[S++]=F);return w(e,t,n,0===o?B:u,f,m,h)}function K(e,t,n){return w(e,t,n,j,o(g),d(e,2,-2),0)}function Y(e,t,n,r){return w(e,t,n,W,d(e,0,r),d(e,r+1,-1),r)}var Q=function(e,t,n){for(var r=0,a=0;r=a,a=F(),38===r&&12===a&&(t[n]=1),!A(a);)T();return x(e,b)},X=function(e,t){return D(function(e,t){var n=-1,r=44;do{switch(A(r)){case 0:38===r&&12===F()&&(t[n]=1),e[n]+=Q(b-1,t,n);break;case 2:e[n]+=P(r);break;case 4:if(44===r){e[++n]=58===F()?"&\f":"",t[n]=e[n].length;break}default:e[n]+=o(r)}}while(r=T());return e}(E(e),t))},ee=new WeakMap,te=function(e){if("rule"===e.type&&e.parent&&!(e.length<1)){for(var t=e.value,n=e.parent,r=e.column===n.column&&e.line===n.line;"rule"!==n.type;)if(!(n=n.parent))return;if((1!==e.props.length||58===t.charCodeAt(0)||ee.get(n))&&!r){ee.set(e,!0);for(var a=[],o=X(t,a),i=n.props,s=0,l=0;s<o.length;s++)for(var c=0;c<i.length;c++,l++)e.props[l]=a[s]?o[s].replace(/&\f/g,i[c]):i[c]+" "+o[s]}}},ne=function(e){if("decl"===e.type){var t=e.value;108===t.charCodeAt(0)&&98===t.charCodeAt(2)&&(e.return="",e.value="")}},re=[function(e,t,n,r){if(e.length>-1&&!e.return)switch(e.type){case W:e.return=J(e.value,e.length);break;case U:return V([S(e,{value:l(e.value,"@","@"+Z)})],r);case B:if(e.length)return function(e,t){return e.map(t).join("")}(e.props,(function(t){switch(function(e,t){return(e=t.exec(e))?e[0]:e}(t,/(::plac\w+|:read-\w+)/)){case":read-only":case":read-write":return V([S(e,{props:[l(t,/:(read-\w+)/,":-moz-$1")]})],r);case"::placeholder":return V([S(e,{props:[l(t,/:(plac\w+)/,":-webkit-input-$1")]}),S(e,{props:[l(t,/:(plac\w+)/,":-moz-$1")]}),S(e,{props:[l(t,/:(plac\w+)/,I+"input-$1")]})],r)}return""}))}}],ae=function(e){var t=e.key;if("css"===t){var n=document.querySelectorAll("style[data-emotion]:not([data-s])");Array.prototype.forEach.call(n,(function(e){-1!==e.getAttribute("data-emotion").indexOf(" ")&&(document.head.appendChild(e),e.setAttribute("data-s",""))}))}var a=e.stylisPlugins||re;var o,i,s={},l=[];o=e.container||document.head,Array.prototype.forEach.call(document.querySelectorAll('style[data-emotion^="'+t+' "]'),(function(e){for(var t=e.getAttribute("data-emotion").split(" "),n=1;n<t.length;n++)s[t[n]]=!0;l.push(e)}));var c,u,d=[G,(u=function(e){c.insert(e)},function(e){e.root||(e=e.return)&&u(e)})],f=function(e){var t=p(e);return function(n,r,a,o){for(var i="",s=0;s<t;s++)i+=e[s](n,r,a,o)||"";return i}}([te,ne].concat(a,d));i=function(e,t,n,r){c=n,V($(e?e+"{"+t.styles+"}":t.styles),f),r&&(m.inserted[t.name]=!0)};var m={key:t,sheet:new r({key:t,container:o,nonce:e.nonce,speedy:e.speedy,prepend:e.prepend,insertionPoint:e.insertionPoint}),nonce:e.nonce,inserted:s,registered:{},insert:i};return m.sheet.hydrate(l),m}},9797:function(e,t){"use strict";t.Z=function(e){var t=Object.create(null);return function(n){return void 0===t[n]&&(t[n]=e(n)),t[n]}}},9886:function(e,t,n){"use strict";n.d(t,{T:function(){return s},w:function(){return i}});var r=n(2791),a=n(76),o=(n(9140),n(2561),(0,r.createContext)("undefined"!==typeof HTMLElement?(0,a.Z)({key:"css"}):null));o.Provider;var i=function(e){return(0,r.forwardRef)((function(t,n){var a=(0,r.useContext)(o);return e(t,a,n)}))},s=(0,r.createContext)({})},9140:function(e,t,n){"use strict";n.d(t,{O:function(){return h}});var r=function(e){for(var t,n=0,r=0,a=e.length;a>=4;++r,a-=4)t=1540483477*(65535&(t=255&e.charCodeAt(r)|(255&e.charCodeAt(++r))<<8|(255&e.charCodeAt(++r))<<16|(255&e.charCodeAt(++r))<<24))+(59797*(t>>>16)<<16),n=1540483477*(65535&(t^=t>>>24))+(59797*(t>>>16)<<16)^1540483477*(65535&n)+(59797*(n>>>16)<<16);switch(a){case 3:n^=(255&e.charCodeAt(r+2))<<16;case 2:n^=(255&e.charCodeAt(r+1))<<8;case 1:n=1540483477*(65535&(n^=255&e.charCodeAt(r)))+(59797*(n>>>16)<<16)}return(((n=1540483477*(65535&(n^=n>>>13))+(59797*(n>>>16)<<16))^n>>>15)>>>0).toString(36)},a={animationIterationCount:1,borderImageOutset:1,borderImageSlice:1,borderImageWidth:1,boxFlex:1,boxFlexGroup:1,boxOrdinalGroup:1,columnCount:1,columns:1,flex:1,flexGrow:1,flexPositive:1,flexShrink:1,flexNegative:1,flexOrder:1,gridRow:1,gridRowEnd:1,gridRowSpan:1,gridRowStart:1,gridColumn:1,gridColumnEnd:1,gridColumnSpan:1,gridColumnStart:1,msGridRow:1,msGridRowSpan:1,msGridColumn:1,msGridColumnSpan:1,fontWeight:1,lineHeight:1,opacity:1,order:1,orphans:1,tabSize:1,widows:1,zIndex:1,zoom:1,WebkitLineClamp:1,fillOpacity:1,floodOpacity:1,stopOpacity:1,strokeDasharray:1,strokeDashoffset:1,strokeMiterlimit:1,strokeOpacity:1,strokeWidth:1},o=n(9797),i=/[A-Z]|^ms/g,s=/_EMO_([^_]+?)_([^]*?)_EMO_/g,l=function(e){return 45===e.charCodeAt(1)},c=function(e){return null!=e&&"boolean"!==typeof e},u=(0,o.Z)((function(e){return l(e)?e:e.replace(i,"-$&").toLowerCase()})),d=function(e,t){switch(e){case"animation":case"animationName":if("string"===typeof t)return t.replace(s,(function(e,t,n){return p={name:t,styles:n,next:p},t}))}return 1===a[e]||l(e)||"number"!==typeof t||0===t?t:t+"px"};function f(e,t,n){if(null==n)return"";if(void 0!==n.__emotion_styles)return n;switch(typeof n){case"boolean":return"";case"object":if(1===n.anim)return p={name:n.name,styles:n.styles,next:p},n.name;if(void 0!==n.styles){var r=n.next;if(void 0!==r)for(;void 0!==r;)p={name:r.name,styles:r.styles,next:p},r=r.next;return n.styles+";"}return function(e,t,n){var r="";if(Array.isArray(n))for(var a=0;a<n.length;a++)r+=f(e,t,n[a])+";";else for(var o in n){var i=n[o];if("object"!==typeof i)null!=t&&void 0!==t[i]?r+=o+"{"+t[i]+"}":c(i)&&(r+=u(o)+":"+d(o,i)+";");else if(!Array.isArray(i)||"string"!==typeof i[0]||null!=t&&void 0!==t[i[0]]){var s=f(e,t,i);switch(o){case"animation":case"animationName":r+=u(o)+":"+s+";";break;default:r+=o+"{"+s+"}"}}else for(var l=0;l<i.length;l++)c(i[l])&&(r+=u(o)+":"+d(o,i[l])+";")}return r}(e,t,n);case"function":if(void 0!==e){var a=p,o=n(e);return p=a,f(e,t,o)}}if(null==t)return n;var i=t[n];return void 0!==i?i:n}var p,m=/label:\s*([^\s;\n{]+)\s*(;|$)/g;var h=function(e,t,n){if(1===e.length&&"object"===typeof e[0]&&null!==e[0]&&void 0!==e[0].styles)return e[0];var a=!0,o="";p=void 0;var i=e[0];null==i||void 0===i.raw?(a=!1,o+=f(n,t,i)):o+=i[0];for(var s=1;s<e.length;s++)o+=f(n,t,e[s]),a&&(o+=i[s]);m.lastIndex=0;for(var l,c="";null!==(l=m.exec(o));)c+="-"+l[1];return{name:r(o)+c,styles:o,next:p}}},2561:function(e,t,n){"use strict";var r;n.d(t,{L:function(){return i},j:function(){return s}});var a=n(2791),o=!!(r||(r=n.t(a,2))).useInsertionEffect&&(r||(r=n.t(a,2))).useInsertionEffect,i=o||function(e){return e()},s=o||a.useLayoutEffect},5438:function(e,t,n){"use strict";n.d(t,{My:function(){return o},fp:function(){return r},hC:function(){return a}});function r(e,t,n){var r="";return n.split(" ").forEach((function(n){void 0!==e[n]?t.push(e[n]+";"):r+=n+" "})),r}var a=function(e,t,n){var r=e.key+"-"+t.name;!1===n&&void 0===e.registered[r]&&(e.registered[r]=t.styles)},o=function(e,t,n){a(e,t,n);var r=e.key+"-"+t.name;if(void 0===e.inserted[t.name]){var o=t;do{e.insert(t===o?"."+r:"",o,e.sheet,!0);o=o.next}while(void 0!==o)}}},2156:function(e,t,n){"use strict";var r=n(4836);t.Z=void 0;var a=r(n(5649)),o=n(184),i=(0,a.default)((0,o.jsx)("path",{d:"M15.41 7.41 14 6l-6 6 6 6 1.41-1.41L10.83 12z"}),"NavigateBefore");t.Z=i},5129:function(e,t,n){"use strict";var r=n(4836);t.Z=void 0;var a=r(n(5649)),o=n(184),i=(0,a.default)((0,o.jsx)("path",{d:"M10 6 8.59 7.41 13.17 12l-4.58 4.59L10 18l6-6z"}),"NavigateNext");t.Z=i},5649:function(e,t,n){"use strict";Object.defineProperty(t,"__esModule",{value:!0}),Object.defineProperty(t,"default",{enumerable:!0,get:function(){return r.createSvgIcon}});var r=n(3111)},4360:function(e,t,n){"use strict";n.d(t,{Z:function(){return Z}});var r=n(7462),a=n(3366),o=n(6189),i=n(2466),s=n(5080),l=n(4942);function c(e,t){var n;return(0,r.Z)({toolbar:(n={minHeight:56},(0,l.Z)(n,e.up("xs"),{"@media (orientation: landscape)":{minHeight:48}}),(0,l.Z)(n,e.up("sm"),{minHeight:64}),n)},t)}var u=n(2065),d={black:"#000",white:"#fff"},f={50:"#fafafa",100:"#f5f5f5",200:"#eeeeee",300:"#e0e0e0",400:"#bdbdbd",500:"#9e9e9e",600:"#757575",700:"#616161",800:"#424242",900:"#212121",A100:"#f5f5f5",A200:"#eeeeee",A400:"#bdbdbd",A700:"#616161"},p={50:"#f3e5f5",100:"#e1bee7",200:"#ce93d8",300:"#ba68c8",400:"#ab47bc",500:"#9c27b0",600:"#8e24aa",700:"#7b1fa2",800:"#6a1b9a",900:"#4a148c",A100:"#ea80fc",A200:"#e040fb",A400:"#d500f9",A700:"#aa00ff"},m={50:"#ffebee",100:"#ffcdd2",200:"#ef9a9a",300:"#e57373",400:"#ef5350",500:"#f44336",600:"#e53935",700:"#d32f2f",800:"#c62828",900:"#b71c1c",A100:"#ff8a80",A200:"#ff5252",A400:"#ff1744",A700:"#d50000"},h={50:"#fff3e0",100:"#ffe0b2",200:"#ffcc80",300:"#ffb74d",400:"#ffa726",500:"#ff9800",600:"#fb8c00",700:"#f57c00",800:"#ef6c00",900:"#e65100",A100:"#ffd180",A200:"#ffab40",A400:"#ff9100",A700:"#ff6d00"},v={50:"#e3f2fd",100:"#bbdefb",200:"#90caf9",300:"#64b5f6",400:"#42a5f5",500:"#2196f3",600:"#1e88e5",700:"#1976d2",800:"#1565c0",900:"#0d47a1",A100:"#82b1ff",A200:"#448aff",A400:"#2979ff",A700:"#2962ff"},y={50:"#e1f5fe",100:"#b3e5fc",200:"#81d4fa",300:"#4fc3f7",400:"#29b6f6",500:"#03a9f4",600:"#039be5",700:"#0288d1",800:"#0277bd",900:"#01579b",A100:"#80d8ff",A200:"#40c4ff",A400:"#00b0ff",A700:"#0091ea"},b={50:"#e8f5e9",100:"#c8e6c9",200:"#a5d6a7",300:"#81c784",400:"#66bb6a",500:"#4caf50",600:"#43a047",700:"#388e3c",800:"#2e7d32",900:"#1b5e20",A100:"#b9f6ca",A200:"#69f0ae",A400:"#00e676",A700:"#00c853"},g=["mode","contrastThreshold","tonalOffset"],_={text:{primary:"rgba(0, 0, 0, 0.87)",secondary:"rgba(0, 0, 0, 0.6)",disabled:"rgba(0, 0, 0, 0.38)"},divider:"rgba(0, 0, 0, 0.12)",background:{paper:d.white,default:d.white},action:{active:"rgba(0, 0, 0, 0.54)",hover:"rgba(0, 0, 0, 0.04)",hoverOpacity:.04,selected:"rgba(0, 0, 0, 0.08)",selectedOpacity:.08,disabled:"rgba(0, 0, 0, 0.26)",disabledBackground:"rgba(0, 0, 0, 0.12)",disabledOpacity:.38,focus:"rgba(0, 0, 0, 0.12)",focusOpacity:.12,activatedOpacity:.12}},w={text:{primary:d.white,secondary:"rgba(255, 255, 255, 0.7)",disabled:"rgba(255, 255, 255, 0.5)",icon:"rgba(255, 255, 255, 0.5)"},divider:"rgba(255, 255, 255, 0.12)",background:{paper:"#121212",default:"#121212"},action:{active:d.white,hover:"rgba(255, 255, 255, 0.08)",hoverOpacity:.08,selected:"rgba(255, 255, 255, 0.16)",selectedOpacity:.16,disabled:"rgba(255, 255, 255, 0.3)",disabledBackground:"rgba(255, 255, 255, 0.12)",disabledOpacity:.38,focus:"rgba(255, 255, 255, 0.12)",focusOpacity:.12,activatedOpacity:.24}};function S(e,t,n,r){var a=r.light||r,o=r.dark||1.5*r;e[t]||(e.hasOwnProperty(n)?e[t]=e[n]:"light"===t?e.light=(0,u.$n)(e.main,a):"dark"===t&&(e.dark=(0,u._j)(e.main,o)))}function k(e){var t=e.mode,n=void 0===t?"light":t,s=e.contrastThreshold,l=void 0===s?3:s,c=e.tonalOffset,k=void 0===c?.2:c,T=(0,a.Z)(e,g),F=e.primary||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:v[200],light:v[50],dark:v[400]}:{main:v[700],light:v[400],dark:v[800]}}(n),C=e.secondary||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:p[200],light:p[50],dark:p[400]}:{main:p[500],light:p[300],dark:p[700]}}(n),x=e.error||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:m[500],light:m[300],dark:m[700]}:{main:m[700],light:m[400],dark:m[800]}}(n),A=e.info||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:y[400],light:y[300],dark:y[700]}:{main:y[700],light:y[500],dark:y[900]}}(n),E=e.success||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:b[400],light:b[300],dark:b[700]}:{main:b[800],light:b[500],dark:b[900]}}(n),D=e.warning||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:h[400],light:h[300],dark:h[700]}:{main:"#ed6c02",light:h[500],dark:h[900]}}(n);function P(e){return(0,u.mi)(e,w.text.primary)>=l?w.text.primary:_.text.primary}var R=function(e){var t=e.color,n=e.name,a=e.mainShade,i=void 0===a?500:a,s=e.lightShade,l=void 0===s?300:s,c=e.darkShade,u=void 0===c?700:c;if(!(t=(0,r.Z)({},t)).main&&t[i]&&(t.main=t[i]),!t.hasOwnProperty("main"))throw new Error((0,o.Z)(11,n?" (".concat(n,")"):"",i));if("string"!==typeof t.main)throw new Error((0,o.Z)(12,n?" (".concat(n,")"):"",JSON.stringify(t.main)));return S(t,"light",l,k),S(t,"dark",u,k),t.contrastText||(t.contrastText=P(t.main)),t},M={dark:w,light:_};return(0,i.Z)((0,r.Z)({common:(0,r.Z)({},d),mode:n,primary:R({color:F,name:"primary"}),secondary:R({color:C,name:"secondary",mainShade:"A400",lightShade:"A200",darkShade:"A700"}),error:R({color:x,name:"error"}),warning:R({color:D,name:"warning"}),info:R({color:A,name:"info"}),success:R({color:E,name:"success"}),grey:f,contrastThreshold:l,getContrastText:P,augmentColor:R,tonalOffset:k},M[n]),T)}var T=["fontFamily","fontSize","fontWeightLight","fontWeightRegular","fontWeightMedium","fontWeightBold","htmlFontSize","allVariants","pxToRem"];var F={textTransform:"uppercase"},C='"Roboto", "Helvetica", "Arial", sans-serif';function x(e,t){var n="function"===typeof t?t(e):t,o=n.fontFamily,s=void 0===o?C:o,l=n.fontSize,c=void 0===l?14:l,u=n.fontWeightLight,d=void 0===u?300:u,f=n.fontWeightRegular,p=void 0===f?400:f,m=n.fontWeightMedium,h=void 0===m?500:m,v=n.fontWeightBold,y=void 0===v?700:v,b=n.htmlFontSize,g=void 0===b?16:b,_=n.allVariants,w=n.pxToRem,S=(0,a.Z)(n,T);var k=c/14,x=w||function(e){return"".concat(e/g*k,"rem")},A=function(e,t,n,a,o){return(0,r.Z)({fontFamily:s,fontWeight:e,fontSize:x(t),lineHeight:n},s===C?{letterSpacing:"".concat((i=a/t,Math.round(1e5*i)/1e5),"em")}:{},o,_);var i},E={h1:A(d,96,1.167,-1.5),h2:A(d,60,1.2,-.5),h3:A(p,48,1.167,0),h4:A(p,34,1.235,.25),h5:A(p,24,1.334,0),h6:A(h,20,1.6,.15),subtitle1:A(p,16,1.75,.15),subtitle2:A(h,14,1.57,.1),body1:A(p,16,1.5,.15),body2:A(p,14,1.43,.15),button:A(h,14,1.75,.4,F),caption:A(p,12,1.66,.4),overline:A(p,12,2.66,1,F)};return(0,i.Z)((0,r.Z)({htmlFontSize:g,pxToRem:x,fontFamily:s,fontSize:c,fontWeightLight:d,fontWeightRegular:p,fontWeightMedium:h,fontWeightBold:y},E),S,{clone:!1})}function A(){return["".concat(arguments.length<=0?void 0:arguments[0],"px ").concat(arguments.length<=1?void 0:arguments[1],"px ").concat(arguments.length<=2?void 0:arguments[2],"px ").concat(arguments.length<=3?void 0:arguments[3],"px rgba(0,0,0,").concat(.2,")"),"".concat(arguments.length<=4?void 0:arguments[4],"px ").concat(arguments.length<=5?void 0:arguments[5],"px ").concat(arguments.length<=6?void 0:arguments[6],"px ").concat(arguments.length<=7?void 0:arguments[7],"px rgba(0,0,0,").concat(.14,")"),"".concat(arguments.length<=8?void 0:arguments[8],"px ").concat(arguments.length<=9?void 0:arguments[9],"px ").concat(arguments.length<=10?void 0:arguments[10],"px ").concat(arguments.length<=11?void 0:arguments[11],"px rgba(0,0,0,").concat(.12,")")].join(",")}var E=["none",A(0,2,1,-1,0,1,1,0,0,1,3,0),A(0,3,1,-2,0,2,2,0,0,1,5,0),A(0,3,3,-2,0,3,4,0,0,1,8,0),A(0,2,4,-1,0,4,5,0,0,1,10,0),A(0,3,5,-1,0,5,8,0,0,1,14,0),A(0,3,5,-1,0,6,10,0,0,1,18,0),A(0,4,5,-2,0,7,10,1,0,2,16,1),A(0,5,5,-3,0,8,10,1,0,3,14,2),A(0,5,6,-3,0,9,12,1,0,3,16,2),A(0,6,6,-3,0,10,14,1,0,4,18,3),A(0,6,7,-4,0,11,15,1,0,4,20,3),A(0,7,8,-4,0,12,17,2,0,5,22,4),A(0,7,8,-4,0,13,19,2,0,5,24,4),A(0,7,9,-4,0,14,21,2,0,5,26,4),A(0,8,9,-5,0,15,22,2,0,6,28,5),A(0,8,10,-5,0,16,24,2,0,6,30,5),A(0,8,11,-5,0,17,26,2,0,6,32,5),A(0,9,11,-5,0,18,28,2,0,7,34,6),A(0,9,12,-6,0,19,29,2,0,7,36,6),A(0,10,13,-6,0,20,31,3,0,8,38,7),A(0,10,13,-6,0,21,33,3,0,8,40,7),A(0,10,14,-6,0,22,35,3,0,8,42,7),A(0,11,14,-7,0,23,36,3,0,9,44,8),A(0,11,15,-7,0,24,38,3,0,9,46,8)],D=["duration","easing","delay"],P={easeInOut:"cubic-bezier(0.4, 0, 0.2, 1)",easeOut:"cubic-bezier(0.0, 0, 0.2, 1)",easeIn:"cubic-bezier(0.4, 0, 1, 1)",sharp:"cubic-bezier(0.4, 0, 0.6, 1)"},R={shortest:150,shorter:200,short:250,standard:300,complex:375,enteringScreen:225,leavingScreen:195};function M(e){return"".concat(Math.round(e),"ms")}function N(e){if(!e)return 0;var t=e/36;return Math.round(10*(4+15*Math.pow(t,.25)+t/5))}function O(e){var t=(0,r.Z)({},P,e.easing),n=(0,r.Z)({},R,e.duration);return(0,r.Z)({getAutoHeightDuration:N,create:function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:["all"],r=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},o=r.duration,i=void 0===o?n.standard:o,s=r.easing,l=void 0===s?t.easeInOut:s,c=r.delay,u=void 0===c?0:c;(0,a.Z)(r,D);return(Array.isArray(e)?e:[e]).map((function(e){return"".concat(e," ").concat("string"===typeof i?i:M(i)," ").concat(l," ").concat("string"===typeof u?u:M(u))})).join(",")}},e,{easing:t,duration:n})}var z={mobileStepper:1e3,fab:1050,speedDial:1050,appBar:1100,drawer:1200,modal:1300,snackbar:1400,tooltip:1500},I=["breakpoints","mixins","spacing","palette","transitions","typography","shape"];function L(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},t=e.mixins,n=void 0===t?{}:t,l=e.palette,u=void 0===l?{}:l,d=e.transitions,f=void 0===d?{}:d,p=e.typography,m=void 0===p?{}:p,h=(0,a.Z)(e,I);if(e.vars)throw new Error((0,o.Z)(18));var v=k(u),y=(0,s.Z)(e),b=(0,i.Z)(y,{mixins:c(y.breakpoints,n),palette:v,shadows:E.slice(),typography:x(v,m),transitions:O(f),zIndex:(0,r.Z)({},z)});b=(0,i.Z)(b,h);for(var g=arguments.length,_=new Array(g>1?g-1:0),w=1;w<g;w++)_[w-1]=arguments[w];return b=_.reduce((function(e,t){return(0,i.Z)(e,t)}),b)}var Z=L},4205:function(e,t,n){"use strict";var r=(0,n(4360).Z)();t.Z=r},277:function(e,t,n){"use strict";var r=n(4046),a=n(4205),o=(0,r.ZP)({defaultTheme:a.Z,rootShouldForwardProp:function(e){return(0,r.x9)(e)&&"classes"!==e}});t.ZP=o},5513:function(e,t,n){"use strict";n.d(t,{Z:function(){return o}});var r=n(8691),a=n(4205);function o(e){var t=e.props,n=e.name;return(0,r.Z)({props:t,name:n,defaultTheme:a.Z})}},9853:function(e,t,n){"use strict";var r=n(7312);t.Z=r.Z},3111:function(e,t,n){"use strict";n.r(t),n.d(t,{capitalize:function(){return a.Z},createChainedFunction:function(){return o},createSvgIcon:function(){return w},debounce:function(){return S},deprecatedPropType:function(){return k},isMuiElement:function(){return T},ownerDocument:function(){return C},ownerWindow:function(){return x},requirePropFactory:function(){return A},setRef:function(){return E},unstable_ClassNameGenerator:function(){return j},unstable_useEnhancedEffect:function(){return D},unstable_useId:function(){return N},unsupportedProp:function(){return O},useControlled:function(){return z},useEventCallback:function(){return I.Z},useForkRef:function(){return L.Z},useIsFocusVisible:function(){return Z.Z}});var r=n(5902),a=n(9853);var o=function(){for(var e=arguments.length,t=new Array(e),n=0;n<e;n++)t[n]=arguments[n];return t.reduce((function(e,t){return null==t?e:function(){for(var n=arguments.length,r=new Array(n),a=0;a<n;a++)r[a]=arguments[a];e.apply(this,r),t.apply(this,r)}}),(function(){}))},i=n(7462),s=n(2791),l=n.t(s,2),c=n(3366),u=n(8182),d=n(4419),f=n(5513),p=n(277),m=n(1217);function h(e){return(0,m.Z)("MuiSvgIcon",e)}(0,n(5878).Z)("MuiSvgIcon",["root","colorPrimary","colorSecondary","colorAction","colorError","colorDisabled","fontSizeInherit","fontSizeSmall","fontSizeMedium","fontSizeLarge"]);var v=n(184),y=["children","className","color","component","fontSize","htmlColor","inheritViewBox","titleAccess","viewBox"],b=(0,p.ZP)("svg",{name:"MuiSvgIcon",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,"inherit"!==n.color&&t["color".concat((0,a.Z)(n.color))],t["fontSize".concat((0,a.Z)(n.fontSize))]]}})((function(e){var t,n,r,a,o,i,s,l,c,u,d,f,p,m,h,v,y,b=e.theme,g=e.ownerState;return{userSelect:"none",width:"1em",height:"1em",display:"inline-block",fill:"currentColor",flexShrink:0,transition:null==(t=b.transitions)||null==(n=t.create)?void 0:n.call(t,"fill",{duration:null==(r=b.transitions)||null==(a=r.duration)?void 0:a.shorter}),fontSize:{inherit:"inherit",small:(null==(o=b.typography)||null==(i=o.pxToRem)?void 0:i.call(o,20))||"1.25rem",medium:(null==(s=b.typography)||null==(l=s.pxToRem)?void 0:l.call(s,24))||"1.5rem",large:(null==(c=b.typography)||null==(u=c.pxToRem)?void 0:u.call(c,35))||"2.1875rem"}[g.fontSize],color:null!=(d=null==(f=(b.vars||b).palette)||null==(p=f[g.color])?void 0:p.main)?d:{action:null==(m=(b.vars||b).palette)||null==(h=m.action)?void 0:h.active,disabled:null==(v=(b.vars||b).palette)||null==(y=v.action)?void 0:y.disabled,inherit:void 0}[g.color]}})),g=s.forwardRef((function(e,t){var n=(0,f.Z)({props:e,name:"MuiSvgIcon"}),r=n.children,o=n.className,s=n.color,l=void 0===s?"inherit":s,p=n.component,m=void 0===p?"svg":p,g=n.fontSize,_=void 0===g?"medium":g,w=n.htmlColor,S=n.inheritViewBox,k=void 0!==S&&S,T=n.titleAccess,F=n.viewBox,C=void 0===F?"0 0 24 24":F,x=(0,c.Z)(n,y),A=(0,i.Z)({},n,{color:l,component:m,fontSize:_,instanceFontSize:e.fontSize,inheritViewBox:k,viewBox:C}),E={};k||(E.viewBox=C);var D=function(e){var t=e.color,n=e.fontSize,r=e.classes,o={root:["root","inherit"!==t&&"color".concat((0,a.Z)(t)),"fontSize".concat((0,a.Z)(n))]};return(0,d.Z)(o,h,r)}(A);return(0,v.jsxs)(b,(0,i.Z)({as:m,className:(0,u.Z)(D.root,o),focusable:"false",color:w,"aria-hidden":!T||void 0,role:T?"img":void 0,ref:t},E,x,{ownerState:A,children:[r,T?(0,v.jsx)("title",{children:T}):null]}))}));g.muiName="SvgIcon";var _=g;function w(e,t){var n=function(n,r){return(0,v.jsx)(_,(0,i.Z)({"data-testid":"".concat(t,"Icon"),ref:r},n,{children:e}))};return n.muiName=_.muiName,s.memo(s.forwardRef(n))}var S=function(e){var t,n=arguments.length>1&&void 0!==arguments[1]?arguments[1]:166;function r(){for(var r=this,a=arguments.length,o=new Array(a),i=0;i<a;i++)o[i]=arguments[i];var s=function(){e.apply(r,o)};clearTimeout(t),t=setTimeout(s,n)}return r.clear=function(){clearTimeout(t)},r};var k=function(e,t){return function(){return null}};var T=function(e,t){return s.isValidElement(e)&&-1!==t.indexOf(e.type.muiName)};function F(e){return e&&e.ownerDocument||document}var C=F;var x=function(e){return F(e).defaultView||window};var A=function(e,t){return function(){return null}},E=n(2971).Z,D=n(5721).Z,P=n(885),R=0;var M=l.useId;var N=function(e){if(void 0!==M){var t=M();return null!=e?e:t}return function(e){var t=s.useState(e),n=(0,P.Z)(t,2),r=n[0],a=n[1],o=e||r;return s.useEffect((function(){null==r&&a("mui-".concat(R+=1))}),[r]),o}(e)};var O=function(e,t,n,r,a){return null};var z=function(e){var t=e.controlled,n=e.default,r=(e.name,e.state,s.useRef(void 0!==t).current),a=s.useState(n),o=(0,P.Z)(a,2),i=o[0],l=o[1];return[r?t:i,s.useCallback((function(e){r||l(e)}),[])]},I=n(6702),L=n(792),Z=n(2763),j={configure:function(e){console.warn(["MUI: `ClassNameGenerator` import from `@mui/material/utils` is outdated and might cause unexpected issues.","","You should use `import { unstable_ClassNameGenerator } from '@mui/material/className'` instead","","The detail of the issue: https://github.com/mui/material-ui/issues/30011#issuecomment-1024993401","","The updated documentation: https://mui.com/guides/classname-generator/"].join("\n")),r.Z.configure(e)}}},6702:function(e,t,n){"use strict";n.d(t,{Z:function(){return o}});var r=n(2791),a=n(5721);var o=function(e){var t=r.useRef(e);return(0,a.Z)((function(){t.current=e})),r.useCallback((function(){return t.current.apply(void 0,arguments)}),[])}},792:function(e,t,n){"use strict";n.d(t,{Z:function(){return o}});var r=n(2791),a=n(2971);var o=function(e,t){return r.useMemo((function(){return null==e&&null==t?null:function(n){(0,a.Z)(e,n),(0,a.Z)(t,n)}}),[e,t])}},2763:function(e,t,n){"use strict";n.d(t,{Z:function(){return f}});var r,a=n(2791),o=!0,i=!1,s={text:!0,search:!0,url:!0,tel:!0,email:!0,password:!0,number:!0,date:!0,month:!0,week:!0,time:!0,datetime:!0,"datetime-local":!0};function l(e){e.metaKey||e.altKey||e.ctrlKey||(o=!0)}function c(){o=!1}function u(){"hidden"===this.visibilityState&&i&&(o=!0)}function d(e){var t=e.target;try{return t.matches(":focus-visible")}catch(n){}return o||function(e){var t=e.type,n=e.tagName;return!("INPUT"!==n||!s[t]||e.readOnly)||"TEXTAREA"===n&&!e.readOnly||!!e.isContentEditable}(t)}var f=function(){var e=a.useCallback((function(e){var t;null!=e&&((t=e.ownerDocument).addEventListener("keydown",l,!0),t.addEventListener("mousedown",c,!0),t.addEventListener("pointerdown",c,!0),t.addEventListener("touchstart",c,!0),t.addEventListener("visibilitychange",u,!0))}),[]),t=a.useRef(!1);return{isFocusVisibleRef:t,onFocus:function(e){return!!d(e)&&(t.current=!0,!0)},onBlur:function(){return!!t.current&&(i=!0,window.clearTimeout(r),r=window.setTimeout((function(){i=!1}),100),t.current=!1,!0)},ref:e}}},2421:function(e,t,n){"use strict";n.d(t,{ZP:function(){return _},Co:function(){return w}});var r=n(2791),a=n(7462),o=n(9797),i=/^((children|dangerouslySetInnerHTML|key|ref|autoFocus|defaultValue|defaultChecked|innerHTML|suppressContentEditableWarning|suppressHydrationWarning|valueLink|abbr|accept|acceptCharset|accessKey|action|allow|allowUserMedia|allowPaymentRequest|allowFullScreen|allowTransparency|alt|async|autoComplete|autoPlay|capture|cellPadding|cellSpacing|challenge|charSet|checked|cite|classID|className|cols|colSpan|content|contentEditable|contextMenu|controls|controlsList|coords|crossOrigin|data|dateTime|decoding|default|defer|dir|disabled|disablePictureInPicture|download|draggable|encType|enterKeyHint|form|formAction|formEncType|formMethod|formNoValidate|formTarget|frameBorder|headers|height|hidden|high|href|hrefLang|htmlFor|httpEquiv|id|inputMode|integrity|is|keyParams|keyType|kind|label|lang|list|loading|loop|low|marginHeight|marginWidth|max|maxLength|media|mediaGroup|method|min|minLength|multiple|muted|name|nonce|noValidate|open|optimum|pattern|placeholder|playsInline|poster|preload|profile|radioGroup|readOnly|referrerPolicy|rel|required|reversed|role|rows|rowSpan|sandbox|scope|scoped|scrolling|seamless|selected|shape|size|sizes|slot|span|spellCheck|src|srcDoc|srcLang|srcSet|start|step|style|summary|tabIndex|target|title|translate|type|useMap|value|width|wmode|wrap|about|datatype|inlist|prefix|property|resource|typeof|vocab|autoCapitalize|autoCorrect|autoSave|color|incremental|fallback|inert|itemProp|itemScope|itemType|itemID|itemRef|on|option|results|security|unselectable|accentHeight|accumulate|additive|alignmentBaseline|allowReorder|alphabetic|amplitude|arabicForm|ascent|attributeName|attributeType|autoReverse|azimuth|baseFrequency|baselineShift|baseProfile|bbox|begin|bias|by|calcMode|capHeight|clip|clipPathUnits|clipPath|clipRule|colorInterpolation|colorInterpolationFilters|colorProfile|colorRendering|contentScriptType|contentStyleType|cursor|cx|cy|d|decelerate|descent|diffuseConstant|direction|display|divisor|dominantBaseline|dur|dx|dy|edgeMode|elevation|enableBackground|end|exponent|externalResourcesRequired|fill|fillOpacity|fillRule|filter|filterRes|filterUnits|floodColor|floodOpacity|focusable|fontFamily|fontSize|fontSizeAdjust|fontStretch|fontStyle|fontVariant|fontWeight|format|from|fr|fx|fy|g1|g2|glyphName|glyphOrientationHorizontal|glyphOrientationVertical|glyphRef|gradientTransform|gradientUnits|hanging|horizAdvX|horizOriginX|ideographic|imageRendering|in|in2|intercept|k|k1|k2|k3|k4|kernelMatrix|kernelUnitLength|kerning|keyPoints|keySplines|keyTimes|lengthAdjust|letterSpacing|lightingColor|limitingConeAngle|local|markerEnd|markerMid|markerStart|markerHeight|markerUnits|markerWidth|mask|maskContentUnits|maskUnits|mathematical|mode|numOctaves|offset|opacity|operator|order|orient|orientation|origin|overflow|overlinePosition|overlineThickness|panose1|paintOrder|pathLength|patternContentUnits|patternTransform|patternUnits|pointerEvents|points|pointsAtX|pointsAtY|pointsAtZ|preserveAlpha|preserveAspectRatio|primitiveUnits|r|radius|refX|refY|renderingIntent|repeatCount|repeatDur|requiredExtensions|requiredFeatures|restart|result|rotate|rx|ry|scale|seed|shapeRendering|slope|spacing|specularConstant|specularExponent|speed|spreadMethod|startOffset|stdDeviation|stemh|stemv|stitchTiles|stopColor|stopOpacity|strikethroughPosition|strikethroughThickness|string|stroke|strokeDasharray|strokeDashoffset|strokeLinecap|strokeLinejoin|strokeMiterlimit|strokeOpacity|strokeWidth|surfaceScale|systemLanguage|tableValues|targetX|targetY|textAnchor|textDecoration|textRendering|textLength|to|transform|u1|u2|underlinePosition|underlineThickness|unicode|unicodeBidi|unicodeRange|unitsPerEm|vAlphabetic|vHanging|vIdeographic|vMathematical|values|vectorEffect|version|vertAdvY|vertOriginX|vertOriginY|viewBox|viewTarget|visibility|widths|wordSpacing|writingMode|x|xHeight|x1|x2|xChannelSelector|xlinkActuate|xlinkArcrole|xlinkHref|xlinkRole|xlinkShow|xlinkTitle|xlinkType|xmlBase|xmlns|xmlnsXlink|xmlLang|xmlSpace|y|y1|y2|yChannelSelector|z|zoomAndPan|for|class|autofocus)|(([Dd][Aa][Tt][Aa]|[Aa][Rr][Ii][Aa]|x)-.*))$/,s=(0,o.Z)((function(e){return i.test(e)||111===e.charCodeAt(0)&&110===e.charCodeAt(1)&&e.charCodeAt(2)<91})),l=n(9886),c=n(5438),u=n(9140),d=n(2561),f=s,p=function(e){return"theme"!==e},m=function(e){return"string"===typeof e&&e.charCodeAt(0)>96?f:p},h=function(e,t,n){var r;if(t){var a=t.shouldForwardProp;r=e.__emotion_forwardProp&&a?function(t){return e.__emotion_forwardProp(t)&&a(t)}:a}return"function"!==typeof r&&n&&(r=e.__emotion_forwardProp),r},v=function(e){var t=e.cache,n=e.serialized,r=e.isStringTag;(0,c.hC)(t,n,r);(0,d.L)((function(){return(0,c.My)(t,n,r)}));return null},y=function e(t,n){var o,i,s=t.__emotion_real===t,d=s&&t.__emotion_base||t;void 0!==n&&(o=n.label,i=n.target);var f=h(t,n,s),p=f||m(d),y=!p("as");return function(){var b=arguments,g=s&&void 0!==t.__emotion_styles?t.__emotion_styles.slice(0):[];if(void 0!==o&&g.push("label:"+o+";"),null==b[0]||void 0===b[0].raw)g.push.apply(g,b);else{0,g.push(b[0][0]);for(var _=b.length,w=1;w<_;w++)g.push(b[w],b[0][w])}var S=(0,l.w)((function(e,t,n){var a=y&&e.as||d,o="",s=[],h=e;if(null==e.theme){for(var b in h={},e)h[b]=e[b];h.theme=(0,r.useContext)(l.T)}"string"===typeof e.className?o=(0,c.fp)(t.registered,s,e.className):null!=e.className&&(o=e.className+" ");var _=(0,u.O)(g.concat(s),t.registered,h);o+=t.key+"-"+_.name,void 0!==i&&(o+=" "+i);var w=y&&void 0===f?m(a):p,S={};for(var k in e)y&&"as"===k||w(k)&&(S[k]=e[k]);return S.className=o,S.ref=n,(0,r.createElement)(r.Fragment,null,(0,r.createElement)(v,{cache:t,serialized:_,isStringTag:"string"===typeof a}),(0,r.createElement)(a,S))}));return S.displayName=void 0!==o?o:"Styled("+("string"===typeof d?d:d.displayName||d.name||"Component")+")",S.defaultProps=t.defaultProps,S.__emotion_real=S,S.__emotion_base=d,S.__emotion_styles=g,S.__emotion_forwardProp=f,Object.defineProperty(S,"toString",{value:function(){return"."+i}}),S.withComponent=function(t,r){return e(t,(0,a.Z)({},n,r,{shouldForwardProp:h(S,r,!0)})).apply(void 0,g)},S}},b=y.bind();["a","abbr","address","area","article","aside","audio","b","base","bdi","bdo","big","blockquote","body","br","button","canvas","caption","cite","code","col","colgroup","data","datalist","dd","del","details","dfn","dialog","div","dl","dt","em","embed","fieldset","figcaption","figure","footer","form","h1","h2","h3","h4","h5","h6","head","header","hgroup","hr","html","i","iframe","img","input","ins","kbd","keygen","label","legend","li","link","main","map","mark","marquee","menu","menuitem","meta","meter","nav","noscript","object","ol","optgroup","option","output","p","param","picture","pre","progress","q","rp","rt","ruby","s","samp","script","section","select","small","source","span","strong","style","sub","summary","sup","table","tbody","td","textarea","tfoot","th","thead","time","title","tr","track","u","ul","var","video","wbr","circle","clipPath","defs","ellipse","foreignObject","g","image","line","linearGradient","mask","path","pattern","polygon","polyline","radialGradient","rect","stop","svg","text","tspan"].forEach((function(e){b[e]=b(e)}));var g=b;function _(e,t){return g(e,t)}var w=function(e,t){Array.isArray(e.__emotion_styles)&&(e.__emotion_styles=t(e.__emotion_styles))}},1184:function(e,t,n){"use strict";n.d(t,{L7:function(){return l},P$:function(){return u},VO:function(){return a},W8:function(){return s},dt:function(){return c},k9:function(){return i}});var r=n(2466),a={xs:0,sm:600,md:900,lg:1200,xl:1536},o={keys:["xs","sm","md","lg","xl"],up:function(e){return"@media (min-width:".concat(a[e],"px)")}};function i(e,t,n){var r=e.theme||{};if(Array.isArray(t)){var i=r.breakpoints||o;return t.reduce((function(e,r,a){return e[i.up(i.keys[a])]=n(t[a]),e}),{})}if("object"===typeof t){var s=r.breakpoints||o;return Object.keys(t).reduce((function(e,r){if(-1!==Object.keys(s.values||a).indexOf(r)){e[s.up(r)]=n(t[r],r)}else{var o=r;e[o]=t[o]}return e}),{})}return n(t)}function s(){var e,t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},n=null==(e=t.keys)?void 0:e.reduce((function(e,n){return e[t.up(n)]={},e}),{});return n||{}}function l(e,t){return e.reduce((function(e,t){var n=e[t];return(!n||0===Object.keys(n).length)&&delete e[t],e}),t)}function c(e){for(var t=s(e),n=arguments.length,a=new Array(n>1?n-1:0),o=1;o<n;o++)a[o-1]=arguments[o];var i=[t].concat(a).reduce((function(e,t){return(0,r.Z)(e,t)}),{});return l(Object.keys(t),i)}function u(e){var t,n=e.values,r=e.breakpoints,a=e.base||function(e,t){if("object"!==typeof e)return{};var n={},r=Object.keys(t);return Array.isArray(e)?r.forEach((function(t,r){r<e.length&&(n[t]=!0)})):r.forEach((function(t){null!=e[t]&&(n[t]=!0)})),n}(n,r),o=Object.keys(a);return 0===o.length?n:o.reduce((function(e,r,a){return Array.isArray(n)?(e[r]=null!=n[a]?n[a]:n[t],t=a):"object"===typeof n?(e[r]=null!=n[r]?n[r]:n[t],t=r):e[r]=n,e}),{})}},2065:function(e,t,n){"use strict";n.d(t,{$n:function(){return d},Fq:function(){return c},_j:function(){return u},mi:function(){return l}});var r=n(6189);function a(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:0,n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:1;return Math.min(Math.max(t,e),n)}function o(e){if(e.type)return e;if("#"===e.charAt(0))return o(function(e){e=e.slice(1);var t=new RegExp(".{1,".concat(e.length>=6?2:1,"}"),"g"),n=e.match(t);return n&&1===n[0].length&&(n=n.map((function(e){return e+e}))),n?"rgb".concat(4===n.length?"a":"","(").concat(n.map((function(e,t){return t<3?parseInt(e,16):Math.round(parseInt(e,16)/255*1e3)/1e3})).join(", "),")"):""}(e));var t=e.indexOf("("),n=e.substring(0,t);if(-1===["rgb","rgba","hsl","hsla","color"].indexOf(n))throw new Error((0,r.Z)(9,e));var a,i=e.substring(t+1,e.length-1);if("color"===n){if(a=(i=i.split(" ")).shift(),4===i.length&&"/"===i[3].charAt(0)&&(i[3]=i[3].slice(1)),-1===["srgb","display-p3","a98-rgb","prophoto-rgb","rec-2020"].indexOf(a))throw new Error((0,r.Z)(10,a))}else i=i.split(",");return{type:n,values:i=i.map((function(e){return parseFloat(e)})),colorSpace:a}}function i(e){var t=e.type,n=e.colorSpace,r=e.values;return-1!==t.indexOf("rgb")?r=r.map((function(e,t){return t<3?parseInt(e,10):e})):-1!==t.indexOf("hsl")&&(r[1]="".concat(r[1],"%"),r[2]="".concat(r[2],"%")),r=-1!==t.indexOf("color")?"".concat(n," ").concat(r.join(" ")):"".concat(r.join(", ")),"".concat(t,"(").concat(r,")")}function s(e){var t="hsl"===(e=o(e)).type||"hsla"===e.type?o(function(e){var t=(e=o(e)).values,n=t[0],r=t[1]/100,a=t[2]/100,s=r*Math.min(a,1-a),l=function(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:(e+n/30)%12;return a-s*Math.max(Math.min(t-3,9-t,1),-1)},c="rgb",u=[Math.round(255*l(0)),Math.round(255*l(8)),Math.round(255*l(4))];return"hsla"===e.type&&(c+="a",u.push(t[3])),i({type:c,values:u})}(e)).values:e.values;return t=t.map((function(t){return"color"!==e.type&&(t/=255),t<=.03928?t/12.92:Math.pow((t+.055)/1.055,2.4)})),Number((.2126*t[0]+.7152*t[1]+.0722*t[2]).toFixed(3))}function l(e,t){var n=s(e),r=s(t);return(Math.max(n,r)+.05)/(Math.min(n,r)+.05)}function c(e,t){return e=o(e),t=a(t),"rgb"!==e.type&&"hsl"!==e.type||(e.type+="a"),"color"===e.type?e.values[3]="/".concat(t):e.values[3]=t,i(e)}function u(e,t){if(e=o(e),t=a(t),-1!==e.type.indexOf("hsl"))e.values[2]*=1-t;else if(-1!==e.type.indexOf("rgb")||-1!==e.type.indexOf("color"))for(var n=0;n<3;n+=1)e.values[n]*=1-t;return i(e)}function d(e,t){if(e=o(e),t=a(t),-1!==e.type.indexOf("hsl"))e.values[2]+=(100-e.values[2])*t;else if(-1!==e.type.indexOf("rgb"))for(var n=0;n<3;n+=1)e.values[n]+=(255-e.values[n])*t;else if(-1!==e.type.indexOf("color"))for(var r=0;r<3;r+=1)e.values[r]+=(1-e.values[r])*t;return i(e)}},4046:function(e,t,n){"use strict";n.d(t,{ZP:function(){return T},x9:function(){return S}});var r=n(2982),a=n(885),o=n(3366),i=n(7462),s=n(2421),l=n(5080),c=n(7312),u=["variant"];function d(e){return 0===e.length}function f(e){var t=e.variant,n=(0,o.Z)(e,u),r=t||"";return Object.keys(n).sort().forEach((function(t){r+="color"===t?d(r)?e[t]:(0,c.Z)(e[t]):"".concat(d(r)?t:(0,c.Z)(t)).concat((0,c.Z)(e[t].toString()))})),r}var p=n(104),m=["name","slot","skipVariantsResolver","skipSx","overridesResolver"],h=["theme"],v=["theme"];function y(e){return 0===Object.keys(e).length}function b(e){return"string"===typeof e&&e.charCodeAt(0)>96}var g=function(e,t){return t.components&&t.components[e]&&t.components[e].styleOverrides?t.components[e].styleOverrides:null},_=function(e,t){var n=[];t&&t.components&&t.components[e]&&t.components[e].variants&&(n=t.components[e].variants);var r={};return n.forEach((function(e){var t=f(e.props);r[t]=e.style})),r},w=function(e,t,n,r){var a,o,i=e.ownerState,s=void 0===i?{}:i,l=[],c=null==n||null==(a=n.components)||null==(o=a[r])?void 0:o.variants;return c&&c.forEach((function(n){var r=!0;Object.keys(n.props).forEach((function(t){s[t]!==n.props[t]&&e[t]!==n.props[t]&&(r=!1)})),r&&l.push(t[f(n.props)])})),l};function S(e){return"ownerState"!==e&&"theme"!==e&&"sx"!==e&&"as"!==e}var k=(0,l.Z)();function T(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},t=e.defaultTheme,n=void 0===t?k:t,l=e.rootShouldForwardProp,c=void 0===l?S:l,u=e.slotShouldForwardProp,d=void 0===u?S:u,f=e.styleFunctionSx,T=void 0===f?p.Z:f,F=function(e){var t=y(e.theme)?n:e.theme;return T((0,i.Z)({},e,{theme:t}))};return F.__mui_systemSx=!0,function(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{};(0,s.Co)(e,(function(e){return e.filter((function(e){return!(null!=e&&e.__mui_systemSx)}))}));var l,u=t.name,f=t.slot,p=t.skipVariantsResolver,k=t.skipSx,T=t.overridesResolver,C=(0,o.Z)(t,m),x=void 0!==p?p:f&&"Root"!==f||!1,A=k||!1;var E=S;"Root"===f?E=c:f?E=d:b(e)&&(E=void 0);var D=(0,s.ZP)(e,(0,i.Z)({shouldForwardProp:E,label:l},C)),P=function(e){for(var t=arguments.length,s=new Array(t>1?t-1:0),l=1;l<t;l++)s[l-1]=arguments[l];var c=s?s.map((function(e){return"function"===typeof e&&e.__emotion_real!==e?function(t){var r=t.theme,a=(0,o.Z)(t,h);return e((0,i.Z)({theme:y(r)?n:r},a))}:e})):[],d=e;u&&T&&c.push((function(e){var t=y(e.theme)?n:e.theme,r=g(u,t);if(r){var o={};return Object.entries(r).forEach((function(n){var r=(0,a.Z)(n,2),s=r[0],l=r[1];o[s]="function"===typeof l?l((0,i.Z)({},e,{theme:t})):l})),T(e,o)}return null})),u&&!x&&c.push((function(e){var t=y(e.theme)?n:e.theme;return w(e,_(u,t),t,u)})),A||c.push(F);var f=c.length-s.length;if(Array.isArray(e)&&f>0){var p=new Array(f).fill("");(d=[].concat((0,r.Z)(e),(0,r.Z)(p))).raw=[].concat((0,r.Z)(e.raw),(0,r.Z)(p))}else"function"===typeof e&&e.__emotion_real!==e&&(d=function(t){var r=t.theme,a=(0,o.Z)(t,v);return e((0,i.Z)({theme:y(r)?n:r},a))});var m=D.apply(void 0,[d].concat((0,r.Z)(c)));return m};return D.withConfig&&(P.withConfig=D.withConfig),P}}},5080:function(e,t,n){"use strict";n.d(t,{Z:function(){return p}});var r=n(7462),a=n(3366),o=n(2466),i=n(4942),s=["values","unit","step"];function l(e){var t=e.values,n=void 0===t?{xs:0,sm:600,md:900,lg:1200,xl:1536}:t,o=e.unit,l=void 0===o?"px":o,c=e.step,u=void 0===c?5:c,d=(0,a.Z)(e,s),f=function(e){var t=Object.keys(e).map((function(t){return{key:t,val:e[t]}}))||[];return t.sort((function(e,t){return e.val-t.val})),t.reduce((function(e,t){return(0,r.Z)({},e,(0,i.Z)({},t.key,t.val))}),{})}(n),p=Object.keys(f);function m(e){var t="number"===typeof n[e]?n[e]:e;return"@media (min-width:".concat(t).concat(l,")")}function h(e){var t="number"===typeof n[e]?n[e]:e;return"@media (max-width:".concat(t-u/100).concat(l,")")}function v(e,t){var r=p.indexOf(t);return"@media (min-width:".concat("number"===typeof n[e]?n[e]:e).concat(l,") and ")+"(max-width:".concat((-1!==r&&"number"===typeof n[p[r]]?n[p[r]]:t)-u/100).concat(l,")")}return(0,r.Z)({keys:p,values:f,up:m,down:h,between:v,only:function(e){return p.indexOf(e)+1<p.length?v(e,p[p.indexOf(e)+1]):m(e)},not:function(e){var t=p.indexOf(e);return 0===t?m(p[1]):t===p.length-1?h(p[t]):v(e,p[p.indexOf(e)+1]).replace("@media","@media not all and")},unit:l},d)}var c={borderRadius:4},u=n(5682);function d(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:8;if(e.mui)return e;var t=(0,u.hB)({spacing:e}),n=function(){for(var e=arguments.length,n=new Array(e),r=0;r<e;r++)n[r]=arguments[r];var a=0===n.length?[1]:n;return a.map((function(e){var n=t(e);return"number"===typeof n?"".concat(n,"px"):n})).join(" ")};return n.mui=!0,n}var f=["breakpoints","palette","spacing","shape"];var p=function(){for(var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},t=e.breakpoints,n=void 0===t?{}:t,i=e.palette,s=void 0===i?{}:i,u=e.spacing,p=e.shape,m=void 0===p?{}:p,h=(0,a.Z)(e,f),v=l(n),y=d(u),b=(0,o.Z)({breakpoints:v,direction:"ltr",components:{},palette:(0,r.Z)({mode:"light"},s),spacing:y,shape:(0,r.Z)({},c,m)},h),g=arguments.length,_=new Array(g>1?g-1:0),w=1;w<g;w++)_[w-1]=arguments[w];return b=_.reduce((function(e,t){return(0,o.Z)(e,t)}),b)}},114:function(e,t,n){"use strict";n.d(t,{Gc:function(){return q},G$:function(){return H}});var r=n(8529),a=n(8247);var o=function(){for(var e=arguments.length,t=new Array(e),n=0;n<e;n++)t[n]=arguments[n];var r=t.reduce((function(e,t){return t.filterProps.forEach((function(n){e[n]=t})),e}),{}),o=function(e){return Object.keys(e).reduce((function(t,n){return r[n]?(0,a.Z)(t,r[n](e)):t}),{})};return o.propTypes={},o.filterProps=t.reduce((function(e,t){return e.concat(t.filterProps)}),[]),o},i=n(5682),s=n(1184);function l(e){return"number"!==typeof e?e:"".concat(e,"px solid")}var c=(0,r.Z)({prop:"border",themeKey:"borders",transform:l}),u=(0,r.Z)({prop:"borderTop",themeKey:"borders",transform:l}),d=(0,r.Z)({prop:"borderRight",themeKey:"borders",transform:l}),f=(0,r.Z)({prop:"borderBottom",themeKey:"borders",transform:l}),p=(0,r.Z)({prop:"borderLeft",themeKey:"borders",transform:l}),m=(0,r.Z)({prop:"borderColor",themeKey:"palette"}),h=(0,r.Z)({prop:"borderTopColor",themeKey:"palette"}),v=(0,r.Z)({prop:"borderRightColor",themeKey:"palette"}),y=(0,r.Z)({prop:"borderBottomColor",themeKey:"palette"}),b=(0,r.Z)({prop:"borderLeftColor",themeKey:"palette"}),g=function(e){if(void 0!==e.borderRadius&&null!==e.borderRadius){var t=(0,i.eI)(e.theme,"shape.borderRadius",4,"borderRadius");return(0,s.k9)(e,e.borderRadius,(function(e){return{borderRadius:(0,i.NA)(t,e)}}))}return null};g.propTypes={},g.filterProps=["borderRadius"];var _=o(c,u,d,f,p,m,h,v,y,b,g),w=o((0,r.Z)({prop:"displayPrint",cssProperty:!1,transform:function(e){return{"@media print":{display:e}}}}),(0,r.Z)({prop:"display"}),(0,r.Z)({prop:"overflow"}),(0,r.Z)({prop:"textOverflow"}),(0,r.Z)({prop:"visibility"}),(0,r.Z)({prop:"whiteSpace"})),S=o((0,r.Z)({prop:"flexBasis"}),(0,r.Z)({prop:"flexDirection"}),(0,r.Z)({prop:"flexWrap"}),(0,r.Z)({prop:"justifyContent"}),(0,r.Z)({prop:"alignItems"}),(0,r.Z)({prop:"alignContent"}),(0,r.Z)({prop:"order"}),(0,r.Z)({prop:"flex"}),(0,r.Z)({prop:"flexGrow"}),(0,r.Z)({prop:"flexShrink"}),(0,r.Z)({prop:"alignSelf"}),(0,r.Z)({prop:"justifyItems"}),(0,r.Z)({prop:"justifySelf"})),k=function(e){if(void 0!==e.gap&&null!==e.gap){var t=(0,i.eI)(e.theme,"spacing",8,"gap");return(0,s.k9)(e,e.gap,(function(e){return{gap:(0,i.NA)(t,e)}}))}return null};k.propTypes={},k.filterProps=["gap"];var T=function(e){if(void 0!==e.columnGap&&null!==e.columnGap){var t=(0,i.eI)(e.theme,"spacing",8,"columnGap");return(0,s.k9)(e,e.columnGap,(function(e){return{columnGap:(0,i.NA)(t,e)}}))}return null};T.propTypes={},T.filterProps=["columnGap"];var F=function(e){if(void 0!==e.rowGap&&null!==e.rowGap){var t=(0,i.eI)(e.theme,"spacing",8,"rowGap");return(0,s.k9)(e,e.rowGap,(function(e){return{rowGap:(0,i.NA)(t,e)}}))}return null};F.propTypes={},F.filterProps=["rowGap"];var C=o(k,T,F,(0,r.Z)({prop:"gridColumn"}),(0,r.Z)({prop:"gridRow"}),(0,r.Z)({prop:"gridAutoFlow"}),(0,r.Z)({prop:"gridAutoColumns"}),(0,r.Z)({prop:"gridAutoRows"}),(0,r.Z)({prop:"gridTemplateColumns"}),(0,r.Z)({prop:"gridTemplateRows"}),(0,r.Z)({prop:"gridTemplateAreas"}),(0,r.Z)({prop:"gridArea"})),x=o((0,r.Z)({prop:"position"}),(0,r.Z)({prop:"zIndex",themeKey:"zIndex"}),(0,r.Z)({prop:"top"}),(0,r.Z)({prop:"right"}),(0,r.Z)({prop:"bottom"}),(0,r.Z)({prop:"left"})),A=o((0,r.Z)({prop:"color",themeKey:"palette"}),(0,r.Z)({prop:"bgcolor",cssProperty:"backgroundColor",themeKey:"palette"}),(0,r.Z)({prop:"backgroundColor",themeKey:"palette"})),E=(0,r.Z)({prop:"boxShadow",themeKey:"shadows"});function D(e){return e<=1&&0!==e?"".concat(100*e,"%"):e}var P=(0,r.Z)({prop:"width",transform:D}),R=function(e){if(void 0!==e.maxWidth&&null!==e.maxWidth){return(0,s.k9)(e,e.maxWidth,(function(t){var n,r,a;return{maxWidth:(null==(n=e.theme)||null==(r=n.breakpoints)||null==(a=r.values)?void 0:a[t])||s.VO[t]||D(t)}}))}return null};R.filterProps=["maxWidth"];var M=(0,r.Z)({prop:"minWidth",transform:D}),N=(0,r.Z)({prop:"height",transform:D}),O=(0,r.Z)({prop:"maxHeight",transform:D}),z=(0,r.Z)({prop:"minHeight",transform:D}),I=((0,r.Z)({prop:"size",cssProperty:"width",transform:D}),(0,r.Z)({prop:"size",cssProperty:"height",transform:D}),o(P,R,M,N,O,z,(0,r.Z)({prop:"boxSizing"}))),L=(0,r.Z)({prop:"fontFamily",themeKey:"typography"}),Z=(0,r.Z)({prop:"fontSize",themeKey:"typography"}),j=(0,r.Z)({prop:"fontStyle",themeKey:"typography"}),B=(0,r.Z)({prop:"fontWeight",themeKey:"typography"}),W=(0,r.Z)({prop:"letterSpacing"}),U=(0,r.Z)({prop:"textTransform"}),V=(0,r.Z)({prop:"lineHeight"}),G=(0,r.Z)({prop:"textAlign"}),J=o((0,r.Z)({prop:"typography",cssProperty:!1,themeKey:"typography"}),L,Z,j,B,W,V,G,U),$={borders:_.filterProps,display:w.filterProps,flexbox:S.filterProps,grid:C.filterProps,positions:x.filterProps,palette:A.filterProps,shadows:E.filterProps,sizing:I.filterProps,spacing:i.ZP.filterProps,typography:J.filterProps},H={borders:_,display:w,flexbox:S,grid:C,positions:x,palette:A,shadows:E,sizing:I,spacing:i.ZP,typography:J},q=Object.keys($).reduce((function(e,t){return $[t].forEach((function(n){e[n]=H[t]})),e}),{})},8247:function(e,t,n){"use strict";var r=n(2466);t.Z=function(e,t){return t?(0,r.Z)(e,t,{clone:!1}):e}},5682:function(e,t,n){"use strict";n.d(t,{hB:function(){return h},eI:function(){return m},ZP:function(){return S},NA:function(){return v}});var r=n(885),a=n(1184),o=n(8529),i=n(8247);var s={m:"margin",p:"padding"},l={t:"Top",r:"Right",b:"Bottom",l:"Left",x:["Left","Right"],y:["Top","Bottom"]},c={marginX:"mx",marginY:"my",paddingX:"px",paddingY:"py"},u=function(e){var t={};return function(n){return void 0===t[n]&&(t[n]=e(n)),t[n]}}((function(e){if(e.length>2){if(!c[e])return[e];e=c[e]}var t=e.split(""),n=(0,r.Z)(t,2),a=n[0],o=n[1],i=s[a],u=l[o]||"";return Array.isArray(u)?u.map((function(e){return i+e})):[i+u]})),d=["m","mt","mr","mb","ml","mx","my","margin","marginTop","marginRight","marginBottom","marginLeft","marginX","marginY","marginInline","marginInlineStart","marginInlineEnd","marginBlock","marginBlockStart","marginBlockEnd"],f=["p","pt","pr","pb","pl","px","py","padding","paddingTop","paddingRight","paddingBottom","paddingLeft","paddingX","paddingY","paddingInline","paddingInlineStart","paddingInlineEnd","paddingBlock","paddingBlockStart","paddingBlockEnd"],p=[].concat(d,f);function m(e,t,n,r){var a,i=null!=(a=(0,o.D)(e,t,!1))?a:n;return"number"===typeof i?function(e){return"string"===typeof e?e:i*e}:Array.isArray(i)?function(e){return"string"===typeof e?e:i[e]}:"function"===typeof i?i:function(){}}function h(e){return m(e,"spacing",8)}function v(e,t){if("string"===typeof t||null==t)return t;var n=e(Math.abs(t));return t>=0?n:"number"===typeof n?-n:"-".concat(n)}function y(e,t,n,r){if(-1===t.indexOf(n))return null;var o=function(e,t){return function(n){return e.reduce((function(e,r){return e[r]=v(t,n),e}),{})}}(u(n),r),i=e[n];return(0,a.k9)(e,i,o)}function b(e,t){var n=h(e.theme);return Object.keys(e).map((function(r){return y(e,t,r,n)})).reduce(i.Z,{})}function g(e){return b(e,d)}function _(e){return b(e,f)}function w(e){return b(e,p)}g.propTypes={},g.filterProps=d,_.propTypes={},_.filterProps=f,w.propTypes={},w.filterProps=p;var S=w},8529:function(e,t,n){"use strict";n.d(t,{D:function(){return i}});var r=n(4942),a=n(7312),o=n(1184);function i(e,t){var n=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];if(!t||"string"!==typeof t)return null;if(e&&e.vars&&n){var r="vars.".concat(t).split(".").reduce((function(e,t){return e&&e[t]?e[t]:null}),e);if(null!=r)return r}return t.split(".").reduce((function(e,t){return e&&null!=e[t]?e[t]:null}),e)}function s(e,t,n){var r,a=arguments.length>3&&void 0!==arguments[3]?arguments[3]:n;return r="function"===typeof e?e(n):Array.isArray(e)?e[n]||a:i(e,n)||a,t&&(r=t(r)),r}t.Z=function(e){var t=e.prop,n=e.cssProperty,l=void 0===n?e.prop:n,c=e.themeKey,u=e.transform,d=function(e){if(null==e[t])return null;var n=e[t],d=i(e.theme,c)||{};return(0,o.k9)(e,n,(function(e){var n=s(d,u,e);return e===n&&"string"===typeof e&&(n=s(d,u,"".concat(t).concat("default"===e?"":(0,a.Z)(e)),e)),!1===l?n:(0,r.Z)({},l,n)}))};return d.propTypes={},d.filterProps=[t],d}},104:function(e,t,n){"use strict";var r=n(4942),a=n(8247),o=n(114),i=n(1184);function s(){for(var e=arguments.length,t=new Array(e),n=0;n<e;n++)t[n]=arguments[n];var r=t.reduce((function(e,t){return e.concat(Object.keys(t))}),[]),a=new Set(r);return t.every((function(e){return a.size===Object.keys(e).length}))}function l(e,t){return"function"===typeof e?e(t):e}var c=function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:o.G$,t=Object.keys(e).reduce((function(t,n){return e[n].filterProps.forEach((function(r){t[r]=e[n]})),t}),{});function n(e,n,a){var o,i=(o={},(0,r.Z)(o,e,n),(0,r.Z)(o,"theme",a),o),s=t[e];return s?s(i):(0,r.Z)({},e,n)}function c(e){var o=e||{},u=o.sx,d=o.theme,f=void 0===d?{}:d;if(!u)return null;function p(e){var o=e;if("function"===typeof e)o=e(f);else if("object"!==typeof e)return e;if(!o)return null;var u=(0,i.W8)(f.breakpoints),d=Object.keys(u),p=u;return Object.keys(o).forEach((function(e){var u=l(o[e],f);if(null!==u&&void 0!==u)if("object"===typeof u)if(t[e])p=(0,a.Z)(p,n(e,u,f));else{var d=(0,i.k9)({theme:f},u,(function(t){return(0,r.Z)({},e,t)}));s(d,u)?p[e]=c({sx:u,theme:f}):p=(0,a.Z)(p,d)}else p=(0,a.Z)(p,n(e,u,f))})),(0,i.L7)(d,p)}return Array.isArray(u)?u.map(p):p(u)}return c}();c.filterProps=["sx"],t.Z=c},886:function(e,t,n){"use strict";n.d(t,{Z:function(){return u}});var r=n(5080),a=n(2791);var o=a.createContext(null);function i(){return a.useContext(o)}function s(e){return 0===Object.keys(e).length}var l=function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:null,t=i();return!t||s(t)?e:t},c=(0,r.Z)();var u=function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:c;return l(e)}},8691:function(e,t,n){"use strict";n.d(t,{Z:function(){return i}});var r=n(7462);function a(e){var t=e.theme,n=e.name,a=e.props;return t&&t.components&&t.components[n]&&t.components[n].defaultProps?function(e,t){var n=(0,r.Z)({},t);return Object.keys(e).forEach((function(t){void 0===n[t]&&(n[t]=e[t])})),n}(t.components[n].defaultProps,a):a}var o=n(886);function i(e){var t=e.props,n=e.name,r=e.defaultTheme;return a({theme:(0,o.Z)(r),name:n,props:t})}},5902:function(e,t){"use strict";var n=function(e){return e},r=function(){var e=n;return{configure:function(t){e=t},generate:function(t){return e(t)},reset:function(){e=n}}}();t.Z=r},7312:function(e,t,n){"use strict";n.d(t,{Z:function(){return a}});var r=n(6189);function a(e){if("string"!==typeof e)throw new Error((0,r.Z)(7));return e.charAt(0).toUpperCase()+e.slice(1)}},4419:function(e,t,n){"use strict";function r(e,t,n){var r={};return Object.keys(e).forEach((function(a){r[a]=e[a].reduce((function(e,r){return r&&(e.push(t(r)),n&&n[r]&&e.push(n[r])),e}),[]).join(" ")})),r}n.d(t,{Z:function(){return r}})},2466:function(e,t,n){"use strict";n.d(t,{P:function(){return a},Z:function(){return o}});var r=n(7462);function a(e){return null!==e&&"object"===typeof e&&e.constructor===Object}function o(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:{clone:!0},i=n.clone?(0,r.Z)({},e):e;return a(e)&&a(t)&&Object.keys(t).forEach((function(r){"__proto__"!==r&&(a(t[r])&&r in e&&a(e[r])?i[r]=o(e[r],t[r],n):i[r]=t[r])})),i}},6189:function(e,t,n){"use strict";function r(e){for(var t="https://mui.com/production-error/?code="+e,n=1;n<arguments.length;n+=1)t+="&args[]="+encodeURIComponent(arguments[n]);return"Minified MUI error #"+e+"; visit "+t+" for the full message."}n.d(t,{Z:function(){return r}})},1217:function(e,t,n){"use strict";n.d(t,{Z:function(){return o}});var r=n(5902),a={active:"active",checked:"checked",completed:"completed",disabled:"disabled",error:"error",expanded:"expanded",focused:"focused",focusVisible:"focusVisible",required:"required",selected:"selected"};function o(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:"Mui",o=a[t];return o?"".concat(n,"-").concat(o):"".concat(r.Z.generate(e),"-").concat(t)}},5878:function(e,t,n){"use strict";n.d(t,{Z:function(){return a}});var r=n(1217);function a(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:"Mui",a={};return t.forEach((function(t){a[t]=(0,r.Z)(e,t,n)})),a}},2971:function(e,t,n){"use strict";function r(e,t){"function"===typeof e?e(t):e&&(e.current=t)}n.d(t,{Z:function(){return r}})},5721:function(e,t,n){"use strict";var r=n(2791),a="undefined"!==typeof window?r.useLayoutEffect:r.useEffect;t.Z=a},1694:function(e,t){var n;!function(){"use strict";var r={}.hasOwnProperty;function a(){for(var e=[],t=0;t<arguments.length;t++){var n=arguments[t];if(n){var o=typeof n;if("string"===o||"number"===o)e.push(n);else if(Array.isArray(n)){if(n.length){var i=a.apply(null,n);i&&e.push(i)}}else if("object"===o){if(n.toString!==Object.prototype.toString&&!n.toString.toString().includes("[native code]")){e.push(n.toString());continue}for(var s in n)r.call(n,s)&&n[s]&&e.push(s)}}}return e.join(" ")}e.exports?(a.default=a,e.exports=a):void 0===(n=function(){return a}.apply(t,[]))||(e.exports=n)}()},8182:function(e,t,n){"use strict";function r(e){var t,n,a="";if("string"==typeof e||"number"==typeof e)a+=e;else if("object"==typeof e)if(Array.isArray(e))for(t=0;t<e.length;t++)e[t]&&(n=r(e[t]))&&(a&&(a+=" "),a+=n);else for(t in e)e[t]&&(a&&(a+=" "),a+=t);return a}t.Z=function(){for(var e,t,n=0,a="";n<arguments.length;)(e=arguments[n++])&&(t=r(e))&&(a&&(a+=" "),a+=t);return a}},4173:function(e,t){!function(e){"use strict";function t(){}function n(e,t,n,r,a){for(var o=0,i=t.length,s=0,l=0;o<i;o++){var c=t[o];if(c.removed){if(c.value=e.join(r.slice(l,l+c.count)),l+=c.count,o&&t[o-1].added){var u=t[o-1];t[o-1]=t[o],t[o]=u}}else{if(!c.added&&a){var d=n.slice(s,s+c.count);d=d.map((function(e,t){var n=r[l+t];return n.length>e.length?n:e})),c.value=e.join(d)}else c.value=e.join(n.slice(s,s+c.count));s+=c.count,c.added||(l+=c.count)}}var f=t[i-1];return i>1&&"string"===typeof f.value&&(f.added||f.removed)&&e.equals("",f.value)&&(t[i-2].value+=f.value,t.pop()),t}function r(e){return{newPos:e.newPos,components:e.components.slice(0)}}t.prototype={diff:function(e,t){var a=arguments.length>2&&void 0!==arguments[2]?arguments[2]:{},o=a.callback;"function"===typeof a&&(o=a,a={}),this.options=a;var i=this;function s(e){return o?(setTimeout((function(){o(void 0,e)}),0),!0):e}e=this.castInput(e),t=this.castInput(t),e=this.removeEmpty(this.tokenize(e));var l=(t=this.removeEmpty(this.tokenize(t))).length,c=e.length,u=1,d=l+c,f=[{newPos:-1,components:[]}],p=this.extractCommon(f[0],t,e,0);if(f[0].newPos+1>=l&&p+1>=c)return s([{value:this.join(t),count:t.length}]);function m(){for(var a=-1*u;a<=u;a+=2){var o=void 0,d=f[a-1],p=f[a+1],m=(p?p.newPos:0)-a;d&&(f[a-1]=void 0);var h=d&&d.newPos+1<l,v=p&&0<=m&&m<c;if(h||v){if(!h||v&&d.newPos<p.newPos?(o=r(p),i.pushComponent(o.components,void 0,!0)):((o=d).newPos++,i.pushComponent(o.components,!0,void 0)),m=i.extractCommon(o,t,e,a),o.newPos+1>=l&&m+1>=c)return s(n(i,o.components,t,e,i.useLongestToken));f[a]=o}else f[a]=void 0}u++}if(o)!function e(){setTimeout((function(){if(u>d)return o();m()||e()}),0)}();else for(;u<=d;){var h=m();if(h)return h}},pushComponent:function(e,t,n){var r=e[e.length-1];r&&r.added===t&&r.removed===n?e[e.length-1]={count:r.count+1,added:t,removed:n}:e.push({count:1,added:t,removed:n})},extractCommon:function(e,t,n,r){for(var a=t.length,o=n.length,i=e.newPos,s=i-r,l=0;i+1<a&&s+1<o&&this.equals(t[i+1],n[s+1]);)i++,s++,l++;return l&&e.components.push({count:l}),e.newPos=i,s},equals:function(e,t){return this.options.comparator?this.options.comparator(e,t):e===t||this.options.ignoreCase&&e.toLowerCase()===t.toLowerCase()},removeEmpty:function(e){for(var t=[],n=0;n<e.length;n++)e[n]&&t.push(e[n]);return t},castInput:function(e){return e},tokenize:function(e){return e.split("")},join:function(e){return e.join("")}};var a=new t;function o(e,t,n){return a.diff(e,t,n)}function i(e,t){if("function"===typeof e)t.callback=e;else if(e)for(var n in e)e.hasOwnProperty(n)&&(t[n]=e[n]);return t}var s=/^[A-Za-z\xC0-\u02C6\u02C8-\u02D7\u02DE-\u02FF\u1E00-\u1EFF]+$/,l=/\S/,c=new t;function u(e,t,n){return n=i(n,{ignoreWhitespace:!0}),c.diff(e,t,n)}function d(e,t,n){return c.diff(e,t,n)}c.equals=function(e,t){return this.options.ignoreCase&&(e=e.toLowerCase(),t=t.toLowerCase()),e===t||this.options.ignoreWhitespace&&!l.test(e)&&!l.test(t)},c.tokenize=function(e){for(var t=e.split(/(\s+|[()[\]{}'"]|\b)/),n=0;n<t.length-1;n++)!t[n+1]&&t[n+2]&&s.test(t[n])&&s.test(t[n+2])&&(t[n]+=t[n+2],t.splice(n+1,2),n--);return t};var f=new t;function p(e,t,n){return f.diff(e,t,n)}function m(e,t,n){var r=i(n,{ignoreWhitespace:!0});return f.diff(e,t,r)}f.tokenize=function(e){var t=[],n=e.split(/(\n|\r\n)/);n[n.length-1]||n.pop();for(var r=0;r<n.length;r++){var a=n[r];r%2&&!this.options.newlineIsToken?t[t.length-1]+=a:(this.options.ignoreWhitespace&&(a=a.trim()),t.push(a))}return t};var h=new t;function v(e,t,n){return h.diff(e,t,n)}h.tokenize=function(e){return e.split(/(\S.+?[.!?])(?=\s+|$)/)};var y=new t;function b(e,t,n){return y.diff(e,t,n)}function g(e){return g="function"===typeof Symbol&&"symbol"===typeof Symbol.iterator?function(e){return typeof e}:function(e){return e&&"function"===typeof Symbol&&e.constructor===Symbol&&e!==Symbol.prototype?"symbol":typeof e},g(e)}function _(e){return w(e)||S(e)||k()}function w(e){if(Array.isArray(e)){for(var t=0,n=new Array(e.length);t<e.length;t++)n[t]=e[t];return n}}function S(e){if(Symbol.iterator in Object(e)||"[object Arguments]"===Object.prototype.toString.call(e))return Array.from(e)}function k(){throw new TypeError("Invalid attempt to spread non-iterable instance")}y.tokenize=function(e){return e.split(/([{}:;,]|\s+)/)};var T=Object.prototype.toString,F=new t;function C(e,t,n){return F.diff(e,t,n)}function x(e,t,n,r,a){var o,i;for(t=t||[],n=n||[],r&&(e=r(a,e)),o=0;o<t.length;o+=1)if(t[o]===e)return n[o];if("[object Array]"===T.call(e)){for(t.push(e),i=new Array(e.length),n.push(i),o=0;o<e.length;o+=1)i[o]=x(e[o],t,n,r,a);return t.pop(),n.pop(),i}if(e&&e.toJSON&&(e=e.toJSON()),"object"===g(e)&&null!==e){t.push(e),i={},n.push(i);var s,l=[];for(s in e)e.hasOwnProperty(s)&&l.push(s);for(l.sort(),o=0;o<l.length;o+=1)i[s=l[o]]=x(e[s],t,n,r,s);t.pop(),n.pop()}else i=e;return i}F.useLongestToken=!0,F.tokenize=f.tokenize,F.castInput=function(e){var t=this.options,n=t.undefinedReplacement,r=t.stringifyReplacer,a=void 0===r?function(e,t){return"undefined"===typeof t?n:t}:r;return"string"===typeof e?e:JSON.stringify(x(e,null,null,a),a,"  ")},F.equals=function(e,n){return t.prototype.equals.call(F,e.replace(/,([\r\n])/g,"$1"),n.replace(/,([\r\n])/g,"$1"))};var A=new t;function E(e,t,n){return A.diff(e,t,n)}function D(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},n=e.split(/\r\n|[\n\v\f\r\x85]/),r=e.match(/\r\n|[\n\v\f\r\x85]/g)||[],a=[],o=0;function i(){var e={};for(a.push(e);o<n.length;){var r=n[o];if(/^(\-\-\-|\+\+\+|@@)\s/.test(r))break;var i=/^(?:Index:|diff(?: -r \w+)+)\s+(.+?)\s*$/.exec(r);i&&(e.index=i[1]),o++}for(s(e),s(e),e.hunks=[];o<n.length;){var c=n[o];if(/^(Index:|diff|\-\-\-|\+\+\+)\s/.test(c))break;if(/^@@/.test(c))e.hunks.push(l());else{if(c&&t.strict)throw new Error("Unknown line "+(o+1)+" "+JSON.stringify(c));o++}}}function s(e){var t=/^(---|\+\+\+)\s+(.*)$/.exec(n[o]);if(t){var r="---"===t[1]?"old":"new",a=t[2].split("\t",2),i=a[0].replace(/\\\\/g,"\\");/^".*"$/.test(i)&&(i=i.substr(1,i.length-2)),e[r+"FileName"]=i,e[r+"Header"]=(a[1]||"").trim(),o++}}function l(){for(var e=o,a=n[o++].split(/@@ -(\d+)(?:,(\d+))? \+(\d+)(?:,(\d+))? @@/),i={oldStart:+a[1],oldLines:+a[2]||1,newStart:+a[3],newLines:+a[4]||1,lines:[],linedelimiters:[]},s=0,l=0;o<n.length&&!(0===n[o].indexOf("--- ")&&o+2<n.length&&0===n[o+1].indexOf("+++ ")&&0===n[o+2].indexOf("@@"));o++){var c=0==n[o].length&&o!=n.length-1?" ":n[o][0];if("+"!==c&&"-"!==c&&" "!==c&&"\\"!==c)break;i.lines.push(n[o]),i.linedelimiters.push(r[o]||"\n"),"+"===c?s++:"-"===c?l++:" "===c&&(s++,l++)}if(s||1!==i.newLines||(i.newLines=0),l||1!==i.oldLines||(i.oldLines=0),t.strict){if(s!==i.newLines)throw new Error("Added line count did not match for hunk at line "+(e+1));if(l!==i.oldLines)throw new Error("Removed line count did not match for hunk at line "+(e+1))}return i}for(;o<n.length;)i();return a}function P(e,t,n){var r=!0,a=!1,o=!1,i=1;return function s(){if(r&&!o){if(a?i++:r=!1,e+i<=n)return i;o=!0}if(!a)return o||(r=!0),t<=e-i?-i++:(a=!0,s())}}function R(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:{};if("string"===typeof t&&(t=D(t)),Array.isArray(t)){if(t.length>1)throw new Error("applyPatch only works with a single input.");t=t[0]}var r,a,o=e.split(/\r\n|[\n\v\f\r\x85]/),i=e.match(/\r\n|[\n\v\f\r\x85]/g)||[],s=t.hunks,l=n.compareLine||function(e,t,n,r){return t===r},c=0,u=n.fuzzFactor||0,d=0,f=0;function p(e,t){for(var n=0;n<e.lines.length;n++){var r=e.lines[n],a=r.length>0?r[0]:" ",i=r.length>0?r.substr(1):r;if(" "===a||"-"===a){if(!l(t+1,o[t],a,i)&&++c>u)return!1;t++}}return!0}for(var m=0;m<s.length;m++){for(var h=s[m],v=o.length-h.oldLines,y=0,b=f+h.oldStart-1,g=P(b,d,v);void 0!==y;y=g())if(p(h,b+y)){h.offset=f+=y;break}if(void 0===y)return!1;d=h.offset+h.oldStart+h.oldLines}for(var _=0,w=0;w<s.length;w++){var S=s[w],k=S.oldStart+S.offset+_-1;_+=S.newLines-S.oldLines,k<0&&(k=0);for(var T=0;T<S.lines.length;T++){var F=S.lines[T],C=F.length>0?F[0]:" ",x=F.length>0?F.substr(1):F,A=S.linedelimiters[T];if(" "===C)k++;else if("-"===C)o.splice(k,1),i.splice(k,1);else if("+"===C)o.splice(k,0,x),i.splice(k,0,A),k++;else if("\\"===C){var E=S.lines[T-1]?S.lines[T-1][0]:null;"+"===E?r=!0:"-"===E&&(a=!0)}}}if(r)for(;!o[o.length-1];)o.pop(),i.pop();else a&&(o.push(""),i.push("\n"));for(var R=0;R<o.length-1;R++)o[R]=o[R]+i[R];return o.join("")}function M(e,t){"string"===typeof e&&(e=D(e));var n=0;function r(){var a=e[n++];if(!a)return t.complete();t.loadFile(a,(function(e,n){if(e)return t.complete(e);var o=R(n,a,t);t.patched(a,o,(function(e){if(e)return t.complete(e);r()}))}))}r()}function N(e,t,n,r,a,o,i){i||(i={}),"undefined"===typeof i.context&&(i.context=4);var s=p(n,r,i);function l(e){return e.map((function(e){return" "+e}))}s.push({value:"",lines:[]});for(var c=[],u=0,d=0,f=[],m=1,h=1,v=function(e){var t=s[e],a=t.lines||t.value.replace(/\n$/,"").split("\n");if(t.lines=a,t.added||t.removed){var o;if(!u){var p=s[e-1];u=m,d=h,p&&(f=i.context>0?l(p.lines.slice(-i.context)):[],u-=f.length,d-=f.length)}(o=f).push.apply(o,_(a.map((function(e){return(t.added?"+":"-")+e})))),t.added?h+=a.length:m+=a.length}else{if(u)if(a.length<=2*i.context&&e<s.length-2){var v;(v=f).push.apply(v,_(l(a)))}else{var y,b=Math.min(a.length,i.context);(y=f).push.apply(y,_(l(a.slice(0,b))));var g={oldStart:u,oldLines:m-u+b,newStart:d,newLines:h-d+b,lines:f};if(e>=s.length-2&&a.length<=i.context){var w=/\n$/.test(n),S=/\n$/.test(r),k=0==a.length&&f.length>g.oldLines;!w&&k&&f.splice(g.oldLines,0,"\\ No newline at end of file"),(w||k)&&S||f.push("\\ No newline at end of file")}c.push(g),u=0,d=0,f=[]}m+=a.length,h+=a.length}},y=0;y<s.length;y++)v(y);return{oldFileName:e,newFileName:t,oldHeader:a,newHeader:o,hunks:c}}function O(e,t,n,r,a,o,i){var s=N(e,t,n,r,a,o,i),l=[];e==t&&l.push("Index: "+e),l.push("==================================================================="),l.push("--- "+s.oldFileName+("undefined"===typeof s.oldHeader?"":"\t"+s.oldHeader)),l.push("+++ "+s.newFileName+("undefined"===typeof s.newHeader?"":"\t"+s.newHeader));for(var c=0;c<s.hunks.length;c++){var u=s.hunks[c];l.push("@@ -"+u.oldStart+","+u.oldLines+" +"+u.newStart+","+u.newLines+" @@"),l.push.apply(l,u.lines)}return l.join("\n")+"\n"}function z(e,t,n,r,a,o){return O(e,e,t,n,r,a,o)}function I(e,t){return e.length===t.length&&L(e,t)}function L(e,t){if(t.length>e.length)return!1;for(var n=0;n<t.length;n++)if(t[n]!==e[n])return!1;return!0}function Z(e){var t=ne(e.lines),n=t.oldLines,r=t.newLines;void 0!==n?e.oldLines=n:delete e.oldLines,void 0!==r?e.newLines=r:delete e.newLines}function j(e,t,n){e=B(e,n),t=B(t,n);var r={};(e.index||t.index)&&(r.index=e.index||t.index),(e.newFileName||t.newFileName)&&(W(e)?W(t)?(r.oldFileName=U(r,e.oldFileName,t.oldFileName),r.newFileName=U(r,e.newFileName,t.newFileName),r.oldHeader=U(r,e.oldHeader,t.oldHeader),r.newHeader=U(r,e.newHeader,t.newHeader)):(r.oldFileName=e.oldFileName,r.newFileName=e.newFileName,r.oldHeader=e.oldHeader,r.newHeader=e.newHeader):(r.oldFileName=t.oldFileName||e.oldFileName,r.newFileName=t.newFileName||e.newFileName,r.oldHeader=t.oldHeader||e.oldHeader,r.newHeader=t.newHeader||e.newHeader)),r.hunks=[];for(var a=0,o=0,i=0,s=0;a<e.hunks.length||o<t.hunks.length;){var l=e.hunks[a]||{oldStart:1/0},c=t.hunks[o]||{oldStart:1/0};if(V(l,c))r.hunks.push(G(l,i)),a++,s+=l.newLines-l.oldLines;else if(V(c,l))r.hunks.push(G(c,s)),o++,i+=c.newLines-c.oldLines;else{var u={oldStart:Math.min(l.oldStart,c.oldStart),oldLines:0,newStart:Math.min(l.newStart+i,c.oldStart+s),newLines:0,lines:[]};J(u,l.oldStart,l.lines,c.oldStart,c.lines),o++,a++,r.hunks.push(u)}}return r}function B(e,t){if("string"===typeof e){if(/^@@/m.test(e)||/^Index:/m.test(e))return D(e)[0];if(!t)throw new Error("Must provide a base reference or pass in a patch");return N(void 0,void 0,t,e)}return e}function W(e){return e.newFileName&&e.newFileName!==e.oldFileName}function U(e,t,n){return t===n?t:(e.conflict=!0,{mine:t,theirs:n})}function V(e,t){return e.oldStart<t.oldStart&&e.oldStart+e.oldLines<t.oldStart}function G(e,t){return{oldStart:e.oldStart,oldLines:e.oldLines,newStart:e.newStart+t,newLines:e.newLines,lines:e.lines}}function J(e,t,n,r,a){var o={offset:t,lines:n,index:0},i={offset:r,lines:a,index:0};for(K(e,o,i),K(e,i,o);o.index<o.lines.length&&i.index<i.lines.length;){var s=o.lines[o.index],l=i.lines[i.index];if("-"!==s[0]&&"+"!==s[0]||"-"!==l[0]&&"+"!==l[0])if("+"===s[0]&&" "===l[0]){var c;(c=e.lines).push.apply(c,_(Q(o)))}else if("+"===l[0]&&" "===s[0]){var u;(u=e.lines).push.apply(u,_(Q(i)))}else"-"===s[0]&&" "===l[0]?H(e,o,i):"-"===l[0]&&" "===s[0]?H(e,i,o,!0):s===l?(e.lines.push(s),o.index++,i.index++):q(e,Q(o),Q(i));else $(e,o,i)}Y(e,o),Y(e,i),Z(e)}function $(e,t,n){var r=Q(t),a=Q(n);if(ee(r)&&ee(a)){var o,i;if(L(r,a)&&te(n,r,r.length-a.length))return void(o=e.lines).push.apply(o,_(r));if(L(a,r)&&te(t,a,a.length-r.length))return void(i=e.lines).push.apply(i,_(a))}else if(I(r,a)){var s;return void(s=e.lines).push.apply(s,_(r))}q(e,r,a)}function H(e,t,n,r){var a,o=Q(t),i=X(n,o);i.merged?(a=e.lines).push.apply(a,_(i.merged)):q(e,r?i:o,r?o:i)}function q(e,t,n){e.conflict=!0,e.lines.push({conflict:!0,mine:t,theirs:n})}function K(e,t,n){for(;t.offset<n.offset&&t.index<t.lines.length;){var r=t.lines[t.index++];e.lines.push(r),t.offset++}}function Y(e,t){for(;t.index<t.lines.length;){var n=t.lines[t.index++];e.lines.push(n)}}function Q(e){for(var t=[],n=e.lines[e.index][0];e.index<e.lines.length;){var r=e.lines[e.index];if("-"===n&&"+"===r[0]&&(n="+"),n!==r[0])break;t.push(r),e.index++}return t}function X(e,t){for(var n=[],r=[],a=0,o=!1,i=!1;a<t.length&&e.index<e.lines.length;){var s=e.lines[e.index],l=t[a];if("+"===l[0])break;if(o=o||" "!==s[0],r.push(l),a++,"+"===s[0])for(i=!0;"+"===s[0];)n.push(s),s=e.lines[++e.index];l.substr(1)===s.substr(1)?(n.push(s),e.index++):i=!0}if("+"===(t[a]||"")[0]&&o&&(i=!0),i)return n;for(;a<t.length;)r.push(t[a++]);return{merged:r,changes:n}}function ee(e){return e.reduce((function(e,t){return e&&"-"===t[0]}),!0)}function te(e,t,n){for(var r=0;r<n;r++){var a=t[t.length-n+r].substr(1);if(e.lines[e.index+r]!==" "+a)return!1}return e.index+=n,!0}function ne(e){var t=0,n=0;return e.forEach((function(e){if("string"!==typeof e){var r=ne(e.mine),a=ne(e.theirs);void 0!==t&&(r.oldLines===a.oldLines?t+=r.oldLines:t=void 0),void 0!==n&&(r.newLines===a.newLines?n+=r.newLines:n=void 0)}else void 0===n||"+"!==e[0]&&" "!==e[0]||n++,void 0===t||"-"!==e[0]&&" "!==e[0]||t++})),{oldLines:t,newLines:n}}function re(e){for(var t,n,r=[],a=0;a<e.length;a++)n=(t=e[a]).added?1:t.removed?-1:0,r.push([n,t.value]);return r}function ae(e){for(var t=[],n=0;n<e.length;n++){var r=e[n];r.added?t.push("<ins>"):r.removed&&t.push("<del>"),t.push(oe(r.value)),r.added?t.push("</ins>"):r.removed&&t.push("</del>")}return t.join("")}function oe(e){var t=e;return t=(t=(t=(t=t.replace(/&/g,"&amp;")).replace(/</g,"&lt;")).replace(/>/g,"&gt;")).replace(/"/g,"&quot;")}A.tokenize=function(e){return e.slice()},A.join=A.removeEmpty=function(e){return e},e.Diff=t,e.diffChars=o,e.diffWords=u,e.diffWordsWithSpace=d,e.diffLines=p,e.diffTrimmedLines=m,e.diffSentences=v,e.diffCss=b,e.diffJson=C,e.diffArrays=E,e.structuredPatch=N,e.createTwoFilesPatch=O,e.createPatch=z,e.applyPatch=R,e.applyPatches=M,e.parsePatch=D,e.merge=j,e.convertChangesToDMP=re,e.convertChangesToXML=ae,e.canonicalize=x,Object.defineProperty(e,"__esModule",{value:!0})}(t)},6025:function(e,t,n){"use strict";n.r(t),n.d(t,{cache:function(){return Z},css:function(){return I},cx:function(){return R},flush:function(){return D},getRegisteredStyles:function(){return N},hydrate:function(){return P},injectGlobal:function(){return O},keyframes:function(){return z},merge:function(){return M},sheet:function(){return L}});var r=function(){function e(e){this.isSpeedy=void 0===e.speedy||e.speedy,this.tags=[],this.ctr=0,this.nonce=e.nonce,this.key=e.key,this.container=e.container,this.before=null}var t=e.prototype;return t.insert=function(e){if(this.ctr%(this.isSpeedy?65e3:1)===0){var t,n=function(e){var t=document.createElement("style");return t.setAttribute("data-emotion",e.key),void 0!==e.nonce&&t.setAttribute("nonce",e.nonce),t.appendChild(document.createTextNode("")),t}(this);t=0===this.tags.length?this.before:this.tags[this.tags.length-1].nextSibling,this.container.insertBefore(n,t),this.tags.push(n)}var r=this.tags[this.tags.length-1];if(this.isSpeedy){var a=function(e){if(e.sheet)return e.sheet;for(var t=0;t<document.styleSheets.length;t++)if(document.styleSheets[t].ownerNode===e)return document.styleSheets[t]}(r);try{var o=105===e.charCodeAt(1)&&64===e.charCodeAt(0);a.insertRule(e,o?0:a.cssRules.length)}catch(i){0}}else r.appendChild(document.createTextNode(e));this.ctr++},t.flush=function(){this.tags.forEach((function(e){return e.parentNode.removeChild(e)})),this.tags=[],this.ctr=0},e}();var a=function(e){function t(e,r,l,c,f){for(var p,m,h,v,_,S=0,k=0,T=0,F=0,C=0,R=0,N=h=p=0,z=0,I=0,L=0,Z=0,j=l.length,B=j-1,W="",U="",V="",G="";z<j;){if(m=l.charCodeAt(z),z===B&&0!==k+F+T+S&&(0!==k&&(m=47===k?10:47),F=T=S=0,j++,B++),0===k+F+T+S){if(z===B&&(0<I&&(W=W.replace(d,"")),0<W.trim().length)){switch(m){case 32:case 9:case 59:case 13:case 10:break;default:W+=l.charAt(z)}m=59}switch(m){case 123:for(p=(W=W.trim()).charCodeAt(0),h=1,Z=++z;z<j;){switch(m=l.charCodeAt(z)){case 123:h++;break;case 125:h--;break;case 47:switch(m=l.charCodeAt(z+1)){case 42:case 47:e:{for(N=z+1;N<B;++N)switch(l.charCodeAt(N)){case 47:if(42===m&&42===l.charCodeAt(N-1)&&z+2!==N){z=N+1;break e}break;case 10:if(47===m){z=N+1;break e}}z=N}}break;case 91:m++;case 40:m++;case 34:case 39:for(;z++<B&&l.charCodeAt(z)!==m;);}if(0===h)break;z++}if(h=l.substring(Z,z),0===p&&(p=(W=W.replace(u,"").trim()).charCodeAt(0)),64===p){switch(0<I&&(W=W.replace(d,"")),m=W.charCodeAt(1)){case 100:case 109:case 115:case 45:I=r;break;default:I=P}if(Z=(h=t(r,I,h,m,f+1)).length,0<M&&(_=s(3,h,I=n(P,W,L),r,A,x,Z,m,f,c),W=I.join(""),void 0!==_&&0===(Z=(h=_.trim()).length)&&(m=0,h="")),0<Z)switch(m){case 115:W=W.replace(w,i);case 100:case 109:case 45:h=W+"{"+h+"}";break;case 107:h=(W=W.replace(y,"$1 $2"))+"{"+h+"}",h=1===D||2===D&&o("@"+h,3)?"@-webkit-"+h+"@"+h:"@"+h;break;default:h=W+h,112===c&&(U+=h,h="")}else h=""}else h=t(r,n(r,W,L),h,c,f+1);V+=h,h=L=I=N=p=0,W="",m=l.charCodeAt(++z);break;case 125:case 59:if(1<(Z=(W=(0<I?W.replace(d,""):W).trim()).length))switch(0===N&&(p=W.charCodeAt(0),45===p||96<p&&123>p)&&(Z=(W=W.replace(" ",":")).length),0<M&&void 0!==(_=s(1,W,r,e,A,x,U.length,c,f,c))&&0===(Z=(W=_.trim()).length)&&(W="\0\0"),p=W.charCodeAt(0),m=W.charCodeAt(1),p){case 0:break;case 64:if(105===m||99===m){G+=W+l.charAt(z);break}default:58!==W.charCodeAt(Z-1)&&(U+=a(W,p,m,W.charCodeAt(2)))}L=I=N=p=0,W="",m=l.charCodeAt(++z)}}switch(m){case 13:case 10:47===k?k=0:0===1+p&&107!==c&&0<W.length&&(I=1,W+="\0"),0<M*O&&s(0,W,r,e,A,x,U.length,c,f,c),x=1,A++;break;case 59:case 125:if(0===k+F+T+S){x++;break}default:switch(x++,v=l.charAt(z),m){case 9:case 32:if(0===F+S+k)switch(C){case 44:case 58:case 9:case 32:v="";break;default:32!==m&&(v=" ")}break;case 0:v="\\0";break;case 12:v="\\f";break;case 11:v="\\v";break;case 38:0===F+k+S&&(I=L=1,v="\f"+v);break;case 108:if(0===F+k+S+E&&0<N)switch(z-N){case 2:112===C&&58===l.charCodeAt(z-3)&&(E=C);case 8:111===R&&(E=R)}break;case 58:0===F+k+S&&(N=z);break;case 44:0===k+T+F+S&&(I=1,v+="\r");break;case 34:case 39:0===k&&(F=F===m?0:0===F?m:F);break;case 91:0===F+k+T&&S++;break;case 93:0===F+k+T&&S--;break;case 41:0===F+k+S&&T--;break;case 40:if(0===F+k+S){if(0===p)if(2*C+3*R===533);else p=1;T++}break;case 64:0===k+T+F+S+N+h&&(h=1);break;case 42:case 47:if(!(0<F+S+T))switch(k){case 0:switch(2*m+3*l.charCodeAt(z+1)){case 235:k=47;break;case 220:Z=z,k=42}break;case 42:47===m&&42===C&&Z+2!==z&&(33===l.charCodeAt(Z+2)&&(U+=l.substring(Z,z+1)),v="",k=0)}}0===k&&(W+=v)}R=C,C=m,z++}if(0<(Z=U.length)){if(I=r,0<M&&(void 0!==(_=s(2,U,I,e,A,x,Z,c,f,c))&&0===(U=_).length))return G+U+V;if(U=I.join(",")+"{"+U+"}",0!==D*E){switch(2!==D||o(U,2)||(E=0),E){case 111:U=U.replace(g,":-moz-$1")+U;break;case 112:U=U.replace(b,"::-webkit-input-$1")+U.replace(b,"::-moz-$1")+U.replace(b,":-ms-input-$1")+U}E=0}}return G+U+V}function n(e,t,n){var a=t.trim().split(h);t=a;var o=a.length,i=e.length;switch(i){case 0:case 1:var s=0;for(e=0===i?"":e[0]+" ";s<o;++s)t[s]=r(e,t[s],n).trim();break;default:var l=s=0;for(t=[];s<o;++s)for(var c=0;c<i;++c)t[l++]=r(e[c]+" ",a[s],n).trim()}return t}function r(e,t,n){var r=t.charCodeAt(0);switch(33>r&&(r=(t=t.trim()).charCodeAt(0)),r){case 38:return t.replace(v,"$1"+e.trim());case 58:return e.trim()+t.replace(v,"$1"+e.trim());default:if(0<1*n&&0<t.indexOf("\f"))return t.replace(v,(58===e.charCodeAt(0)?"":"$1")+e.trim())}return e+t}function a(e,t,n,r){var i=e+";",s=2*t+3*n+4*r;if(944===s){e=i.indexOf(":",9)+1;var l=i.substring(e,i.length-1).trim();return l=i.substring(0,e).trim()+l+";",1===D||2===D&&o(l,1)?"-webkit-"+l+l:l}if(0===D||2===D&&!o(i,1))return i;switch(s){case 1015:return 97===i.charCodeAt(10)?"-webkit-"+i+i:i;case 951:return 116===i.charCodeAt(3)?"-webkit-"+i+i:i;case 963:return 110===i.charCodeAt(5)?"-webkit-"+i+i:i;case 1009:if(100!==i.charCodeAt(4))break;case 969:case 942:return"-webkit-"+i+i;case 978:return"-webkit-"+i+"-moz-"+i+i;case 1019:case 983:return"-webkit-"+i+"-moz-"+i+"-ms-"+i+i;case 883:if(45===i.charCodeAt(8))return"-webkit-"+i+i;if(0<i.indexOf("image-set(",11))return i.replace(C,"$1-webkit-$2")+i;break;case 932:if(45===i.charCodeAt(4))switch(i.charCodeAt(5)){case 103:return"-webkit-box-"+i.replace("-grow","")+"-webkit-"+i+"-ms-"+i.replace("grow","positive")+i;case 115:return"-webkit-"+i+"-ms-"+i.replace("shrink","negative")+i;case 98:return"-webkit-"+i+"-ms-"+i.replace("basis","preferred-size")+i}return"-webkit-"+i+"-ms-"+i+i;case 964:return"-webkit-"+i+"-ms-flex-"+i+i;case 1023:if(99!==i.charCodeAt(8))break;return"-webkit-box-pack"+(l=i.substring(i.indexOf(":",15)).replace("flex-","").replace("space-between","justify"))+"-webkit-"+i+"-ms-flex-pack"+l+i;case 1005:return p.test(i)?i.replace(f,":-webkit-")+i.replace(f,":-moz-")+i:i;case 1e3:switch(t=(l=i.substring(13).trim()).indexOf("-")+1,l.charCodeAt(0)+l.charCodeAt(t)){case 226:l=i.replace(_,"tb");break;case 232:l=i.replace(_,"tb-rl");break;case 220:l=i.replace(_,"lr");break;default:return i}return"-webkit-"+i+"-ms-"+l+i;case 1017:if(-1===i.indexOf("sticky",9))break;case 975:switch(t=(i=e).length-10,s=(l=(33===i.charCodeAt(t)?i.substring(0,t):i).substring(e.indexOf(":",7)+1).trim()).charCodeAt(0)+(0|l.charCodeAt(7))){case 203:if(111>l.charCodeAt(8))break;case 115:i=i.replace(l,"-webkit-"+l)+";"+i;break;case 207:case 102:i=i.replace(l,"-webkit-"+(102<s?"inline-":"")+"box")+";"+i.replace(l,"-webkit-"+l)+";"+i.replace(l,"-ms-"+l+"box")+";"+i}return i+";";case 938:if(45===i.charCodeAt(5))switch(i.charCodeAt(6)){case 105:return l=i.replace("-items",""),"-webkit-"+i+"-webkit-box-"+l+"-ms-flex-"+l+i;case 115:return"-webkit-"+i+"-ms-flex-item-"+i.replace(k,"")+i;default:return"-webkit-"+i+"-ms-flex-line-pack"+i.replace("align-content","").replace(k,"")+i}break;case 973:case 989:if(45!==i.charCodeAt(3)||122===i.charCodeAt(4))break;case 931:case 953:if(!0===F.test(e))return 115===(l=e.substring(e.indexOf(":")+1)).charCodeAt(0)?a(e.replace("stretch","fill-available"),t,n,r).replace(":fill-available",":stretch"):i.replace(l,"-webkit-"+l)+i.replace(l,"-moz-"+l.replace("fill-",""))+i;break;case 962:if(i="-webkit-"+i+(102===i.charCodeAt(5)?"-ms-"+i:"")+i,211===n+r&&105===i.charCodeAt(13)&&0<i.indexOf("transform",10))return i.substring(0,i.indexOf(";",27)+1).replace(m,"$1-webkit-$2")+i}return i}function o(e,t){var n=e.indexOf(1===t?":":"{"),r=e.substring(0,3!==t?n:10);return n=e.substring(n+1,e.length-1),N(2!==t?r:r.replace(T,"$1"),n,t)}function i(e,t){var n=a(t,t.charCodeAt(0),t.charCodeAt(1),t.charCodeAt(2));return n!==t+";"?n.replace(S," or ($1)").substring(4):"("+t+")"}function s(e,t,n,r,a,o,i,s,l,u){for(var d,f=0,p=t;f<M;++f)switch(d=R[f].call(c,e,p,n,r,a,o,i,s,l,u)){case void 0:case!1:case!0:case null:break;default:p=d}if(p!==t)return p}function l(e){return void 0!==(e=e.prefix)&&(N=null,e?"function"!==typeof e?D=1:(D=2,N=e):D=0),l}function c(e,n){var r=e;if(33>r.charCodeAt(0)&&(r=r.trim()),r=[r],0<M){var a=s(-1,n,r,r,A,x,0,0,0,0);void 0!==a&&"string"===typeof a&&(n=a)}var o=t(P,r,n,0,0);return 0<M&&(void 0!==(a=s(-2,o,r,r,A,x,o.length,0,0,0))&&(o=a)),"",E=0,x=A=1,o}var u=/^\0+/g,d=/[\0\r\f]/g,f=/: */g,p=/zoo|gra/,m=/([,: ])(transform)/g,h=/,\r+?/g,v=/([\t\r\n ])*\f?&/g,y=/@(k\w+)\s*(\S*)\s*/,b=/::(place)/g,g=/:(read-only)/g,_=/[svh]\w+-[tblr]{2}/,w=/\(\s*(.*)\s*\)/g,S=/([\s\S]*?);/g,k=/-self|flex-/g,T=/[^]*?(:[rp][el]a[\w-]+)[^]*/,F=/stretch|:\s*\w+\-(?:conte|avail)/,C=/([^-])(image-set\()/,x=1,A=1,E=0,D=1,P=[],R=[],M=0,N=null,O=0;return c.use=function e(t){switch(t){case void 0:case null:M=R.length=0;break;default:if("function"===typeof t)R[M++]=t;else if("object"===typeof t)for(var n=0,r=t.length;n<r;++n)e(t[n]);else O=0|!!t}return e},c.set=l,void 0!==e&&l(e),c},o="/*|*/";function i(e){e&&s.current.insert(e+"}")}var s={current:null},l=function(e,t,n,r,a,l,c,u,d,f){switch(e){case 1:switch(t.charCodeAt(0)){case 64:return s.current.insert(t+";"),"";case 108:if(98===t.charCodeAt(2))return""}break;case 2:if(0===u)return t+o;break;case 3:switch(u){case 102:case 112:return s.current.insert(n[0]+t),"";default:return t+(0===f?o:"")}case-2:t.split("/*|*/}").forEach(i)}},c=function(e){void 0===e&&(e={});var t,n=e.key||"css";void 0!==e.prefix&&(t={prefix:e.prefix});var o=new a(t);var i,c={};i=e.container||document.head;var u,d=document.querySelectorAll("style[data-emotion-"+n+"]");Array.prototype.forEach.call(d,(function(e){e.getAttribute("data-emotion-"+n).split(" ").forEach((function(e){c[e]=!0})),e.parentNode!==i&&i.appendChild(e)})),o.use(e.stylisPlugins)(l),u=function(e,t,n,r){var a=t.name;s.current=n,o(e,t.styles),r&&(f.inserted[a]=!0)};var f={key:n,sheet:new r({key:n,container:i,nonce:e.nonce,speedy:e.speedy}),nonce:e.nonce,inserted:c,registered:{},insert:u};return f};var u=function(e){for(var t,n=0,r=0,a=e.length;a>=4;++r,a-=4)t=1540483477*(65535&(t=255&e.charCodeAt(r)|(255&e.charCodeAt(++r))<<8|(255&e.charCodeAt(++r))<<16|(255&e.charCodeAt(++r))<<24))+(59797*(t>>>16)<<16),n=1540483477*(65535&(t^=t>>>24))+(59797*(t>>>16)<<16)^1540483477*(65535&n)+(59797*(n>>>16)<<16);switch(a){case 3:n^=(255&e.charCodeAt(r+2))<<16;case 2:n^=(255&e.charCodeAt(r+1))<<8;case 1:n=1540483477*(65535&(n^=255&e.charCodeAt(r)))+(59797*(n>>>16)<<16)}return(((n=1540483477*(65535&(n^=n>>>13))+(59797*(n>>>16)<<16))^n>>>15)>>>0).toString(36)},d={animationIterationCount:1,borderImageOutset:1,borderImageSlice:1,borderImageWidth:1,boxFlex:1,boxFlexGroup:1,boxOrdinalGroup:1,columnCount:1,columns:1,flex:1,flexGrow:1,flexPositive:1,flexShrink:1,flexNegative:1,flexOrder:1,gridRow:1,gridRowEnd:1,gridRowSpan:1,gridRowStart:1,gridColumn:1,gridColumnEnd:1,gridColumnSpan:1,gridColumnStart:1,msGridRow:1,msGridRowSpan:1,msGridColumn:1,msGridColumnSpan:1,fontWeight:1,lineHeight:1,opacity:1,order:1,orphans:1,tabSize:1,widows:1,zIndex:1,zoom:1,WebkitLineClamp:1,fillOpacity:1,floodOpacity:1,stopOpacity:1,strokeDasharray:1,strokeDashoffset:1,strokeMiterlimit:1,strokeOpacity:1,strokeWidth:1};var f=function(e){var t={};return function(n){return void 0===t[n]&&(t[n]=e(n)),t[n]}},p=/[A-Z]|^ms/g,m=/_EMO_([^_]+?)_([^]*?)_EMO_/g,h=function(e){return 45===e.charCodeAt(1)},v=function(e){return null!=e&&"boolean"!==typeof e},y=f((function(e){return h(e)?e:e.replace(p,"-$&").toLowerCase()})),b=function(e,t){switch(e){case"animation":case"animationName":if("string"===typeof t)return t.replace(m,(function(e,t,n){return _={name:t,styles:n,next:_},t}))}return 1===d[e]||h(e)||"number"!==typeof t||0===t?t:t+"px"};function g(e,t,n,r){if(null==n)return"";if(void 0!==n.__emotion_styles)return n;switch(typeof n){case"boolean":return"";case"object":if(1===n.anim)return _={name:n.name,styles:n.styles,next:_},n.name;if(void 0!==n.styles){var a=n.next;if(void 0!==a)for(;void 0!==a;)_={name:a.name,styles:a.styles,next:_},a=a.next;return n.styles+";"}return function(e,t,n){var r="";if(Array.isArray(n))for(var a=0;a<n.length;a++)r+=g(e,t,n[a],!1);else for(var o in n){var i=n[o];if("object"!==typeof i)null!=t&&void 0!==t[i]?r+=o+"{"+t[i]+"}":v(i)&&(r+=y(o)+":"+b(o,i)+";");else if(!Array.isArray(i)||"string"!==typeof i[0]||null!=t&&void 0!==t[i[0]]){var s=g(e,t,i,!1);switch(o){case"animation":case"animationName":r+=y(o)+":"+s+";";break;default:r+=o+"{"+s+"}"}}else for(var l=0;l<i.length;l++)v(i[l])&&(r+=y(o)+":"+b(o,i[l])+";")}return r}(e,t,n);case"function":if(void 0!==e){var o=_,i=n(e);return _=o,g(e,t,i,r)}}if(null==t)return n;var s=t[n];return void 0===s||r?n:s}var _,w=/label:\s*([^\s;\n{]+)\s*;/g;var S=function(e,t,n){if(1===e.length&&"object"===typeof e[0]&&null!==e[0]&&void 0!==e[0].styles)return e[0];var r=!0,a="";_=void 0;var o=e[0];null==o||void 0===o.raw?(r=!1,a+=g(n,t,o,!1)):a+=o[0];for(var i=1;i<e.length;i++)a+=g(n,t,e[i],46===a.charCodeAt(a.length-1)),r&&(a+=o[i]);w.lastIndex=0;for(var s,l="";null!==(s=w.exec(a));)l+="-"+s[1];return{name:u(a)+l,styles:a,next:_}};function k(e,t,n){var r="";return n.split(" ").forEach((function(n){void 0!==e[n]?t.push(e[n]):r+=n+" "})),r}var T=function(e,t,n){var r=e.key+"-"+t.name;if(!1===n&&void 0===e.registered[r]&&(e.registered[r]=t.styles),void 0===e.inserted[t.name]){var a=t;do{e.insert("."+r,a,e.sheet,!0);a=a.next}while(void 0!==a)}};function F(e,t){if(void 0===e.inserted[t.name])return e.insert("",t,e.sheet,!0)}function C(e,t,n){var r=[],a=k(e,r,n);return r.length<2?n:a+t(r)}var x=function e(t){for(var n="",r=0;r<t.length;r++){var a=t[r];if(null!=a){var o=void 0;switch(typeof a){case"boolean":break;case"object":if(Array.isArray(a))o=e(a);else for(var i in o="",a)a[i]&&i&&(o&&(o+=" "),o+=i);break;default:o=a}o&&(n&&(n+=" "),n+=o)}}return n},A=function(e){var t=c(e);t.sheet.speedy=function(e){this.isSpeedy=e},t.compat=!0;var n=function(){for(var e=arguments.length,n=new Array(e),r=0;r<e;r++)n[r]=arguments[r];var a=S(n,t.registered,void 0);return T(t,a,!1),t.key+"-"+a.name};return{css:n,cx:function(){for(var e=arguments.length,r=new Array(e),a=0;a<e;a++)r[a]=arguments[a];return C(t.registered,n,x(r))},injectGlobal:function(){for(var e=arguments.length,n=new Array(e),r=0;r<e;r++)n[r]=arguments[r];var a=S(n,t.registered);F(t,a)},keyframes:function(){for(var e=arguments.length,n=new Array(e),r=0;r<e;r++)n[r]=arguments[r];var a=S(n,t.registered),o="animation-"+a.name;return F(t,{name:a.name,styles:"@keyframes "+o+"{"+a.styles+"}"}),o},hydrate:function(e){e.forEach((function(e){t.inserted[e]=!0}))},flush:function(){t.registered={},t.inserted={},t.sheet.flush()},sheet:t.sheet,cache:t,getRegisteredStyles:k.bind(null,t.registered),merge:C.bind(null,t.registered,n)}},E=A(),D=E.flush,P=E.hydrate,R=E.cx,M=E.merge,N=E.getRegisteredStyles,O=E.injectGlobal,z=E.keyframes,I=E.css,L=E.sheet,Z=E.cache},2110:function(e,t,n){"use strict";var r=n(8309),a={childContextTypes:!0,contextType:!0,contextTypes:!0,defaultProps:!0,displayName:!0,getDefaultProps:!0,getDerivedStateFromError:!0,getDerivedStateFromProps:!0,mixins:!0,propTypes:!0,type:!0},o={name:!0,length:!0,prototype:!0,caller:!0,callee:!0,arguments:!0,arity:!0},i={$$typeof:!0,compare:!0,defaultProps:!0,displayName:!0,propTypes:!0,type:!0},s={};function l(e){return r.isMemo(e)?i:s[e.$$typeof]||a}s[r.ForwardRef]={$$typeof:!0,render:!0,defaultProps:!0,displayName:!0,propTypes:!0},s[r.Memo]=i;var c=Object.defineProperty,u=Object.getOwnPropertyNames,d=Object.getOwnPropertySymbols,f=Object.getOwnPropertyDescriptor,p=Object.getPrototypeOf,m=Object.prototype;e.exports=function e(t,n,r){if("string"!==typeof n){if(m){var a=p(n);a&&a!==m&&e(t,a,r)}var i=u(n);d&&(i=i.concat(d(n)));for(var s=l(t),h=l(n),v=0;v<i.length;++v){var y=i[v];if(!o[y]&&(!r||!r[y])&&(!h||!h[y])&&(!s||!s[y])){var b=f(n,y);try{c(t,y,b)}catch(g){}}}}return t}},746:function(e,t){"use strict";var n="function"===typeof Symbol&&Symbol.for,r=n?Symbol.for("react.element"):60103,a=n?Symbol.for("react.portal"):60106,o=n?Symbol.for("react.fragment"):60107,i=n?Symbol.for("react.strict_mode"):60108,s=n?Symbol.for("react.profiler"):60114,l=n?Symbol.for("react.provider"):60109,c=n?Symbol.for("react.context"):60110,u=n?Symbol.for("react.async_mode"):60111,d=n?Symbol.for("react.concurrent_mode"):60111,f=n?Symbol.for("react.forward_ref"):60112,p=n?Symbol.for("react.suspense"):60113,m=n?Symbol.for("react.suspense_list"):60120,h=n?Symbol.for("react.memo"):60115,v=n?Symbol.for("react.lazy"):60116,y=n?Symbol.for("react.block"):60121,b=n?Symbol.for("react.fundamental"):60117,g=n?Symbol.for("react.responder"):60118,_=n?Symbol.for("react.scope"):60119;function w(e){if("object"===typeof e&&null!==e){var t=e.$$typeof;switch(t){case r:switch(e=e.type){case u:case d:case o:case s:case i:case p:return e;default:switch(e=e&&e.$$typeof){case c:case f:case v:case h:case l:return e;default:return t}}case a:return t}}}function S(e){return w(e)===d}t.AsyncMode=u,t.ConcurrentMode=d,t.ContextConsumer=c,t.ContextProvider=l,t.Element=r,t.ForwardRef=f,t.Fragment=o,t.Lazy=v,t.Memo=h,t.Portal=a,t.Profiler=s,t.StrictMode=i,t.Suspense=p,t.isAsyncMode=function(e){return S(e)||w(e)===u},t.isConcurrentMode=S,t.isContextConsumer=function(e){return w(e)===c},t.isContextProvider=function(e){return w(e)===l},t.isElement=function(e){return"object"===typeof e&&null!==e&&e.$$typeof===r},t.isForwardRef=function(e){return w(e)===f},t.isFragment=function(e){return w(e)===o},t.isLazy=function(e){return w(e)===v},t.isMemo=function(e){return w(e)===h},t.isPortal=function(e){return w(e)===a},t.isProfiler=function(e){return w(e)===s},t.isStrictMode=function(e){return w(e)===i},t.isSuspense=function(e){return w(e)===p},t.isValidElementType=function(e){return"string"===typeof e||"function"===typeof e||e===o||e===d||e===s||e===i||e===p||e===m||"object"===typeof e&&null!==e&&(e.$$typeof===v||e.$$typeof===h||e.$$typeof===l||e.$$typeof===c||e.$$typeof===f||e.$$typeof===b||e.$$typeof===g||e.$$typeof===_||e.$$typeof===y)},t.typeOf=w},8309:function(e,t,n){"use strict";e.exports=n(746)},5781:function(e,t,n){"use strict";n.r(t);var r=Number.isNaN||function(e){return"number"===typeof e&&e!==e};function a(e,t){if(e.length!==t.length)return!1;for(var n=0;n<e.length;n++)if(a=e[n],o=t[n],!(a===o||r(a)&&r(o)))return!1;var a,o;return!0}t.default=function(e,t){var n;void 0===t&&(t=a);var r,o=[],i=!1;return function(){for(var a=[],s=0;s<arguments.length;s++)a[s]=arguments[s];return i&&n===this&&t(a,o)||(r=e.apply(this,a),i=!0,n=this,o=a),r}}},888:function(e,t,n){"use strict";var r=n(9047);function a(){}function o(){}o.resetWarningCache=a,e.exports=function(){function e(e,t,n,a,o,i){if(i!==r){var s=new Error("Calling PropTypes validators directly is not supported by the `prop-types` package. Use PropTypes.checkPropTypes() to call them. Read more at http://fb.me/use-check-prop-types");throw s.name="Invariant Violation",s}}function t(){return e}e.isRequired=e;var n={array:e,bigint:e,bool:e,func:e,number:e,object:e,string:e,symbol:e,any:e,arrayOf:t,element:e,elementType:e,instanceOf:t,node:e,objectOf:t,oneOf:t,oneOfType:t,shape:t,exact:t,checkPropTypes:o,resetWarningCache:a};return n.PropTypes=n,n}},2007:function(e,t,n){e.exports=n(888)()},9047:function(e){"use strict";e.exports="SECRET_DO_NOT_PASS_THIS_OR_YOU_WILL_BE_FIRED"},8472:function(e,t,n){n(3561)},8015:function(e,t,n){"use strict";Object.defineProperty(t,"__esModule",{value:!0});var r,a=function(){function e(e,t){for(var n=0;n<t.length;n++){var r=t[n];r.enumerable=r.enumerable||!1,r.configurable=!0,"value"in r&&(r.writable=!0),Object.defineProperty(e,r.key,r)}}return function(t,n,r){return n&&e(t.prototype,n),r&&e(t,r),t}}(),o=n(2791),i=(r=o)&&r.__esModule?r:{default:r},s=n(1509),l=n(8333);var c=function(e){function t(e){!function(e,t){if(!(e instanceof t))throw new TypeError("Cannot call a class as a function")}(this,t);var n=function(e,t){if(!e)throw new ReferenceError("this hasn't been initialised - super() hasn't been called");return!t||"object"!==typeof t&&"function"!==typeof t?e:t}(this,(t.__proto__||Object.getPrototypeOf(t)).call(this,e));return n.state={},n}return function(e,t){if("function"!==typeof t&&null!==t)throw new TypeError("Super expression must either be null or a function, not "+typeof t);e.prototype=Object.create(t&&t.prototype,{constructor:{value:e,enumerable:!1,writable:!0,configurable:!0}}),t&&(Object.setPrototypeOf?Object.setPrototypeOf(e,t):e.__proto__=t)}(t,e),a(t,[{key:"buildURI",value:function(){return s.buildURI.apply(void 0,arguments)}},{key:"componentDidMount",value:function(){var e=this.props,t=e.data,n=e.headers,r=e.separator,a=e.enclosingCharacter,o=e.uFEFF,i=e.target,s=e.specs,l=e.replace;this.state.page=window.open(this.buildURI(t,o,n,r,a),i,s,l)}},{key:"getWindow",value:function(){return this.state.page}},{key:"render",value:function(){return null}}]),t}(i.default.Component);c.defaultProps=Object.assign(l.defaultProps,{target:"_blank"}),c.propTypes=l.propTypes,t.default=c},9088:function(e,t,n){"use strict";Object.defineProperty(t,"__esModule",{value:!0});var r,a=Object.assign||function(e){for(var t=1;t<arguments.length;t++){var n=arguments[t];for(var r in n)Object.prototype.hasOwnProperty.call(n,r)&&(e[r]=n[r])}return e},o=function(){function e(e,t){for(var n=0;n<t.length;n++){var r=t[n];r.enumerable=r.enumerable||!1,r.configurable=!0,"value"in r&&(r.writable=!0),Object.defineProperty(e,r.key,r)}}return function(t,n,r){return n&&e(t.prototype,n),r&&e(t,r),t}}(),i=n(2791),s=(r=i)&&r.__esModule?r:{default:r},l=n(1509),c=n(8333);var u=function(e){function t(e){!function(e,t){if(!(e instanceof t))throw new TypeError("Cannot call a class as a function")}(this,t);var n=function(e,t){if(!e)throw new ReferenceError("this hasn't been initialised - super() hasn't been called");return!t||"object"!==typeof t&&"function"!==typeof t?e:t}(this,(t.__proto__||Object.getPrototypeOf(t)).call(this,e));return n.buildURI=n.buildURI.bind(n),n}return function(e,t){if("function"!==typeof t&&null!==t)throw new TypeError("Super expression must either be null or a function, not "+typeof t);e.prototype=Object.create(t&&t.prototype,{constructor:{value:e,enumerable:!1,writable:!0,configurable:!0}}),t&&(Object.setPrototypeOf?Object.setPrototypeOf(e,t):e.__proto__=t)}(t,e),o(t,[{key:"buildURI",value:function(){return l.buildURI.apply(void 0,arguments)}},{key:"handleLegacy",value:function(e){var t=arguments.length>1&&void 0!==arguments[1]&&arguments[1];if(window.navigator.msSaveOrOpenBlob){e.preventDefault();var n=this.props,r=n.data,a=n.headers,o=n.separator,i=n.filename,s=n.enclosingCharacter,c=n.uFEFF,u=t&&"function"===typeof r?r():r,d=new Blob([c?"\ufeff":"",(0,l.toCSV)(u,a,o,s)]);return window.navigator.msSaveBlob(d,i),!1}}},{key:"handleAsyncClick",value:function(e){var t=this;this.props.onClick(e,(function(n){!1!==n?t.handleLegacy(e,!0):e.preventDefault()}))}},{key:"handleSyncClick",value:function(e){!1===this.props.onClick(e)?e.preventDefault():this.handleLegacy(e)}},{key:"handleClick",value:function(){var e=this;return function(t){if("function"===typeof e.props.onClick)return e.props.asyncOnClick?e.handleAsyncClick(t):e.handleSyncClick(t);e.handleLegacy(t)}}},{key:"render",value:function(){var e=this,t=this.props,n=t.data,r=t.headers,o=t.separator,i=t.filename,l=t.uFEFF,c=t.children,u=(t.onClick,t.asyncOnClick,t.enclosingCharacter),d=function(e,t){var n={};for(var r in e)t.indexOf(r)>=0||Object.prototype.hasOwnProperty.call(e,r)&&(n[r]=e[r]);return n}(t,["data","headers","separator","filename","uFEFF","children","onClick","asyncOnClick","enclosingCharacter"]),f="undefined"===typeof window?"":this.buildURI(n,l,r,o,u);return s.default.createElement("a",a({download:i},d,{ref:function(t){return e.link=t},target:"_self",href:f,onClick:this.handleClick()}),c)}}]),t}(s.default.Component);u.defaultProps=c.defaultProps,u.propTypes=c.propTypes,t.default=u},1509:function(e,t){"use strict";Object.defineProperty(t,"__esModule",{value:!0});var n="function"===typeof Symbol&&"symbol"===typeof Symbol.iterator?function(e){return typeof e}:function(e){return e&&"function"===typeof Symbol&&e.constructor===Symbol&&e!==Symbol.prototype?"symbol":typeof e};function r(e){if(Array.isArray(e)){for(var t=0,n=Array(e.length);t<e.length;t++)n[t]=e[t];return n}return Array.from(e)}var a=t.isSafari=function(){return/^((?!chrome|android).)*safari/i.test(navigator.userAgent)},o=t.isJsons=function(e){return Array.isArray(e)&&e.every((function(e){return"object"===("undefined"===typeof e?"undefined":n(e))&&!(e instanceof Array)}))},i=t.isArrays=function(e){return Array.isArray(e)&&e.every((function(e){return Array.isArray(e)}))},s=t.jsonsHeaders=function(e){return Array.from(e.map((function(e){return Object.keys(e)})).reduce((function(e,t){return new Set([].concat(r(e),r(t)))}),[]))},l=t.jsons2arrays=function(e,t){var n=t=t||s(e),a=t;o(t)&&(n=t.map((function(e){return e.label})),a=t.map((function(e){return e.key})));var i=e.map((function(e){return a.map((function(t){return c(t,e)}))}));return[n].concat(r(i))},c=t.getHeaderValue=function(e,t){var n=e.replace(/\[([^\]]+)]/g,".$1").split(".").reduce((function(e,t,n,r){var a=e[t];if(void 0!==a&&null!==a)return a;r.splice(1)}),t);return void 0===n?e in t?t[e]:"":n},u=t.elementOrEmpty=function(e){return"undefined"===typeof e||null===e?"":e},d=t.joiner=function(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:",",n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:'"';return e.filter((function(e){return e})).map((function(e){return e.map((function(e){return u(e)})).map((function(e){return""+n+e+n})).join(t)})).join("\n")},f=t.arrays2csv=function(e,t,n,a){return d(t?[t].concat(r(e)):e,n,a)},p=t.jsons2csv=function(e,t,n,r){return d(l(e,t),n,r)},m=t.string2csv=function(e,t,n,r){return t?t.join(n)+"\n"+e:e.replace(/"/g,'""')},h=t.toCSV=function(e,t,n,r){if(o(e))return p(e,t,n,r);if(i(e))return f(e,t,n,r);if("string"===typeof e)return m(e,t,n);throw new TypeError('Data should be a "String", "Array of arrays" OR "Array of objects" ')};t.buildURI=function(e,t,n,r,o){var i=h(e,n,r,o),s=a()?"application/csv":"text/csv",l=new Blob([t?"\ufeff":"",i],{type:s}),c="data:"+s+";charset=utf-8,"+(t?"\ufeff":"")+i,u=window.URL||window.webkitURL;return"undefined"===typeof u.createObjectURL?c:u.createObjectURL(l)}},3561:function(e,t,n){"use strict";var r=o(n(8015)),a=o(n(9088));function o(e){return e&&e.__esModule?e:{default:e}}r.default,a.default},8333:function(e,t,n){"use strict";Object.defineProperty(t,"__esModule",{value:!0}),t.PropsNotForwarded=t.defaultProps=t.propTypes=void 0;var r,a=n(2791),o=((r=a)&&r.__esModule,n(2007));t.propTypes={data:(0,o.oneOfType)([o.string,o.array,o.func]).isRequired,headers:o.array,target:o.string,separator:o.string,filename:o.string,uFEFF:o.bool,onClick:o.func,asyncOnClick:o.bool,enclosingCharacter:o.string},t.defaultProps={separator:",",filename:"generatedBy_react-csv.csv",uFEFF:!0,asyncOnClick:!1,enclosingCharacter:'"'},t.PropsNotForwarded=["data","headers"]},7786:function(e,t,n){"use strict";var r=this&&this.__read||function(e,t){var n="function"===typeof Symbol&&e[Symbol.iterator];if(!n)return e;var r,a,o=n.call(e),i=[];try{for(;(void 0===t||t-- >0)&&!(r=o.next()).done;)i.push(r.value)}catch(s){a={error:s}}finally{try{r&&!r.done&&(n=o.return)&&n.call(o)}finally{if(a)throw a.error}}return i},a=this&&this.__spread||function(){for(var e=[],t=0;t<arguments.length;t++)e=e.concat(r(arguments[t]));return e};Object.defineProperty(t,"__esModule",{value:!0});var o,i,s=n(4173),l=s;!function(e){e[e.DEFAULT=0]="DEFAULT",e[e.ADDED=1]="ADDED",e[e.REMOVED=2]="REMOVED"}(o=t.DiffType||(t.DiffType={})),function(e){e.CHARS="diffChars",e.WORDS="diffWords",e.WORDS_WITH_SPACE="diffWordsWithSpace",e.LINES="diffLines",e.TRIMMED_LINES="diffTrimmedLines",e.SENTENCES="diffSentences",e.CSS="diffCss"}(i=t.DiffMethod||(t.DiffMethod={}));var c=function(e){var t=e.split("\n");if(t.every((function(e){return!e})))return 2===t.length?[]:(t.pop(),t);var n=t[t.length-1],r=t[0];return n||t.pop(),r||t.shift(),t};t.computeLineInformation=function(e,t,n,r,u){void 0===n&&(n=!1),void 0===r&&(r=i.CHARS),void 0===u&&(u=0);var d=s.diffLines(e.trimRight(),t.trimRight(),{newlineIsToken:!0,ignoreWhitespace:!1,ignoreCase:!1}),f=u,p=u,m=[],h=0,v=[],y=[],b=function e(t,a,s,u,m){return c(t).map((function(t,b){var g={},_={};if(!(y.includes(a+"-"+b)||m&&0!==b)){if(s||u)if(v.includes(h)||v.push(h),u){p+=1,g.lineNumber=p,g.type=o.REMOVED,g.value=t||" ";var w=d[a+1];if(w&&w.added)if(c(w.value)[b]){var S=e(w.value,a,!0,!1,!0)[0].right,k=S.value,T=S.lineNumber,F=S.type;if(y.push(a+1+"-"+b),_.lineNumber=T,_.type=F,n)_.value=k;else{var C=function(e,t,n){void 0===n&&(n=i.CHARS);var r=l[n](e,t),a={left:[],right:[]};return r.forEach((function(e){var t=e.added,n=e.removed,r=e.value,i={};return t&&(i.type=o.ADDED,i.value=r,a.right.push(i)),n&&(i.type=o.REMOVED,i.value=r,a.left.push(i)),n||t||(i.type=o.DEFAULT,i.value=r,a.right.push(i),a.left.push(i)),i})),a}(t,k,r);_.value=C.right,g.value=C.left}}}else f+=1,_.lineNumber=f,_.type=o.ADDED,_.value=t;else p+=1,f+=1,g.lineNumber=p,g.type=o.DEFAULT,g.value=t,_.lineNumber=f,_.type=o.DEFAULT,_.value=t;return h+=1,{right:_,left:g}}})).filter(Boolean)};return d.forEach((function(e,t){var n=e.added,r=e.removed,o=e.value;m=a(m,b(o,t,n,r))})),{lineInformation:m,diffLines:v}}},1774:function(e,t,n){"use strict";var r=this&&this.__extends||function(){var e=function(t,n){return e=Object.setPrototypeOf||{__proto__:[]}instanceof Array&&function(e,t){e.__proto__=t}||function(e,t){for(var n in t)t.hasOwnProperty(n)&&(e[n]=t[n])},e(t,n)};return function(t,n){function r(){this.constructor=t}e(t,n),t.prototype=null===n?Object.create(n):(r.prototype=n.prototype,new r)}}();Object.defineProperty(t,"__esModule",{value:!0});var a=n(2791),o=n(2007),i=n(1694),s=n(7786);t.DiffMethod=s.DiffMethod;var l,c=n(2813),u=n(5781),d=u.default||u;!function(e){e.LEFT="L",e.RIGHT="R"}(l=t.LineNumberPrefix||(t.LineNumberPrefix={}));var f=function(e){function t(t){var n=e.call(this,t)||this;return n.resetCodeBlocks=function(){return n.state.expandedBlocks.length>0&&(n.setState({expandedBlocks:[]}),!0)},n.onBlockExpand=function(e){var t=n.state.expandedBlocks.slice();t.push(e),n.setState({expandedBlocks:t})},n.computeStyles=d(c.default),n.onLineNumberClickProxy=function(e){return n.props.onLineNumberClick?function(t){return n.props.onLineNumberClick(e,t)}:function(){}},n.renderWordDiff=function(e,t){return e.map((function(e,r){var o;return a.createElement("span",{key:r,className:i.default(n.styles.wordDiff,(o={},o[n.styles.wordAdded]=e.type===s.DiffType.ADDED,o[n.styles.wordRemoved]=e.type===s.DiffType.REMOVED,o))},t?t(e.value):e.value)}))},n.renderLine=function(e,t,r,o,l,c){var u,d,f,p,m,h=r+"-"+e,v=c+"-"+l,y=n.props.highlightLines.includes(h)||n.props.highlightLines.includes(v),b=t===s.DiffType.ADDED,g=t===s.DiffType.REMOVED;return m=Array.isArray(o)?n.renderWordDiff(o,n.props.renderContent):n.props.renderContent?n.props.renderContent(o):o,a.createElement(a.Fragment,null,!n.props.hideLineNumbers&&a.createElement("td",{onClick:e&&n.onLineNumberClickProxy(h),className:i.default(n.styles.gutter,(u={},u[n.styles.emptyGutter]=!e,u[n.styles.diffAdded]=b,u[n.styles.diffRemoved]=g,u[n.styles.highlightedGutter]=y,u))},a.createElement("pre",{className:n.styles.lineNumber},e)),!n.props.splitView&&!n.props.hideLineNumbers&&a.createElement("td",{onClick:l&&n.onLineNumberClickProxy(v),className:i.default(n.styles.gutter,(d={},d[n.styles.emptyGutter]=!l,d[n.styles.diffAdded]=b,d[n.styles.diffRemoved]=g,d[n.styles.highlightedGutter]=y,d))},a.createElement("pre",{className:n.styles.lineNumber},l)),a.createElement("td",{className:i.default(n.styles.marker,(f={},f[n.styles.emptyLine]=!m,f[n.styles.diffAdded]=b,f[n.styles.diffRemoved]=g,f[n.styles.highlightedLine]=y,f))},a.createElement("pre",null,b&&"+",g&&"-")),a.createElement("td",{className:i.default(n.styles.content,(p={},p[n.styles.emptyLine]=!m,p[n.styles.diffAdded]=b,p[n.styles.diffRemoved]=g,p[n.styles.highlightedLine]=y,p))},a.createElement("pre",{className:n.styles.contentText},m)))},n.renderSplitView=function(e,t){var r=e.left,o=e.right;return a.createElement("tr",{key:t,className:n.styles.line},n.renderLine(r.lineNumber,r.type,l.LEFT,r.value),n.renderLine(o.lineNumber,o.type,l.RIGHT,o.value))},n.renderInlineView=function(e,t){var r,o=e.left,i=e.right;return o.type===s.DiffType.REMOVED&&i.type===s.DiffType.ADDED?a.createElement(a.Fragment,{key:t},a.createElement("tr",{className:n.styles.line},n.renderLine(o.lineNumber,o.type,l.LEFT,o.value,null)),a.createElement("tr",{className:n.styles.line},n.renderLine(null,i.type,l.RIGHT,i.value,i.lineNumber))):(o.type===s.DiffType.REMOVED&&(r=n.renderLine(o.lineNumber,o.type,l.LEFT,o.value,null)),o.type===s.DiffType.DEFAULT&&(r=n.renderLine(o.lineNumber,o.type,l.LEFT,o.value,i.lineNumber,l.RIGHT)),i.type===s.DiffType.ADDED&&(r=n.renderLine(null,i.type,l.RIGHT,i.value,i.lineNumber)),a.createElement("tr",{key:t,className:n.styles.line},r))},n.onBlockClickProxy=function(e){return function(){return n.onBlockExpand(e)}},n.renderSkippedLineIndicator=function(e,t,r,o){var s,l=n.props,c=l.hideLineNumbers,u=l.splitView,d=n.props.codeFoldMessageRenderer?n.props.codeFoldMessageRenderer(e,r,o):a.createElement("pre",{className:n.styles.codeFoldContent},"Expand ",e," lines ..."),f=a.createElement("td",null,a.createElement("a",{onClick:n.onBlockClickProxy(t),tabIndex:0},d)),p=!u&&!c;return a.createElement("tr",{key:r+"-"+o,className:n.styles.codeFold},!c&&a.createElement("td",{className:n.styles.codeFoldGutter}),a.createElement("td",{className:i.default((s={},s[n.styles.codeFoldGutter]=p,s))}),p?a.createElement(a.Fragment,null,a.createElement("td",null),f):a.createElement(a.Fragment,null,f,a.createElement("td",null)),a.createElement("td",null),a.createElement("td",null))},n.renderDiff=function(){var e=n.props,t=e.oldValue,r=e.newValue,o=e.splitView,i=e.disableWordDiff,l=e.compareMethod,c=e.linesOffset,u=s.computeLineInformation(t,r,i,l,c),d=u.lineInformation,f=u.diffLines,p=n.props.extraLinesSurroundingDiff<0?0:n.props.extraLinesSurroundingDiff,m=[];return d.map((function(e,t){var r=f[0],i=r-t;if(n.props.showDiffOnly&&(i===-p&&(m=[],f.shift()),e.left.type===s.DiffType.DEFAULT&&(i>p||"undefined"===typeof r)&&!n.state.expandedBlocks.includes(r)))return m.push(t+1),t===d.length-1&&m.length>1?n.renderSkippedLineIndicator(m.length,r,e.left.lineNumber,e.right.lineNumber):null;var l=o?n.renderSplitView(e,t):n.renderInlineView(e,t);if(i===p&&m.length>0){var c=m.length;return m=[],a.createElement(a.Fragment,{key:t},n.renderSkippedLineIndicator(c,r,e.left.lineNumber,e.right.lineNumber),l)}return l}))},n.render=function(){var e,t=n.props,r=t.oldValue,o=t.newValue,s=t.useDarkTheme,l=t.leftTitle,c=t.rightTitle,u=t.splitView,d=t.hideLineNumbers;if("string"!==typeof r||"string"!==typeof o)throw Error('"oldValue" and "newValue" should be strings');n.styles=n.computeStyles(n.props.styles,s);var f=n.renderDiff(),p=d?2:3,m=d?2:4,h=(l||c)&&a.createElement("tr",null,a.createElement("td",{colSpan:u?p:m,className:n.styles.titleBlock},a.createElement("pre",{className:n.styles.contentText},l)),u&&a.createElement("td",{colSpan:p,className:n.styles.titleBlock},a.createElement("pre",{className:n.styles.contentText},c)));return a.createElement("table",{className:i.default(n.styles.diffContainer,(e={},e[n.styles.splitView]=u,e))},a.createElement("tbody",null,h,f))},n.state={expandedBlocks:[]},n}return r(t,e),t.defaultProps={oldValue:"",newValue:"",splitView:!0,highlightLines:[],disableWordDiff:!1,compareMethod:s.DiffMethod.CHARS,styles:{},hideLineNumbers:!1,extraLinesSurroundingDiff:3,showDiffOnly:!0,useDarkTheme:!1,linesOffset:0},t.propTypes={oldValue:o.string.isRequired,newValue:o.string.isRequired,splitView:o.bool,disableWordDiff:o.bool,compareMethod:o.oneOf(Object.values(s.DiffMethod)),renderContent:o.func,onLineNumberClick:o.func,extraLinesSurroundingDiff:o.number,styles:o.object,hideLineNumbers:o.bool,showDiffOnly:o.bool,highlightLines:o.arrayOf(o.string),leftTitle:o.oneOfType([o.string,o.element]),rightTitle:o.oneOfType([o.string,o.element]),linesOffset:o.number},t}(a.Component);t.default=f},2813:function(e,t,n){"use strict";var r=this&&this.__assign||function(){return r=Object.assign||function(e){for(var t,n=1,r=arguments.length;n<r;n++)for(var a in t=arguments[n])Object.prototype.hasOwnProperty.call(t,a)&&(e[a]=t[a]);return e},r.apply(this,arguments)},a=this&&this.__rest||function(e,t){var n={};for(var r in e)Object.prototype.hasOwnProperty.call(e,r)&&t.indexOf(r)<0&&(n[r]=e[r]);if(null!=e&&"function"===typeof Object.getOwnPropertySymbols){var a=0;for(r=Object.getOwnPropertySymbols(e);a<r.length;a++)t.indexOf(r[a])<0&&Object.prototype.propertyIsEnumerable.call(e,r[a])&&(n[r[a]]=e[r[a]])}return n};Object.defineProperty(t,"__esModule",{value:!0});var o=n(6025);t.default=function(e,t){var n,i,s,l,c,u,d;void 0===t&&(t=!1);var f=e.variables,p=void 0===f?{}:f,m=a(e,["variables"]),h={light:r({diffViewerBackground:"#fff",diffViewerColor:"212529",addedBackground:"#e6ffed",addedColor:"#24292e",removedBackground:"#ffeef0",removedColor:"#24292e",wordAddedBackground:"#acf2bd",wordRemovedBackground:"#fdb8c0",addedGutterBackground:"#cdffd8",removedGutterBackground:"#ffdce0",gutterBackground:"#f7f7f7",gutterBackgroundDark:"#f3f1f1",highlightBackground:"#fffbdd",highlightGutterBackground:"#fff5b1",codeFoldGutterBackground:"#dbedff",codeFoldBackground:"#f1f8ff",emptyLineBackground:"#fafbfc",gutterColor:"#212529",addedGutterColor:"#212529",removedGutterColor:"#212529",codeFoldContentColor:"#212529",diffViewerTitleBackground:"#fafbfc",diffViewerTitleColor:"#212529",diffViewerTitleBorderColor:"#eee"},p.light||{}),dark:r({diffViewerBackground:"#2e303c",diffViewerColor:"#FFF",addedBackground:"#044B53",addedColor:"white",removedBackground:"#632F34",removedColor:"white",wordAddedBackground:"#055d67",wordRemovedBackground:"#7d383f",addedGutterBackground:"#034148",removedGutterBackground:"#632b30",gutterBackground:"#2c2f3a",gutterBackgroundDark:"#262933",highlightBackground:"#2a3967",highlightGutterBackground:"#2d4077",codeFoldGutterBackground:"#21232b",codeFoldBackground:"#262831",emptyLineBackground:"#363946",gutterColor:"#464c67",addedGutterColor:"#8c8c8c",removedGutterColor:"#8c8c8c",codeFoldContentColor:"#555a7b",diffViewerTitleBackground:"#2f323e",diffViewerTitleColor:"#555a7b",diffViewerTitleBorderColor:"#353846"},p.dark||{})},v=t?h.dark:h.light,y=o.css({width:"100%",label:"content"}),b=o.css(((n={})["."+y]={width:"50%"},n.label="split-view",n)),g=o.css({width:"100%",background:v.diffViewerBackground,pre:{margin:0,whiteSpace:"pre-wrap",lineHeight:"25px"},label:"diff-container",borderCollapse:"collapse"}),_=o.css({color:v.codeFoldContentColor,label:"code-fold-content"}),w=o.css({color:v.diffViewerColor,label:"content-text"}),S=o.css(((i={background:v.diffViewerTitleBackground,padding:10,borderBottom:"1px solid "+v.diffViewerTitleBorderColor,label:"title-block",":last-child":{borderLeft:"1px solid "+v.diffViewerTitleBorderColor}})["."+w]={color:v.diffViewerTitleColor},i)),k=o.css({color:v.gutterColor,label:"line-number"}),T=o.css(((s={background:v.removedBackground,color:v.removedColor,pre:{color:v.removedColor}})["."+k]={color:v.removedGutterColor},s.label="diff-removed",s)),F=o.css(((l={background:v.addedBackground,color:v.addedColor,pre:{color:v.addedColor}})["."+k]={color:v.addedGutterColor},l.label="diff-added",l)),C=o.css({padding:2,display:"inline-flex",borderRadius:1,label:"word-diff"}),x=o.css({background:v.wordAddedBackground,label:"word-added"}),A=o.css({background:v.wordRemovedBackground,label:"word-removed"}),E=o.css({backgroundColor:v.codeFoldGutterBackground,label:"code-fold-gutter"}),D=o.css({backgroundColor:v.codeFoldBackground,height:40,fontSize:14,fontWeight:700,label:"code-fold",a:{textDecoration:"underline !important",cursor:"pointer",pre:{display:"inline"}}}),P=o.css({backgroundColor:v.emptyLineBackground,label:"empty-line"}),R=o.css(((c={width:25,paddingLeft:10,paddingRight:10,userSelect:"none",label:"marker"})["&."+F]={pre:{color:v.addedColor}},c["&."+T]={pre:{color:v.removedColor}},c)),M=o.css(((u={background:v.highlightBackground,label:"highlighted-line"})["."+x+", ."+A]={backgroundColor:"initial"},u)),N=o.css({label:"highlighted-gutter"}),O=o.css(((d={userSelect:"none",minWidth:50,padding:"0 10px",label:"gutter",textAlign:"right",background:v.gutterBackground,"&:hover":{cursor:"pointer",background:v.gutterBackgroundDark,pre:{opacity:1}},pre:{opacity:.5}})["&."+F]={background:v.addedGutterBackground},d["&."+T]={background:v.removedGutterBackground},d["&."+N]={background:v.highlightGutterBackground,"&:hover":{background:v.highlightGutterBackground}},d)),z=o.css({"&:hover":{background:v.gutterBackground,cursor:"initial"},label:"empty-gutter"}),I={diffContainer:g,diffRemoved:T,diffAdded:F,splitView:b,marker:R,highlightedGutter:N,highlightedLine:M,gutter:O,line:o.css({verticalAlign:"baseline",label:"line"}),wordDiff:C,wordAdded:x,wordRemoved:A,codeFoldGutter:E,codeFold:D,emptyGutter:z,emptyLine:P,lineNumber:k,contentText:w,content:y,codeFoldContent:_,titleBlock:S},L=Object.keys(m).reduce((function(e,t){var n;return r({},e,((n={})[t]=o.css(m[t]),n))}),{});return Object.keys(I).reduce((function(e,t){var n;return r({},e,((n={})[t]=L[t]?o.cx(I[t],L[t]):I[t],n))}),{})}},4463:function(e,t,n){"use strict";var r=n(2791),a=n(5296);function o(e){for(var t="https://reactjs.org/docs/error-decoder.html?invariant="+e,n=1;n<arguments.length;n++)t+="&args[]="+encodeURIComponent(arguments[n]);return"Minified React error #"+e+"; visit "+t+" for the full message or use the non-minified dev environment for full errors and additional helpful warnings."}var i=new Set,s={};function l(e,t){c(e,t),c(e+"Capture",t)}function c(e,t){for(s[e]=t,e=0;e<t.length;e++)i.add(t[e])}var u=!("undefined"===typeof window||"undefined"===typeof window.document||"undefined"===typeof window.document.createElement),d=Object.prototype.hasOwnProperty,f=/^[:A-Z_a-z\u00C0-\u00D6\u00D8-\u00F6\u00F8-\u02FF\u0370-\u037D\u037F-\u1FFF\u200C-\u200D\u2070-\u218F\u2C00-\u2FEF\u3001-\uD7FF\uF900-\uFDCF\uFDF0-\uFFFD][:A-Z_a-z\u00C0-\u00D6\u00D8-\u00F6\u00F8-\u02FF\u0370-\u037D\u037F-\u1FFF\u200C-\u200D\u2070-\u218F\u2C00-\u2FEF\u3001-\uD7FF\uF900-\uFDCF\uFDF0-\uFFFD\-.0-9\u00B7\u0300-\u036F\u203F-\u2040]*$/,p={},m={};function h(e,t,n,r,a,o,i){this.acceptsBooleans=2===t||3===t||4===t,this.attributeName=r,this.attributeNamespace=a,this.mustUseProperty=n,this.propertyName=e,this.type=t,this.sanitizeURL=o,this.removeEmptyString=i}var v={};"children dangerouslySetInnerHTML defaultValue defaultChecked innerHTML suppressContentEditableWarning suppressHydrationWarning style".split(" ").forEach((function(e){v[e]=new h(e,0,!1,e,null,!1,!1)})),[["acceptCharset","accept-charset"],["className","class"],["htmlFor","for"],["httpEquiv","http-equiv"]].forEach((function(e){var t=e[0];v[t]=new h(t,1,!1,e[1],null,!1,!1)})),["contentEditable","draggable","spellCheck","value"].forEach((function(e){v[e]=new h(e,2,!1,e.toLowerCase(),null,!1,!1)})),["autoReverse","externalResourcesRequired","focusable","preserveAlpha"].forEach((function(e){v[e]=new h(e,2,!1,e,null,!1,!1)})),"allowFullScreen async autoFocus autoPlay controls default defer disabled disablePictureInPicture disableRemotePlayback formNoValidate hidden loop noModule noValidate open playsInline readOnly required reversed scoped seamless itemScope".split(" ").forEach((function(e){v[e]=new h(e,3,!1,e.toLowerCase(),null,!1,!1)})),["checked","multiple","muted","selected"].forEach((function(e){v[e]=new h(e,3,!0,e,null,!1,!1)})),["capture","download"].forEach((function(e){v[e]=new h(e,4,!1,e,null,!1,!1)})),["cols","rows","size","span"].forEach((function(e){v[e]=new h(e,6,!1,e,null,!1,!1)})),["rowSpan","start"].forEach((function(e){v[e]=new h(e,5,!1,e.toLowerCase(),null,!1,!1)}));var y=/[\-:]([a-z])/g;function b(e){return e[1].toUpperCase()}function g(e,t,n,r){var a=v.hasOwnProperty(t)?v[t]:null;(null!==a?0!==a.type:r||!(2<t.length)||"o"!==t[0]&&"O"!==t[0]||"n"!==t[1]&&"N"!==t[1])&&(function(e,t,n,r){if(null===t||"undefined"===typeof t||function(e,t,n,r){if(null!==n&&0===n.type)return!1;switch(typeof t){case"function":case"symbol":return!0;case"boolean":return!r&&(null!==n?!n.acceptsBooleans:"data-"!==(e=e.toLowerCase().slice(0,5))&&"aria-"!==e);default:return!1}}(e,t,n,r))return!0;if(r)return!1;if(null!==n)switch(n.type){case 3:return!t;case 4:return!1===t;case 5:return isNaN(t);case 6:return isNaN(t)||1>t}return!1}(t,n,a,r)&&(n=null),r||null===a?function(e){return!!d.call(m,e)||!d.call(p,e)&&(f.test(e)?m[e]=!0:(p[e]=!0,!1))}(t)&&(null===n?e.removeAttribute(t):e.setAttribute(t,""+n)):a.mustUseProperty?e[a.propertyName]=null===n?3!==a.type&&"":n:(t=a.attributeName,r=a.attributeNamespace,null===n?e.removeAttribute(t):(n=3===(a=a.type)||4===a&&!0===n?"":""+n,r?e.setAttributeNS(r,t,n):e.setAttribute(t,n))))}"accent-height alignment-baseline arabic-form baseline-shift cap-height clip-path clip-rule color-interpolation color-interpolation-filters color-profile color-rendering dominant-baseline enable-background fill-opacity fill-rule flood-color flood-opacity font-family font-size font-size-adjust font-stretch font-style font-variant font-weight glyph-name glyph-orientation-horizontal glyph-orientation-vertical horiz-adv-x horiz-origin-x image-rendering letter-spacing lighting-color marker-end marker-mid marker-start overline-position overline-thickness paint-order panose-1 pointer-events rendering-intent shape-rendering stop-color stop-opacity strikethrough-position strikethrough-thickness stroke-dasharray stroke-dashoffset stroke-linecap stroke-linejoin stroke-miterlimit stroke-opacity stroke-width text-anchor text-decoration text-rendering underline-position underline-thickness unicode-bidi unicode-range units-per-em v-alphabetic v-hanging v-ideographic v-mathematical vector-effect vert-adv-y vert-origin-x vert-origin-y word-spacing writing-mode xmlns:xlink x-height".split(" ").forEach((function(e){var t=e.replace(y,b);v[t]=new h(t,1,!1,e,null,!1,!1)})),"xlink:actuate xlink:arcrole xlink:role xlink:show xlink:title xlink:type".split(" ").forEach((function(e){var t=e.replace(y,b);v[t]=new h(t,1,!1,e,"http://www.w3.org/1999/xlink",!1,!1)})),["xml:base","xml:lang","xml:space"].forEach((function(e){var t=e.replace(y,b);v[t]=new h(t,1,!1,e,"http://www.w3.org/XML/1998/namespace",!1,!1)})),["tabIndex","crossOrigin"].forEach((function(e){v[e]=new h(e,1,!1,e.toLowerCase(),null,!1,!1)})),v.xlinkHref=new h("xlinkHref",1,!1,"xlink:href","http://www.w3.org/1999/xlink",!0,!1),["src","href","action","formAction"].forEach((function(e){v[e]=new h(e,1,!1,e.toLowerCase(),null,!0,!0)}));var _=r.__SECRET_INTERNALS_DO_NOT_USE_OR_YOU_WILL_BE_FIRED,w=Symbol.for("react.element"),S=Symbol.for("react.portal"),k=Symbol.for("react.fragment"),T=Symbol.for("react.strict_mode"),F=Symbol.for("react.profiler"),C=Symbol.for("react.provider"),x=Symbol.for("react.context"),A=Symbol.for("react.forward_ref"),E=Symbol.for("react.suspense"),D=Symbol.for("react.suspense_list"),P=Symbol.for("react.memo"),R=Symbol.for("react.lazy");Symbol.for("react.scope"),Symbol.for("react.debug_trace_mode");var M=Symbol.for("react.offscreen");Symbol.for("react.legacy_hidden"),Symbol.for("react.cache"),Symbol.for("react.tracing_marker");var N=Symbol.iterator;function O(e){return null===e||"object"!==typeof e?null:"function"===typeof(e=N&&e[N]||e["@@iterator"])?e:null}var z,I=Object.assign;function L(e){if(void 0===z)try{throw Error()}catch(n){var t=n.stack.trim().match(/\n( *(at )?)/);z=t&&t[1]||""}return"\n"+z+e}var Z=!1;function j(e,t){if(!e||Z)return"";Z=!0;var n=Error.prepareStackTrace;Error.prepareStackTrace=void 0;try{if(t)if(t=function(){throw Error()},Object.defineProperty(t.prototype,"props",{set:function(){throw Error()}}),"object"===typeof Reflect&&Reflect.construct){try{Reflect.construct(t,[])}catch(c){var r=c}Reflect.construct(e,[],t)}else{try{t.call()}catch(c){r=c}e.call(t.prototype)}else{try{throw Error()}catch(c){r=c}e()}}catch(c){if(c&&r&&"string"===typeof c.stack){for(var a=c.stack.split("\n"),o=r.stack.split("\n"),i=a.length-1,s=o.length-1;1<=i&&0<=s&&a[i]!==o[s];)s--;for(;1<=i&&0<=s;i--,s--)if(a[i]!==o[s]){if(1!==i||1!==s)do{if(i--,0>--s||a[i]!==o[s]){var l="\n"+a[i].replace(" at new "," at ");return e.displayName&&l.includes("<anonymous>")&&(l=l.replace("<anonymous>",e.displayName)),l}}while(1<=i&&0<=s);break}}}finally{Z=!1,Error.prepareStackTrace=n}return(e=e?e.displayName||e.name:"")?L(e):""}function B(e){switch(e.tag){case 5:return L(e.type);case 16:return L("Lazy");case 13:return L("Suspense");case 19:return L("SuspenseList");case 0:case 2:case 15:return e=j(e.type,!1);case 11:return e=j(e.type.render,!1);case 1:return e=j(e.type,!0);default:return""}}function W(e){if(null==e)return null;if("function"===typeof e)return e.displayName||e.name||null;if("string"===typeof e)return e;switch(e){case k:return"Fragment";case S:return"Portal";case F:return"Profiler";case T:return"StrictMode";case E:return"Suspense";case D:return"SuspenseList"}if("object"===typeof e)switch(e.$$typeof){case x:return(e.displayName||"Context")+".Consumer";case C:return(e._context.displayName||"Context")+".Provider";case A:var t=e.render;return(e=e.displayName)||(e=""!==(e=t.displayName||t.name||"")?"ForwardRef("+e+")":"ForwardRef"),e;case P:return null!==(t=e.displayName||null)?t:W(e.type)||"Memo";case R:t=e._payload,e=e._init;try{return W(e(t))}catch(n){}}return null}function U(e){var t=e.type;switch(e.tag){case 24:return"Cache";case 9:return(t.displayName||"Context")+".Consumer";case 10:return(t._context.displayName||"Context")+".Provider";case 18:return"DehydratedFragment";case 11:return e=(e=t.render).displayName||e.name||"",t.displayName||(""!==e?"ForwardRef("+e+")":"ForwardRef");case 7:return"Fragment";case 5:return t;case 4:return"Portal";case 3:return"Root";case 6:return"Text";case 16:return W(t);case 8:return t===T?"StrictMode":"Mode";case 22:return"Offscreen";case 12:return"Profiler";case 21:return"Scope";case 13:return"Suspense";case 19:return"SuspenseList";case 25:return"TracingMarker";case 1:case 0:case 17:case 2:case 14:case 15:if("function"===typeof t)return t.displayName||t.name||null;if("string"===typeof t)return t}return null}function V(e){switch(typeof e){case"boolean":case"number":case"string":case"undefined":case"object":return e;default:return""}}function G(e){var t=e.type;return(e=e.nodeName)&&"input"===e.toLowerCase()&&("checkbox"===t||"radio"===t)}function J(e){e._valueTracker||(e._valueTracker=function(e){var t=G(e)?"checked":"value",n=Object.getOwnPropertyDescriptor(e.constructor.prototype,t),r=""+e[t];if(!e.hasOwnProperty(t)&&"undefined"!==typeof n&&"function"===typeof n.get&&"function"===typeof n.set){var a=n.get,o=n.set;return Object.defineProperty(e,t,{configurable:!0,get:function(){return a.call(this)},set:function(e){r=""+e,o.call(this,e)}}),Object.defineProperty(e,t,{enumerable:n.enumerable}),{getValue:function(){return r},setValue:function(e){r=""+e},stopTracking:function(){e._valueTracker=null,delete e[t]}}}}(e))}function $(e){if(!e)return!1;var t=e._valueTracker;if(!t)return!0;var n=t.getValue(),r="";return e&&(r=G(e)?e.checked?"true":"false":e.value),(e=r)!==n&&(t.setValue(e),!0)}function H(e){if("undefined"===typeof(e=e||("undefined"!==typeof document?document:void 0)))return null;try{return e.activeElement||e.body}catch(t){return e.body}}function q(e,t){var n=t.checked;return I({},t,{defaultChecked:void 0,defaultValue:void 0,value:void 0,checked:null!=n?n:e._wrapperState.initialChecked})}function K(e,t){var n=null==t.defaultValue?"":t.defaultValue,r=null!=t.checked?t.checked:t.defaultChecked;n=V(null!=t.value?t.value:n),e._wrapperState={initialChecked:r,initialValue:n,controlled:"checkbox"===t.type||"radio"===t.type?null!=t.checked:null!=t.value}}function Y(e,t){null!=(t=t.checked)&&g(e,"checked",t,!1)}function Q(e,t){Y(e,t);var n=V(t.value),r=t.type;if(null!=n)"number"===r?(0===n&&""===e.value||e.value!=n)&&(e.value=""+n):e.value!==""+n&&(e.value=""+n);else if("submit"===r||"reset"===r)return void e.removeAttribute("value");t.hasOwnProperty("value")?ee(e,t.type,n):t.hasOwnProperty("defaultValue")&&ee(e,t.type,V(t.defaultValue)),null==t.checked&&null!=t.defaultChecked&&(e.defaultChecked=!!t.defaultChecked)}function X(e,t,n){if(t.hasOwnProperty("value")||t.hasOwnProperty("defaultValue")){var r=t.type;if(!("submit"!==r&&"reset"!==r||void 0!==t.value&&null!==t.value))return;t=""+e._wrapperState.initialValue,n||t===e.value||(e.value=t),e.defaultValue=t}""!==(n=e.name)&&(e.name=""),e.defaultChecked=!!e._wrapperState.initialChecked,""!==n&&(e.name=n)}function ee(e,t,n){"number"===t&&H(e.ownerDocument)===e||(null==n?e.defaultValue=""+e._wrapperState.initialValue:e.defaultValue!==""+n&&(e.defaultValue=""+n))}var te=Array.isArray;function ne(e,t,n,r){if(e=e.options,t){t={};for(var a=0;a<n.length;a++)t["$"+n[a]]=!0;for(n=0;n<e.length;n++)a=t.hasOwnProperty("$"+e[n].value),e[n].selected!==a&&(e[n].selected=a),a&&r&&(e[n].defaultSelected=!0)}else{for(n=""+V(n),t=null,a=0;a<e.length;a++){if(e[a].value===n)return e[a].selected=!0,void(r&&(e[a].defaultSelected=!0));null!==t||e[a].disabled||(t=e[a])}null!==t&&(t.selected=!0)}}function re(e,t){if(null!=t.dangerouslySetInnerHTML)throw Error(o(91));return I({},t,{value:void 0,defaultValue:void 0,children:""+e._wrapperState.initialValue})}function ae(e,t){var n=t.value;if(null==n){if(n=t.children,t=t.defaultValue,null!=n){if(null!=t)throw Error(o(92));if(te(n)){if(1<n.length)throw Error(o(93));n=n[0]}t=n}null==t&&(t=""),n=t}e._wrapperState={initialValue:V(n)}}function oe(e,t){var n=V(t.value),r=V(t.defaultValue);null!=n&&((n=""+n)!==e.value&&(e.value=n),null==t.defaultValue&&e.defaultValue!==n&&(e.defaultValue=n)),null!=r&&(e.defaultValue=""+r)}function ie(e){var t=e.textContent;t===e._wrapperState.initialValue&&""!==t&&null!==t&&(e.value=t)}function se(e){switch(e){case"svg":return"http://www.w3.org/2000/svg";case"math":return"http://www.w3.org/1998/Math/MathML";default:return"http://www.w3.org/1999/xhtml"}}function le(e,t){return null==e||"http://www.w3.org/1999/xhtml"===e?se(t):"http://www.w3.org/2000/svg"===e&&"foreignObject"===t?"http://www.w3.org/1999/xhtml":e}var ce,ue,de=(ue=function(e,t){if("http://www.w3.org/2000/svg"!==e.namespaceURI||"innerHTML"in e)e.innerHTML=t;else{for((ce=ce||document.createElement("div")).innerHTML="<svg>"+t.valueOf().toString()+"</svg>",t=ce.firstChild;e.firstChild;)e.removeChild(e.firstChild);for(;t.firstChild;)e.appendChild(t.firstChild)}},"undefined"!==typeof MSApp&&MSApp.execUnsafeLocalFunction?function(e,t,n,r){MSApp.execUnsafeLocalFunction((function(){return ue(e,t)}))}:ue);function fe(e,t){if(t){var n=e.firstChild;if(n&&n===e.lastChild&&3===n.nodeType)return void(n.nodeValue=t)}e.textContent=t}var pe={animationIterationCount:!0,aspectRatio:!0,borderImageOutset:!0,borderImageSlice:!0,borderImageWidth:!0,boxFlex:!0,boxFlexGroup:!0,boxOrdinalGroup:!0,columnCount:!0,columns:!0,flex:!0,flexGrow:!0,flexPositive:!0,flexShrink:!0,flexNegative:!0,flexOrder:!0,gridArea:!0,gridRow:!0,gridRowEnd:!0,gridRowSpan:!0,gridRowStart:!0,gridColumn:!0,gridColumnEnd:!0,gridColumnSpan:!0,gridColumnStart:!0,fontWeight:!0,lineClamp:!0,lineHeight:!0,opacity:!0,order:!0,orphans:!0,tabSize:!0,widows:!0,zIndex:!0,zoom:!0,fillOpacity:!0,floodOpacity:!0,stopOpacity:!0,strokeDasharray:!0,strokeDashoffset:!0,strokeMiterlimit:!0,strokeOpacity:!0,strokeWidth:!0},me=["Webkit","ms","Moz","O"];function he(e,t,n){return null==t||"boolean"===typeof t||""===t?"":n||"number"!==typeof t||0===t||pe.hasOwnProperty(e)&&pe[e]?(""+t).trim():t+"px"}function ve(e,t){for(var n in e=e.style,t)if(t.hasOwnProperty(n)){var r=0===n.indexOf("--"),a=he(n,t[n],r);"float"===n&&(n="cssFloat"),r?e.setProperty(n,a):e[n]=a}}Object.keys(pe).forEach((function(e){me.forEach((function(t){t=t+e.charAt(0).toUpperCase()+e.substring(1),pe[t]=pe[e]}))}));var ye=I({menuitem:!0},{area:!0,base:!0,br:!0,col:!0,embed:!0,hr:!0,img:!0,input:!0,keygen:!0,link:!0,meta:!0,param:!0,source:!0,track:!0,wbr:!0});function be(e,t){if(t){if(ye[e]&&(null!=t.children||null!=t.dangerouslySetInnerHTML))throw Error(o(137,e));if(null!=t.dangerouslySetInnerHTML){if(null!=t.children)throw Error(o(60));if("object"!==typeof t.dangerouslySetInnerHTML||!("__html"in t.dangerouslySetInnerHTML))throw Error(o(61))}if(null!=t.style&&"object"!==typeof t.style)throw Error(o(62))}}function ge(e,t){if(-1===e.indexOf("-"))return"string"===typeof t.is;switch(e){case"annotation-xml":case"color-profile":case"font-face":case"font-face-src":case"font-face-uri":case"font-face-format":case"font-face-name":case"missing-glyph":return!1;default:return!0}}var _e=null;function we(e){return(e=e.target||e.srcElement||window).correspondingUseElement&&(e=e.correspondingUseElement),3===e.nodeType?e.parentNode:e}var Se=null,ke=null,Te=null;function Fe(e){if(e=ga(e)){if("function"!==typeof Se)throw Error(o(280));var t=e.stateNode;t&&(t=wa(t),Se(e.stateNode,e.type,t))}}function Ce(e){ke?Te?Te.push(e):Te=[e]:ke=e}function xe(){if(ke){var e=ke,t=Te;if(Te=ke=null,Fe(e),t)for(e=0;e<t.length;e++)Fe(t[e])}}function Ae(e,t){return e(t)}function Ee(){}var De=!1;function Pe(e,t,n){if(De)return e(t,n);De=!0;try{return Ae(e,t,n)}finally{De=!1,(null!==ke||null!==Te)&&(Ee(),xe())}}function Re(e,t){var n=e.stateNode;if(null===n)return null;var r=wa(n);if(null===r)return null;n=r[t];e:switch(t){case"onClick":case"onClickCapture":case"onDoubleClick":case"onDoubleClickCapture":case"onMouseDown":case"onMouseDownCapture":case"onMouseMove":case"onMouseMoveCapture":case"onMouseUp":case"onMouseUpCapture":case"onMouseEnter":(r=!r.disabled)||(r=!("button"===(e=e.type)||"input"===e||"select"===e||"textarea"===e)),e=!r;break e;default:e=!1}if(e)return null;if(n&&"function"!==typeof n)throw Error(o(231,t,typeof n));return n}var Me=!1;if(u)try{var Ne={};Object.defineProperty(Ne,"passive",{get:function(){Me=!0}}),window.addEventListener("test",Ne,Ne),window.removeEventListener("test",Ne,Ne)}catch(ue){Me=!1}function Oe(e,t,n,r,a,o,i,s,l){var c=Array.prototype.slice.call(arguments,3);try{t.apply(n,c)}catch(u){this.onError(u)}}var ze=!1,Ie=null,Le=!1,Ze=null,je={onError:function(e){ze=!0,Ie=e}};function Be(e,t,n,r,a,o,i,s,l){ze=!1,Ie=null,Oe.apply(je,arguments)}function We(e){var t=e,n=e;if(e.alternate)for(;t.return;)t=t.return;else{e=t;do{0!==(4098&(t=e).flags)&&(n=t.return),e=t.return}while(e)}return 3===t.tag?n:null}function Ue(e){if(13===e.tag){var t=e.memoizedState;if(null===t&&(null!==(e=e.alternate)&&(t=e.memoizedState)),null!==t)return t.dehydrated}return null}function Ve(e){if(We(e)!==e)throw Error(o(188))}function Ge(e){return null!==(e=function(e){var t=e.alternate;if(!t){if(null===(t=We(e)))throw Error(o(188));return t!==e?null:e}for(var n=e,r=t;;){var a=n.return;if(null===a)break;var i=a.alternate;if(null===i){if(null!==(r=a.return)){n=r;continue}break}if(a.child===i.child){for(i=a.child;i;){if(i===n)return Ve(a),e;if(i===r)return Ve(a),t;i=i.sibling}throw Error(o(188))}if(n.return!==r.return)n=a,r=i;else{for(var s=!1,l=a.child;l;){if(l===n){s=!0,n=a,r=i;break}if(l===r){s=!0,r=a,n=i;break}l=l.sibling}if(!s){for(l=i.child;l;){if(l===n){s=!0,n=i,r=a;break}if(l===r){s=!0,r=i,n=a;break}l=l.sibling}if(!s)throw Error(o(189))}}if(n.alternate!==r)throw Error(o(190))}if(3!==n.tag)throw Error(o(188));return n.stateNode.current===n?e:t}(e))?Je(e):null}function Je(e){if(5===e.tag||6===e.tag)return e;for(e=e.child;null!==e;){var t=Je(e);if(null!==t)return t;e=e.sibling}return null}var $e=a.unstable_scheduleCallback,He=a.unstable_cancelCallback,qe=a.unstable_shouldYield,Ke=a.unstable_requestPaint,Ye=a.unstable_now,Qe=a.unstable_getCurrentPriorityLevel,Xe=a.unstable_ImmediatePriority,et=a.unstable_UserBlockingPriority,tt=a.unstable_NormalPriority,nt=a.unstable_LowPriority,rt=a.unstable_IdlePriority,at=null,ot=null;var it=Math.clz32?Math.clz32:function(e){return 0===(e>>>=0)?32:31-(st(e)/lt|0)|0},st=Math.log,lt=Math.LN2;var ct=64,ut=4194304;function dt(e){switch(e&-e){case 1:return 1;case 2:return 2;case 4:return 4;case 8:return 8;case 16:return 16;case 32:return 32;case 64:case 128:case 256:case 512:case 1024:case 2048:case 4096:case 8192:case 16384:case 32768:case 65536:case 131072:case 262144:case 524288:case 1048576:case 2097152:return 4194240&e;case 4194304:case 8388608:case 16777216:case 33554432:case 67108864:return 130023424&e;case 134217728:return 134217728;case 268435456:return 268435456;case 536870912:return 536870912;case 1073741824:return 1073741824;default:return e}}function ft(e,t){var n=e.pendingLanes;if(0===n)return 0;var r=0,a=e.suspendedLanes,o=e.pingedLanes,i=268435455&n;if(0!==i){var s=i&~a;0!==s?r=dt(s):0!==(o&=i)&&(r=dt(o))}else 0!==(i=n&~a)?r=dt(i):0!==o&&(r=dt(o));if(0===r)return 0;if(0!==t&&t!==r&&0===(t&a)&&((a=r&-r)>=(o=t&-t)||16===a&&0!==(4194240&o)))return t;if(0!==(4&r)&&(r|=16&n),0!==(t=e.entangledLanes))for(e=e.entanglements,t&=r;0<t;)a=1<<(n=31-it(t)),r|=e[n],t&=~a;return r}function pt(e,t){switch(e){case 1:case 2:case 4:return t+250;case 8:case 16:case 32:case 64:case 128:case 256:case 512:case 1024:case 2048:case 4096:case 8192:case 16384:case 32768:case 65536:case 131072:case 262144:case 524288:case 1048576:case 2097152:return t+5e3;default:return-1}}function mt(e){return 0!==(e=-1073741825&e.pendingLanes)?e:1073741824&e?1073741824:0}function ht(){var e=ct;return 0===(4194240&(ct<<=1))&&(ct=64),e}function vt(e){for(var t=[],n=0;31>n;n++)t.push(e);return t}function yt(e,t,n){e.pendingLanes|=t,536870912!==t&&(e.suspendedLanes=0,e.pingedLanes=0),(e=e.eventTimes)[t=31-it(t)]=n}function bt(e,t){var n=e.entangledLanes|=t;for(e=e.entanglements;n;){var r=31-it(n),a=1<<r;a&t|e[r]&t&&(e[r]|=t),n&=~a}}var gt=0;function _t(e){return 1<(e&=-e)?4<e?0!==(268435455&e)?16:536870912:4:1}var wt,St,kt,Tt,Ft,Ct=!1,xt=[],At=null,Et=null,Dt=null,Pt=new Map,Rt=new Map,Mt=[],Nt="mousedown mouseup touchcancel touchend touchstart auxclick dblclick pointercancel pointerdown pointerup dragend dragstart drop compositionend compositionstart keydown keypress keyup input textInput copy cut paste click change contextmenu reset submit".split(" ");function Ot(e,t){switch(e){case"focusin":case"focusout":At=null;break;case"dragenter":case"dragleave":Et=null;break;case"mouseover":case"mouseout":Dt=null;break;case"pointerover":case"pointerout":Pt.delete(t.pointerId);break;case"gotpointercapture":case"lostpointercapture":Rt.delete(t.pointerId)}}function zt(e,t,n,r,a,o){return null===e||e.nativeEvent!==o?(e={blockedOn:t,domEventName:n,eventSystemFlags:r,nativeEvent:o,targetContainers:[a]},null!==t&&(null!==(t=ga(t))&&St(t)),e):(e.eventSystemFlags|=r,t=e.targetContainers,null!==a&&-1===t.indexOf(a)&&t.push(a),e)}function It(e){var t=ba(e.target);if(null!==t){var n=We(t);if(null!==n)if(13===(t=n.tag)){if(null!==(t=Ue(n)))return e.blockedOn=t,void Ft(e.priority,(function(){kt(n)}))}else if(3===t&&n.stateNode.current.memoizedState.isDehydrated)return void(e.blockedOn=3===n.tag?n.stateNode.containerInfo:null)}e.blockedOn=null}function Lt(e){if(null!==e.blockedOn)return!1;for(var t=e.targetContainers;0<t.length;){var n=qt(e.domEventName,e.eventSystemFlags,t[0],e.nativeEvent);if(null!==n)return null!==(t=ga(n))&&St(t),e.blockedOn=n,!1;var r=new(n=e.nativeEvent).constructor(n.type,n);_e=r,n.target.dispatchEvent(r),_e=null,t.shift()}return!0}function Zt(e,t,n){Lt(e)&&n.delete(t)}function jt(){Ct=!1,null!==At&&Lt(At)&&(At=null),null!==Et&&Lt(Et)&&(Et=null),null!==Dt&&Lt(Dt)&&(Dt=null),Pt.forEach(Zt),Rt.forEach(Zt)}function Bt(e,t){e.blockedOn===t&&(e.blockedOn=null,Ct||(Ct=!0,a.unstable_scheduleCallback(a.unstable_NormalPriority,jt)))}function Wt(e){function t(t){return Bt(t,e)}if(0<xt.length){Bt(xt[0],e);for(var n=1;n<xt.length;n++){var r=xt[n];r.blockedOn===e&&(r.blockedOn=null)}}for(null!==At&&Bt(At,e),null!==Et&&Bt(Et,e),null!==Dt&&Bt(Dt,e),Pt.forEach(t),Rt.forEach(t),n=0;n<Mt.length;n++)(r=Mt[n]).blockedOn===e&&(r.blockedOn=null);for(;0<Mt.length&&null===(n=Mt[0]).blockedOn;)It(n),null===n.blockedOn&&Mt.shift()}var Ut=_.ReactCurrentBatchConfig,Vt=!0;function Gt(e,t,n,r){var a=gt,o=Ut.transition;Ut.transition=null;try{gt=1,$t(e,t,n,r)}finally{gt=a,Ut.transition=o}}function Jt(e,t,n,r){var a=gt,o=Ut.transition;Ut.transition=null;try{gt=4,$t(e,t,n,r)}finally{gt=a,Ut.transition=o}}function $t(e,t,n,r){if(Vt){var a=qt(e,t,n,r);if(null===a)Vr(e,t,r,Ht,n),Ot(e,r);else if(function(e,t,n,r,a){switch(t){case"focusin":return At=zt(At,e,t,n,r,a),!0;case"dragenter":return Et=zt(Et,e,t,n,r,a),!0;case"mouseover":return Dt=zt(Dt,e,t,n,r,a),!0;case"pointerover":var o=a.pointerId;return Pt.set(o,zt(Pt.get(o)||null,e,t,n,r,a)),!0;case"gotpointercapture":return o=a.pointerId,Rt.set(o,zt(Rt.get(o)||null,e,t,n,r,a)),!0}return!1}(a,e,t,n,r))r.stopPropagation();else if(Ot(e,r),4&t&&-1<Nt.indexOf(e)){for(;null!==a;){var o=ga(a);if(null!==o&&wt(o),null===(o=qt(e,t,n,r))&&Vr(e,t,r,Ht,n),o===a)break;a=o}null!==a&&r.stopPropagation()}else Vr(e,t,r,null,n)}}var Ht=null;function qt(e,t,n,r){if(Ht=null,null!==(e=ba(e=we(r))))if(null===(t=We(e)))e=null;else if(13===(n=t.tag)){if(null!==(e=Ue(t)))return e;e=null}else if(3===n){if(t.stateNode.current.memoizedState.isDehydrated)return 3===t.tag?t.stateNode.containerInfo:null;e=null}else t!==e&&(e=null);return Ht=e,null}function Kt(e){switch(e){case"cancel":case"click":case"close":case"contextmenu":case"copy":case"cut":case"auxclick":case"dblclick":case"dragend":case"dragstart":case"drop":case"focusin":case"focusout":case"input":case"invalid":case"keydown":case"keypress":case"keyup":case"mousedown":case"mouseup":case"paste":case"pause":case"play":case"pointercancel":case"pointerdown":case"pointerup":case"ratechange":case"reset":case"resize":case"seeked":case"submit":case"touchcancel":case"touchend":case"touchstart":case"volumechange":case"change":case"selectionchange":case"textInput":case"compositionstart":case"compositionend":case"compositionupdate":case"beforeblur":case"afterblur":case"beforeinput":case"blur":case"fullscreenchange":case"focus":case"hashchange":case"popstate":case"select":case"selectstart":return 1;case"drag":case"dragenter":case"dragexit":case"dragleave":case"dragover":case"mousemove":case"mouseout":case"mouseover":case"pointermove":case"pointerout":case"pointerover":case"scroll":case"toggle":case"touchmove":case"wheel":case"mouseenter":case"mouseleave":case"pointerenter":case"pointerleave":return 4;case"message":switch(Qe()){case Xe:return 1;case et:return 4;case tt:case nt:return 16;case rt:return 536870912;default:return 16}default:return 16}}var Yt=null,Qt=null,Xt=null;function en(){if(Xt)return Xt;var e,t,n=Qt,r=n.length,a="value"in Yt?Yt.value:Yt.textContent,o=a.length;for(e=0;e<r&&n[e]===a[e];e++);var i=r-e;for(t=1;t<=i&&n[r-t]===a[o-t];t++);return Xt=a.slice(e,1<t?1-t:void 0)}function tn(e){var t=e.keyCode;return"charCode"in e?0===(e=e.charCode)&&13===t&&(e=13):e=t,10===e&&(e=13),32<=e||13===e?e:0}function nn(){return!0}function rn(){return!1}function an(e){function t(t,n,r,a,o){for(var i in this._reactName=t,this._targetInst=r,this.type=n,this.nativeEvent=a,this.target=o,this.currentTarget=null,e)e.hasOwnProperty(i)&&(t=e[i],this[i]=t?t(a):a[i]);return this.isDefaultPrevented=(null!=a.defaultPrevented?a.defaultPrevented:!1===a.returnValue)?nn:rn,this.isPropagationStopped=rn,this}return I(t.prototype,{preventDefault:function(){this.defaultPrevented=!0;var e=this.nativeEvent;e&&(e.preventDefault?e.preventDefault():"unknown"!==typeof e.returnValue&&(e.returnValue=!1),this.isDefaultPrevented=nn)},stopPropagation:function(){var e=this.nativeEvent;e&&(e.stopPropagation?e.stopPropagation():"unknown"!==typeof e.cancelBubble&&(e.cancelBubble=!0),this.isPropagationStopped=nn)},persist:function(){},isPersistent:nn}),t}var on,sn,ln,cn={eventPhase:0,bubbles:0,cancelable:0,timeStamp:function(e){return e.timeStamp||Date.now()},defaultPrevented:0,isTrusted:0},un=an(cn),dn=I({},cn,{view:0,detail:0}),fn=an(dn),pn=I({},dn,{screenX:0,screenY:0,clientX:0,clientY:0,pageX:0,pageY:0,ctrlKey:0,shiftKey:0,altKey:0,metaKey:0,getModifierState:Fn,button:0,buttons:0,relatedTarget:function(e){return void 0===e.relatedTarget?e.fromElement===e.srcElement?e.toElement:e.fromElement:e.relatedTarget},movementX:function(e){return"movementX"in e?e.movementX:(e!==ln&&(ln&&"mousemove"===e.type?(on=e.screenX-ln.screenX,sn=e.screenY-ln.screenY):sn=on=0,ln=e),on)},movementY:function(e){return"movementY"in e?e.movementY:sn}}),mn=an(pn),hn=an(I({},pn,{dataTransfer:0})),vn=an(I({},dn,{relatedTarget:0})),yn=an(I({},cn,{animationName:0,elapsedTime:0,pseudoElement:0})),bn=I({},cn,{clipboardData:function(e){return"clipboardData"in e?e.clipboardData:window.clipboardData}}),gn=an(bn),_n=an(I({},cn,{data:0})),wn={Esc:"Escape",Spacebar:" ",Left:"ArrowLeft",Up:"ArrowUp",Right:"ArrowRight",Down:"ArrowDown",Del:"Delete",Win:"OS",Menu:"ContextMenu",Apps:"ContextMenu",Scroll:"ScrollLock",MozPrintableKey:"Unidentified"},Sn={8:"Backspace",9:"Tab",12:"Clear",13:"Enter",16:"Shift",17:"Control",18:"Alt",19:"Pause",20:"CapsLock",27:"Escape",32:" ",33:"PageUp",34:"PageDown",35:"End",36:"Home",37:"ArrowLeft",38:"ArrowUp",39:"ArrowRight",40:"ArrowDown",45:"Insert",46:"Delete",112:"F1",113:"F2",114:"F3",115:"F4",116:"F5",117:"F6",118:"F7",119:"F8",120:"F9",121:"F10",122:"F11",123:"F12",144:"NumLock",145:"ScrollLock",224:"Meta"},kn={Alt:"altKey",Control:"ctrlKey",Meta:"metaKey",Shift:"shiftKey"};function Tn(e){var t=this.nativeEvent;return t.getModifierState?t.getModifierState(e):!!(e=kn[e])&&!!t[e]}function Fn(){return Tn}var Cn=I({},dn,{key:function(e){if(e.key){var t=wn[e.key]||e.key;if("Unidentified"!==t)return t}return"keypress"===e.type?13===(e=tn(e))?"Enter":String.fromCharCode(e):"keydown"===e.type||"keyup"===e.type?Sn[e.keyCode]||"Unidentified":""},code:0,location:0,ctrlKey:0,shiftKey:0,altKey:0,metaKey:0,repeat:0,locale:0,getModifierState:Fn,charCode:function(e){return"keypress"===e.type?tn(e):0},keyCode:function(e){return"keydown"===e.type||"keyup"===e.type?e.keyCode:0},which:function(e){return"keypress"===e.type?tn(e):"keydown"===e.type||"keyup"===e.type?e.keyCode:0}}),xn=an(Cn),An=an(I({},pn,{pointerId:0,width:0,height:0,pressure:0,tangentialPressure:0,tiltX:0,tiltY:0,twist:0,pointerType:0,isPrimary:0})),En=an(I({},dn,{touches:0,targetTouches:0,changedTouches:0,altKey:0,metaKey:0,ctrlKey:0,shiftKey:0,getModifierState:Fn})),Dn=an(I({},cn,{propertyName:0,elapsedTime:0,pseudoElement:0})),Pn=I({},pn,{deltaX:function(e){return"deltaX"in e?e.deltaX:"wheelDeltaX"in e?-e.wheelDeltaX:0},deltaY:function(e){return"deltaY"in e?e.deltaY:"wheelDeltaY"in e?-e.wheelDeltaY:"wheelDelta"in e?-e.wheelDelta:0},deltaZ:0,deltaMode:0}),Rn=an(Pn),Mn=[9,13,27,32],Nn=u&&"CompositionEvent"in window,On=null;u&&"documentMode"in document&&(On=document.documentMode);var zn=u&&"TextEvent"in window&&!On,In=u&&(!Nn||On&&8<On&&11>=On),Ln=String.fromCharCode(32),Zn=!1;function jn(e,t){switch(e){case"keyup":return-1!==Mn.indexOf(t.keyCode);case"keydown":return 229!==t.keyCode;case"keypress":case"mousedown":case"focusout":return!0;default:return!1}}function Bn(e){return"object"===typeof(e=e.detail)&&"data"in e?e.data:null}var Wn=!1;var Un={color:!0,date:!0,datetime:!0,"datetime-local":!0,email:!0,month:!0,number:!0,password:!0,range:!0,search:!0,tel:!0,text:!0,time:!0,url:!0,week:!0};function Vn(e){var t=e&&e.nodeName&&e.nodeName.toLowerCase();return"input"===t?!!Un[e.type]:"textarea"===t}function Gn(e,t,n,r){Ce(r),0<(t=Jr(t,"onChange")).length&&(n=new un("onChange","change",null,n,r),e.push({event:n,listeners:t}))}var Jn=null,$n=null;function Hn(e){Lr(e,0)}function qn(e){if($(_a(e)))return e}function Kn(e,t){if("change"===e)return t}var Yn=!1;if(u){var Qn;if(u){var Xn="oninput"in document;if(!Xn){var er=document.createElement("div");er.setAttribute("oninput","return;"),Xn="function"===typeof er.oninput}Qn=Xn}else Qn=!1;Yn=Qn&&(!document.documentMode||9<document.documentMode)}function tr(){Jn&&(Jn.detachEvent("onpropertychange",nr),$n=Jn=null)}function nr(e){if("value"===e.propertyName&&qn($n)){var t=[];Gn(t,$n,e,we(e)),Pe(Hn,t)}}function rr(e,t,n){"focusin"===e?(tr(),$n=n,(Jn=t).attachEvent("onpropertychange",nr)):"focusout"===e&&tr()}function ar(e){if("selectionchange"===e||"keyup"===e||"keydown"===e)return qn($n)}function or(e,t){if("click"===e)return qn(t)}function ir(e,t){if("input"===e||"change"===e)return qn(t)}var sr="function"===typeof Object.is?Object.is:function(e,t){return e===t&&(0!==e||1/e===1/t)||e!==e&&t!==t};function lr(e,t){if(sr(e,t))return!0;if("object"!==typeof e||null===e||"object"!==typeof t||null===t)return!1;var n=Object.keys(e),r=Object.keys(t);if(n.length!==r.length)return!1;for(r=0;r<n.length;r++){var a=n[r];if(!d.call(t,a)||!sr(e[a],t[a]))return!1}return!0}function cr(e){for(;e&&e.firstChild;)e=e.firstChild;return e}function ur(e,t){var n,r=cr(e);for(e=0;r;){if(3===r.nodeType){if(n=e+r.textContent.length,e<=t&&n>=t)return{node:r,offset:t-e};e=n}e:{for(;r;){if(r.nextSibling){r=r.nextSibling;break e}r=r.parentNode}r=void 0}r=cr(r)}}function dr(e,t){return!(!e||!t)&&(e===t||(!e||3!==e.nodeType)&&(t&&3===t.nodeType?dr(e,t.parentNode):"contains"in e?e.contains(t):!!e.compareDocumentPosition&&!!(16&e.compareDocumentPosition(t))))}function fr(){for(var e=window,t=H();t instanceof e.HTMLIFrameElement;){try{var n="string"===typeof t.contentWindow.location.href}catch(r){n=!1}if(!n)break;t=H((e=t.contentWindow).document)}return t}function pr(e){var t=e&&e.nodeName&&e.nodeName.toLowerCase();return t&&("input"===t&&("text"===e.type||"search"===e.type||"tel"===e.type||"url"===e.type||"password"===e.type)||"textarea"===t||"true"===e.contentEditable)}function mr(e){var t=fr(),n=e.focusedElem,r=e.selectionRange;if(t!==n&&n&&n.ownerDocument&&dr(n.ownerDocument.documentElement,n)){if(null!==r&&pr(n))if(t=r.start,void 0===(e=r.end)&&(e=t),"selectionStart"in n)n.selectionStart=t,n.selectionEnd=Math.min(e,n.value.length);else if((e=(t=n.ownerDocument||document)&&t.defaultView||window).getSelection){e=e.getSelection();var a=n.textContent.length,o=Math.min(r.start,a);r=void 0===r.end?o:Math.min(r.end,a),!e.extend&&o>r&&(a=r,r=o,o=a),a=ur(n,o);var i=ur(n,r);a&&i&&(1!==e.rangeCount||e.anchorNode!==a.node||e.anchorOffset!==a.offset||e.focusNode!==i.node||e.focusOffset!==i.offset)&&((t=t.createRange()).setStart(a.node,a.offset),e.removeAllRanges(),o>r?(e.addRange(t),e.extend(i.node,i.offset)):(t.setEnd(i.node,i.offset),e.addRange(t)))}for(t=[],e=n;e=e.parentNode;)1===e.nodeType&&t.push({element:e,left:e.scrollLeft,top:e.scrollTop});for("function"===typeof n.focus&&n.focus(),n=0;n<t.length;n++)(e=t[n]).element.scrollLeft=e.left,e.element.scrollTop=e.top}}var hr=u&&"documentMode"in document&&11>=document.documentMode,vr=null,yr=null,br=null,gr=!1;function _r(e,t,n){var r=n.window===n?n.document:9===n.nodeType?n:n.ownerDocument;gr||null==vr||vr!==H(r)||("selectionStart"in(r=vr)&&pr(r)?r={start:r.selectionStart,end:r.selectionEnd}:r={anchorNode:(r=(r.ownerDocument&&r.ownerDocument.defaultView||window).getSelection()).anchorNode,anchorOffset:r.anchorOffset,focusNode:r.focusNode,focusOffset:r.focusOffset},br&&lr(br,r)||(br=r,0<(r=Jr(yr,"onSelect")).length&&(t=new un("onSelect","select",null,t,n),e.push({event:t,listeners:r}),t.target=vr)))}function wr(e,t){var n={};return n[e.toLowerCase()]=t.toLowerCase(),n["Webkit"+e]="webkit"+t,n["Moz"+e]="moz"+t,n}var Sr={animationend:wr("Animation","AnimationEnd"),animationiteration:wr("Animation","AnimationIteration"),animationstart:wr("Animation","AnimationStart"),transitionend:wr("Transition","TransitionEnd")},kr={},Tr={};function Fr(e){if(kr[e])return kr[e];if(!Sr[e])return e;var t,n=Sr[e];for(t in n)if(n.hasOwnProperty(t)&&t in Tr)return kr[e]=n[t];return e}u&&(Tr=document.createElement("div").style,"AnimationEvent"in window||(delete Sr.animationend.animation,delete Sr.animationiteration.animation,delete Sr.animationstart.animation),"TransitionEvent"in window||delete Sr.transitionend.transition);var Cr=Fr("animationend"),xr=Fr("animationiteration"),Ar=Fr("animationstart"),Er=Fr("transitionend"),Dr=new Map,Pr="abort auxClick cancel canPlay canPlayThrough click close contextMenu copy cut drag dragEnd dragEnter dragExit dragLeave dragOver dragStart drop durationChange emptied encrypted ended error gotPointerCapture input invalid keyDown keyPress keyUp load loadedData loadedMetadata loadStart lostPointerCapture mouseDown mouseMove mouseOut mouseOver mouseUp paste pause play playing pointerCancel pointerDown pointerMove pointerOut pointerOver pointerUp progress rateChange reset resize seeked seeking stalled submit suspend timeUpdate touchCancel touchEnd touchStart volumeChange scroll toggle touchMove waiting wheel".split(" ");function Rr(e,t){Dr.set(e,t),l(t,[e])}for(var Mr=0;Mr<Pr.length;Mr++){var Nr=Pr[Mr];Rr(Nr.toLowerCase(),"on"+(Nr[0].toUpperCase()+Nr.slice(1)))}Rr(Cr,"onAnimationEnd"),Rr(xr,"onAnimationIteration"),Rr(Ar,"onAnimationStart"),Rr("dblclick","onDoubleClick"),Rr("focusin","onFocus"),Rr("focusout","onBlur"),Rr(Er,"onTransitionEnd"),c("onMouseEnter",["mouseout","mouseover"]),c("onMouseLeave",["mouseout","mouseover"]),c("onPointerEnter",["pointerout","pointerover"]),c("onPointerLeave",["pointerout","pointerover"]),l("onChange","change click focusin focusout input keydown keyup selectionchange".split(" ")),l("onSelect","focusout contextmenu dragend focusin keydown keyup mousedown mouseup selectionchange".split(" ")),l("onBeforeInput",["compositionend","keypress","textInput","paste"]),l("onCompositionEnd","compositionend focusout keydown keypress keyup mousedown".split(" ")),l("onCompositionStart","compositionstart focusout keydown keypress keyup mousedown".split(" ")),l("onCompositionUpdate","compositionupdate focusout keydown keypress keyup mousedown".split(" "));var Or="abort canplay canplaythrough durationchange emptied encrypted ended error loadeddata loadedmetadata loadstart pause play playing progress ratechange resize seeked seeking stalled suspend timeupdate volumechange waiting".split(" "),zr=new Set("cancel close invalid load scroll toggle".split(" ").concat(Or));function Ir(e,t,n){var r=e.type||"unknown-event";e.currentTarget=n,function(e,t,n,r,a,i,s,l,c){if(Be.apply(this,arguments),ze){if(!ze)throw Error(o(198));var u=Ie;ze=!1,Ie=null,Le||(Le=!0,Ze=u)}}(r,t,void 0,e),e.currentTarget=null}function Lr(e,t){t=0!==(4&t);for(var n=0;n<e.length;n++){var r=e[n],a=r.event;r=r.listeners;e:{var o=void 0;if(t)for(var i=r.length-1;0<=i;i--){var s=r[i],l=s.instance,c=s.currentTarget;if(s=s.listener,l!==o&&a.isPropagationStopped())break e;Ir(a,s,c),o=l}else for(i=0;i<r.length;i++){if(l=(s=r[i]).instance,c=s.currentTarget,s=s.listener,l!==o&&a.isPropagationStopped())break e;Ir(a,s,c),o=l}}}if(Le)throw e=Ze,Le=!1,Ze=null,e}function Zr(e,t){var n=t[ha];void 0===n&&(n=t[ha]=new Set);var r=e+"__bubble";n.has(r)||(Ur(t,e,2,!1),n.add(r))}function jr(e,t,n){var r=0;t&&(r|=4),Ur(n,e,r,t)}var Br="_reactListening"+Math.random().toString(36).slice(2);function Wr(e){if(!e[Br]){e[Br]=!0,i.forEach((function(t){"selectionchange"!==t&&(zr.has(t)||jr(t,!1,e),jr(t,!0,e))}));var t=9===e.nodeType?e:e.ownerDocument;null===t||t[Br]||(t[Br]=!0,jr("selectionchange",!1,t))}}function Ur(e,t,n,r){switch(Kt(t)){case 1:var a=Gt;break;case 4:a=Jt;break;default:a=$t}n=a.bind(null,t,n,e),a=void 0,!Me||"touchstart"!==t&&"touchmove"!==t&&"wheel"!==t||(a=!0),r?void 0!==a?e.addEventListener(t,n,{capture:!0,passive:a}):e.addEventListener(t,n,!0):void 0!==a?e.addEventListener(t,n,{passive:a}):e.addEventListener(t,n,!1)}function Vr(e,t,n,r,a){var o=r;if(0===(1&t)&&0===(2&t)&&null!==r)e:for(;;){if(null===r)return;var i=r.tag;if(3===i||4===i){var s=r.stateNode.containerInfo;if(s===a||8===s.nodeType&&s.parentNode===a)break;if(4===i)for(i=r.return;null!==i;){var l=i.tag;if((3===l||4===l)&&((l=i.stateNode.containerInfo)===a||8===l.nodeType&&l.parentNode===a))return;i=i.return}for(;null!==s;){if(null===(i=ba(s)))return;if(5===(l=i.tag)||6===l){r=o=i;continue e}s=s.parentNode}}r=r.return}Pe((function(){var r=o,a=we(n),i=[];e:{var s=Dr.get(e);if(void 0!==s){var l=un,c=e;switch(e){case"keypress":if(0===tn(n))break e;case"keydown":case"keyup":l=xn;break;case"focusin":c="focus",l=vn;break;case"focusout":c="blur",l=vn;break;case"beforeblur":case"afterblur":l=vn;break;case"click":if(2===n.button)break e;case"auxclick":case"dblclick":case"mousedown":case"mousemove":case"mouseup":case"mouseout":case"mouseover":case"contextmenu":l=mn;break;case"drag":case"dragend":case"dragenter":case"dragexit":case"dragleave":case"dragover":case"dragstart":case"drop":l=hn;break;case"touchcancel":case"touchend":case"touchmove":case"touchstart":l=En;break;case Cr:case xr:case Ar:l=yn;break;case Er:l=Dn;break;case"scroll":l=fn;break;case"wheel":l=Rn;break;case"copy":case"cut":case"paste":l=gn;break;case"gotpointercapture":case"lostpointercapture":case"pointercancel":case"pointerdown":case"pointermove":case"pointerout":case"pointerover":case"pointerup":l=An}var u=0!==(4&t),d=!u&&"scroll"===e,f=u?null!==s?s+"Capture":null:s;u=[];for(var p,m=r;null!==m;){var h=(p=m).stateNode;if(5===p.tag&&null!==h&&(p=h,null!==f&&(null!=(h=Re(m,f))&&u.push(Gr(m,h,p)))),d)break;m=m.return}0<u.length&&(s=new l(s,c,null,n,a),i.push({event:s,listeners:u}))}}if(0===(7&t)){if(l="mouseout"===e||"pointerout"===e,(!(s="mouseover"===e||"pointerover"===e)||n===_e||!(c=n.relatedTarget||n.fromElement)||!ba(c)&&!c[ma])&&(l||s)&&(s=a.window===a?a:(s=a.ownerDocument)?s.defaultView||s.parentWindow:window,l?(l=r,null!==(c=(c=n.relatedTarget||n.toElement)?ba(c):null)&&(c!==(d=We(c))||5!==c.tag&&6!==c.tag)&&(c=null)):(l=null,c=r),l!==c)){if(u=mn,h="onMouseLeave",f="onMouseEnter",m="mouse","pointerout"!==e&&"pointerover"!==e||(u=An,h="onPointerLeave",f="onPointerEnter",m="pointer"),d=null==l?s:_a(l),p=null==c?s:_a(c),(s=new u(h,m+"leave",l,n,a)).target=d,s.relatedTarget=p,h=null,ba(a)===r&&((u=new u(f,m+"enter",c,n,a)).target=p,u.relatedTarget=d,h=u),d=h,l&&c)e:{for(f=c,m=0,p=u=l;p;p=$r(p))m++;for(p=0,h=f;h;h=$r(h))p++;for(;0<m-p;)u=$r(u),m--;for(;0<p-m;)f=$r(f),p--;for(;m--;){if(u===f||null!==f&&u===f.alternate)break e;u=$r(u),f=$r(f)}u=null}else u=null;null!==l&&Hr(i,s,l,u,!1),null!==c&&null!==d&&Hr(i,d,c,u,!0)}if("select"===(l=(s=r?_a(r):window).nodeName&&s.nodeName.toLowerCase())||"input"===l&&"file"===s.type)var v=Kn;else if(Vn(s))if(Yn)v=ir;else{v=ar;var y=rr}else(l=s.nodeName)&&"input"===l.toLowerCase()&&("checkbox"===s.type||"radio"===s.type)&&(v=or);switch(v&&(v=v(e,r))?Gn(i,v,n,a):(y&&y(e,s,r),"focusout"===e&&(y=s._wrapperState)&&y.controlled&&"number"===s.type&&ee(s,"number",s.value)),y=r?_a(r):window,e){case"focusin":(Vn(y)||"true"===y.contentEditable)&&(vr=y,yr=r,br=null);break;case"focusout":br=yr=vr=null;break;case"mousedown":gr=!0;break;case"contextmenu":case"mouseup":case"dragend":gr=!1,_r(i,n,a);break;case"selectionchange":if(hr)break;case"keydown":case"keyup":_r(i,n,a)}var b;if(Nn)e:{switch(e){case"compositionstart":var g="onCompositionStart";break e;case"compositionend":g="onCompositionEnd";break e;case"compositionupdate":g="onCompositionUpdate";break e}g=void 0}else Wn?jn(e,n)&&(g="onCompositionEnd"):"keydown"===e&&229===n.keyCode&&(g="onCompositionStart");g&&(In&&"ko"!==n.locale&&(Wn||"onCompositionStart"!==g?"onCompositionEnd"===g&&Wn&&(b=en()):(Qt="value"in(Yt=a)?Yt.value:Yt.textContent,Wn=!0)),0<(y=Jr(r,g)).length&&(g=new _n(g,e,null,n,a),i.push({event:g,listeners:y}),b?g.data=b:null!==(b=Bn(n))&&(g.data=b))),(b=zn?function(e,t){switch(e){case"compositionend":return Bn(t);case"keypress":return 32!==t.which?null:(Zn=!0,Ln);case"textInput":return(e=t.data)===Ln&&Zn?null:e;default:return null}}(e,n):function(e,t){if(Wn)return"compositionend"===e||!Nn&&jn(e,t)?(e=en(),Xt=Qt=Yt=null,Wn=!1,e):null;switch(e){case"paste":default:return null;case"keypress":if(!(t.ctrlKey||t.altKey||t.metaKey)||t.ctrlKey&&t.altKey){if(t.char&&1<t.char.length)return t.char;if(t.which)return String.fromCharCode(t.which)}return null;case"compositionend":return In&&"ko"!==t.locale?null:t.data}}(e,n))&&(0<(r=Jr(r,"onBeforeInput")).length&&(a=new _n("onBeforeInput","beforeinput",null,n,a),i.push({event:a,listeners:r}),a.data=b))}Lr(i,t)}))}function Gr(e,t,n){return{instance:e,listener:t,currentTarget:n}}function Jr(e,t){for(var n=t+"Capture",r=[];null!==e;){var a=e,o=a.stateNode;5===a.tag&&null!==o&&(a=o,null!=(o=Re(e,n))&&r.unshift(Gr(e,o,a)),null!=(o=Re(e,t))&&r.push(Gr(e,o,a))),e=e.return}return r}function $r(e){if(null===e)return null;do{e=e.return}while(e&&5!==e.tag);return e||null}function Hr(e,t,n,r,a){for(var o=t._reactName,i=[];null!==n&&n!==r;){var s=n,l=s.alternate,c=s.stateNode;if(null!==l&&l===r)break;5===s.tag&&null!==c&&(s=c,a?null!=(l=Re(n,o))&&i.unshift(Gr(n,l,s)):a||null!=(l=Re(n,o))&&i.push(Gr(n,l,s))),n=n.return}0!==i.length&&e.push({event:t,listeners:i})}var qr=/\r\n?/g,Kr=/\u0000|\uFFFD/g;function Yr(e){return("string"===typeof e?e:""+e).replace(qr,"\n").replace(Kr,"")}function Qr(e,t,n){if(t=Yr(t),Yr(e)!==t&&n)throw Error(o(425))}function Xr(){}var ea=null,ta=null;function na(e,t){return"textarea"===e||"noscript"===e||"string"===typeof t.children||"number"===typeof t.children||"object"===typeof t.dangerouslySetInnerHTML&&null!==t.dangerouslySetInnerHTML&&null!=t.dangerouslySetInnerHTML.__html}var ra="function"===typeof setTimeout?setTimeout:void 0,aa="function"===typeof clearTimeout?clearTimeout:void 0,oa="function"===typeof Promise?Promise:void 0,ia="function"===typeof queueMicrotask?queueMicrotask:"undefined"!==typeof oa?function(e){return oa.resolve(null).then(e).catch(sa)}:ra;function sa(e){setTimeout((function(){throw e}))}function la(e,t){var n=t,r=0;do{var a=n.nextSibling;if(e.removeChild(n),a&&8===a.nodeType)if("/$"===(n=a.data)){if(0===r)return e.removeChild(a),void Wt(t);r--}else"$"!==n&&"$?"!==n&&"$!"!==n||r++;n=a}while(n);Wt(t)}function ca(e){for(;null!=e;e=e.nextSibling){var t=e.nodeType;if(1===t||3===t)break;if(8===t){if("$"===(t=e.data)||"$!"===t||"$?"===t)break;if("/$"===t)return null}}return e}function ua(e){e=e.previousSibling;for(var t=0;e;){if(8===e.nodeType){var n=e.data;if("$"===n||"$!"===n||"$?"===n){if(0===t)return e;t--}else"/$"===n&&t++}e=e.previousSibling}return null}var da=Math.random().toString(36).slice(2),fa="__reactFiber$"+da,pa="__reactProps$"+da,ma="__reactContainer$"+da,ha="__reactEvents$"+da,va="__reactListeners$"+da,ya="__reactHandles$"+da;function ba(e){var t=e[fa];if(t)return t;for(var n=e.parentNode;n;){if(t=n[ma]||n[fa]){if(n=t.alternate,null!==t.child||null!==n&&null!==n.child)for(e=ua(e);null!==e;){if(n=e[fa])return n;e=ua(e)}return t}n=(e=n).parentNode}return null}function ga(e){return!(e=e[fa]||e[ma])||5!==e.tag&&6!==e.tag&&13!==e.tag&&3!==e.tag?null:e}function _a(e){if(5===e.tag||6===e.tag)return e.stateNode;throw Error(o(33))}function wa(e){return e[pa]||null}var Sa=[],ka=-1;function Ta(e){return{current:e}}function Fa(e){0>ka||(e.current=Sa[ka],Sa[ka]=null,ka--)}function Ca(e,t){ka++,Sa[ka]=e.current,e.current=t}var xa={},Aa=Ta(xa),Ea=Ta(!1),Da=xa;function Pa(e,t){var n=e.type.contextTypes;if(!n)return xa;var r=e.stateNode;if(r&&r.__reactInternalMemoizedUnmaskedChildContext===t)return r.__reactInternalMemoizedMaskedChildContext;var a,o={};for(a in n)o[a]=t[a];return r&&((e=e.stateNode).__reactInternalMemoizedUnmaskedChildContext=t,e.__reactInternalMemoizedMaskedChildContext=o),o}function Ra(e){return null!==(e=e.childContextTypes)&&void 0!==e}function Ma(){Fa(Ea),Fa(Aa)}function Na(e,t,n){if(Aa.current!==xa)throw Error(o(168));Ca(Aa,t),Ca(Ea,n)}function Oa(e,t,n){var r=e.stateNode;if(t=t.childContextTypes,"function"!==typeof r.getChildContext)return n;for(var a in r=r.getChildContext())if(!(a in t))throw Error(o(108,U(e)||"Unknown",a));return I({},n,r)}function za(e){return e=(e=e.stateNode)&&e.__reactInternalMemoizedMergedChildContext||xa,Da=Aa.current,Ca(Aa,e),Ca(Ea,Ea.current),!0}function Ia(e,t,n){var r=e.stateNode;if(!r)throw Error(o(169));n?(e=Oa(e,t,Da),r.__reactInternalMemoizedMergedChildContext=e,Fa(Ea),Fa(Aa),Ca(Aa,e)):Fa(Ea),Ca(Ea,n)}var La=null,Za=!1,ja=!1;function Ba(e){null===La?La=[e]:La.push(e)}function Wa(){if(!ja&&null!==La){ja=!0;var e=0,t=gt;try{var n=La;for(gt=1;e<n.length;e++){var r=n[e];do{r=r(!0)}while(null!==r)}La=null,Za=!1}catch(a){throw null!==La&&(La=La.slice(e+1)),$e(Xe,Wa),a}finally{gt=t,ja=!1}}return null}var Ua=[],Va=0,Ga=null,Ja=0,$a=[],Ha=0,qa=null,Ka=1,Ya="";function Qa(e,t){Ua[Va++]=Ja,Ua[Va++]=Ga,Ga=e,Ja=t}function Xa(e,t,n){$a[Ha++]=Ka,$a[Ha++]=Ya,$a[Ha++]=qa,qa=e;var r=Ka;e=Ya;var a=32-it(r)-1;r&=~(1<<a),n+=1;var o=32-it(t)+a;if(30<o){var i=a-a%5;o=(r&(1<<i)-1).toString(32),r>>=i,a-=i,Ka=1<<32-it(t)+a|n<<a|r,Ya=o+e}else Ka=1<<o|n<<a|r,Ya=e}function eo(e){null!==e.return&&(Qa(e,1),Xa(e,1,0))}function to(e){for(;e===Ga;)Ga=Ua[--Va],Ua[Va]=null,Ja=Ua[--Va],Ua[Va]=null;for(;e===qa;)qa=$a[--Ha],$a[Ha]=null,Ya=$a[--Ha],$a[Ha]=null,Ka=$a[--Ha],$a[Ha]=null}var no=null,ro=null,ao=!1,oo=null;function io(e,t){var n=Pc(5,null,null,0);n.elementType="DELETED",n.stateNode=t,n.return=e,null===(t=e.deletions)?(e.deletions=[n],e.flags|=16):t.push(n)}function so(e,t){switch(e.tag){case 5:var n=e.type;return null!==(t=1!==t.nodeType||n.toLowerCase()!==t.nodeName.toLowerCase()?null:t)&&(e.stateNode=t,no=e,ro=ca(t.firstChild),!0);case 6:return null!==(t=""===e.pendingProps||3!==t.nodeType?null:t)&&(e.stateNode=t,no=e,ro=null,!0);case 13:return null!==(t=8!==t.nodeType?null:t)&&(n=null!==qa?{id:Ka,overflow:Ya}:null,e.memoizedState={dehydrated:t,treeContext:n,retryLane:1073741824},(n=Pc(18,null,null,0)).stateNode=t,n.return=e,e.child=n,no=e,ro=null,!0);default:return!1}}function lo(e){return 0!==(1&e.mode)&&0===(128&e.flags)}function co(e){if(ao){var t=ro;if(t){var n=t;if(!so(e,t)){if(lo(e))throw Error(o(418));t=ca(n.nextSibling);var r=no;t&&so(e,t)?io(r,n):(e.flags=-4097&e.flags|2,ao=!1,no=e)}}else{if(lo(e))throw Error(o(418));e.flags=-4097&e.flags|2,ao=!1,no=e}}}function uo(e){for(e=e.return;null!==e&&5!==e.tag&&3!==e.tag&&13!==e.tag;)e=e.return;no=e}function fo(e){if(e!==no)return!1;if(!ao)return uo(e),ao=!0,!1;var t;if((t=3!==e.tag)&&!(t=5!==e.tag)&&(t="head"!==(t=e.type)&&"body"!==t&&!na(e.type,e.memoizedProps)),t&&(t=ro)){if(lo(e))throw po(),Error(o(418));for(;t;)io(e,t),t=ca(t.nextSibling)}if(uo(e),13===e.tag){if(!(e=null!==(e=e.memoizedState)?e.dehydrated:null))throw Error(o(317));e:{for(e=e.nextSibling,t=0;e;){if(8===e.nodeType){var n=e.data;if("/$"===n){if(0===t){ro=ca(e.nextSibling);break e}t--}else"$"!==n&&"$!"!==n&&"$?"!==n||t++}e=e.nextSibling}ro=null}}else ro=no?ca(e.stateNode.nextSibling):null;return!0}function po(){for(var e=ro;e;)e=ca(e.nextSibling)}function mo(){ro=no=null,ao=!1}function ho(e){null===oo?oo=[e]:oo.push(e)}var vo=_.ReactCurrentBatchConfig;function yo(e,t){if(e&&e.defaultProps){for(var n in t=I({},t),e=e.defaultProps)void 0===t[n]&&(t[n]=e[n]);return t}return t}var bo=Ta(null),go=null,_o=null,wo=null;function So(){wo=_o=go=null}function ko(e){var t=bo.current;Fa(bo),e._currentValue=t}function To(e,t,n){for(;null!==e;){var r=e.alternate;if((e.childLanes&t)!==t?(e.childLanes|=t,null!==r&&(r.childLanes|=t)):null!==r&&(r.childLanes&t)!==t&&(r.childLanes|=t),e===n)break;e=e.return}}function Fo(e,t){go=e,wo=_o=null,null!==(e=e.dependencies)&&null!==e.firstContext&&(0!==(e.lanes&t)&&(_s=!0),e.firstContext=null)}function Co(e){var t=e._currentValue;if(wo!==e)if(e={context:e,memoizedValue:t,next:null},null===_o){if(null===go)throw Error(o(308));_o=e,go.dependencies={lanes:0,firstContext:e}}else _o=_o.next=e;return t}var xo=null;function Ao(e){null===xo?xo=[e]:xo.push(e)}function Eo(e,t,n,r){var a=t.interleaved;return null===a?(n.next=n,Ao(t)):(n.next=a.next,a.next=n),t.interleaved=n,Do(e,r)}function Do(e,t){e.lanes|=t;var n=e.alternate;for(null!==n&&(n.lanes|=t),n=e,e=e.return;null!==e;)e.childLanes|=t,null!==(n=e.alternate)&&(n.childLanes|=t),n=e,e=e.return;return 3===n.tag?n.stateNode:null}var Po=!1;function Ro(e){e.updateQueue={baseState:e.memoizedState,firstBaseUpdate:null,lastBaseUpdate:null,shared:{pending:null,interleaved:null,lanes:0},effects:null}}function Mo(e,t){e=e.updateQueue,t.updateQueue===e&&(t.updateQueue={baseState:e.baseState,firstBaseUpdate:e.firstBaseUpdate,lastBaseUpdate:e.lastBaseUpdate,shared:e.shared,effects:e.effects})}function No(e,t){return{eventTime:e,lane:t,tag:0,payload:null,callback:null,next:null}}function Oo(e,t,n){var r=e.updateQueue;if(null===r)return null;if(r=r.shared,0!==(2&Al)){var a=r.pending;return null===a?t.next=t:(t.next=a.next,a.next=t),r.pending=t,Do(e,n)}return null===(a=r.interleaved)?(t.next=t,Ao(r)):(t.next=a.next,a.next=t),r.interleaved=t,Do(e,n)}function zo(e,t,n){if(null!==(t=t.updateQueue)&&(t=t.shared,0!==(4194240&n))){var r=t.lanes;n|=r&=e.pendingLanes,t.lanes=n,bt(e,n)}}function Io(e,t){var n=e.updateQueue,r=e.alternate;if(null!==r&&n===(r=r.updateQueue)){var a=null,o=null;if(null!==(n=n.firstBaseUpdate)){do{var i={eventTime:n.eventTime,lane:n.lane,tag:n.tag,payload:n.payload,callback:n.callback,next:null};null===o?a=o=i:o=o.next=i,n=n.next}while(null!==n);null===o?a=o=t:o=o.next=t}else a=o=t;return n={baseState:r.baseState,firstBaseUpdate:a,lastBaseUpdate:o,shared:r.shared,effects:r.effects},void(e.updateQueue=n)}null===(e=n.lastBaseUpdate)?n.firstBaseUpdate=t:e.next=t,n.lastBaseUpdate=t}function Lo(e,t,n,r){var a=e.updateQueue;Po=!1;var o=a.firstBaseUpdate,i=a.lastBaseUpdate,s=a.shared.pending;if(null!==s){a.shared.pending=null;var l=s,c=l.next;l.next=null,null===i?o=c:i.next=c,i=l;var u=e.alternate;null!==u&&((s=(u=u.updateQueue).lastBaseUpdate)!==i&&(null===s?u.firstBaseUpdate=c:s.next=c,u.lastBaseUpdate=l))}if(null!==o){var d=a.baseState;for(i=0,u=c=l=null,s=o;;){var f=s.lane,p=s.eventTime;if((r&f)===f){null!==u&&(u=u.next={eventTime:p,lane:0,tag:s.tag,payload:s.payload,callback:s.callback,next:null});e:{var m=e,h=s;switch(f=t,p=n,h.tag){case 1:if("function"===typeof(m=h.payload)){d=m.call(p,d,f);break e}d=m;break e;case 3:m.flags=-65537&m.flags|128;case 0:if(null===(f="function"===typeof(m=h.payload)?m.call(p,d,f):m)||void 0===f)break e;d=I({},d,f);break e;case 2:Po=!0}}null!==s.callback&&0!==s.lane&&(e.flags|=64,null===(f=a.effects)?a.effects=[s]:f.push(s))}else p={eventTime:p,lane:f,tag:s.tag,payload:s.payload,callback:s.callback,next:null},null===u?(c=u=p,l=d):u=u.next=p,i|=f;if(null===(s=s.next)){if(null===(s=a.shared.pending))break;s=(f=s).next,f.next=null,a.lastBaseUpdate=f,a.shared.pending=null}}if(null===u&&(l=d),a.baseState=l,a.firstBaseUpdate=c,a.lastBaseUpdate=u,null!==(t=a.shared.interleaved)){a=t;do{i|=a.lane,a=a.next}while(a!==t)}else null===o&&(a.shared.lanes=0);zl|=i,e.lanes=i,e.memoizedState=d}}function Zo(e,t,n){if(e=t.effects,t.effects=null,null!==e)for(t=0;t<e.length;t++){var r=e[t],a=r.callback;if(null!==a){if(r.callback=null,r=n,"function"!==typeof a)throw Error(o(191,a));a.call(r)}}}var jo=(new r.Component).refs;function Bo(e,t,n,r){n=null===(n=n(r,t=e.memoizedState))||void 0===n?t:I({},t,n),e.memoizedState=n,0===e.lanes&&(e.updateQueue.baseState=n)}var Wo={isMounted:function(e){return!!(e=e._reactInternals)&&We(e)===e},enqueueSetState:function(e,t,n){e=e._reactInternals;var r=ec(),a=tc(e),o=No(r,a);o.payload=t,void 0!==n&&null!==n&&(o.callback=n),null!==(t=Oo(e,o,a))&&(nc(t,e,a,r),zo(t,e,a))},enqueueReplaceState:function(e,t,n){e=e._reactInternals;var r=ec(),a=tc(e),o=No(r,a);o.tag=1,o.payload=t,void 0!==n&&null!==n&&(o.callback=n),null!==(t=Oo(e,o,a))&&(nc(t,e,a,r),zo(t,e,a))},enqueueForceUpdate:function(e,t){e=e._reactInternals;var n=ec(),r=tc(e),a=No(n,r);a.tag=2,void 0!==t&&null!==t&&(a.callback=t),null!==(t=Oo(e,a,r))&&(nc(t,e,r,n),zo(t,e,r))}};function Uo(e,t,n,r,a,o,i){return"function"===typeof(e=e.stateNode).shouldComponentUpdate?e.shouldComponentUpdate(r,o,i):!t.prototype||!t.prototype.isPureReactComponent||(!lr(n,r)||!lr(a,o))}function Vo(e,t,n){var r=!1,a=xa,o=t.contextType;return"object"===typeof o&&null!==o?o=Co(o):(a=Ra(t)?Da:Aa.current,o=(r=null!==(r=t.contextTypes)&&void 0!==r)?Pa(e,a):xa),t=new t(n,o),e.memoizedState=null!==t.state&&void 0!==t.state?t.state:null,t.updater=Wo,e.stateNode=t,t._reactInternals=e,r&&((e=e.stateNode).__reactInternalMemoizedUnmaskedChildContext=a,e.__reactInternalMemoizedMaskedChildContext=o),t}function Go(e,t,n,r){e=t.state,"function"===typeof t.componentWillReceiveProps&&t.componentWillReceiveProps(n,r),"function"===typeof t.UNSAFE_componentWillReceiveProps&&t.UNSAFE_componentWillReceiveProps(n,r),t.state!==e&&Wo.enqueueReplaceState(t,t.state,null)}function Jo(e,t,n,r){var a=e.stateNode;a.props=n,a.state=e.memoizedState,a.refs=jo,Ro(e);var o=t.contextType;"object"===typeof o&&null!==o?a.context=Co(o):(o=Ra(t)?Da:Aa.current,a.context=Pa(e,o)),a.state=e.memoizedState,"function"===typeof(o=t.getDerivedStateFromProps)&&(Bo(e,t,o,n),a.state=e.memoizedState),"function"===typeof t.getDerivedStateFromProps||"function"===typeof a.getSnapshotBeforeUpdate||"function"!==typeof a.UNSAFE_componentWillMount&&"function"!==typeof a.componentWillMount||(t=a.state,"function"===typeof a.componentWillMount&&a.componentWillMount(),"function"===typeof a.UNSAFE_componentWillMount&&a.UNSAFE_componentWillMount(),t!==a.state&&Wo.enqueueReplaceState(a,a.state,null),Lo(e,n,a,r),a.state=e.memoizedState),"function"===typeof a.componentDidMount&&(e.flags|=4194308)}function $o(e,t,n){if(null!==(e=n.ref)&&"function"!==typeof e&&"object"!==typeof e){if(n._owner){if(n=n._owner){if(1!==n.tag)throw Error(o(309));var r=n.stateNode}if(!r)throw Error(o(147,e));var a=r,i=""+e;return null!==t&&null!==t.ref&&"function"===typeof t.ref&&t.ref._stringRef===i?t.ref:(t=function(e){var t=a.refs;t===jo&&(t=a.refs={}),null===e?delete t[i]:t[i]=e},t._stringRef=i,t)}if("string"!==typeof e)throw Error(o(284));if(!n._owner)throw Error(o(290,e))}return e}function Ho(e,t){throw e=Object.prototype.toString.call(t),Error(o(31,"[object Object]"===e?"object with keys {"+Object.keys(t).join(", ")+"}":e))}function qo(e){return(0,e._init)(e._payload)}function Ko(e){function t(t,n){if(e){var r=t.deletions;null===r?(t.deletions=[n],t.flags|=16):r.push(n)}}function n(n,r){if(!e)return null;for(;null!==r;)t(n,r),r=r.sibling;return null}function r(e,t){for(e=new Map;null!==t;)null!==t.key?e.set(t.key,t):e.set(t.index,t),t=t.sibling;return e}function a(e,t){return(e=Mc(e,t)).index=0,e.sibling=null,e}function i(t,n,r){return t.index=r,e?null!==(r=t.alternate)?(r=r.index)<n?(t.flags|=2,n):r:(t.flags|=2,n):(t.flags|=1048576,n)}function s(t){return e&&null===t.alternate&&(t.flags|=2),t}function l(e,t,n,r){return null===t||6!==t.tag?((t=Ic(n,e.mode,r)).return=e,t):((t=a(t,n)).return=e,t)}function c(e,t,n,r){var o=n.type;return o===k?d(e,t,n.props.children,r,n.key):null!==t&&(t.elementType===o||"object"===typeof o&&null!==o&&o.$$typeof===R&&qo(o)===t.type)?((r=a(t,n.props)).ref=$o(e,t,n),r.return=e,r):((r=Nc(n.type,n.key,n.props,null,e.mode,r)).ref=$o(e,t,n),r.return=e,r)}function u(e,t,n,r){return null===t||4!==t.tag||t.stateNode.containerInfo!==n.containerInfo||t.stateNode.implementation!==n.implementation?((t=Lc(n,e.mode,r)).return=e,t):((t=a(t,n.children||[])).return=e,t)}function d(e,t,n,r,o){return null===t||7!==t.tag?((t=Oc(n,e.mode,r,o)).return=e,t):((t=a(t,n)).return=e,t)}function f(e,t,n){if("string"===typeof t&&""!==t||"number"===typeof t)return(t=Ic(""+t,e.mode,n)).return=e,t;if("object"===typeof t&&null!==t){switch(t.$$typeof){case w:return(n=Nc(t.type,t.key,t.props,null,e.mode,n)).ref=$o(e,null,t),n.return=e,n;case S:return(t=Lc(t,e.mode,n)).return=e,t;case R:return f(e,(0,t._init)(t._payload),n)}if(te(t)||O(t))return(t=Oc(t,e.mode,n,null)).return=e,t;Ho(e,t)}return null}function p(e,t,n,r){var a=null!==t?t.key:null;if("string"===typeof n&&""!==n||"number"===typeof n)return null!==a?null:l(e,t,""+n,r);if("object"===typeof n&&null!==n){switch(n.$$typeof){case w:return n.key===a?c(e,t,n,r):null;case S:return n.key===a?u(e,t,n,r):null;case R:return p(e,t,(a=n._init)(n._payload),r)}if(te(n)||O(n))return null!==a?null:d(e,t,n,r,null);Ho(e,n)}return null}function m(e,t,n,r,a){if("string"===typeof r&&""!==r||"number"===typeof r)return l(t,e=e.get(n)||null,""+r,a);if("object"===typeof r&&null!==r){switch(r.$$typeof){case w:return c(t,e=e.get(null===r.key?n:r.key)||null,r,a);case S:return u(t,e=e.get(null===r.key?n:r.key)||null,r,a);case R:return m(e,t,n,(0,r._init)(r._payload),a)}if(te(r)||O(r))return d(t,e=e.get(n)||null,r,a,null);Ho(t,r)}return null}function h(a,o,s,l){for(var c=null,u=null,d=o,h=o=0,v=null;null!==d&&h<s.length;h++){d.index>h?(v=d,d=null):v=d.sibling;var y=p(a,d,s[h],l);if(null===y){null===d&&(d=v);break}e&&d&&null===y.alternate&&t(a,d),o=i(y,o,h),null===u?c=y:u.sibling=y,u=y,d=v}if(h===s.length)return n(a,d),ao&&Qa(a,h),c;if(null===d){for(;h<s.length;h++)null!==(d=f(a,s[h],l))&&(o=i(d,o,h),null===u?c=d:u.sibling=d,u=d);return ao&&Qa(a,h),c}for(d=r(a,d);h<s.length;h++)null!==(v=m(d,a,h,s[h],l))&&(e&&null!==v.alternate&&d.delete(null===v.key?h:v.key),o=i(v,o,h),null===u?c=v:u.sibling=v,u=v);return e&&d.forEach((function(e){return t(a,e)})),ao&&Qa(a,h),c}function v(a,s,l,c){var u=O(l);if("function"!==typeof u)throw Error(o(150));if(null==(l=u.call(l)))throw Error(o(151));for(var d=u=null,h=s,v=s=0,y=null,b=l.next();null!==h&&!b.done;v++,b=l.next()){h.index>v?(y=h,h=null):y=h.sibling;var g=p(a,h,b.value,c);if(null===g){null===h&&(h=y);break}e&&h&&null===g.alternate&&t(a,h),s=i(g,s,v),null===d?u=g:d.sibling=g,d=g,h=y}if(b.done)return n(a,h),ao&&Qa(a,v),u;if(null===h){for(;!b.done;v++,b=l.next())null!==(b=f(a,b.value,c))&&(s=i(b,s,v),null===d?u=b:d.sibling=b,d=b);return ao&&Qa(a,v),u}for(h=r(a,h);!b.done;v++,b=l.next())null!==(b=m(h,a,v,b.value,c))&&(e&&null!==b.alternate&&h.delete(null===b.key?v:b.key),s=i(b,s,v),null===d?u=b:d.sibling=b,d=b);return e&&h.forEach((function(e){return t(a,e)})),ao&&Qa(a,v),u}return function e(r,o,i,l){if("object"===typeof i&&null!==i&&i.type===k&&null===i.key&&(i=i.props.children),"object"===typeof i&&null!==i){switch(i.$$typeof){case w:e:{for(var c=i.key,u=o;null!==u;){if(u.key===c){if((c=i.type)===k){if(7===u.tag){n(r,u.sibling),(o=a(u,i.props.children)).return=r,r=o;break e}}else if(u.elementType===c||"object"===typeof c&&null!==c&&c.$$typeof===R&&qo(c)===u.type){n(r,u.sibling),(o=a(u,i.props)).ref=$o(r,u,i),o.return=r,r=o;break e}n(r,u);break}t(r,u),u=u.sibling}i.type===k?((o=Oc(i.props.children,r.mode,l,i.key)).return=r,r=o):((l=Nc(i.type,i.key,i.props,null,r.mode,l)).ref=$o(r,o,i),l.return=r,r=l)}return s(r);case S:e:{for(u=i.key;null!==o;){if(o.key===u){if(4===o.tag&&o.stateNode.containerInfo===i.containerInfo&&o.stateNode.implementation===i.implementation){n(r,o.sibling),(o=a(o,i.children||[])).return=r,r=o;break e}n(r,o);break}t(r,o),o=o.sibling}(o=Lc(i,r.mode,l)).return=r,r=o}return s(r);case R:return e(r,o,(u=i._init)(i._payload),l)}if(te(i))return h(r,o,i,l);if(O(i))return v(r,o,i,l);Ho(r,i)}return"string"===typeof i&&""!==i||"number"===typeof i?(i=""+i,null!==o&&6===o.tag?(n(r,o.sibling),(o=a(o,i)).return=r,r=o):(n(r,o),(o=Ic(i,r.mode,l)).return=r,r=o),s(r)):n(r,o)}}var Yo=Ko(!0),Qo=Ko(!1),Xo={},ei=Ta(Xo),ti=Ta(Xo),ni=Ta(Xo);function ri(e){if(e===Xo)throw Error(o(174));return e}function ai(e,t){switch(Ca(ni,t),Ca(ti,e),Ca(ei,Xo),e=t.nodeType){case 9:case 11:t=(t=t.documentElement)?t.namespaceURI:le(null,"");break;default:t=le(t=(e=8===e?t.parentNode:t).namespaceURI||null,e=e.tagName)}Fa(ei),Ca(ei,t)}function oi(){Fa(ei),Fa(ti),Fa(ni)}function ii(e){ri(ni.current);var t=ri(ei.current),n=le(t,e.type);t!==n&&(Ca(ti,e),Ca(ei,n))}function si(e){ti.current===e&&(Fa(ei),Fa(ti))}var li=Ta(0);function ci(e){for(var t=e;null!==t;){if(13===t.tag){var n=t.memoizedState;if(null!==n&&(null===(n=n.dehydrated)||"$?"===n.data||"$!"===n.data))return t}else if(19===t.tag&&void 0!==t.memoizedProps.revealOrder){if(0!==(128&t.flags))return t}else if(null!==t.child){t.child.return=t,t=t.child;continue}if(t===e)break;for(;null===t.sibling;){if(null===t.return||t.return===e)return null;t=t.return}t.sibling.return=t.return,t=t.sibling}return null}var ui=[];function di(){for(var e=0;e<ui.length;e++)ui[e]._workInProgressVersionPrimary=null;ui.length=0}var fi=_.ReactCurrentDispatcher,pi=_.ReactCurrentBatchConfig,mi=0,hi=null,vi=null,yi=null,bi=!1,gi=!1,_i=0,wi=0;function Si(){throw Error(o(321))}function ki(e,t){if(null===t)return!1;for(var n=0;n<t.length&&n<e.length;n++)if(!sr(e[n],t[n]))return!1;return!0}function Ti(e,t,n,r,a,i){if(mi=i,hi=t,t.memoizedState=null,t.updateQueue=null,t.lanes=0,fi.current=null===e||null===e.memoizedState?ss:ls,e=n(r,a),gi){i=0;do{if(gi=!1,_i=0,25<=i)throw Error(o(301));i+=1,yi=vi=null,t.updateQueue=null,fi.current=cs,e=n(r,a)}while(gi)}if(fi.current=is,t=null!==vi&&null!==vi.next,mi=0,yi=vi=hi=null,bi=!1,t)throw Error(o(300));return e}function Fi(){var e=0!==_i;return _i=0,e}function Ci(){var e={memoizedState:null,baseState:null,baseQueue:null,queue:null,next:null};return null===yi?hi.memoizedState=yi=e:yi=yi.next=e,yi}function xi(){if(null===vi){var e=hi.alternate;e=null!==e?e.memoizedState:null}else e=vi.next;var t=null===yi?hi.memoizedState:yi.next;if(null!==t)yi=t,vi=e;else{if(null===e)throw Error(o(310));e={memoizedState:(vi=e).memoizedState,baseState:vi.baseState,baseQueue:vi.baseQueue,queue:vi.queue,next:null},null===yi?hi.memoizedState=yi=e:yi=yi.next=e}return yi}function Ai(e,t){return"function"===typeof t?t(e):t}function Ei(e){var t=xi(),n=t.queue;if(null===n)throw Error(o(311));n.lastRenderedReducer=e;var r=vi,a=r.baseQueue,i=n.pending;if(null!==i){if(null!==a){var s=a.next;a.next=i.next,i.next=s}r.baseQueue=a=i,n.pending=null}if(null!==a){i=a.next,r=r.baseState;var l=s=null,c=null,u=i;do{var d=u.lane;if((mi&d)===d)null!==c&&(c=c.next={lane:0,action:u.action,hasEagerState:u.hasEagerState,eagerState:u.eagerState,next:null}),r=u.hasEagerState?u.eagerState:e(r,u.action);else{var f={lane:d,action:u.action,hasEagerState:u.hasEagerState,eagerState:u.eagerState,next:null};null===c?(l=c=f,s=r):c=c.next=f,hi.lanes|=d,zl|=d}u=u.next}while(null!==u&&u!==i);null===c?s=r:c.next=l,sr(r,t.memoizedState)||(_s=!0),t.memoizedState=r,t.baseState=s,t.baseQueue=c,n.lastRenderedState=r}if(null!==(e=n.interleaved)){a=e;do{i=a.lane,hi.lanes|=i,zl|=i,a=a.next}while(a!==e)}else null===a&&(n.lanes=0);return[t.memoizedState,n.dispatch]}function Di(e){var t=xi(),n=t.queue;if(null===n)throw Error(o(311));n.lastRenderedReducer=e;var r=n.dispatch,a=n.pending,i=t.memoizedState;if(null!==a){n.pending=null;var s=a=a.next;do{i=e(i,s.action),s=s.next}while(s!==a);sr(i,t.memoizedState)||(_s=!0),t.memoizedState=i,null===t.baseQueue&&(t.baseState=i),n.lastRenderedState=i}return[i,r]}function Pi(){}function Ri(e,t){var n=hi,r=xi(),a=t(),i=!sr(r.memoizedState,a);if(i&&(r.memoizedState=a,_s=!0),r=r.queue,Vi(Oi.bind(null,n,r,e),[e]),r.getSnapshot!==t||i||null!==yi&&1&yi.memoizedState.tag){if(n.flags|=2048,Zi(9,Ni.bind(null,n,r,a,t),void 0,null),null===El)throw Error(o(349));0!==(30&mi)||Mi(n,t,a)}return a}function Mi(e,t,n){e.flags|=16384,e={getSnapshot:t,value:n},null===(t=hi.updateQueue)?(t={lastEffect:null,stores:null},hi.updateQueue=t,t.stores=[e]):null===(n=t.stores)?t.stores=[e]:n.push(e)}function Ni(e,t,n,r){t.value=n,t.getSnapshot=r,zi(t)&&Ii(e)}function Oi(e,t,n){return n((function(){zi(t)&&Ii(e)}))}function zi(e){var t=e.getSnapshot;e=e.value;try{var n=t();return!sr(e,n)}catch(r){return!0}}function Ii(e){var t=Do(e,1);null!==t&&nc(t,e,1,-1)}function Li(e){var t=Ci();return"function"===typeof e&&(e=e()),t.memoizedState=t.baseState=e,e={pending:null,interleaved:null,lanes:0,dispatch:null,lastRenderedReducer:Ai,lastRenderedState:e},t.queue=e,e=e.dispatch=ns.bind(null,hi,e),[t.memoizedState,e]}function Zi(e,t,n,r){return e={tag:e,create:t,destroy:n,deps:r,next:null},null===(t=hi.updateQueue)?(t={lastEffect:null,stores:null},hi.updateQueue=t,t.lastEffect=e.next=e):null===(n=t.lastEffect)?t.lastEffect=e.next=e:(r=n.next,n.next=e,e.next=r,t.lastEffect=e),e}function ji(){return xi().memoizedState}function Bi(e,t,n,r){var a=Ci();hi.flags|=e,a.memoizedState=Zi(1|t,n,void 0,void 0===r?null:r)}function Wi(e,t,n,r){var a=xi();r=void 0===r?null:r;var o=void 0;if(null!==vi){var i=vi.memoizedState;if(o=i.destroy,null!==r&&ki(r,i.deps))return void(a.memoizedState=Zi(t,n,o,r))}hi.flags|=e,a.memoizedState=Zi(1|t,n,o,r)}function Ui(e,t){return Bi(8390656,8,e,t)}function Vi(e,t){return Wi(2048,8,e,t)}function Gi(e,t){return Wi(4,2,e,t)}function Ji(e,t){return Wi(4,4,e,t)}function $i(e,t){return"function"===typeof t?(e=e(),t(e),function(){t(null)}):null!==t&&void 0!==t?(e=e(),t.current=e,function(){t.current=null}):void 0}function Hi(e,t,n){return n=null!==n&&void 0!==n?n.concat([e]):null,Wi(4,4,$i.bind(null,t,e),n)}function qi(){}function Ki(e,t){var n=xi();t=void 0===t?null:t;var r=n.memoizedState;return null!==r&&null!==t&&ki(t,r[1])?r[0]:(n.memoizedState=[e,t],e)}function Yi(e,t){var n=xi();t=void 0===t?null:t;var r=n.memoizedState;return null!==r&&null!==t&&ki(t,r[1])?r[0]:(e=e(),n.memoizedState=[e,t],e)}function Qi(e,t,n){return 0===(21&mi)?(e.baseState&&(e.baseState=!1,_s=!0),e.memoizedState=n):(sr(n,t)||(n=ht(),hi.lanes|=n,zl|=n,e.baseState=!0),t)}function Xi(e,t){var n=gt;gt=0!==n&&4>n?n:4,e(!0);var r=pi.transition;pi.transition={};try{e(!1),t()}finally{gt=n,pi.transition=r}}function es(){return xi().memoizedState}function ts(e,t,n){var r=tc(e);if(n={lane:r,action:n,hasEagerState:!1,eagerState:null,next:null},rs(e))as(t,n);else if(null!==(n=Eo(e,t,n,r))){nc(n,e,r,ec()),os(n,t,r)}}function ns(e,t,n){var r=tc(e),a={lane:r,action:n,hasEagerState:!1,eagerState:null,next:null};if(rs(e))as(t,a);else{var o=e.alternate;if(0===e.lanes&&(null===o||0===o.lanes)&&null!==(o=t.lastRenderedReducer))try{var i=t.lastRenderedState,s=o(i,n);if(a.hasEagerState=!0,a.eagerState=s,sr(s,i)){var l=t.interleaved;return null===l?(a.next=a,Ao(t)):(a.next=l.next,l.next=a),void(t.interleaved=a)}}catch(c){}null!==(n=Eo(e,t,a,r))&&(nc(n,e,r,a=ec()),os(n,t,r))}}function rs(e){var t=e.alternate;return e===hi||null!==t&&t===hi}function as(e,t){gi=bi=!0;var n=e.pending;null===n?t.next=t:(t.next=n.next,n.next=t),e.pending=t}function os(e,t,n){if(0!==(4194240&n)){var r=t.lanes;n|=r&=e.pendingLanes,t.lanes=n,bt(e,n)}}var is={readContext:Co,useCallback:Si,useContext:Si,useEffect:Si,useImperativeHandle:Si,useInsertionEffect:Si,useLayoutEffect:Si,useMemo:Si,useReducer:Si,useRef:Si,useState:Si,useDebugValue:Si,useDeferredValue:Si,useTransition:Si,useMutableSource:Si,useSyncExternalStore:Si,useId:Si,unstable_isNewReconciler:!1},ss={readContext:Co,useCallback:function(e,t){return Ci().memoizedState=[e,void 0===t?null:t],e},useContext:Co,useEffect:Ui,useImperativeHandle:function(e,t,n){return n=null!==n&&void 0!==n?n.concat([e]):null,Bi(4194308,4,$i.bind(null,t,e),n)},useLayoutEffect:function(e,t){return Bi(4194308,4,e,t)},useInsertionEffect:function(e,t){return Bi(4,2,e,t)},useMemo:function(e,t){var n=Ci();return t=void 0===t?null:t,e=e(),n.memoizedState=[e,t],e},useReducer:function(e,t,n){var r=Ci();return t=void 0!==n?n(t):t,r.memoizedState=r.baseState=t,e={pending:null,interleaved:null,lanes:0,dispatch:null,lastRenderedReducer:e,lastRenderedState:t},r.queue=e,e=e.dispatch=ts.bind(null,hi,e),[r.memoizedState,e]},useRef:function(e){return e={current:e},Ci().memoizedState=e},useState:Li,useDebugValue:qi,useDeferredValue:function(e){return Ci().memoizedState=e},useTransition:function(){var e=Li(!1),t=e[0];return e=Xi.bind(null,e[1]),Ci().memoizedState=e,[t,e]},useMutableSource:function(){},useSyncExternalStore:function(e,t,n){var r=hi,a=Ci();if(ao){if(void 0===n)throw Error(o(407));n=n()}else{if(n=t(),null===El)throw Error(o(349));0!==(30&mi)||Mi(r,t,n)}a.memoizedState=n;var i={value:n,getSnapshot:t};return a.queue=i,Ui(Oi.bind(null,r,i,e),[e]),r.flags|=2048,Zi(9,Ni.bind(null,r,i,n,t),void 0,null),n},useId:function(){var e=Ci(),t=El.identifierPrefix;if(ao){var n=Ya;t=":"+t+"R"+(n=(Ka&~(1<<32-it(Ka)-1)).toString(32)+n),0<(n=_i++)&&(t+="H"+n.toString(32)),t+=":"}else t=":"+t+"r"+(n=wi++).toString(32)+":";return e.memoizedState=t},unstable_isNewReconciler:!1},ls={readContext:Co,useCallback:Ki,useContext:Co,useEffect:Vi,useImperativeHandle:Hi,useInsertionEffect:Gi,useLayoutEffect:Ji,useMemo:Yi,useReducer:Ei,useRef:ji,useState:function(){return Ei(Ai)},useDebugValue:qi,useDeferredValue:function(e){return Qi(xi(),vi.memoizedState,e)},useTransition:function(){return[Ei(Ai)[0],xi().memoizedState]},useMutableSource:Pi,useSyncExternalStore:Ri,useId:es,unstable_isNewReconciler:!1},cs={readContext:Co,useCallback:Ki,useContext:Co,useEffect:Vi,useImperativeHandle:Hi,useInsertionEffect:Gi,useLayoutEffect:Ji,useMemo:Yi,useReducer:Di,useRef:ji,useState:function(){return Di(Ai)},useDebugValue:qi,useDeferredValue:function(e){var t=xi();return null===vi?t.memoizedState=e:Qi(t,vi.memoizedState,e)},useTransition:function(){return[Di(Ai)[0],xi().memoizedState]},useMutableSource:Pi,useSyncExternalStore:Ri,useId:es,unstable_isNewReconciler:!1};function us(e,t){try{var n="",r=t;do{n+=B(r),r=r.return}while(r);var a=n}catch(o){a="\nError generating stack: "+o.message+"\n"+o.stack}return{value:e,source:t,stack:a,digest:null}}function ds(e,t,n){return{value:e,source:null,stack:null!=n?n:null,digest:null!=t?t:null}}function fs(e,t){try{console.error(t.value)}catch(n){setTimeout((function(){throw n}))}}var ps="function"===typeof WeakMap?WeakMap:Map;function ms(e,t,n){(n=No(-1,n)).tag=3,n.payload={element:null};var r=t.value;return n.callback=function(){Vl||(Vl=!0,Gl=r),fs(0,t)},n}function hs(e,t,n){(n=No(-1,n)).tag=3;var r=e.type.getDerivedStateFromError;if("function"===typeof r){var a=t.value;n.payload=function(){return r(a)},n.callback=function(){fs(0,t)}}var o=e.stateNode;return null!==o&&"function"===typeof o.componentDidCatch&&(n.callback=function(){fs(0,t),"function"!==typeof r&&(null===Jl?Jl=new Set([this]):Jl.add(this));var e=t.stack;this.componentDidCatch(t.value,{componentStack:null!==e?e:""})}),n}function vs(e,t,n){var r=e.pingCache;if(null===r){r=e.pingCache=new ps;var a=new Set;r.set(t,a)}else void 0===(a=r.get(t))&&(a=new Set,r.set(t,a));a.has(n)||(a.add(n),e=Fc.bind(null,e,t,n),t.then(e,e))}function ys(e){do{var t;if((t=13===e.tag)&&(t=null===(t=e.memoizedState)||null!==t.dehydrated),t)return e;e=e.return}while(null!==e);return null}function bs(e,t,n,r,a){return 0===(1&e.mode)?(e===t?e.flags|=65536:(e.flags|=128,n.flags|=131072,n.flags&=-52805,1===n.tag&&(null===n.alternate?n.tag=17:((t=No(-1,1)).tag=2,Oo(n,t,1))),n.lanes|=1),e):(e.flags|=65536,e.lanes=a,e)}var gs=_.ReactCurrentOwner,_s=!1;function ws(e,t,n,r){t.child=null===e?Qo(t,null,n,r):Yo(t,e.child,n,r)}function Ss(e,t,n,r,a){n=n.render;var o=t.ref;return Fo(t,a),r=Ti(e,t,n,r,o,a),n=Fi(),null===e||_s?(ao&&n&&eo(t),t.flags|=1,ws(e,t,r,a),t.child):(t.updateQueue=e.updateQueue,t.flags&=-2053,e.lanes&=~a,Vs(e,t,a))}function ks(e,t,n,r,a){if(null===e){var o=n.type;return"function"!==typeof o||Rc(o)||void 0!==o.defaultProps||null!==n.compare||void 0!==n.defaultProps?((e=Nc(n.type,null,r,t,t.mode,a)).ref=t.ref,e.return=t,t.child=e):(t.tag=15,t.type=o,Ts(e,t,o,r,a))}if(o=e.child,0===(e.lanes&a)){var i=o.memoizedProps;if((n=null!==(n=n.compare)?n:lr)(i,r)&&e.ref===t.ref)return Vs(e,t,a)}return t.flags|=1,(e=Mc(o,r)).ref=t.ref,e.return=t,t.child=e}function Ts(e,t,n,r,a){if(null!==e){var o=e.memoizedProps;if(lr(o,r)&&e.ref===t.ref){if(_s=!1,t.pendingProps=r=o,0===(e.lanes&a))return t.lanes=e.lanes,Vs(e,t,a);0!==(131072&e.flags)&&(_s=!0)}}return xs(e,t,n,r,a)}function Fs(e,t,n){var r=t.pendingProps,a=r.children,o=null!==e?e.memoizedState:null;if("hidden"===r.mode)if(0===(1&t.mode))t.memoizedState={baseLanes:0,cachePool:null,transitions:null},Ca(Ml,Rl),Rl|=n;else{if(0===(1073741824&n))return e=null!==o?o.baseLanes|n:n,t.lanes=t.childLanes=1073741824,t.memoizedState={baseLanes:e,cachePool:null,transitions:null},t.updateQueue=null,Ca(Ml,Rl),Rl|=e,null;t.memoizedState={baseLanes:0,cachePool:null,transitions:null},r=null!==o?o.baseLanes:n,Ca(Ml,Rl),Rl|=r}else null!==o?(r=o.baseLanes|n,t.memoizedState=null):r=n,Ca(Ml,Rl),Rl|=r;return ws(e,t,a,n),t.child}function Cs(e,t){var n=t.ref;(null===e&&null!==n||null!==e&&e.ref!==n)&&(t.flags|=512,t.flags|=2097152)}function xs(e,t,n,r,a){var o=Ra(n)?Da:Aa.current;return o=Pa(t,o),Fo(t,a),n=Ti(e,t,n,r,o,a),r=Fi(),null===e||_s?(ao&&r&&eo(t),t.flags|=1,ws(e,t,n,a),t.child):(t.updateQueue=e.updateQueue,t.flags&=-2053,e.lanes&=~a,Vs(e,t,a))}function As(e,t,n,r,a){if(Ra(n)){var o=!0;za(t)}else o=!1;if(Fo(t,a),null===t.stateNode)Us(e,t),Vo(t,n,r),Jo(t,n,r,a),r=!0;else if(null===e){var i=t.stateNode,s=t.memoizedProps;i.props=s;var l=i.context,c=n.contextType;"object"===typeof c&&null!==c?c=Co(c):c=Pa(t,c=Ra(n)?Da:Aa.current);var u=n.getDerivedStateFromProps,d="function"===typeof u||"function"===typeof i.getSnapshotBeforeUpdate;d||"function"!==typeof i.UNSAFE_componentWillReceiveProps&&"function"!==typeof i.componentWillReceiveProps||(s!==r||l!==c)&&Go(t,i,r,c),Po=!1;var f=t.memoizedState;i.state=f,Lo(t,r,i,a),l=t.memoizedState,s!==r||f!==l||Ea.current||Po?("function"===typeof u&&(Bo(t,n,u,r),l=t.memoizedState),(s=Po||Uo(t,n,s,r,f,l,c))?(d||"function"!==typeof i.UNSAFE_componentWillMount&&"function"!==typeof i.componentWillMount||("function"===typeof i.componentWillMount&&i.componentWillMount(),"function"===typeof i.UNSAFE_componentWillMount&&i.UNSAFE_componentWillMount()),"function"===typeof i.componentDidMount&&(t.flags|=4194308)):("function"===typeof i.componentDidMount&&(t.flags|=4194308),t.memoizedProps=r,t.memoizedState=l),i.props=r,i.state=l,i.context=c,r=s):("function"===typeof i.componentDidMount&&(t.flags|=4194308),r=!1)}else{i=t.stateNode,Mo(e,t),s=t.memoizedProps,c=t.type===t.elementType?s:yo(t.type,s),i.props=c,d=t.pendingProps,f=i.context,"object"===typeof(l=n.contextType)&&null!==l?l=Co(l):l=Pa(t,l=Ra(n)?Da:Aa.current);var p=n.getDerivedStateFromProps;(u="function"===typeof p||"function"===typeof i.getSnapshotBeforeUpdate)||"function"!==typeof i.UNSAFE_componentWillReceiveProps&&"function"!==typeof i.componentWillReceiveProps||(s!==d||f!==l)&&Go(t,i,r,l),Po=!1,f=t.memoizedState,i.state=f,Lo(t,r,i,a);var m=t.memoizedState;s!==d||f!==m||Ea.current||Po?("function"===typeof p&&(Bo(t,n,p,r),m=t.memoizedState),(c=Po||Uo(t,n,c,r,f,m,l)||!1)?(u||"function"!==typeof i.UNSAFE_componentWillUpdate&&"function"!==typeof i.componentWillUpdate||("function"===typeof i.componentWillUpdate&&i.componentWillUpdate(r,m,l),"function"===typeof i.UNSAFE_componentWillUpdate&&i.UNSAFE_componentWillUpdate(r,m,l)),"function"===typeof i.componentDidUpdate&&(t.flags|=4),"function"===typeof i.getSnapshotBeforeUpdate&&(t.flags|=1024)):("function"!==typeof i.componentDidUpdate||s===e.memoizedProps&&f===e.memoizedState||(t.flags|=4),"function"!==typeof i.getSnapshotBeforeUpdate||s===e.memoizedProps&&f===e.memoizedState||(t.flags|=1024),t.memoizedProps=r,t.memoizedState=m),i.props=r,i.state=m,i.context=l,r=c):("function"!==typeof i.componentDidUpdate||s===e.memoizedProps&&f===e.memoizedState||(t.flags|=4),"function"!==typeof i.getSnapshotBeforeUpdate||s===e.memoizedProps&&f===e.memoizedState||(t.flags|=1024),r=!1)}return Es(e,t,n,r,o,a)}function Es(e,t,n,r,a,o){Cs(e,t);var i=0!==(128&t.flags);if(!r&&!i)return a&&Ia(t,n,!1),Vs(e,t,o);r=t.stateNode,gs.current=t;var s=i&&"function"!==typeof n.getDerivedStateFromError?null:r.render();return t.flags|=1,null!==e&&i?(t.child=Yo(t,e.child,null,o),t.child=Yo(t,null,s,o)):ws(e,t,s,o),t.memoizedState=r.state,a&&Ia(t,n,!0),t.child}function Ds(e){var t=e.stateNode;t.pendingContext?Na(0,t.pendingContext,t.pendingContext!==t.context):t.context&&Na(0,t.context,!1),ai(e,t.containerInfo)}function Ps(e,t,n,r,a){return mo(),ho(a),t.flags|=256,ws(e,t,n,r),t.child}var Rs,Ms,Ns,Os={dehydrated:null,treeContext:null,retryLane:0};function zs(e){return{baseLanes:e,cachePool:null,transitions:null}}function Is(e,t,n){var r,a=t.pendingProps,i=li.current,s=!1,l=0!==(128&t.flags);if((r=l)||(r=(null===e||null!==e.memoizedState)&&0!==(2&i)),r?(s=!0,t.flags&=-129):null!==e&&null===e.memoizedState||(i|=1),Ca(li,1&i),null===e)return co(t),null!==(e=t.memoizedState)&&null!==(e=e.dehydrated)?(0===(1&t.mode)?t.lanes=1:"$!"===e.data?t.lanes=8:t.lanes=1073741824,null):(l=a.children,e=a.fallback,s?(a=t.mode,s=t.child,l={mode:"hidden",children:l},0===(1&a)&&null!==s?(s.childLanes=0,s.pendingProps=l):s=zc(l,a,0,null),e=Oc(e,a,n,null),s.return=t,e.return=t,s.sibling=e,t.child=s,t.child.memoizedState=zs(n),t.memoizedState=Os,e):Ls(t,l));if(null!==(i=e.memoizedState)&&null!==(r=i.dehydrated))return function(e,t,n,r,a,i,s){if(n)return 256&t.flags?(t.flags&=-257,Zs(e,t,s,r=ds(Error(o(422))))):null!==t.memoizedState?(t.child=e.child,t.flags|=128,null):(i=r.fallback,a=t.mode,r=zc({mode:"visible",children:r.children},a,0,null),(i=Oc(i,a,s,null)).flags|=2,r.return=t,i.return=t,r.sibling=i,t.child=r,0!==(1&t.mode)&&Yo(t,e.child,null,s),t.child.memoizedState=zs(s),t.memoizedState=Os,i);if(0===(1&t.mode))return Zs(e,t,s,null);if("$!"===a.data){if(r=a.nextSibling&&a.nextSibling.dataset)var l=r.dgst;return r=l,Zs(e,t,s,r=ds(i=Error(o(419)),r,void 0))}if(l=0!==(s&e.childLanes),_s||l){if(null!==(r=El)){switch(s&-s){case 4:a=2;break;case 16:a=8;break;case 64:case 128:case 256:case 512:case 1024:case 2048:case 4096:case 8192:case 16384:case 32768:case 65536:case 131072:case 262144:case 524288:case 1048576:case 2097152:case 4194304:case 8388608:case 16777216:case 33554432:case 67108864:a=32;break;case 536870912:a=268435456;break;default:a=0}0!==(a=0!==(a&(r.suspendedLanes|s))?0:a)&&a!==i.retryLane&&(i.retryLane=a,Do(e,a),nc(r,e,a,-1))}return hc(),Zs(e,t,s,r=ds(Error(o(421))))}return"$?"===a.data?(t.flags|=128,t.child=e.child,t=xc.bind(null,e),a._reactRetry=t,null):(e=i.treeContext,ro=ca(a.nextSibling),no=t,ao=!0,oo=null,null!==e&&($a[Ha++]=Ka,$a[Ha++]=Ya,$a[Ha++]=qa,Ka=e.id,Ya=e.overflow,qa=t),(t=Ls(t,r.children)).flags|=4096,t)}(e,t,l,a,r,i,n);if(s){s=a.fallback,l=t.mode,r=(i=e.child).sibling;var c={mode:"hidden",children:a.children};return 0===(1&l)&&t.child!==i?((a=t.child).childLanes=0,a.pendingProps=c,t.deletions=null):(a=Mc(i,c)).subtreeFlags=14680064&i.subtreeFlags,null!==r?s=Mc(r,s):(s=Oc(s,l,n,null)).flags|=2,s.return=t,a.return=t,a.sibling=s,t.child=a,a=s,s=t.child,l=null===(l=e.child.memoizedState)?zs(n):{baseLanes:l.baseLanes|n,cachePool:null,transitions:l.transitions},s.memoizedState=l,s.childLanes=e.childLanes&~n,t.memoizedState=Os,a}return e=(s=e.child).sibling,a=Mc(s,{mode:"visible",children:a.children}),0===(1&t.mode)&&(a.lanes=n),a.return=t,a.sibling=null,null!==e&&(null===(n=t.deletions)?(t.deletions=[e],t.flags|=16):n.push(e)),t.child=a,t.memoizedState=null,a}function Ls(e,t){return(t=zc({mode:"visible",children:t},e.mode,0,null)).return=e,e.child=t}function Zs(e,t,n,r){return null!==r&&ho(r),Yo(t,e.child,null,n),(e=Ls(t,t.pendingProps.children)).flags|=2,t.memoizedState=null,e}function js(e,t,n){e.lanes|=t;var r=e.alternate;null!==r&&(r.lanes|=t),To(e.return,t,n)}function Bs(e,t,n,r,a){var o=e.memoizedState;null===o?e.memoizedState={isBackwards:t,rendering:null,renderingStartTime:0,last:r,tail:n,tailMode:a}:(o.isBackwards=t,o.rendering=null,o.renderingStartTime=0,o.last=r,o.tail=n,o.tailMode=a)}function Ws(e,t,n){var r=t.pendingProps,a=r.revealOrder,o=r.tail;if(ws(e,t,r.children,n),0!==(2&(r=li.current)))r=1&r|2,t.flags|=128;else{if(null!==e&&0!==(128&e.flags))e:for(e=t.child;null!==e;){if(13===e.tag)null!==e.memoizedState&&js(e,n,t);else if(19===e.tag)js(e,n,t);else if(null!==e.child){e.child.return=e,e=e.child;continue}if(e===t)break e;for(;null===e.sibling;){if(null===e.return||e.return===t)break e;e=e.return}e.sibling.return=e.return,e=e.sibling}r&=1}if(Ca(li,r),0===(1&t.mode))t.memoizedState=null;else switch(a){case"forwards":for(n=t.child,a=null;null!==n;)null!==(e=n.alternate)&&null===ci(e)&&(a=n),n=n.sibling;null===(n=a)?(a=t.child,t.child=null):(a=n.sibling,n.sibling=null),Bs(t,!1,a,n,o);break;case"backwards":for(n=null,a=t.child,t.child=null;null!==a;){if(null!==(e=a.alternate)&&null===ci(e)){t.child=a;break}e=a.sibling,a.sibling=n,n=a,a=e}Bs(t,!0,n,null,o);break;case"together":Bs(t,!1,null,null,void 0);break;default:t.memoizedState=null}return t.child}function Us(e,t){0===(1&t.mode)&&null!==e&&(e.alternate=null,t.alternate=null,t.flags|=2)}function Vs(e,t,n){if(null!==e&&(t.dependencies=e.dependencies),zl|=t.lanes,0===(n&t.childLanes))return null;if(null!==e&&t.child!==e.child)throw Error(o(153));if(null!==t.child){for(n=Mc(e=t.child,e.pendingProps),t.child=n,n.return=t;null!==e.sibling;)e=e.sibling,(n=n.sibling=Mc(e,e.pendingProps)).return=t;n.sibling=null}return t.child}function Gs(e,t){if(!ao)switch(e.tailMode){case"hidden":t=e.tail;for(var n=null;null!==t;)null!==t.alternate&&(n=t),t=t.sibling;null===n?e.tail=null:n.sibling=null;break;case"collapsed":n=e.tail;for(var r=null;null!==n;)null!==n.alternate&&(r=n),n=n.sibling;null===r?t||null===e.tail?e.tail=null:e.tail.sibling=null:r.sibling=null}}function Js(e){var t=null!==e.alternate&&e.alternate.child===e.child,n=0,r=0;if(t)for(var a=e.child;null!==a;)n|=a.lanes|a.childLanes,r|=14680064&a.subtreeFlags,r|=14680064&a.flags,a.return=e,a=a.sibling;else for(a=e.child;null!==a;)n|=a.lanes|a.childLanes,r|=a.subtreeFlags,r|=a.flags,a.return=e,a=a.sibling;return e.subtreeFlags|=r,e.childLanes=n,t}function $s(e,t,n){var r=t.pendingProps;switch(to(t),t.tag){case 2:case 16:case 15:case 0:case 11:case 7:case 8:case 12:case 9:case 14:return Js(t),null;case 1:case 17:return Ra(t.type)&&Ma(),Js(t),null;case 3:return r=t.stateNode,oi(),Fa(Ea),Fa(Aa),di(),r.pendingContext&&(r.context=r.pendingContext,r.pendingContext=null),null!==e&&null!==e.child||(fo(t)?t.flags|=4:null===e||e.memoizedState.isDehydrated&&0===(256&t.flags)||(t.flags|=1024,null!==oo&&(ic(oo),oo=null))),Js(t),null;case 5:si(t);var a=ri(ni.current);if(n=t.type,null!==e&&null!=t.stateNode)Ms(e,t,n,r),e.ref!==t.ref&&(t.flags|=512,t.flags|=2097152);else{if(!r){if(null===t.stateNode)throw Error(o(166));return Js(t),null}if(e=ri(ei.current),fo(t)){r=t.stateNode,n=t.type;var i=t.memoizedProps;switch(r[fa]=t,r[pa]=i,e=0!==(1&t.mode),n){case"dialog":Zr("cancel",r),Zr("close",r);break;case"iframe":case"object":case"embed":Zr("load",r);break;case"video":case"audio":for(a=0;a<Or.length;a++)Zr(Or[a],r);break;case"source":Zr("error",r);break;case"img":case"image":case"link":Zr("error",r),Zr("load",r);break;case"details":Zr("toggle",r);break;case"input":K(r,i),Zr("invalid",r);break;case"select":r._wrapperState={wasMultiple:!!i.multiple},Zr("invalid",r);break;case"textarea":ae(r,i),Zr("invalid",r)}for(var l in be(n,i),a=null,i)if(i.hasOwnProperty(l)){var c=i[l];"children"===l?"string"===typeof c?r.textContent!==c&&(!0!==i.suppressHydrationWarning&&Qr(r.textContent,c,e),a=["children",c]):"number"===typeof c&&r.textContent!==""+c&&(!0!==i.suppressHydrationWarning&&Qr(r.textContent,c,e),a=["children",""+c]):s.hasOwnProperty(l)&&null!=c&&"onScroll"===l&&Zr("scroll",r)}switch(n){case"input":J(r),X(r,i,!0);break;case"textarea":J(r),ie(r);break;case"select":case"option":break;default:"function"===typeof i.onClick&&(r.onclick=Xr)}r=a,t.updateQueue=r,null!==r&&(t.flags|=4)}else{l=9===a.nodeType?a:a.ownerDocument,"http://www.w3.org/1999/xhtml"===e&&(e=se(n)),"http://www.w3.org/1999/xhtml"===e?"script"===n?((e=l.createElement("div")).innerHTML="<script><\/script>",e=e.removeChild(e.firstChild)):"string"===typeof r.is?e=l.createElement(n,{is:r.is}):(e=l.createElement(n),"select"===n&&(l=e,r.multiple?l.multiple=!0:r.size&&(l.size=r.size))):e=l.createElementNS(e,n),e[fa]=t,e[pa]=r,Rs(e,t),t.stateNode=e;e:{switch(l=ge(n,r),n){case"dialog":Zr("cancel",e),Zr("close",e),a=r;break;case"iframe":case"object":case"embed":Zr("load",e),a=r;break;case"video":case"audio":for(a=0;a<Or.length;a++)Zr(Or[a],e);a=r;break;case"source":Zr("error",e),a=r;break;case"img":case"image":case"link":Zr("error",e),Zr("load",e),a=r;break;case"details":Zr("toggle",e),a=r;break;case"input":K(e,r),a=q(e,r),Zr("invalid",e);break;case"option":default:a=r;break;case"select":e._wrapperState={wasMultiple:!!r.multiple},a=I({},r,{value:void 0}),Zr("invalid",e);break;case"textarea":ae(e,r),a=re(e,r),Zr("invalid",e)}for(i in be(n,a),c=a)if(c.hasOwnProperty(i)){var u=c[i];"style"===i?ve(e,u):"dangerouslySetInnerHTML"===i?null!=(u=u?u.__html:void 0)&&de(e,u):"children"===i?"string"===typeof u?("textarea"!==n||""!==u)&&fe(e,u):"number"===typeof u&&fe(e,""+u):"suppressContentEditableWarning"!==i&&"suppressHydrationWarning"!==i&&"autoFocus"!==i&&(s.hasOwnProperty(i)?null!=u&&"onScroll"===i&&Zr("scroll",e):null!=u&&g(e,i,u,l))}switch(n){case"input":J(e),X(e,r,!1);break;case"textarea":J(e),ie(e);break;case"option":null!=r.value&&e.setAttribute("value",""+V(r.value));break;case"select":e.multiple=!!r.multiple,null!=(i=r.value)?ne(e,!!r.multiple,i,!1):null!=r.defaultValue&&ne(e,!!r.multiple,r.defaultValue,!0);break;default:"function"===typeof a.onClick&&(e.onclick=Xr)}switch(n){case"button":case"input":case"select":case"textarea":r=!!r.autoFocus;break e;case"img":r=!0;break e;default:r=!1}}r&&(t.flags|=4)}null!==t.ref&&(t.flags|=512,t.flags|=2097152)}return Js(t),null;case 6:if(e&&null!=t.stateNode)Ns(0,t,e.memoizedProps,r);else{if("string"!==typeof r&&null===t.stateNode)throw Error(o(166));if(n=ri(ni.current),ri(ei.current),fo(t)){if(r=t.stateNode,n=t.memoizedProps,r[fa]=t,(i=r.nodeValue!==n)&&null!==(e=no))switch(e.tag){case 3:Qr(r.nodeValue,n,0!==(1&e.mode));break;case 5:!0!==e.memoizedProps.suppressHydrationWarning&&Qr(r.nodeValue,n,0!==(1&e.mode))}i&&(t.flags|=4)}else(r=(9===n.nodeType?n:n.ownerDocument).createTextNode(r))[fa]=t,t.stateNode=r}return Js(t),null;case 13:if(Fa(li),r=t.memoizedState,null===e||null!==e.memoizedState&&null!==e.memoizedState.dehydrated){if(ao&&null!==ro&&0!==(1&t.mode)&&0===(128&t.flags))po(),mo(),t.flags|=98560,i=!1;else if(i=fo(t),null!==r&&null!==r.dehydrated){if(null===e){if(!i)throw Error(o(318));if(!(i=null!==(i=t.memoizedState)?i.dehydrated:null))throw Error(o(317));i[fa]=t}else mo(),0===(128&t.flags)&&(t.memoizedState=null),t.flags|=4;Js(t),i=!1}else null!==oo&&(ic(oo),oo=null),i=!0;if(!i)return 65536&t.flags?t:null}return 0!==(128&t.flags)?(t.lanes=n,t):((r=null!==r)!==(null!==e&&null!==e.memoizedState)&&r&&(t.child.flags|=8192,0!==(1&t.mode)&&(null===e||0!==(1&li.current)?0===Nl&&(Nl=3):hc())),null!==t.updateQueue&&(t.flags|=4),Js(t),null);case 4:return oi(),null===e&&Wr(t.stateNode.containerInfo),Js(t),null;case 10:return ko(t.type._context),Js(t),null;case 19:if(Fa(li),null===(i=t.memoizedState))return Js(t),null;if(r=0!==(128&t.flags),null===(l=i.rendering))if(r)Gs(i,!1);else{if(0!==Nl||null!==e&&0!==(128&e.flags))for(e=t.child;null!==e;){if(null!==(l=ci(e))){for(t.flags|=128,Gs(i,!1),null!==(r=l.updateQueue)&&(t.updateQueue=r,t.flags|=4),t.subtreeFlags=0,r=n,n=t.child;null!==n;)e=r,(i=n).flags&=14680066,null===(l=i.alternate)?(i.childLanes=0,i.lanes=e,i.child=null,i.subtreeFlags=0,i.memoizedProps=null,i.memoizedState=null,i.updateQueue=null,i.dependencies=null,i.stateNode=null):(i.childLanes=l.childLanes,i.lanes=l.lanes,i.child=l.child,i.subtreeFlags=0,i.deletions=null,i.memoizedProps=l.memoizedProps,i.memoizedState=l.memoizedState,i.updateQueue=l.updateQueue,i.type=l.type,e=l.dependencies,i.dependencies=null===e?null:{lanes:e.lanes,firstContext:e.firstContext}),n=n.sibling;return Ca(li,1&li.current|2),t.child}e=e.sibling}null!==i.tail&&Ye()>Wl&&(t.flags|=128,r=!0,Gs(i,!1),t.lanes=4194304)}else{if(!r)if(null!==(e=ci(l))){if(t.flags|=128,r=!0,null!==(n=e.updateQueue)&&(t.updateQueue=n,t.flags|=4),Gs(i,!0),null===i.tail&&"hidden"===i.tailMode&&!l.alternate&&!ao)return Js(t),null}else 2*Ye()-i.renderingStartTime>Wl&&1073741824!==n&&(t.flags|=128,r=!0,Gs(i,!1),t.lanes=4194304);i.isBackwards?(l.sibling=t.child,t.child=l):(null!==(n=i.last)?n.sibling=l:t.child=l,i.last=l)}return null!==i.tail?(t=i.tail,i.rendering=t,i.tail=t.sibling,i.renderingStartTime=Ye(),t.sibling=null,n=li.current,Ca(li,r?1&n|2:1&n),t):(Js(t),null);case 22:case 23:return dc(),r=null!==t.memoizedState,null!==e&&null!==e.memoizedState!==r&&(t.flags|=8192),r&&0!==(1&t.mode)?0!==(1073741824&Rl)&&(Js(t),6&t.subtreeFlags&&(t.flags|=8192)):Js(t),null;case 24:case 25:return null}throw Error(o(156,t.tag))}function Hs(e,t){switch(to(t),t.tag){case 1:return Ra(t.type)&&Ma(),65536&(e=t.flags)?(t.flags=-65537&e|128,t):null;case 3:return oi(),Fa(Ea),Fa(Aa),di(),0!==(65536&(e=t.flags))&&0===(128&e)?(t.flags=-65537&e|128,t):null;case 5:return si(t),null;case 13:if(Fa(li),null!==(e=t.memoizedState)&&null!==e.dehydrated){if(null===t.alternate)throw Error(o(340));mo()}return 65536&(e=t.flags)?(t.flags=-65537&e|128,t):null;case 19:return Fa(li),null;case 4:return oi(),null;case 10:return ko(t.type._context),null;case 22:case 23:return dc(),null;default:return null}}Rs=function(e,t){for(var n=t.child;null!==n;){if(5===n.tag||6===n.tag)e.appendChild(n.stateNode);else if(4!==n.tag&&null!==n.child){n.child.return=n,n=n.child;continue}if(n===t)break;for(;null===n.sibling;){if(null===n.return||n.return===t)return;n=n.return}n.sibling.return=n.return,n=n.sibling}},Ms=function(e,t,n,r){var a=e.memoizedProps;if(a!==r){e=t.stateNode,ri(ei.current);var o,i=null;switch(n){case"input":a=q(e,a),r=q(e,r),i=[];break;case"select":a=I({},a,{value:void 0}),r=I({},r,{value:void 0}),i=[];break;case"textarea":a=re(e,a),r=re(e,r),i=[];break;default:"function"!==typeof a.onClick&&"function"===typeof r.onClick&&(e.onclick=Xr)}for(u in be(n,r),n=null,a)if(!r.hasOwnProperty(u)&&a.hasOwnProperty(u)&&null!=a[u])if("style"===u){var l=a[u];for(o in l)l.hasOwnProperty(o)&&(n||(n={}),n[o]="")}else"dangerouslySetInnerHTML"!==u&&"children"!==u&&"suppressContentEditableWarning"!==u&&"suppressHydrationWarning"!==u&&"autoFocus"!==u&&(s.hasOwnProperty(u)?i||(i=[]):(i=i||[]).push(u,null));for(u in r){var c=r[u];if(l=null!=a?a[u]:void 0,r.hasOwnProperty(u)&&c!==l&&(null!=c||null!=l))if("style"===u)if(l){for(o in l)!l.hasOwnProperty(o)||c&&c.hasOwnProperty(o)||(n||(n={}),n[o]="");for(o in c)c.hasOwnProperty(o)&&l[o]!==c[o]&&(n||(n={}),n[o]=c[o])}else n||(i||(i=[]),i.push(u,n)),n=c;else"dangerouslySetInnerHTML"===u?(c=c?c.__html:void 0,l=l?l.__html:void 0,null!=c&&l!==c&&(i=i||[]).push(u,c)):"children"===u?"string"!==typeof c&&"number"!==typeof c||(i=i||[]).push(u,""+c):"suppressContentEditableWarning"!==u&&"suppressHydrationWarning"!==u&&(s.hasOwnProperty(u)?(null!=c&&"onScroll"===u&&Zr("scroll",e),i||l===c||(i=[])):(i=i||[]).push(u,c))}n&&(i=i||[]).push("style",n);var u=i;(t.updateQueue=u)&&(t.flags|=4)}},Ns=function(e,t,n,r){n!==r&&(t.flags|=4)};var qs=!1,Ks=!1,Ys="function"===typeof WeakSet?WeakSet:Set,Qs=null;function Xs(e,t){var n=e.ref;if(null!==n)if("function"===typeof n)try{n(null)}catch(r){Tc(e,t,r)}else n.current=null}function el(e,t,n){try{n()}catch(r){Tc(e,t,r)}}var tl=!1;function nl(e,t,n){var r=t.updateQueue;if(null!==(r=null!==r?r.lastEffect:null)){var a=r=r.next;do{if((a.tag&e)===e){var o=a.destroy;a.destroy=void 0,void 0!==o&&el(t,n,o)}a=a.next}while(a!==r)}}function rl(e,t){if(null!==(t=null!==(t=t.updateQueue)?t.lastEffect:null)){var n=t=t.next;do{if((n.tag&e)===e){var r=n.create;n.destroy=r()}n=n.next}while(n!==t)}}function al(e){var t=e.ref;if(null!==t){var n=e.stateNode;e.tag,e=n,"function"===typeof t?t(e):t.current=e}}function ol(e){var t=e.alternate;null!==t&&(e.alternate=null,ol(t)),e.child=null,e.deletions=null,e.sibling=null,5===e.tag&&(null!==(t=e.stateNode)&&(delete t[fa],delete t[pa],delete t[ha],delete t[va],delete t[ya])),e.stateNode=null,e.return=null,e.dependencies=null,e.memoizedProps=null,e.memoizedState=null,e.pendingProps=null,e.stateNode=null,e.updateQueue=null}function il(e){return 5===e.tag||3===e.tag||4===e.tag}function sl(e){e:for(;;){for(;null===e.sibling;){if(null===e.return||il(e.return))return null;e=e.return}for(e.sibling.return=e.return,e=e.sibling;5!==e.tag&&6!==e.tag&&18!==e.tag;){if(2&e.flags)continue e;if(null===e.child||4===e.tag)continue e;e.child.return=e,e=e.child}if(!(2&e.flags))return e.stateNode}}function ll(e,t,n){var r=e.tag;if(5===r||6===r)e=e.stateNode,t?8===n.nodeType?n.parentNode.insertBefore(e,t):n.insertBefore(e,t):(8===n.nodeType?(t=n.parentNode).insertBefore(e,n):(t=n).appendChild(e),null!==(n=n._reactRootContainer)&&void 0!==n||null!==t.onclick||(t.onclick=Xr));else if(4!==r&&null!==(e=e.child))for(ll(e,t,n),e=e.sibling;null!==e;)ll(e,t,n),e=e.sibling}function cl(e,t,n){var r=e.tag;if(5===r||6===r)e=e.stateNode,t?n.insertBefore(e,t):n.appendChild(e);else if(4!==r&&null!==(e=e.child))for(cl(e,t,n),e=e.sibling;null!==e;)cl(e,t,n),e=e.sibling}var ul=null,dl=!1;function fl(e,t,n){for(n=n.child;null!==n;)pl(e,t,n),n=n.sibling}function pl(e,t,n){if(ot&&"function"===typeof ot.onCommitFiberUnmount)try{ot.onCommitFiberUnmount(at,n)}catch(s){}switch(n.tag){case 5:Ks||Xs(n,t);case 6:var r=ul,a=dl;ul=null,fl(e,t,n),dl=a,null!==(ul=r)&&(dl?(e=ul,n=n.stateNode,8===e.nodeType?e.parentNode.removeChild(n):e.removeChild(n)):ul.removeChild(n.stateNode));break;case 18:null!==ul&&(dl?(e=ul,n=n.stateNode,8===e.nodeType?la(e.parentNode,n):1===e.nodeType&&la(e,n),Wt(e)):la(ul,n.stateNode));break;case 4:r=ul,a=dl,ul=n.stateNode.containerInfo,dl=!0,fl(e,t,n),ul=r,dl=a;break;case 0:case 11:case 14:case 15:if(!Ks&&(null!==(r=n.updateQueue)&&null!==(r=r.lastEffect))){a=r=r.next;do{var o=a,i=o.destroy;o=o.tag,void 0!==i&&(0!==(2&o)||0!==(4&o))&&el(n,t,i),a=a.next}while(a!==r)}fl(e,t,n);break;case 1:if(!Ks&&(Xs(n,t),"function"===typeof(r=n.stateNode).componentWillUnmount))try{r.props=n.memoizedProps,r.state=n.memoizedState,r.componentWillUnmount()}catch(s){Tc(n,t,s)}fl(e,t,n);break;case 21:fl(e,t,n);break;case 22:1&n.mode?(Ks=(r=Ks)||null!==n.memoizedState,fl(e,t,n),Ks=r):fl(e,t,n);break;default:fl(e,t,n)}}function ml(e){var t=e.updateQueue;if(null!==t){e.updateQueue=null;var n=e.stateNode;null===n&&(n=e.stateNode=new Ys),t.forEach((function(t){var r=Ac.bind(null,e,t);n.has(t)||(n.add(t),t.then(r,r))}))}}function hl(e,t){var n=t.deletions;if(null!==n)for(var r=0;r<n.length;r++){var a=n[r];try{var i=e,s=t,l=s;e:for(;null!==l;){switch(l.tag){case 5:ul=l.stateNode,dl=!1;break e;case 3:case 4:ul=l.stateNode.containerInfo,dl=!0;break e}l=l.return}if(null===ul)throw Error(o(160));pl(i,s,a),ul=null,dl=!1;var c=a.alternate;null!==c&&(c.return=null),a.return=null}catch(u){Tc(a,t,u)}}if(12854&t.subtreeFlags)for(t=t.child;null!==t;)vl(t,e),t=t.sibling}function vl(e,t){var n=e.alternate,r=e.flags;switch(e.tag){case 0:case 11:case 14:case 15:if(hl(t,e),yl(e),4&r){try{nl(3,e,e.return),rl(3,e)}catch(v){Tc(e,e.return,v)}try{nl(5,e,e.return)}catch(v){Tc(e,e.return,v)}}break;case 1:hl(t,e),yl(e),512&r&&null!==n&&Xs(n,n.return);break;case 5:if(hl(t,e),yl(e),512&r&&null!==n&&Xs(n,n.return),32&e.flags){var a=e.stateNode;try{fe(a,"")}catch(v){Tc(e,e.return,v)}}if(4&r&&null!=(a=e.stateNode)){var i=e.memoizedProps,s=null!==n?n.memoizedProps:i,l=e.type,c=e.updateQueue;if(e.updateQueue=null,null!==c)try{"input"===l&&"radio"===i.type&&null!=i.name&&Y(a,i),ge(l,s);var u=ge(l,i);for(s=0;s<c.length;s+=2){var d=c[s],f=c[s+1];"style"===d?ve(a,f):"dangerouslySetInnerHTML"===d?de(a,f):"children"===d?fe(a,f):g(a,d,f,u)}switch(l){case"input":Q(a,i);break;case"textarea":oe(a,i);break;case"select":var p=a._wrapperState.wasMultiple;a._wrapperState.wasMultiple=!!i.multiple;var m=i.value;null!=m?ne(a,!!i.multiple,m,!1):p!==!!i.multiple&&(null!=i.defaultValue?ne(a,!!i.multiple,i.defaultValue,!0):ne(a,!!i.multiple,i.multiple?[]:"",!1))}a[pa]=i}catch(v){Tc(e,e.return,v)}}break;case 6:if(hl(t,e),yl(e),4&r){if(null===e.stateNode)throw Error(o(162));a=e.stateNode,i=e.memoizedProps;try{a.nodeValue=i}catch(v){Tc(e,e.return,v)}}break;case 3:if(hl(t,e),yl(e),4&r&&null!==n&&n.memoizedState.isDehydrated)try{Wt(t.containerInfo)}catch(v){Tc(e,e.return,v)}break;case 4:default:hl(t,e),yl(e);break;case 13:hl(t,e),yl(e),8192&(a=e.child).flags&&(i=null!==a.memoizedState,a.stateNode.isHidden=i,!i||null!==a.alternate&&null!==a.alternate.memoizedState||(Bl=Ye())),4&r&&ml(e);break;case 22:if(d=null!==n&&null!==n.memoizedState,1&e.mode?(Ks=(u=Ks)||d,hl(t,e),Ks=u):hl(t,e),yl(e),8192&r){if(u=null!==e.memoizedState,(e.stateNode.isHidden=u)&&!d&&0!==(1&e.mode))for(Qs=e,d=e.child;null!==d;){for(f=Qs=d;null!==Qs;){switch(m=(p=Qs).child,p.tag){case 0:case 11:case 14:case 15:nl(4,p,p.return);break;case 1:Xs(p,p.return);var h=p.stateNode;if("function"===typeof h.componentWillUnmount){r=p,n=p.return;try{t=r,h.props=t.memoizedProps,h.state=t.memoizedState,h.componentWillUnmount()}catch(v){Tc(r,n,v)}}break;case 5:Xs(p,p.return);break;case 22:if(null!==p.memoizedState){wl(f);continue}}null!==m?(m.return=p,Qs=m):wl(f)}d=d.sibling}e:for(d=null,f=e;;){if(5===f.tag){if(null===d){d=f;try{a=f.stateNode,u?"function"===typeof(i=a.style).setProperty?i.setProperty("display","none","important"):i.display="none":(l=f.stateNode,s=void 0!==(c=f.memoizedProps.style)&&null!==c&&c.hasOwnProperty("display")?c.display:null,l.style.display=he("display",s))}catch(v){Tc(e,e.return,v)}}}else if(6===f.tag){if(null===d)try{f.stateNode.nodeValue=u?"":f.memoizedProps}catch(v){Tc(e,e.return,v)}}else if((22!==f.tag&&23!==f.tag||null===f.memoizedState||f===e)&&null!==f.child){f.child.return=f,f=f.child;continue}if(f===e)break e;for(;null===f.sibling;){if(null===f.return||f.return===e)break e;d===f&&(d=null),f=f.return}d===f&&(d=null),f.sibling.return=f.return,f=f.sibling}}break;case 19:hl(t,e),yl(e),4&r&&ml(e);case 21:}}function yl(e){var t=e.flags;if(2&t){try{e:{for(var n=e.return;null!==n;){if(il(n)){var r=n;break e}n=n.return}throw Error(o(160))}switch(r.tag){case 5:var a=r.stateNode;32&r.flags&&(fe(a,""),r.flags&=-33),cl(e,sl(e),a);break;case 3:case 4:var i=r.stateNode.containerInfo;ll(e,sl(e),i);break;default:throw Error(o(161))}}catch(s){Tc(e,e.return,s)}e.flags&=-3}4096&t&&(e.flags&=-4097)}function bl(e,t,n){Qs=e,gl(e,t,n)}function gl(e,t,n){for(var r=0!==(1&e.mode);null!==Qs;){var a=Qs,o=a.child;if(22===a.tag&&r){var i=null!==a.memoizedState||qs;if(!i){var s=a.alternate,l=null!==s&&null!==s.memoizedState||Ks;s=qs;var c=Ks;if(qs=i,(Ks=l)&&!c)for(Qs=a;null!==Qs;)l=(i=Qs).child,22===i.tag&&null!==i.memoizedState?Sl(a):null!==l?(l.return=i,Qs=l):Sl(a);for(;null!==o;)Qs=o,gl(o,t,n),o=o.sibling;Qs=a,qs=s,Ks=c}_l(e)}else 0!==(8772&a.subtreeFlags)&&null!==o?(o.return=a,Qs=o):_l(e)}}function _l(e){for(;null!==Qs;){var t=Qs;if(0!==(8772&t.flags)){var n=t.alternate;try{if(0!==(8772&t.flags))switch(t.tag){case 0:case 11:case 15:Ks||rl(5,t);break;case 1:var r=t.stateNode;if(4&t.flags&&!Ks)if(null===n)r.componentDidMount();else{var a=t.elementType===t.type?n.memoizedProps:yo(t.type,n.memoizedProps);r.componentDidUpdate(a,n.memoizedState,r.__reactInternalSnapshotBeforeUpdate)}var i=t.updateQueue;null!==i&&Zo(t,i,r);break;case 3:var s=t.updateQueue;if(null!==s){if(n=null,null!==t.child)switch(t.child.tag){case 5:case 1:n=t.child.stateNode}Zo(t,s,n)}break;case 5:var l=t.stateNode;if(null===n&&4&t.flags){n=l;var c=t.memoizedProps;switch(t.type){case"button":case"input":case"select":case"textarea":c.autoFocus&&n.focus();break;case"img":c.src&&(n.src=c.src)}}break;case 6:case 4:case 12:case 19:case 17:case 21:case 22:case 23:case 25:break;case 13:if(null===t.memoizedState){var u=t.alternate;if(null!==u){var d=u.memoizedState;if(null!==d){var f=d.dehydrated;null!==f&&Wt(f)}}}break;default:throw Error(o(163))}Ks||512&t.flags&&al(t)}catch(p){Tc(t,t.return,p)}}if(t===e){Qs=null;break}if(null!==(n=t.sibling)){n.return=t.return,Qs=n;break}Qs=t.return}}function wl(e){for(;null!==Qs;){var t=Qs;if(t===e){Qs=null;break}var n=t.sibling;if(null!==n){n.return=t.return,Qs=n;break}Qs=t.return}}function Sl(e){for(;null!==Qs;){var t=Qs;try{switch(t.tag){case 0:case 11:case 15:var n=t.return;try{rl(4,t)}catch(l){Tc(t,n,l)}break;case 1:var r=t.stateNode;if("function"===typeof r.componentDidMount){var a=t.return;try{r.componentDidMount()}catch(l){Tc(t,a,l)}}var o=t.return;try{al(t)}catch(l){Tc(t,o,l)}break;case 5:var i=t.return;try{al(t)}catch(l){Tc(t,i,l)}}}catch(l){Tc(t,t.return,l)}if(t===e){Qs=null;break}var s=t.sibling;if(null!==s){s.return=t.return,Qs=s;break}Qs=t.return}}var kl,Tl=Math.ceil,Fl=_.ReactCurrentDispatcher,Cl=_.ReactCurrentOwner,xl=_.ReactCurrentBatchConfig,Al=0,El=null,Dl=null,Pl=0,Rl=0,Ml=Ta(0),Nl=0,Ol=null,zl=0,Il=0,Ll=0,Zl=null,jl=null,Bl=0,Wl=1/0,Ul=null,Vl=!1,Gl=null,Jl=null,$l=!1,Hl=null,ql=0,Kl=0,Yl=null,Ql=-1,Xl=0;function ec(){return 0!==(6&Al)?Ye():-1!==Ql?Ql:Ql=Ye()}function tc(e){return 0===(1&e.mode)?1:0!==(2&Al)&&0!==Pl?Pl&-Pl:null!==vo.transition?(0===Xl&&(Xl=ht()),Xl):0!==(e=gt)?e:e=void 0===(e=window.event)?16:Kt(e.type)}function nc(e,t,n,r){if(50<Kl)throw Kl=0,Yl=null,Error(o(185));yt(e,n,r),0!==(2&Al)&&e===El||(e===El&&(0===(2&Al)&&(Il|=n),4===Nl&&sc(e,Pl)),rc(e,r),1===n&&0===Al&&0===(1&t.mode)&&(Wl=Ye()+500,Za&&Wa()))}function rc(e,t){var n=e.callbackNode;!function(e,t){for(var n=e.suspendedLanes,r=e.pingedLanes,a=e.expirationTimes,o=e.pendingLanes;0<o;){var i=31-it(o),s=1<<i,l=a[i];-1===l?0!==(s&n)&&0===(s&r)||(a[i]=pt(s,t)):l<=t&&(e.expiredLanes|=s),o&=~s}}(e,t);var r=ft(e,e===El?Pl:0);if(0===r)null!==n&&He(n),e.callbackNode=null,e.callbackPriority=0;else if(t=r&-r,e.callbackPriority!==t){if(null!=n&&He(n),1===t)0===e.tag?function(e){Za=!0,Ba(e)}(lc.bind(null,e)):Ba(lc.bind(null,e)),ia((function(){0===(6&Al)&&Wa()})),n=null;else{switch(_t(r)){case 1:n=Xe;break;case 4:n=et;break;case 16:default:n=tt;break;case 536870912:n=rt}n=Ec(n,ac.bind(null,e))}e.callbackPriority=t,e.callbackNode=n}}function ac(e,t){if(Ql=-1,Xl=0,0!==(6&Al))throw Error(o(327));var n=e.callbackNode;if(Sc()&&e.callbackNode!==n)return null;var r=ft(e,e===El?Pl:0);if(0===r)return null;if(0!==(30&r)||0!==(r&e.expiredLanes)||t)t=vc(e,r);else{t=r;var a=Al;Al|=2;var i=mc();for(El===e&&Pl===t||(Ul=null,Wl=Ye()+500,fc(e,t));;)try{bc();break}catch(l){pc(e,l)}So(),Fl.current=i,Al=a,null!==Dl?t=0:(El=null,Pl=0,t=Nl)}if(0!==t){if(2===t&&(0!==(a=mt(e))&&(r=a,t=oc(e,a))),1===t)throw n=Ol,fc(e,0),sc(e,r),rc(e,Ye()),n;if(6===t)sc(e,r);else{if(a=e.current.alternate,0===(30&r)&&!function(e){for(var t=e;;){if(16384&t.flags){var n=t.updateQueue;if(null!==n&&null!==(n=n.stores))for(var r=0;r<n.length;r++){var a=n[r],o=a.getSnapshot;a=a.value;try{if(!sr(o(),a))return!1}catch(s){return!1}}}if(n=t.child,16384&t.subtreeFlags&&null!==n)n.return=t,t=n;else{if(t===e)break;for(;null===t.sibling;){if(null===t.return||t.return===e)return!0;t=t.return}t.sibling.return=t.return,t=t.sibling}}return!0}(a)&&(2===(t=vc(e,r))&&(0!==(i=mt(e))&&(r=i,t=oc(e,i))),1===t))throw n=Ol,fc(e,0),sc(e,r),rc(e,Ye()),n;switch(e.finishedWork=a,e.finishedLanes=r,t){case 0:case 1:throw Error(o(345));case 2:case 5:wc(e,jl,Ul);break;case 3:if(sc(e,r),(130023424&r)===r&&10<(t=Bl+500-Ye())){if(0!==ft(e,0))break;if(((a=e.suspendedLanes)&r)!==r){ec(),e.pingedLanes|=e.suspendedLanes&a;break}e.timeoutHandle=ra(wc.bind(null,e,jl,Ul),t);break}wc(e,jl,Ul);break;case 4:if(sc(e,r),(4194240&r)===r)break;for(t=e.eventTimes,a=-1;0<r;){var s=31-it(r);i=1<<s,(s=t[s])>a&&(a=s),r&=~i}if(r=a,10<(r=(120>(r=Ye()-r)?120:480>r?480:1080>r?1080:1920>r?1920:3e3>r?3e3:4320>r?4320:1960*Tl(r/1960))-r)){e.timeoutHandle=ra(wc.bind(null,e,jl,Ul),r);break}wc(e,jl,Ul);break;default:throw Error(o(329))}}}return rc(e,Ye()),e.callbackNode===n?ac.bind(null,e):null}function oc(e,t){var n=Zl;return e.current.memoizedState.isDehydrated&&(fc(e,t).flags|=256),2!==(e=vc(e,t))&&(t=jl,jl=n,null!==t&&ic(t)),e}function ic(e){null===jl?jl=e:jl.push.apply(jl,e)}function sc(e,t){for(t&=~Ll,t&=~Il,e.suspendedLanes|=t,e.pingedLanes&=~t,e=e.expirationTimes;0<t;){var n=31-it(t),r=1<<n;e[n]=-1,t&=~r}}function lc(e){if(0!==(6&Al))throw Error(o(327));Sc();var t=ft(e,0);if(0===(1&t))return rc(e,Ye()),null;var n=vc(e,t);if(0!==e.tag&&2===n){var r=mt(e);0!==r&&(t=r,n=oc(e,r))}if(1===n)throw n=Ol,fc(e,0),sc(e,t),rc(e,Ye()),n;if(6===n)throw Error(o(345));return e.finishedWork=e.current.alternate,e.finishedLanes=t,wc(e,jl,Ul),rc(e,Ye()),null}function cc(e,t){var n=Al;Al|=1;try{return e(t)}finally{0===(Al=n)&&(Wl=Ye()+500,Za&&Wa())}}function uc(e){null!==Hl&&0===Hl.tag&&0===(6&Al)&&Sc();var t=Al;Al|=1;var n=xl.transition,r=gt;try{if(xl.transition=null,gt=1,e)return e()}finally{gt=r,xl.transition=n,0===(6&(Al=t))&&Wa()}}function dc(){Rl=Ml.current,Fa(Ml)}function fc(e,t){e.finishedWork=null,e.finishedLanes=0;var n=e.timeoutHandle;if(-1!==n&&(e.timeoutHandle=-1,aa(n)),null!==Dl)for(n=Dl.return;null!==n;){var r=n;switch(to(r),r.tag){case 1:null!==(r=r.type.childContextTypes)&&void 0!==r&&Ma();break;case 3:oi(),Fa(Ea),Fa(Aa),di();break;case 5:si(r);break;case 4:oi();break;case 13:case 19:Fa(li);break;case 10:ko(r.type._context);break;case 22:case 23:dc()}n=n.return}if(El=e,Dl=e=Mc(e.current,null),Pl=Rl=t,Nl=0,Ol=null,Ll=Il=zl=0,jl=Zl=null,null!==xo){for(t=0;t<xo.length;t++)if(null!==(r=(n=xo[t]).interleaved)){n.interleaved=null;var a=r.next,o=n.pending;if(null!==o){var i=o.next;o.next=a,r.next=i}n.pending=r}xo=null}return e}function pc(e,t){for(;;){var n=Dl;try{if(So(),fi.current=is,bi){for(var r=hi.memoizedState;null!==r;){var a=r.queue;null!==a&&(a.pending=null),r=r.next}bi=!1}if(mi=0,yi=vi=hi=null,gi=!1,_i=0,Cl.current=null,null===n||null===n.return){Nl=1,Ol=t,Dl=null;break}e:{var i=e,s=n.return,l=n,c=t;if(t=Pl,l.flags|=32768,null!==c&&"object"===typeof c&&"function"===typeof c.then){var u=c,d=l,f=d.tag;if(0===(1&d.mode)&&(0===f||11===f||15===f)){var p=d.alternate;p?(d.updateQueue=p.updateQueue,d.memoizedState=p.memoizedState,d.lanes=p.lanes):(d.updateQueue=null,d.memoizedState=null)}var m=ys(s);if(null!==m){m.flags&=-257,bs(m,s,l,0,t),1&m.mode&&vs(i,u,t),c=u;var h=(t=m).updateQueue;if(null===h){var v=new Set;v.add(c),t.updateQueue=v}else h.add(c);break e}if(0===(1&t)){vs(i,u,t),hc();break e}c=Error(o(426))}else if(ao&&1&l.mode){var y=ys(s);if(null!==y){0===(65536&y.flags)&&(y.flags|=256),bs(y,s,l,0,t),ho(us(c,l));break e}}i=c=us(c,l),4!==Nl&&(Nl=2),null===Zl?Zl=[i]:Zl.push(i),i=s;do{switch(i.tag){case 3:i.flags|=65536,t&=-t,i.lanes|=t,Io(i,ms(0,c,t));break e;case 1:l=c;var b=i.type,g=i.stateNode;if(0===(128&i.flags)&&("function"===typeof b.getDerivedStateFromError||null!==g&&"function"===typeof g.componentDidCatch&&(null===Jl||!Jl.has(g)))){i.flags|=65536,t&=-t,i.lanes|=t,Io(i,hs(i,l,t));break e}}i=i.return}while(null!==i)}_c(n)}catch(_){t=_,Dl===n&&null!==n&&(Dl=n=n.return);continue}break}}function mc(){var e=Fl.current;return Fl.current=is,null===e?is:e}function hc(){0!==Nl&&3!==Nl&&2!==Nl||(Nl=4),null===El||0===(268435455&zl)&&0===(268435455&Il)||sc(El,Pl)}function vc(e,t){var n=Al;Al|=2;var r=mc();for(El===e&&Pl===t||(Ul=null,fc(e,t));;)try{yc();break}catch(a){pc(e,a)}if(So(),Al=n,Fl.current=r,null!==Dl)throw Error(o(261));return El=null,Pl=0,Nl}function yc(){for(;null!==Dl;)gc(Dl)}function bc(){for(;null!==Dl&&!qe();)gc(Dl)}function gc(e){var t=kl(e.alternate,e,Rl);e.memoizedProps=e.pendingProps,null===t?_c(e):Dl=t,Cl.current=null}function _c(e){var t=e;do{var n=t.alternate;if(e=t.return,0===(32768&t.flags)){if(null!==(n=$s(n,t,Rl)))return void(Dl=n)}else{if(null!==(n=Hs(n,t)))return n.flags&=32767,void(Dl=n);if(null===e)return Nl=6,void(Dl=null);e.flags|=32768,e.subtreeFlags=0,e.deletions=null}if(null!==(t=t.sibling))return void(Dl=t);Dl=t=e}while(null!==t);0===Nl&&(Nl=5)}function wc(e,t,n){var r=gt,a=xl.transition;try{xl.transition=null,gt=1,function(e,t,n,r){do{Sc()}while(null!==Hl);if(0!==(6&Al))throw Error(o(327));n=e.finishedWork;var a=e.finishedLanes;if(null===n)return null;if(e.finishedWork=null,e.finishedLanes=0,n===e.current)throw Error(o(177));e.callbackNode=null,e.callbackPriority=0;var i=n.lanes|n.childLanes;if(function(e,t){var n=e.pendingLanes&~t;e.pendingLanes=t,e.suspendedLanes=0,e.pingedLanes=0,e.expiredLanes&=t,e.mutableReadLanes&=t,e.entangledLanes&=t,t=e.entanglements;var r=e.eventTimes;for(e=e.expirationTimes;0<n;){var a=31-it(n),o=1<<a;t[a]=0,r[a]=-1,e[a]=-1,n&=~o}}(e,i),e===El&&(Dl=El=null,Pl=0),0===(2064&n.subtreeFlags)&&0===(2064&n.flags)||$l||($l=!0,Ec(tt,(function(){return Sc(),null}))),i=0!==(15990&n.flags),0!==(15990&n.subtreeFlags)||i){i=xl.transition,xl.transition=null;var s=gt;gt=1;var l=Al;Al|=4,Cl.current=null,function(e,t){if(ea=Vt,pr(e=fr())){if("selectionStart"in e)var n={start:e.selectionStart,end:e.selectionEnd};else e:{var r=(n=(n=e.ownerDocument)&&n.defaultView||window).getSelection&&n.getSelection();if(r&&0!==r.rangeCount){n=r.anchorNode;var a=r.anchorOffset,i=r.focusNode;r=r.focusOffset;try{n.nodeType,i.nodeType}catch(w){n=null;break e}var s=0,l=-1,c=-1,u=0,d=0,f=e,p=null;t:for(;;){for(var m;f!==n||0!==a&&3!==f.nodeType||(l=s+a),f!==i||0!==r&&3!==f.nodeType||(c=s+r),3===f.nodeType&&(s+=f.nodeValue.length),null!==(m=f.firstChild);)p=f,f=m;for(;;){if(f===e)break t;if(p===n&&++u===a&&(l=s),p===i&&++d===r&&(c=s),null!==(m=f.nextSibling))break;p=(f=p).parentNode}f=m}n=-1===l||-1===c?null:{start:l,end:c}}else n=null}n=n||{start:0,end:0}}else n=null;for(ta={focusedElem:e,selectionRange:n},Vt=!1,Qs=t;null!==Qs;)if(e=(t=Qs).child,0!==(1028&t.subtreeFlags)&&null!==e)e.return=t,Qs=e;else for(;null!==Qs;){t=Qs;try{var h=t.alternate;if(0!==(1024&t.flags))switch(t.tag){case 0:case 11:case 15:case 5:case 6:case 4:case 17:break;case 1:if(null!==h){var v=h.memoizedProps,y=h.memoizedState,b=t.stateNode,g=b.getSnapshotBeforeUpdate(t.elementType===t.type?v:yo(t.type,v),y);b.__reactInternalSnapshotBeforeUpdate=g}break;case 3:var _=t.stateNode.containerInfo;1===_.nodeType?_.textContent="":9===_.nodeType&&_.documentElement&&_.removeChild(_.documentElement);break;default:throw Error(o(163))}}catch(w){Tc(t,t.return,w)}if(null!==(e=t.sibling)){e.return=t.return,Qs=e;break}Qs=t.return}h=tl,tl=!1}(e,n),vl(n,e),mr(ta),Vt=!!ea,ta=ea=null,e.current=n,bl(n,e,a),Ke(),Al=l,gt=s,xl.transition=i}else e.current=n;if($l&&($l=!1,Hl=e,ql=a),0===(i=e.pendingLanes)&&(Jl=null),function(e){if(ot&&"function"===typeof ot.onCommitFiberRoot)try{ot.onCommitFiberRoot(at,e,void 0,128===(128&e.current.flags))}catch(t){}}(n.stateNode),rc(e,Ye()),null!==t)for(r=e.onRecoverableError,n=0;n<t.length;n++)r((a=t[n]).value,{componentStack:a.stack,digest:a.digest});if(Vl)throw Vl=!1,e=Gl,Gl=null,e;0!==(1&ql)&&0!==e.tag&&Sc(),0!==(1&(i=e.pendingLanes))?e===Yl?Kl++:(Kl=0,Yl=e):Kl=0,Wa()}(e,t,n,r)}finally{xl.transition=a,gt=r}return null}function Sc(){if(null!==Hl){var e=_t(ql),t=xl.transition,n=gt;try{if(xl.transition=null,gt=16>e?16:e,null===Hl)var r=!1;else{if(e=Hl,Hl=null,ql=0,0!==(6&Al))throw Error(o(331));var a=Al;for(Al|=4,Qs=e.current;null!==Qs;){var i=Qs,s=i.child;if(0!==(16&Qs.flags)){var l=i.deletions;if(null!==l){for(var c=0;c<l.length;c++){var u=l[c];for(Qs=u;null!==Qs;){var d=Qs;switch(d.tag){case 0:case 11:case 15:nl(8,d,i)}var f=d.child;if(null!==f)f.return=d,Qs=f;else for(;null!==Qs;){var p=(d=Qs).sibling,m=d.return;if(ol(d),d===u){Qs=null;break}if(null!==p){p.return=m,Qs=p;break}Qs=m}}}var h=i.alternate;if(null!==h){var v=h.child;if(null!==v){h.child=null;do{var y=v.sibling;v.sibling=null,v=y}while(null!==v)}}Qs=i}}if(0!==(2064&i.subtreeFlags)&&null!==s)s.return=i,Qs=s;else e:for(;null!==Qs;){if(0!==(2048&(i=Qs).flags))switch(i.tag){case 0:case 11:case 15:nl(9,i,i.return)}var b=i.sibling;if(null!==b){b.return=i.return,Qs=b;break e}Qs=i.return}}var g=e.current;for(Qs=g;null!==Qs;){var _=(s=Qs).child;if(0!==(2064&s.subtreeFlags)&&null!==_)_.return=s,Qs=_;else e:for(s=g;null!==Qs;){if(0!==(2048&(l=Qs).flags))try{switch(l.tag){case 0:case 11:case 15:rl(9,l)}}catch(S){Tc(l,l.return,S)}if(l===s){Qs=null;break e}var w=l.sibling;if(null!==w){w.return=l.return,Qs=w;break e}Qs=l.return}}if(Al=a,Wa(),ot&&"function"===typeof ot.onPostCommitFiberRoot)try{ot.onPostCommitFiberRoot(at,e)}catch(S){}r=!0}return r}finally{gt=n,xl.transition=t}}return!1}function kc(e,t,n){e=Oo(e,t=ms(0,t=us(n,t),1),1),t=ec(),null!==e&&(yt(e,1,t),rc(e,t))}function Tc(e,t,n){if(3===e.tag)kc(e,e,n);else for(;null!==t;){if(3===t.tag){kc(t,e,n);break}if(1===t.tag){var r=t.stateNode;if("function"===typeof t.type.getDerivedStateFromError||"function"===typeof r.componentDidCatch&&(null===Jl||!Jl.has(r))){t=Oo(t,e=hs(t,e=us(n,e),1),1),e=ec(),null!==t&&(yt(t,1,e),rc(t,e));break}}t=t.return}}function Fc(e,t,n){var r=e.pingCache;null!==r&&r.delete(t),t=ec(),e.pingedLanes|=e.suspendedLanes&n,El===e&&(Pl&n)===n&&(4===Nl||3===Nl&&(130023424&Pl)===Pl&&500>Ye()-Bl?fc(e,0):Ll|=n),rc(e,t)}function Cc(e,t){0===t&&(0===(1&e.mode)?t=1:(t=ut,0===(130023424&(ut<<=1))&&(ut=4194304)));var n=ec();null!==(e=Do(e,t))&&(yt(e,t,n),rc(e,n))}function xc(e){var t=e.memoizedState,n=0;null!==t&&(n=t.retryLane),Cc(e,n)}function Ac(e,t){var n=0;switch(e.tag){case 13:var r=e.stateNode,a=e.memoizedState;null!==a&&(n=a.retryLane);break;case 19:r=e.stateNode;break;default:throw Error(o(314))}null!==r&&r.delete(t),Cc(e,n)}function Ec(e,t){return $e(e,t)}function Dc(e,t,n,r){this.tag=e,this.key=n,this.sibling=this.child=this.return=this.stateNode=this.type=this.elementType=null,this.index=0,this.ref=null,this.pendingProps=t,this.dependencies=this.memoizedState=this.updateQueue=this.memoizedProps=null,this.mode=r,this.subtreeFlags=this.flags=0,this.deletions=null,this.childLanes=this.lanes=0,this.alternate=null}function Pc(e,t,n,r){return new Dc(e,t,n,r)}function Rc(e){return!(!(e=e.prototype)||!e.isReactComponent)}function Mc(e,t){var n=e.alternate;return null===n?((n=Pc(e.tag,t,e.key,e.mode)).elementType=e.elementType,n.type=e.type,n.stateNode=e.stateNode,n.alternate=e,e.alternate=n):(n.pendingProps=t,n.type=e.type,n.flags=0,n.subtreeFlags=0,n.deletions=null),n.flags=14680064&e.flags,n.childLanes=e.childLanes,n.lanes=e.lanes,n.child=e.child,n.memoizedProps=e.memoizedProps,n.memoizedState=e.memoizedState,n.updateQueue=e.updateQueue,t=e.dependencies,n.dependencies=null===t?null:{lanes:t.lanes,firstContext:t.firstContext},n.sibling=e.sibling,n.index=e.index,n.ref=e.ref,n}function Nc(e,t,n,r,a,i){var s=2;if(r=e,"function"===typeof e)Rc(e)&&(s=1);else if("string"===typeof e)s=5;else e:switch(e){case k:return Oc(n.children,a,i,t);case T:s=8,a|=8;break;case F:return(e=Pc(12,n,t,2|a)).elementType=F,e.lanes=i,e;case E:return(e=Pc(13,n,t,a)).elementType=E,e.lanes=i,e;case D:return(e=Pc(19,n,t,a)).elementType=D,e.lanes=i,e;case M:return zc(n,a,i,t);default:if("object"===typeof e&&null!==e)switch(e.$$typeof){case C:s=10;break e;case x:s=9;break e;case A:s=11;break e;case P:s=14;break e;case R:s=16,r=null;break e}throw Error(o(130,null==e?e:typeof e,""))}return(t=Pc(s,n,t,a)).elementType=e,t.type=r,t.lanes=i,t}function Oc(e,t,n,r){return(e=Pc(7,e,r,t)).lanes=n,e}function zc(e,t,n,r){return(e=Pc(22,e,r,t)).elementType=M,e.lanes=n,e.stateNode={isHidden:!1},e}function Ic(e,t,n){return(e=Pc(6,e,null,t)).lanes=n,e}function Lc(e,t,n){return(t=Pc(4,null!==e.children?e.children:[],e.key,t)).lanes=n,t.stateNode={containerInfo:e.containerInfo,pendingChildren:null,implementation:e.implementation},t}function Zc(e,t,n,r,a){this.tag=t,this.containerInfo=e,this.finishedWork=this.pingCache=this.current=this.pendingChildren=null,this.timeoutHandle=-1,this.callbackNode=this.pendingContext=this.context=null,this.callbackPriority=0,this.eventTimes=vt(0),this.expirationTimes=vt(-1),this.entangledLanes=this.finishedLanes=this.mutableReadLanes=this.expiredLanes=this.pingedLanes=this.suspendedLanes=this.pendingLanes=0,this.entanglements=vt(0),this.identifierPrefix=r,this.onRecoverableError=a,this.mutableSourceEagerHydrationData=null}function jc(e,t,n,r,a,o,i,s,l){return e=new Zc(e,t,n,s,l),1===t?(t=1,!0===o&&(t|=8)):t=0,o=Pc(3,null,null,t),e.current=o,o.stateNode=e,o.memoizedState={element:r,isDehydrated:n,cache:null,transitions:null,pendingSuspenseBoundaries:null},Ro(o),e}function Bc(e,t,n){var r=3<arguments.length&&void 0!==arguments[3]?arguments[3]:null;return{$$typeof:S,key:null==r?null:""+r,children:e,containerInfo:t,implementation:n}}function Wc(e){if(!e)return xa;e:{if(We(e=e._reactInternals)!==e||1!==e.tag)throw Error(o(170));var t=e;do{switch(t.tag){case 3:t=t.stateNode.context;break e;case 1:if(Ra(t.type)){t=t.stateNode.__reactInternalMemoizedMergedChildContext;break e}}t=t.return}while(null!==t);throw Error(o(171))}if(1===e.tag){var n=e.type;if(Ra(n))return Oa(e,n,t)}return t}function Uc(e,t,n,r,a,o,i,s,l){return(e=jc(n,r,!0,e,0,o,0,s,l)).context=Wc(null),n=e.current,(o=No(r=ec(),a=tc(n))).callback=void 0!==t&&null!==t?t:null,Oo(n,o,a),e.current.lanes=a,yt(e,a,r),rc(e,r),e}function Vc(e,t,n,r){var a=t.current,o=ec(),i=tc(a);return n=Wc(n),null===t.context?t.context=n:t.pendingContext=n,(t=No(o,i)).payload={element:e},null!==(r=void 0===r?null:r)&&(t.callback=r),null!==(e=Oo(a,t,i))&&(nc(e,a,i,o),zo(e,a,i)),i}function Gc(e){return(e=e.current).child?(e.child.tag,e.child.stateNode):null}function Jc(e,t){if(null!==(e=e.memoizedState)&&null!==e.dehydrated){var n=e.retryLane;e.retryLane=0!==n&&n<t?n:t}}function $c(e,t){Jc(e,t),(e=e.alternate)&&Jc(e,t)}kl=function(e,t,n){if(null!==e)if(e.memoizedProps!==t.pendingProps||Ea.current)_s=!0;else{if(0===(e.lanes&n)&&0===(128&t.flags))return _s=!1,function(e,t,n){switch(t.tag){case 3:Ds(t),mo();break;case 5:ii(t);break;case 1:Ra(t.type)&&za(t);break;case 4:ai(t,t.stateNode.containerInfo);break;case 10:var r=t.type._context,a=t.memoizedProps.value;Ca(bo,r._currentValue),r._currentValue=a;break;case 13:if(null!==(r=t.memoizedState))return null!==r.dehydrated?(Ca(li,1&li.current),t.flags|=128,null):0!==(n&t.child.childLanes)?Is(e,t,n):(Ca(li,1&li.current),null!==(e=Vs(e,t,n))?e.sibling:null);Ca(li,1&li.current);break;case 19:if(r=0!==(n&t.childLanes),0!==(128&e.flags)){if(r)return Ws(e,t,n);t.flags|=128}if(null!==(a=t.memoizedState)&&(a.rendering=null,a.tail=null,a.lastEffect=null),Ca(li,li.current),r)break;return null;case 22:case 23:return t.lanes=0,Fs(e,t,n)}return Vs(e,t,n)}(e,t,n);_s=0!==(131072&e.flags)}else _s=!1,ao&&0!==(1048576&t.flags)&&Xa(t,Ja,t.index);switch(t.lanes=0,t.tag){case 2:var r=t.type;Us(e,t),e=t.pendingProps;var a=Pa(t,Aa.current);Fo(t,n),a=Ti(null,t,r,e,a,n);var i=Fi();return t.flags|=1,"object"===typeof a&&null!==a&&"function"===typeof a.render&&void 0===a.$$typeof?(t.tag=1,t.memoizedState=null,t.updateQueue=null,Ra(r)?(i=!0,za(t)):i=!1,t.memoizedState=null!==a.state&&void 0!==a.state?a.state:null,Ro(t),a.updater=Wo,t.stateNode=a,a._reactInternals=t,Jo(t,r,e,n),t=Es(null,t,r,!0,i,n)):(t.tag=0,ao&&i&&eo(t),ws(null,t,a,n),t=t.child),t;case 16:r=t.elementType;e:{switch(Us(e,t),e=t.pendingProps,r=(a=r._init)(r._payload),t.type=r,a=t.tag=function(e){if("function"===typeof e)return Rc(e)?1:0;if(void 0!==e&&null!==e){if((e=e.$$typeof)===A)return 11;if(e===P)return 14}return 2}(r),e=yo(r,e),a){case 0:t=xs(null,t,r,e,n);break e;case 1:t=As(null,t,r,e,n);break e;case 11:t=Ss(null,t,r,e,n);break e;case 14:t=ks(null,t,r,yo(r.type,e),n);break e}throw Error(o(306,r,""))}return t;case 0:return r=t.type,a=t.pendingProps,xs(e,t,r,a=t.elementType===r?a:yo(r,a),n);case 1:return r=t.type,a=t.pendingProps,As(e,t,r,a=t.elementType===r?a:yo(r,a),n);case 3:e:{if(Ds(t),null===e)throw Error(o(387));r=t.pendingProps,a=(i=t.memoizedState).element,Mo(e,t),Lo(t,r,null,n);var s=t.memoizedState;if(r=s.element,i.isDehydrated){if(i={element:r,isDehydrated:!1,cache:s.cache,pendingSuspenseBoundaries:s.pendingSuspenseBoundaries,transitions:s.transitions},t.updateQueue.baseState=i,t.memoizedState=i,256&t.flags){t=Ps(e,t,r,n,a=us(Error(o(423)),t));break e}if(r!==a){t=Ps(e,t,r,n,a=us(Error(o(424)),t));break e}for(ro=ca(t.stateNode.containerInfo.firstChild),no=t,ao=!0,oo=null,n=Qo(t,null,r,n),t.child=n;n;)n.flags=-3&n.flags|4096,n=n.sibling}else{if(mo(),r===a){t=Vs(e,t,n);break e}ws(e,t,r,n)}t=t.child}return t;case 5:return ii(t),null===e&&co(t),r=t.type,a=t.pendingProps,i=null!==e?e.memoizedProps:null,s=a.children,na(r,a)?s=null:null!==i&&na(r,i)&&(t.flags|=32),Cs(e,t),ws(e,t,s,n),t.child;case 6:return null===e&&co(t),null;case 13:return Is(e,t,n);case 4:return ai(t,t.stateNode.containerInfo),r=t.pendingProps,null===e?t.child=Yo(t,null,r,n):ws(e,t,r,n),t.child;case 11:return r=t.type,a=t.pendingProps,Ss(e,t,r,a=t.elementType===r?a:yo(r,a),n);case 7:return ws(e,t,t.pendingProps,n),t.child;case 8:case 12:return ws(e,t,t.pendingProps.children,n),t.child;case 10:e:{if(r=t.type._context,a=t.pendingProps,i=t.memoizedProps,s=a.value,Ca(bo,r._currentValue),r._currentValue=s,null!==i)if(sr(i.value,s)){if(i.children===a.children&&!Ea.current){t=Vs(e,t,n);break e}}else for(null!==(i=t.child)&&(i.return=t);null!==i;){var l=i.dependencies;if(null!==l){s=i.child;for(var c=l.firstContext;null!==c;){if(c.context===r){if(1===i.tag){(c=No(-1,n&-n)).tag=2;var u=i.updateQueue;if(null!==u){var d=(u=u.shared).pending;null===d?c.next=c:(c.next=d.next,d.next=c),u.pending=c}}i.lanes|=n,null!==(c=i.alternate)&&(c.lanes|=n),To(i.return,n,t),l.lanes|=n;break}c=c.next}}else if(10===i.tag)s=i.type===t.type?null:i.child;else if(18===i.tag){if(null===(s=i.return))throw Error(o(341));s.lanes|=n,null!==(l=s.alternate)&&(l.lanes|=n),To(s,n,t),s=i.sibling}else s=i.child;if(null!==s)s.return=i;else for(s=i;null!==s;){if(s===t){s=null;break}if(null!==(i=s.sibling)){i.return=s.return,s=i;break}s=s.return}i=s}ws(e,t,a.children,n),t=t.child}return t;case 9:return a=t.type,r=t.pendingProps.children,Fo(t,n),r=r(a=Co(a)),t.flags|=1,ws(e,t,r,n),t.child;case 14:return a=yo(r=t.type,t.pendingProps),ks(e,t,r,a=yo(r.type,a),n);case 15:return Ts(e,t,t.type,t.pendingProps,n);case 17:return r=t.type,a=t.pendingProps,a=t.elementType===r?a:yo(r,a),Us(e,t),t.tag=1,Ra(r)?(e=!0,za(t)):e=!1,Fo(t,n),Vo(t,r,a),Jo(t,r,a,n),Es(null,t,r,!0,e,n);case 19:return Ws(e,t,n);case 22:return Fs(e,t,n)}throw Error(o(156,t.tag))};var Hc="function"===typeof reportError?reportError:function(e){console.error(e)};function qc(e){this._internalRoot=e}function Kc(e){this._internalRoot=e}function Yc(e){return!(!e||1!==e.nodeType&&9!==e.nodeType&&11!==e.nodeType)}function Qc(e){return!(!e||1!==e.nodeType&&9!==e.nodeType&&11!==e.nodeType&&(8!==e.nodeType||" react-mount-point-unstable "!==e.nodeValue))}function Xc(){}function eu(e,t,n,r,a){var o=n._reactRootContainer;if(o){var i=o;if("function"===typeof a){var s=a;a=function(){var e=Gc(i);s.call(e)}}Vc(t,i,e,a)}else i=function(e,t,n,r,a){if(a){if("function"===typeof r){var o=r;r=function(){var e=Gc(i);o.call(e)}}var i=Uc(t,r,e,0,null,!1,0,"",Xc);return e._reactRootContainer=i,e[ma]=i.current,Wr(8===e.nodeType?e.parentNode:e),uc(),i}for(;a=e.lastChild;)e.removeChild(a);if("function"===typeof r){var s=r;r=function(){var e=Gc(l);s.call(e)}}var l=jc(e,0,!1,null,0,!1,0,"",Xc);return e._reactRootContainer=l,e[ma]=l.current,Wr(8===e.nodeType?e.parentNode:e),uc((function(){Vc(t,l,n,r)})),l}(n,t,e,a,r);return Gc(i)}Kc.prototype.render=qc.prototype.render=function(e){var t=this._internalRoot;if(null===t)throw Error(o(409));Vc(e,t,null,null)},Kc.prototype.unmount=qc.prototype.unmount=function(){var e=this._internalRoot;if(null!==e){this._internalRoot=null;var t=e.containerInfo;uc((function(){Vc(null,e,null,null)})),t[ma]=null}},Kc.prototype.unstable_scheduleHydration=function(e){if(e){var t=Tt();e={blockedOn:null,target:e,priority:t};for(var n=0;n<Mt.length&&0!==t&&t<Mt[n].priority;n++);Mt.splice(n,0,e),0===n&&It(e)}},wt=function(e){switch(e.tag){case 3:var t=e.stateNode;if(t.current.memoizedState.isDehydrated){var n=dt(t.pendingLanes);0!==n&&(bt(t,1|n),rc(t,Ye()),0===(6&Al)&&(Wl=Ye()+500,Wa()))}break;case 13:uc((function(){var t=Do(e,1);if(null!==t){var n=ec();nc(t,e,1,n)}})),$c(e,1)}},St=function(e){if(13===e.tag){var t=Do(e,134217728);if(null!==t)nc(t,e,134217728,ec());$c(e,134217728)}},kt=function(e){if(13===e.tag){var t=tc(e),n=Do(e,t);if(null!==n)nc(n,e,t,ec());$c(e,t)}},Tt=function(){return gt},Ft=function(e,t){var n=gt;try{return gt=e,t()}finally{gt=n}},Se=function(e,t,n){switch(t){case"input":if(Q(e,n),t=n.name,"radio"===n.type&&null!=t){for(n=e;n.parentNode;)n=n.parentNode;for(n=n.querySelectorAll("input[name="+JSON.stringify(""+t)+'][type="radio"]'),t=0;t<n.length;t++){var r=n[t];if(r!==e&&r.form===e.form){var a=wa(r);if(!a)throw Error(o(90));$(r),Q(r,a)}}}break;case"textarea":oe(e,n);break;case"select":null!=(t=n.value)&&ne(e,!!n.multiple,t,!1)}},Ae=cc,Ee=uc;var tu={usingClientEntryPoint:!1,Events:[ga,_a,wa,Ce,xe,cc]},nu={findFiberByHostInstance:ba,bundleType:0,version:"18.2.0",rendererPackageName:"react-dom"},ru={bundleType:nu.bundleType,version:nu.version,rendererPackageName:nu.rendererPackageName,rendererConfig:nu.rendererConfig,overrideHookState:null,overrideHookStateDeletePath:null,overrideHookStateRenamePath:null,overrideProps:null,overridePropsDeletePath:null,overridePropsRenamePath:null,setErrorHandler:null,setSuspenseHandler:null,scheduleUpdate:null,currentDispatcherRef:_.ReactCurrentDispatcher,findHostInstanceByFiber:function(e){return null===(e=Ge(e))?null:e.stateNode},findFiberByHostInstance:nu.findFiberByHostInstance||function(){return null},findHostInstancesForRefresh:null,scheduleRefresh:null,scheduleRoot:null,setRefreshHandler:null,getCurrentFiber:null,reconcilerVersion:"18.2.0-next-9e3b772b8-20220608"};if("undefined"!==typeof __REACT_DEVTOOLS_GLOBAL_HOOK__){var au=__REACT_DEVTOOLS_GLOBAL_HOOK__;if(!au.isDisabled&&au.supportsFiber)try{at=au.inject(ru),ot=au}catch(ue){}}t.__SECRET_INTERNALS_DO_NOT_USE_OR_YOU_WILL_BE_FIRED=tu,t.createPortal=function(e,t){var n=2<arguments.length&&void 0!==arguments[2]?arguments[2]:null;if(!Yc(t))throw Error(o(200));return Bc(e,t,null,n)},t.createRoot=function(e,t){if(!Yc(e))throw Error(o(299));var n=!1,r="",a=Hc;return null!==t&&void 0!==t&&(!0===t.unstable_strictMode&&(n=!0),void 0!==t.identifierPrefix&&(r=t.identifierPrefix),void 0!==t.onRecoverableError&&(a=t.onRecoverableError)),t=jc(e,1,!1,null,0,n,0,r,a),e[ma]=t.current,Wr(8===e.nodeType?e.parentNode:e),new qc(t)},t.findDOMNode=function(e){if(null==e)return null;if(1===e.nodeType)return e;var t=e._reactInternals;if(void 0===t){if("function"===typeof e.render)throw Error(o(188));throw e=Object.keys(e).join(","),Error(o(268,e))}return e=null===(e=Ge(t))?null:e.stateNode},t.flushSync=function(e){return uc(e)},t.hydrate=function(e,t,n){if(!Qc(t))throw Error(o(200));return eu(null,e,t,!0,n)},t.hydrateRoot=function(e,t,n){if(!Yc(e))throw Error(o(405));var r=null!=n&&n.hydratedSources||null,a=!1,i="",s=Hc;if(null!==n&&void 0!==n&&(!0===n.unstable_strictMode&&(a=!0),void 0!==n.identifierPrefix&&(i=n.identifierPrefix),void 0!==n.onRecoverableError&&(s=n.onRecoverableError)),t=Uc(t,null,e,1,null!=n?n:null,a,0,i,s),e[ma]=t.current,Wr(e),r)for(e=0;e<r.length;e++)a=(a=(n=r[e])._getVersion)(n._source),null==t.mutableSourceEagerHydrationData?t.mutableSourceEagerHydrationData=[n,a]:t.mutableSourceEagerHydrationData.push(n,a);return new Kc(t)},t.render=function(e,t,n){if(!Qc(t))throw Error(o(200));return eu(null,e,t,!1,n)},t.unmountComponentAtNode=function(e){if(!Qc(e))throw Error(o(40));return!!e._reactRootContainer&&(uc((function(){eu(null,null,e,!1,(function(){e._reactRootContainer=null,e[ma]=null}))})),!0)},t.unstable_batchedUpdates=cc,t.unstable_renderSubtreeIntoContainer=function(e,t,n,r){if(!Qc(n))throw Error(o(200));if(null==e||void 0===e._reactInternals)throw Error(o(38));return eu(e,t,n,!1,r)},t.version="18.2.0-next-9e3b772b8-20220608"},1250:function(e,t,n){"use strict";var r=n(4164);t.createRoot=r.createRoot,t.hydrateRoot=r.hydrateRoot},4164:function(e,t,n){"use strict";!function e(){if("undefined"!==typeof __REACT_DEVTOOLS_GLOBAL_HOOK__&&"function"===typeof __REACT_DEVTOOLS_GLOBAL_HOOK__.checkDCE)try{__REACT_DEVTOOLS_GLOBAL_HOOK__.checkDCE(e)}catch(t){console.error(t)}}(),e.exports=n(4463)},6374:function(e,t,n){"use strict";var r=n(2791),a=Symbol.for("react.element"),o=Symbol.for("react.fragment"),i=Object.prototype.hasOwnProperty,s=r.__SECRET_INTERNALS_DO_NOT_USE_OR_YOU_WILL_BE_FIRED.ReactCurrentOwner,l={key:!0,ref:!0,__self:!0,__source:!0};function c(e,t,n){var r,o={},c=null,u=null;for(r in void 0!==n&&(c=""+n),void 0!==t.key&&(c=""+t.key),void 0!==t.ref&&(u=t.ref),t)i.call(t,r)&&!l.hasOwnProperty(r)&&(o[r]=t[r]);if(e&&e.defaultProps)for(r in t=e.defaultProps)void 0===o[r]&&(o[r]=t[r]);return{$$typeof:a,type:e,key:c,ref:u,props:o,_owner:s.current}}t.Fragment=o,t.jsx=c,t.jsxs=c},9117:function(e,t){"use strict";var n=Symbol.for("react.element"),r=Symbol.for("react.portal"),a=Symbol.for("react.fragment"),o=Symbol.for("react.strict_mode"),i=Symbol.for("react.profiler"),s=Symbol.for("react.provider"),l=Symbol.for("react.context"),c=Symbol.for("react.forward_ref"),u=Symbol.for("react.suspense"),d=Symbol.for("react.memo"),f=Symbol.for("react.lazy"),p=Symbol.iterator;var m={isMounted:function(){return!1},enqueueForceUpdate:function(){},enqueueReplaceState:function(){},enqueueSetState:function(){}},h=Object.assign,v={};function y(e,t,n){this.props=e,this.context=t,this.refs=v,this.updater=n||m}function b(){}function g(e,t,n){this.props=e,this.context=t,this.refs=v,this.updater=n||m}y.prototype.isReactComponent={},y.prototype.setState=function(e,t){if("object"!==typeof e&&"function"!==typeof e&&null!=e)throw Error("setState(...): takes an object of state variables to update or a function which returns an object of state variables.");this.updater.enqueueSetState(this,e,t,"setState")},y.prototype.forceUpdate=function(e){this.updater.enqueueForceUpdate(this,e,"forceUpdate")},b.prototype=y.prototype;var _=g.prototype=new b;_.constructor=g,h(_,y.prototype),_.isPureReactComponent=!0;var w=Array.isArray,S=Object.prototype.hasOwnProperty,k={current:null},T={key:!0,ref:!0,__self:!0,__source:!0};function F(e,t,r){var a,o={},i=null,s=null;if(null!=t)for(a in void 0!==t.ref&&(s=t.ref),void 0!==t.key&&(i=""+t.key),t)S.call(t,a)&&!T.hasOwnProperty(a)&&(o[a]=t[a]);var l=arguments.length-2;if(1===l)o.children=r;else if(1<l){for(var c=Array(l),u=0;u<l;u++)c[u]=arguments[u+2];o.children=c}if(e&&e.defaultProps)for(a in l=e.defaultProps)void 0===o[a]&&(o[a]=l[a]);return{$$typeof:n,type:e,key:i,ref:s,props:o,_owner:k.current}}function C(e){return"object"===typeof e&&null!==e&&e.$$typeof===n}var x=/\/+/g;function A(e,t){return"object"===typeof e&&null!==e&&null!=e.key?function(e){var t={"=":"=0",":":"=2"};return"$"+e.replace(/[=:]/g,(function(e){return t[e]}))}(""+e.key):t.toString(36)}function E(e,t,a,o,i){var s=typeof e;"undefined"!==s&&"boolean"!==s||(e=null);var l=!1;if(null===e)l=!0;else switch(s){case"string":case"number":l=!0;break;case"object":switch(e.$$typeof){case n:case r:l=!0}}if(l)return i=i(l=e),e=""===o?"."+A(l,0):o,w(i)?(a="",null!=e&&(a=e.replace(x,"$&/")+"/"),E(i,t,a,"",(function(e){return e}))):null!=i&&(C(i)&&(i=function(e,t){return{$$typeof:n,type:e.type,key:t,ref:e.ref,props:e.props,_owner:e._owner}}(i,a+(!i.key||l&&l.key===i.key?"":(""+i.key).replace(x,"$&/")+"/")+e)),t.push(i)),1;if(l=0,o=""===o?".":o+":",w(e))for(var c=0;c<e.length;c++){var u=o+A(s=e[c],c);l+=E(s,t,a,u,i)}else if(u=function(e){return null===e||"object"!==typeof e?null:"function"===typeof(e=p&&e[p]||e["@@iterator"])?e:null}(e),"function"===typeof u)for(e=u.call(e),c=0;!(s=e.next()).done;)l+=E(s=s.value,t,a,u=o+A(s,c++),i);else if("object"===s)throw t=String(e),Error("Objects are not valid as a React child (found: "+("[object Object]"===t?"object with keys {"+Object.keys(e).join(", ")+"}":t)+"). If you meant to render a collection of children, use an array instead.");return l}function D(e,t,n){if(null==e)return e;var r=[],a=0;return E(e,r,"","",(function(e){return t.call(n,e,a++)})),r}function P(e){if(-1===e._status){var t=e._result;(t=t()).then((function(t){0!==e._status&&-1!==e._status||(e._status=1,e._result=t)}),(function(t){0!==e._status&&-1!==e._status||(e._status=2,e._result=t)})),-1===e._status&&(e._status=0,e._result=t)}if(1===e._status)return e._result.default;throw e._result}var R={current:null},M={transition:null},N={ReactCurrentDispatcher:R,ReactCurrentBatchConfig:M,ReactCurrentOwner:k};t.Children={map:D,forEach:function(e,t,n){D(e,(function(){t.apply(this,arguments)}),n)},count:function(e){var t=0;return D(e,(function(){t++})),t},toArray:function(e){return D(e,(function(e){return e}))||[]},only:function(e){if(!C(e))throw Error("React.Children.only expected to receive a single React element child.");return e}},t.Component=y,t.Fragment=a,t.Profiler=i,t.PureComponent=g,t.StrictMode=o,t.Suspense=u,t.__SECRET_INTERNALS_DO_NOT_USE_OR_YOU_WILL_BE_FIRED=N,t.cloneElement=function(e,t,r){if(null===e||void 0===e)throw Error("React.cloneElement(...): The argument must be a React element, but you passed "+e+".");var a=h({},e.props),o=e.key,i=e.ref,s=e._owner;if(null!=t){if(void 0!==t.ref&&(i=t.ref,s=k.current),void 0!==t.key&&(o=""+t.key),e.type&&e.type.defaultProps)var l=e.type.defaultProps;for(c in t)S.call(t,c)&&!T.hasOwnProperty(c)&&(a[c]=void 0===t[c]&&void 0!==l?l[c]:t[c])}var c=arguments.length-2;if(1===c)a.children=r;else if(1<c){l=Array(c);for(var u=0;u<c;u++)l[u]=arguments[u+2];a.children=l}return{$$typeof:n,type:e.type,key:o,ref:i,props:a,_owner:s}},t.createContext=function(e){return(e={$$typeof:l,_currentValue:e,_currentValue2:e,_threadCount:0,Provider:null,Consumer:null,_defaultValue:null,_globalName:null}).Provider={$$typeof:s,_context:e},e.Consumer=e},t.createElement=F,t.createFactory=function(e){var t=F.bind(null,e);return t.type=e,t},t.createRef=function(){return{current:null}},t.forwardRef=function(e){return{$$typeof:c,render:e}},t.isValidElement=C,t.lazy=function(e){return{$$typeof:f,_payload:{_status:-1,_result:e},_init:P}},t.memo=function(e,t){return{$$typeof:d,type:e,compare:void 0===t?null:t}},t.startTransition=function(e){var t=M.transition;M.transition={};try{e()}finally{M.transition=t}},t.unstable_act=function(){throw Error("act(...) is not supported in production builds of React.")},t.useCallback=function(e,t){return R.current.useCallback(e,t)},t.useContext=function(e){return R.current.useContext(e)},t.useDebugValue=function(){},t.useDeferredValue=function(e){return R.current.useDeferredValue(e)},t.useEffect=function(e,t){return R.current.useEffect(e,t)},t.useId=function(){return R.current.useId()},t.useImperativeHandle=function(e,t,n){return R.current.useImperativeHandle(e,t,n)},t.useInsertionEffect=function(e,t){return R.current.useInsertionEffect(e,t)},t.useLayoutEffect=function(e,t){return R.current.useLayoutEffect(e,t)},t.useMemo=function(e,t){return R.current.useMemo(e,t)},t.useReducer=function(e,t,n){return R.current.useReducer(e,t,n)},t.useRef=function(e){return R.current.useRef(e)},t.useState=function(e){return R.current.useState(e)},t.useSyncExternalStore=function(e,t,n){return R.current.useSyncExternalStore(e,t,n)},t.useTransition=function(){return R.current.useTransition()},t.version="18.2.0"},2791:function(e,t,n){"use strict";e.exports=n(9117)},184:function(e,t,n){"use strict";e.exports=n(6374)},6813:function(e,t){"use strict";function n(e,t){var n=e.length;e.push(t);e:for(;0<n;){var r=n-1>>>1,a=e[r];if(!(0<o(a,t)))break e;e[r]=t,e[n]=a,n=r}}function r(e){return 0===e.length?null:e[0]}function a(e){if(0===e.length)return null;var t=e[0],n=e.pop();if(n!==t){e[0]=n;e:for(var r=0,a=e.length,i=a>>>1;r<i;){var s=2*(r+1)-1,l=e[s],c=s+1,u=e[c];if(0>o(l,n))c<a&&0>o(u,l)?(e[r]=u,e[c]=n,r=c):(e[r]=l,e[s]=n,r=s);else{if(!(c<a&&0>o(u,n)))break e;e[r]=u,e[c]=n,r=c}}}return t}function o(e,t){var n=e.sortIndex-t.sortIndex;return 0!==n?n:e.id-t.id}if("object"===typeof performance&&"function"===typeof performance.now){var i=performance;t.unstable_now=function(){return i.now()}}else{var s=Date,l=s.now();t.unstable_now=function(){return s.now()-l}}var c=[],u=[],d=1,f=null,p=3,m=!1,h=!1,v=!1,y="function"===typeof setTimeout?setTimeout:null,b="function"===typeof clearTimeout?clearTimeout:null,g="undefined"!==typeof setImmediate?setImmediate:null;function _(e){for(var t=r(u);null!==t;){if(null===t.callback)a(u);else{if(!(t.startTime<=e))break;a(u),t.sortIndex=t.expirationTime,n(c,t)}t=r(u)}}function w(e){if(v=!1,_(e),!h)if(null!==r(c))h=!0,M(S);else{var t=r(u);null!==t&&N(w,t.startTime-e)}}function S(e,n){h=!1,v&&(v=!1,b(C),C=-1),m=!0;var o=p;try{for(_(n),f=r(c);null!==f&&(!(f.expirationTime>n)||e&&!E());){var i=f.callback;if("function"===typeof i){f.callback=null,p=f.priorityLevel;var s=i(f.expirationTime<=n);n=t.unstable_now(),"function"===typeof s?f.callback=s:f===r(c)&&a(c),_(n)}else a(c);f=r(c)}if(null!==f)var l=!0;else{var d=r(u);null!==d&&N(w,d.startTime-n),l=!1}return l}finally{f=null,p=o,m=!1}}"undefined"!==typeof navigator&&void 0!==navigator.scheduling&&void 0!==navigator.scheduling.isInputPending&&navigator.scheduling.isInputPending.bind(navigator.scheduling);var k,T=!1,F=null,C=-1,x=5,A=-1;function E(){return!(t.unstable_now()-A<x)}function D(){if(null!==F){var e=t.unstable_now();A=e;var n=!0;try{n=F(!0,e)}finally{n?k():(T=!1,F=null)}}else T=!1}if("function"===typeof g)k=function(){g(D)};else if("undefined"!==typeof MessageChannel){var P=new MessageChannel,R=P.port2;P.port1.onmessage=D,k=function(){R.postMessage(null)}}else k=function(){y(D,0)};function M(e){F=e,T||(T=!0,k())}function N(e,n){C=y((function(){e(t.unstable_now())}),n)}t.unstable_IdlePriority=5,t.unstable_ImmediatePriority=1,t.unstable_LowPriority=4,t.unstable_NormalPriority=3,t.unstable_Profiling=null,t.unstable_UserBlockingPriority=2,t.unstable_cancelCallback=function(e){e.callback=null},t.unstable_continueExecution=function(){h||m||(h=!0,M(S))},t.unstable_forceFrameRate=function(e){0>e||125<e?console.error("forceFrameRate takes a positive int between 0 and 125, forcing frame rates higher than 125 fps is not supported"):x=0<e?Math.floor(1e3/e):5},t.unstable_getCurrentPriorityLevel=function(){return p},t.unstable_getFirstCallbackNode=function(){return r(c)},t.unstable_next=function(e){switch(p){case 1:case 2:case 3:var t=3;break;default:t=p}var n=p;p=t;try{return e()}finally{p=n}},t.unstable_pauseExecution=function(){},t.unstable_requestPaint=function(){},t.unstable_runWithPriority=function(e,t){switch(e){case 1:case 2:case 3:case 4:case 5:break;default:e=3}var n=p;p=e;try{return t()}finally{p=n}},t.unstable_scheduleCallback=function(e,a,o){var i=t.unstable_now();switch("object"===typeof o&&null!==o?o="number"===typeof(o=o.delay)&&0<o?i+o:i:o=i,e){case 1:var s=-1;break;case 2:s=250;break;case 5:s=1073741823;break;case 4:s=1e4;break;default:s=5e3}return e={id:d++,callback:a,priorityLevel:e,startTime:o,expirationTime:s=o+s,sortIndex:-1},o>i?(e.sortIndex=o,n(u,e),null===r(c)&&e===r(u)&&(v?(b(C),C=-1):v=!0,N(w,o-i))):(e.sortIndex=s,n(c,e),h||m||(h=!0,M(S))),e},t.unstable_shouldYield=E,t.unstable_wrapCallback=function(e){var t=p;return function(){var n=p;p=t;try{return e.apply(this,arguments)}finally{p=n}}}},5296:function(e,t,n){"use strict";e.exports=n(6813)},4836:function(e){e.exports=function(e){return e&&e.__esModule?e:{default:e}},e.exports.__esModule=!0,e.exports.default=e.exports},907:function(e,t,n){"use strict";function r(e,t){(null==t||t>e.length)&&(t=e.length);for(var n=0,r=new Array(t);n<t;n++)r[n]=e[n];return r}n.d(t,{Z:function(){return r}})},4942:function(e,t,n){"use strict";function r(e,t,n){return t in e?Object.defineProperty(e,t,{value:n,enumerable:!0,configurable:!0,writable:!0}):e[t]=n,e}n.d(t,{Z:function(){return r}})},7462:function(e,t,n){"use strict";function r(){return r=Object.assign?Object.assign.bind():function(e){for(var t=1;t<arguments.length;t++){var n=arguments[t];for(var r in n)Object.prototype.hasOwnProperty.call(n,r)&&(e[r]=n[r])}return e},r.apply(this,arguments)}n.d(t,{Z:function(){return r}})},3366:function(e,t,n){"use strict";function r(e,t){if(null==e)return{};var n,r,a={},o=Object.keys(e);for(r=0;r<o.length;r++)n=o[r],t.indexOf(n)>=0||(a[n]=e[n]);return a}n.d(t,{Z:function(){return r}})},885:function(e,t,n){"use strict";n.d(t,{Z:function(){return a}});var r=n(181);function a(e,t){return function(e){if(Array.isArray(e))return e}(e)||function(e,t){var n=null==e?null:"undefined"!==typeof Symbol&&e[Symbol.iterator]||e["@@iterator"];if(null!=n){var r,a,o=[],i=!0,s=!1;try{for(n=n.call(e);!(i=(r=n.next()).done)&&(o.push(r.value),!t||o.length!==t);i=!0);}catch(l){s=!0,a=l}finally{try{i||null==n.return||n.return()}finally{if(s)throw a}}return o}}(e,t)||(0,r.Z)(e,t)||function(){throw new TypeError("Invalid attempt to destructure non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}()}},2982:function(e,t,n){"use strict";n.d(t,{Z:function(){return o}});var r=n(907);var a=n(181);function o(e){return function(e){if(Array.isArray(e))return(0,r.Z)(e)}(e)||function(e){if("undefined"!==typeof Symbol&&null!=e[Symbol.iterator]||null!=e["@@iterator"])return Array.from(e)}(e)||(0,a.Z)(e)||function(){throw new TypeError("Invalid attempt to spread non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}()}},181:function(e,t,n){"use strict";n.d(t,{Z:function(){return a}});var r=n(907);function a(e,t){if(e){if("string"===typeof e)return(0,r.Z)(e,t);var n=Object.prototype.toString.call(e).slice(8,-1);return"Object"===n&&e.constructor&&(n=e.constructor.name),"Map"===n||"Set"===n?Array.from(e):"Arguments"===n||/^(?:Ui|I)nt(?:8|16|32)(?:Clamped)?Array$/.test(n)?(0,r.Z)(e,t):void 0}}}},t={};function n(r){var a=t[r];if(void 0!==a)return a.exports;var o=t[r]={exports:{}};return e[r].call(o.exports,o,o.exports,n),o.exports}n.n=function(e){var t=e&&e.__esModule?function(){return e.default}:function(){return e};return n.d(t,{a:t}),t},function(){var e,t=Object.getPrototypeOf?function(e){return Object.getPrototypeOf(e)}:function(e){return e.__proto__};n.t=function(r,a){if(1&a&&(r=this(r)),8&a)return r;if("object"===typeof r&&r){if(4&a&&r.__esModule)return r;if(16&a&&"function"===typeof r.then)return r}var o=Object.create(null);n.r(o);var i={};e=e||[null,t({}),t([]),t(t)];for(var s=2&a&&r;"object"==typeof s&&!~e.indexOf(s);s=t(s))Object.getOwnPropertyNames(s).forEach((function(e){i[e]=function(){return r[e]}}));return i.default=function(){return r},n.d(o,i),o}}(),n.d=function(e,t){for(var r in t)n.o(t,r)&&!n.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},n.o=function(e,t){return Object.prototype.hasOwnProperty.call(e,t)},n.r=function(e){"undefined"!==typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},function(){"use strict";var e=n(2791),t=n(1250),r=n(7462),a=n(5513),o=(n(76),n(9886)),i=(n(2110),n(5438)),s=n(9140),l=n(2561),c=(0,o.w)((function(t,n){var r=t.styles,a=(0,s.O)([r],void 0,(0,e.useContext)(o.T)),c=(0,e.useRef)();return(0,l.j)((function(){var e=n.key+"-global",t=new n.sheet.constructor({key:e,nonce:n.sheet.nonce,container:n.sheet.container,speedy:n.sheet.isSpeedy}),r=!1,o=document.querySelector('style[data-emotion="'+e+" "+a.name+'"]');return n.sheet.tags.length&&(t.before=n.sheet.tags[0]),null!==o&&(r=!0,o.setAttribute("data-emotion",e),t.hydrate([o])),c.current=[t,r],function(){t.flush()}}),[n]),(0,l.j)((function(){var e=c.current,t=e[0];if(e[1])e[1]=!1;else{if(void 0!==a.next&&(0,i.My)(n,a.next,!0),t.tags.length){var r=t.tags[t.tags.length-1].nextElementSibling;t.before=r,t.flush()}n.insert("",a,t,!1)}}),[n,a.name]),null}));function u(){for(var e=arguments.length,t=new Array(e),n=0;n<e;n++)t[n]=arguments[n];return(0,s.O)(t)}var d=function(){var e=u.apply(void 0,arguments),t="animation-"+e.name;return{name:t,styles:"@keyframes "+t+"{"+e.styles+"}",anim:1,toString:function(){return"_EMO_"+this.name+"_"+this.styles+"_EMO_"}}};var f=n(184);function p(e){var t=e.styles,n=e.defaultTheme,r=void 0===n?{}:n,a="function"===typeof t?function(e){return t(void 0===(n=e)||null===n||0===Object.keys(n).length?r:e);var n}:t;return(0,f.jsx)(c,{styles:a})}var m=n(4205);var h=function(e){return(0,f.jsx)(p,(0,r.Z)({},e,{defaultTheme:m.Z}))},v=function(e,t){return(0,r.Z)({WebkitFontSmoothing:"antialiased",MozOsxFontSmoothing:"grayscale",boxSizing:"border-box",WebkitTextSizeAdjust:"100%"},t&&{colorScheme:e.palette.mode})},y=function(e){return(0,r.Z)({color:(e.vars||e).palette.text.primary},e.typography.body1,{backgroundColor:(e.vars||e).palette.background.default,"@media print":{backgroundColor:(e.vars||e).palette.common.white}})};var b=function(t){var n=(0,a.Z)({props:t,name:"MuiCssBaseline"}),o=n.children,i=n.enableColorScheme,s=void 0!==i&&i;return(0,f.jsxs)(e.Fragment,{children:[(0,f.jsx)(h,{styles:function(e){return function(e){var t,n,a={html:v(e,arguments.length>1&&void 0!==arguments[1]&&arguments[1]),"*, *::before, *::after":{boxSizing:"inherit"},"strong, b":{fontWeight:e.typography.fontWeightBold},body:(0,r.Z)({margin:0},y(e),{"&::backdrop":{backgroundColor:(e.vars||e).palette.background.default}})},o=null==(t=e.components)||null==(n=t.MuiCssBaseline)?void 0:n.styleOverrides;return o&&(a=[a,o]),a}(e,s)}}),o]})},g=n(885),_=n(4942),w=n(3366),S=n(8182),k=n(7312),T=n(1217),F=n(4419),C=n(8691),x=(0,n(4046).ZP)(),A=n(5080),E=["className","component","disableGutters","fixed","maxWidth","classes"],D=(0,A.Z)(),P=x("div",{name:"MuiContainer",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,t["maxWidth".concat((0,k.Z)(String(n.maxWidth)))],n.fixed&&t.fixed,n.disableGutters&&t.disableGutters]}}),R=function(e){return(0,C.Z)({props:e,name:"MuiContainer",defaultTheme:D})},M=function(e,t){var n=e.classes,r=e.fixed,a=e.disableGutters,o=e.maxWidth,i={root:["root",o&&"maxWidth".concat((0,k.Z)(String(o))),r&&"fixed",a&&"disableGutters"]};return(0,F.Z)(i,(function(e){return(0,T.Z)(t,e)}),n)};var N=n(9853),O=n(277),z=function(){var t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},n=t.createStyledComponent,a=void 0===n?P:n,o=t.useThemeProps,i=void 0===o?R:o,s=t.componentName,l=void 0===s?"MuiContainer":s,c=a((function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({width:"100%",marginLeft:"auto",boxSizing:"border-box",marginRight:"auto",display:"block"},!n.disableGutters&&(0,_.Z)({paddingLeft:t.spacing(2),paddingRight:t.spacing(2)},t.breakpoints.up("sm"),{paddingLeft:t.spacing(3),paddingRight:t.spacing(3)}))}),(function(e){var t=e.theme;return e.ownerState.fixed&&Object.keys(t.breakpoints.values).reduce((function(e,n){var r=n,a=t.breakpoints.values[r];return 0!==a&&(e[t.breakpoints.up(r)]={maxWidth:"".concat(a).concat(t.breakpoints.unit)}),e}),{})}),(function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({},"xs"===n.maxWidth&&(0,_.Z)({},t.breakpoints.up("xs"),{maxWidth:Math.max(t.breakpoints.values.xs,444)}),n.maxWidth&&"xs"!==n.maxWidth&&(0,_.Z)({},t.breakpoints.up(n.maxWidth),{maxWidth:"".concat(t.breakpoints.values[n.maxWidth]).concat(t.breakpoints.unit)}))})),u=e.forwardRef((function(e,t){var n=i(e),a=n.className,o=n.component,s=void 0===o?"div":o,u=n.disableGutters,d=void 0!==u&&u,p=n.fixed,m=void 0!==p&&p,h=n.maxWidth,v=void 0===h?"lg":h,y=(0,w.Z)(n,E),b=(0,r.Z)({},n,{component:s,disableGutters:d,fixed:m,maxWidth:v}),g=M(b,l);return(0,f.jsx)(c,(0,r.Z)({as:s,ownerState:b,className:(0,S.Z)(g.root,a),ref:t},y))}));return u}({createStyledComponent:(0,O.ZP)("div",{name:"MuiContainer",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,t["maxWidth".concat((0,N.Z)(String(n.maxWidth)))],n.fixed&&t.fixed,n.disableGutters&&t.disableGutters]}}),useThemeProps:function(e){return(0,a.Z)({props:e,name:"MuiContainer"})}}),I=z,L=n(2421),Z=n(104),j=n(2982),B=n(2466),W=n(114),U=["sx"];function V(e){var t,n=e.sx,a=function(e){var t={systemProps:{},otherProps:{}};return Object.keys(e).forEach((function(n){W.Gc[n]?t.systemProps[n]=e[n]:t.otherProps[n]=e[n]})),t}((0,w.Z)(e,U)),o=a.systemProps,i=a.otherProps;return t=Array.isArray(n)?[o].concat((0,j.Z)(n)):"function"===typeof n?function(){var e=n.apply(void 0,arguments);return(0,B.P)(e)?(0,r.Z)({},o,e):o}:(0,r.Z)({},o,n),(0,r.Z)({},i,{sx:t})}var G=n(886),J=["className","component"];var $=n(5902),H=n(4360),q=function(){var t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},n=t.defaultTheme,a=t.defaultClassName,o=void 0===a?"MuiBox-root":a,i=t.generateClassName,s=t.styleFunctionSx,l=void 0===s?Z.Z:s,c=(0,L.ZP)("div",{shouldForwardProp:function(e){return"theme"!==e&&"sx"!==e&&"as"!==e}})(l),u=e.forwardRef((function(e,t){var a=(0,G.Z)(n),s=V(e),l=s.className,u=s.component,d=void 0===u?"div":u,p=(0,w.Z)(s,J);return(0,f.jsx)(c,(0,r.Z)({as:d,ref:t,className:(0,S.Z)(l,i?i(o):o),theme:a},p))}));return u}({defaultTheme:(0,H.Z)(),defaultClassName:"MuiBox-root",generateClassName:$.Z.generate}),K=q,Y=JSON.parse('{"e":15,"C":[{"nctid":"NCT01953913","version_a":18,"version_b":19,"version_a_date":"2014-07-09","version_b_date":"2014-07-23","pom_a":[{"label":"1.","content":"Number of patients with drug related adverse events according to CTCAE 3.0.[ Time Frame: up to 65 weeks ]"}],"pom_b":[{"label":"1.","content":"Number of patients with serious adverse events (SAEs).[ Time Frame: up to 65 weeks ]"}],"first_posted":"August 12, 2019","completion_date":"July 6, 2018","primary_completion_date":"July 6, 2018","start_date":"September 30, 2013","last_update_posted":"August 12, 2019"},{"nctid":"NCT01953913","version_a":85,"version_b":86,"version_a_date":"2018-07-19","version_b_date":"2019-06-27","pom_a":[{"label":"1.","content":"Number of patients with serious adverse events (SAEs).[ Time Frame: up to 65 weeks ]"}],"pom_b":[{"label":"1.","content":"Percentage of Participants With Serious Adverse Events (SAEs)[ Time Frame: From first drug administration up to 28 days after last drug administration, up to 1624 days. ]Percentage of participants with serious adverse events (SAEs)."}],"first_posted":"August 12, 2019","completion_date":"July 6, 2018","primary_completion_date":"July 6, 2018","start_date":"September 30, 2013","last_update_posted":"August 12, 2019"},{"nctid":"NCT00824265","version_a":6,"version_b":7,"version_a_date":"2009-03-26","version_b_date":"2009-04-02","pom_a":[{"label":"1.","content":"Progression-free-survival[ Time Frame: 234 events, 39.1 months ]"}],"pom_b":[{"label":"1.","content":"Progression-free-survival[ Time Frame: 3 years ]"}],"first_posted":"July 25, 2016","completion_date":"October 25, 2017","primary_completion_date":"December 17, 2014","start_date":"March 12, 2009","last_update_posted":"June 18, 2020"},{"nctid":"NCT00824265","version_a":143,"version_b":144,"version_a_date":"2015-07-16","version_b_date":"2016-06-15","pom_a":[{"label":"1.","content":"Progression-free-survival[ Time Frame: 3 years ]"}],"pom_b":[{"label":"1.","content":"Progression-free Survival (PFS), as Assessed by the Independent Review Committee (IRC)[ Time Frame: From randomization up to 5 years after last dose of study drug ]PFS is defined as the interval of time between the date of randomization and the earlier of the date of disease progression (progressive disease,PD) and the date of death due to any cause. PD requires at least one of the following: lymphadenopathy, appearance of any new lesion such as enlargerd lymph nodes (>1.5 cm) spleen or liver or other infiltrates or an increase by 50% or more in the greatest diameter of any previous site; an increase by 50% or more in the previously noted enlargement of the liver or spleen, an increase by 50% or more in the numbers of blood lymphocytes with at least 5000 lymphocytes per microliter, transformation to a more aggressive histology, or occurrence of cytopenia attributable to chronic lymphocytic leukaemia."}],"first_posted":"July 25, 2016","completion_date":"October 25, 2017","primary_completion_date":"December 17, 2014","start_date":"March 12, 2009","last_update_posted":"June 18, 2020"},{"nctid":"NCT00824265","version_a":146,"version_b":147,"version_a_date":"2017-12-13","version_b_date":"2018-10-10","pom_a":[{"label":"1.","content":"Progression-free Survival (PFS), as Assessed by the Independent Review Committee (IRC)[ Time Frame: From randomization up to 5 years after last dose of study drug ]PFS is defined as the interval of time between the date of randomization and the earlier of the date of disease progression (progressive disease,PD) and the date of death due to any cause. PD requires at least one of the following: lymphadenopathy, appearance of any new lesion such as enlargerd lymph nodes (>1.5 cm) spleen or liver or other infiltrates or an increase by 50% or more in the greatest diameter of any previous site; an increase by 50% or more in the previously noted enlargement of the liver or spleen, an increase by 50% or more in the numbers of blood lymphocytes with at least 5000 lymphocytes per microliter, transformation to a more aggressive histology, or occurrence of cytopenia attributable to chronic lymphocytic leukaemia."}],"pom_b":[{"label":"1.","content":"Progression-free Survival (PFS), as Assessed by the Independent Review Committee (IRC)[ Time Frame: From randomization up to 5 years after last dose of study drug ]PFS is defined as the interval of time between the date of randomization and the earlier of the date of disease progression (progressive disease,PD) and the date of death due to any cause. PD requires at least one of the following: lymphadenopathy, appearance of any new lesion such as enlargerd lymph nodes (>1.5 cm) spleen or liver or other infiltrates or an increase by 50% or more in the greatest diameter of any previous site; an increase by 50% or more in the previously noted enlargement of the liver or spleen, an increase by 50% or more in the numbers of blood lymphocytes with at least 5000 lymphocytes per microliter, transformation to a more aggressive histology, or occurrence of cytopenia attributable to chronic lymphocytic leukaemia (CLL)."}],"first_posted":"July 25, 2016","completion_date":"October 25, 2017","primary_completion_date":"December 17, 2014","start_date":"March 12, 2009","last_update_posted":"June 18, 2020"},{"nctid":"NCT00295750","version_a":4,"version_b":5,"version_a_date":"2008-06-20","version_b_date":"2009-03-13","pom_a":[{"label":"1.","content":"To demonstrate non-inferiority with respect to the proportion of patients achieving and maintaining testosterone suppression to castrate levels using a degarelix dosing regimen compared to LUPRON DEPOT\xae during 12 months treatment"}],"pom_b":[{"label":"1.","content":"Percentage of Patients With Testosterone <=0.5ng/mL From Day 28 Through Day 364[ Time Frame: 12 months ]Kaplan-Maier estimates of the cumulative probabilities of testosterone <=0.5 ng/mL from Day 28 to Day 364. The degarelix response rate estimation determined whether the lower bound of the 95% confidence interval for the cumulative probability of testosterone <=0.5 ng/mL from Day 28 to Day 364 was no lower than 90%."}],"first_posted":"April 16, 2009","completion_date":"October 2007","primary_completion_date":"October 2007","start_date":"February 2006","last_update_posted":"December 19, 2012"},{"nctid":"NCT00144495","version_a":7,"version_b":8,"version_a_date":"2008-01-16","version_b_date":"2008-02-13","pom_a":[{"label":"1.","content":"The increase in Hb concentration"}],"pom_b":[{"label":"1.","content":"The increase in Hb concentration[ Time Frame: Day 28th or later ]"}],"first_posted":"No date provided","completion_date":"May 2005","primary_completion_date":"November 2004","start_date":"February 2004","last_update_posted":"February 2, 2009"},{"nctid":"NCT00149162","version_a":3,"version_b":4,"version_a_date":"2006-03-30","version_b_date":"2007-11-06","pom_a":[{"label":"1.","content":"Interest of interleukin-2 in complete remission after induction and consolidation chemotherapy concerning the event free survival (event = relapse of toxic death)"}],"pom_b":[{"label":"1.","content":"Interest of interleukin-2 in complete remission after induction and consolidation chemotherapy concerning the event free survival (event = relapse of toxic death)[ Time Frame: 1 year ]"}],"first_posted":"No date provided","completion_date":"March 2012","primary_completion_date":"December 2010","start_date":"March 2005","last_update_posted":"February 12, 2009"},{"nctid":"NCT03711032","version_a":62,"version_b":63,"version_a_date":"2020-10-23","version_b_date":"2020-11-11","pom_a":[{"label":"1.","content":"Complete Response Rate (CRR) by Blinded Independent Central Review (BICR)[ Time Frame: Up to ~3.5 years ]CRR is defined as the percentage of participants with CIS achieving a complete response (CR)."}],"pom_b":[{"label":"1.","content":"Complete Response Rate (CRR) by Blinded Independent Central Review (BICR) (Cohort A)[ Time Frame: Up to ~3.5 years ]CRR is defined as the percentage of participants with CIS achieving a complete response (CR)."},{"label":"2.","content":"Event-Free Survival (EFS) (Cohort B)[ Time Frame: Up to ~5 years ]EFS is defined as the time from randomization until urothelial carcinoma (UC)-defined event, or death due to any cause."}],"first_posted":"No date provided","completion_date":"October 12, 2028","primary_completion_date":"December 31, 2025","start_date":"December 24, 2018","last_update_posted":"September 6, 2022"},{"nctid":"NCT01190930","version_a":116,"version_b":117,"version_a_date":"2012-11-22","version_b_date":"2013-06-14","pom_a":[{"label":"1.","content":"Improvement in 5-year disease-free survival (DFS) from 93% to 96% in average-risk (AR) patients based on the methotrexate randomization"},{"label":"2.","content":"Determination of whether the 5-year DFS in AR patients is adversely affected by the reduced pulses in maintenance"},{"label":"3.","content":"Determination of whether less intensive therapy will maintain a 5-year DFS \u2265 95% for low-risk patients randomized to 1 of 2 low-intensity regimens"},{"label":"4.","content":"5-year DFS for Down syndrome patients"}],"pom_b":[{"label":"1.","content":"Improvement in disease-free survival (DFS) from 93% to 96% in average-risk (AR) patients based on the methotrexate randomization[ Time Frame: 5 years ]"},{"label":"2.","content":"Determination of whether the DFS in AR patients is adversely affected by the reduced pulses in maintenance[ Time Frame: 5 years ]"},{"label":"3.","content":"Determination of whether less intensive therapy will maintain a DFS \u2265 95% for low-risk patients randomized to 1 of 2 low-intensity regimens[ Time Frame: 5 years ]"},{"label":"4.","content":"DFS for Down syndrome patients[ Time Frame: 5 years ]"}],"first_posted":"June 23, 2020","completion_date":"March 31, 2028","primary_completion_date":"March 31, 2019","start_date":"August 9, 2010","last_update_posted":"July 12, 2022"},{"nctid":"NCT01190930","version_a":117,"version_b":118,"version_a_date":"2013-06-14","version_b_date":"2013-06-19","pom_a":[{"label":"1.","content":"Improvement in disease-free survival (DFS) from 93% to 96% in average-risk (AR) patients based on the methotrexate randomization[ Time Frame: 5 years ]"},{"label":"2.","content":"Determination of whether the DFS in AR patients is adversely affected by the reduced pulses in maintenance[ Time Frame: 5 years ]"},{"label":"3.","content":"Determination of whether less intensive therapy will maintain a DFS \u2265 95% for low-risk patients randomized to 1 of 2 low-intensity regimens[ Time Frame: 5 years ]"},{"label":"4.","content":"DFS for Down syndrome patients[ Time Frame: 5 years ]"}],"pom_b":[{"label":"1.","content":"Improvement in DFS from 93% to 96% in AR patients based on the methotrexate randomization[ Time Frame: Time from randomization at the end of interim maintenance II to first event (relapse, second malignancy, remission death) or date of last contact, assessed up to 5 years ]All power calculations are based on the assumption of proportional hazards, and using the log rank test (alpha = 5%) with 5 planned analyses of the data for interim monitoring purposes (MTX question for AR patients). The study will also be monitored for futility."},{"label":"2.","content":"Determination of whether the 5-year DFS in AR patients is adversely affected by the reduced pulses in maintenance[ Time Frame: Every 4 weeks versus every 8 weeks from the start of reduced pulse maintenance, assessed up to 5 years ]If it is found that there is a decrease in DFS due to the reduced pulses, comparison of outcomes between the two MTX regimens will be restricted to the every 4 week pulses arms. A Cox proportional hazards model will be used to test for quantitative interaction in this 2x2 factorial design."},{"label":"3.","content":"Determination of whether less intensive therapy will maintain DFS >= 95% for LR patients randomized to 1 of 2 low-intensity regimens[ Time Frame: Time from end of Induction to first event (relapse, second malignancy, remission death) or date of last contact, assessed up to 5 years ]The 5-year DFS for these patients will be estimated on the 2 low intensity regimens. Interim analysis will also be conducted, for each of the 2 low intensity regimens to protect against lower DFS for the LR patients, based on the estimated hazard rate."},{"label":"4.","content":"DFS for Down syndrome patients[ Time Frame: Time from end of Induction to first event (relapse, second malignancy, remission death) or date of last contact, assessed up to 5 years ]The 5-year DFS for these patients will be estimated on modified therapy."}],"first_posted":"June 23, 2020","completion_date":"March 31, 2028","primary_completion_date":"March 31, 2019","start_date":"August 9, 2010","last_update_posted":"July 12, 2022"},{"nctid":"NCT01190930","version_a":119,"version_b":120,"version_a_date":"2014-02-17","version_b_date":"2015-03-03","pom_a":[{"label":"1.","content":"Improvement in DFS from 93% to 96% in AR patients based on the methotrexate randomization[ Time Frame: Time from randomization at the end of interim maintenance II to first event (relapse, second malignancy, remission death) or date of last contact, assessed up to 5 years ]All power calculations are based on the assumption of proportional hazards, and using the log rank test (alpha = 5%) with 5 planned analyses of the data for interim monitoring purposes (MTX question for AR patients). The study will also be monitored for futility."},{"label":"2.","content":"Determination of whether the 5-year DFS in AR patients is adversely affected by the reduced pulses in maintenance[ Time Frame: Every 4 weeks versus every 8 weeks from the start of reduced pulse maintenance, assessed up to 5 years ]If it is found that there is a decrease in DFS due to the reduced pulses, comparison of outcomes between the two MTX regimens will be restricted to the every 4 week pulses arms. A Cox proportional hazards model will be used to test for quantitative interaction in this 2x2 factorial design."},{"label":"3.","content":"Determination of whether less intensive therapy will maintain DFS >= 95% for LR patients randomized to 1 of 2 low-intensity regimens[ Time Frame: Time from end of Induction to first event (relapse, second malignancy, remission death) or date of last contact, assessed up to 5 years ]The 5-year DFS for these patients will be estimated on the 2 low intensity regimens. Interim analysis will also be conducted, for each of the 2 low intensity regimens to protect against lower DFS for the LR patients, based on the estimated hazard rate."},{"label":"4.","content":"DFS for Down syndrome patients[ Time Frame: Time from end of Induction to first event (relapse, second malignancy, remission death) or date of last contact, assessed up to 5 years ]The 5-year DFS for these patients will be estimated on modified therapy."}],"pom_b":[{"label":"1.","content":"Improvement in DFS in AR patients based on the methotrexate randomization[ Time Frame: Time from randomization to 5 years ]"},{"label":"2.","content":"Determination of whether the DFS in AR patients is adversely affected by the reduced pulses in maintenance[ Time Frame: Time from randomization to 5 years ]"},{"label":"3.","content":"Determination of whether less intensive therapy will maintain 5 year DFS >= 95% for LR patients on each randomized arm[ Time Frame: Time from end of Induction to 5 years ]"},{"label":"4.","content":"DFS for Down syndrome patients[ Time Frame: Time from end of Induction to 5 years ]"}],"first_posted":"June 23, 2020","completion_date":"March 31, 2028","primary_completion_date":"March 31, 2019","start_date":"August 9, 2010","last_update_posted":"July 12, 2022"},{"nctid":"NCT01190930","version_a":121,"version_b":122,"version_a_date":"2015-05-01","version_b_date":"2015-08-06","pom_a":[{"label":"1.","content":"Improvement in DFS in AR patients based on the methotrexate randomization[ Time Frame: Time from randomization to 5 years ]"},{"label":"2.","content":"Determination of whether the DFS in AR patients is adversely affected by the reduced pulses in maintenance[ Time Frame: Time from randomization to 5 years ]"},{"label":"3.","content":"Determination of whether less intensive therapy will maintain 5 year DFS >= 95% for LR patients on each randomized arm[ Time Frame: Time from end of Induction to 5 years ]"},{"label":"4.","content":"DFS for Down syndrome patients[ Time Frame: Time from end of Induction to 5 years ]"}],"pom_b":[{"label":"1.","content":"Determination of whether less intensive therapy will maintain DFS >= 95% for LR patients randomized to 1 of 2 low-intensity regimens[ Time Frame: Time from end of Induction to first event (relapse, second malignancy, remission death) or date of last contact, assessed up to 5 years ]The 5-year DFS for these patients will be estimated on the 2 low intensity regimens. Interim analysis based on the estimated hazard rate will also be conducted, for each of the 2 low intensity regimens to protect against lower DFS for the LR patients."},{"label":"2.","content":"Determination of whether the 5-year DFS in AR patients is adversely affected by the reduced pulses in maintenance[ Time Frame: Every 4 weeks versus every 8 weeks from the start of reduced pulse maintenance, assessed up to 5 years ]If it is found that there is a decrease in DFS due to the reduced pulses, comparison of outcomes between the two MTX regimens will be restricted to the every 4 week pulses arms. A Cox proportional hazards model will be used to test for quantitative interaction in this 2x2 factorial design."},{"label":"3.","content":"DFS for B-LLy patients[ Time Frame: Time from end of Induction to first event (relapse, second malignancy, remission death) or date of last contact, assessed up to 5 years ]EFS rate will be estimated for this group of patients. The 95% confidence interval will be computed for the same. Biology data captured for these patients will be summarized."},{"label":"4.","content":"DFS for Down syndrome patients[ Time Frame: Time from end of Induction to first event (relapse, second malignancy, remission death) or date of last contact, assessed up to 5 years ]The 5-year DFS for these patients will be estimated on modified therapy."},{"label":"5.","content":"Improvement in DFS from 93% to 96% in AR patients based on the methotrexate randomization[ Time Frame: Time from randomization at the end of interim maintenance II to first event (relapse, second malignancy, remission death) or date of last contact, assessed up to 5 years ]All power calculations are based on the assumption of proportional hazards, and using the log rank test (alpha = 5%) with 5 planned analyses of the data for interim monitoring purposes (MTX question for AR patients). The study will also be monitored for futility."}],"first_posted":"June 23, 2020","completion_date":"March 31, 2028","primary_completion_date":"March 31, 2019","start_date":"August 9, 2010","last_update_posted":"July 12, 2022"},{"nctid":"NCT01190930","version_a":126,"version_b":127,"version_a_date":"2018-03-19","version_b_date":"2018-07-02","pom_a":[{"label":"1.","content":"Determination of whether less intensive therapy will maintain DFS >= 95% for LR patients randomized to 1 of 2 low-intensity regimens[ Time Frame: Time from end of Induction to first event (relapse, second malignancy, remission death) or date of last contact, assessed up to 5 years ]The 5-year DFS for these patients will be estimated on the 2 low intensity regimens. Interim analysis based on the estimated hazard rate will also be conducted, for each of the 2 low intensity regimens to protect against lower DFS for the LR patients."},{"label":"2.","content":"Determination of whether the 5-year DFS in AR patients is adversely affected by the reduced pulses in maintenance[ Time Frame: Every 4 weeks versus every 8 weeks from the start of reduced pulse maintenance, assessed up to 5 years ]If it is found that there is a decrease in DFS due to the reduced pulses, comparison of outcomes between the two MTX regimens will be restricted to the every 4 week pulses arms. A Cox proportional hazards model will be used to test for quantitative interaction in this 2x2 factorial design."},{"label":"3.","content":"DFS for B-LLy patients[ Time Frame: Time from end of Induction to first event (relapse, second malignancy, remission death) or date of last contact, assessed up to 5 years ]EFS rate will be estimated for this group of patients. The 95% confidence interval will be computed for the same. Biology data captured for these patients will be summarized."},{"label":"4.","content":"DFS for Down syndrome patients[ Time Frame: Time from end of Induction to first event (relapse, second malignancy, remission death) or date of last contact, assessed up to 5 years ]The 5-year DFS for these patients will be estimated on modified therapy."},{"label":"5.","content":"Improvement in DFS from 93% to 96% in AR patients based on the methotrexate randomization[ Time Frame: Time from randomization at the end of interim maintenance II to first event (relapse, second malignancy, remission death) or date of last contact, assessed up to 5 years ]All power calculations are based on the assumption of proportional hazards, and using the log rank test (alpha = 5%) with 5 planned analyses of the data for interim monitoring purposes (MTX question for AR patients). The study will also be monitored for futility."}],"pom_b":[{"label":"1.","content":"Improvement in DFS from 93% to 96% in AR patients based on the methotrexate randomization[ Time Frame: Time from randomization at the end of interim maintenance II to first event (relapse, second malignancy, remission death) or date of last contact, assessed up to 5 years ]All power calculations are based on the assumption of proportional hazards, and using the log rank test (alpha = 5%) with 5 planned analyses of the data for interim monitoring purposes (MTX question for AR patients). The study will also be monitored for futility."},{"label":"2.","content":"Determination of whether the 5-year DFS in AR patients is adversely affected by the reduced pulses in maintenance[ Time Frame: Every 4 weeks versus every 8 weeks from the start of reduced pulse maintenance, assessed up to 5 years ]If it is found that there is a decrease in DFS due to the reduced pulses, comparison of outcomes between the two MTX regimens will be restricted to the every 4 week pulses arms. A Cox proportional hazards model will be used to test for quantitative interaction in this 2x2 factorial design."},{"label":"3.","content":"Determination of whether less intensive therapy will maintain DFS >= 95% for LR patients randomized to 1 of 2 low-intensity regimens[ Time Frame: Time from end of Induction to first event (relapse, second malignancy, remission death) or date of last contact, assessed up to 5 years ]The 5-year DFS for these patients will be estimated on the 2 low intensity regimens. Interim analysis based on the estimated hazard rate will also be conducted, for each of the 2 low intensity regimens to protect against lower DFS for the LR patients."},{"label":"4.","content":"DFS for B-LLy patients[ Time Frame: Time from end of Induction to first event (relapse, second malignancy, remission death) or date of last contact, assessed up to 5 years ]EFS rate will be estimated for this group of patients. The 95% confidence interval will be computed for the same. Biology data captured for these patients will be summarized."},{"label":"5.","content":"DFS for Down syndrome patients[ Time Frame: Time from end of Induction to first event (relapse, second malignancy, remission death) or date of last contact, assessed up to 5 years ]The 5-year DFS for these patients will be estimated on modified therapy."}],"first_posted":"June 23, 2020","completion_date":"March 31, 2028","primary_completion_date":"March 31, 2019","start_date":"August 9, 2010","last_update_posted":"July 12, 2022"},{"nctid":"NCT01190930","version_a":130,"version_b":131,"version_a_date":"2019-11-14","version_b_date":"2019-11-22","pom_a":[{"label":"1.","content":"Improvement in DFS from 93% to 96% in AR patients based on the methotrexate randomization[ Time Frame: Time from randomization at the end of interim maintenance II to first event (relapse, second malignancy, remission death) or date of last contact, assessed up to 5 years ]All power calculations are based on the assumption of proportional hazards, and using the log rank test (alpha = 5%) with 5 planned analyses of the data for interim monitoring purposes (MTX question for AR patients). The study will also be monitored for futility."},{"label":"2.","content":"Determination of whether the 5-year DFS in AR patients is adversely affected by the reduced pulses in maintenance[ Time Frame: Every 4 weeks versus every 8 weeks from the start of reduced pulse maintenance, assessed up to 5 years ]If it is found that there is a decrease in DFS due to the reduced pulses, comparison of outcomes between the two MTX regimens will be restricted to the every 4 week pulses arms. A Cox proportional hazards model will be used to test for quantitative interaction in this 2x2 factorial design."},{"label":"3.","content":"Determination of whether less intensive therapy will maintain DFS >= 95% for LR patients randomized to 1 of 2 low-intensity regimens[ Time Frame: Time from end of Induction to first event (relapse, second malignancy, remission death) or date of last contact, assessed up to 5 years ]The 5-year DFS for these patients will be estimated on the 2 low intensity regimens. Interim analysis based on the estimated hazard rate will also be conducted, for each of the 2 low intensity regimens to protect against lower DFS for the LR patients."},{"label":"4.","content":"DFS for B-LLy patients[ Time Frame: Time from end of Induction to first event (relapse, second malignancy, remission death) or date of last contact, assessed up to 5 years ]EFS rate will be estimated for this group of patients. The 95% confidence interval will be computed for the same. Biology data captured for these patients will be summarized."},{"label":"5.","content":"DFS for Down syndrome patients[ Time Frame: Time from end of Induction to first event (relapse, second malignancy, remission death) or date of last contact, assessed up to 5 years ]The 5-year DFS for these patients will be estimated on modified therapy."}],"pom_b":[{"label":"1.","content":"Disease free survival (DFS) in average risk (AR) patients based on the methotrexate dose randomization[ Time Frame: 5.7 years ]DFS is calculated as the time from randomization at the end of interim maintenance II to first event (relapse, second malignancy, remission death) or date of last contact. Five year DFS estimates will be calculated from the point of randomization for both groups. Two-sided 95% confidence intervals will be calculated."},{"label":"2.","content":"DFS in average risk (AR) patients based on the pulse frequency randomization[ Time Frame: 5.7 years ]DFS is calculated as the time from randomization at the end of interim maintenance II to first event (relapse, second malignancy, remission death) or date of last contact. Five year DFS estimates will be calculated from the point of randomization for both groups. Two-sided 95% confidence intervals will be calculated."},{"label":"3.","content":"DFS in low risk (LR) patients based on randomization to 1 of 2 low-intensity regimens[ Time Frame: 5.1 years ]DFS is calculated as the time from randomization at the end of Induction to first event (relapse, second malignancy, remission death) or date of last contact. Five year DFS estimates will be calculated from the point of randomization for both groups. Two-sided 95% confidence intervals will be calculated."},{"label":"4.","content":"DFS for SR Down syndrome patients with standardized treatment and enhanced supportive care[ Time Frame: 5.1 years ]DFS is calculated as the time from end of Induction to first event (relapse, second malignancy, remission death) or date of last contact. The 5-year DFS and 95% confidence interval for these patients will be estimated."},{"label":"5.","content":"Sample collection of central path review slides in B-LLy patients event free survival (EFS) for B-LLy patients[ Time Frame: 5 years ]EFS is calculated as the Time from study enrollment to first event (induction failure, relapse, second malignancy, remission death) or date of last contact. The 5-year EFS and 95% confidence interval for these patients will be estimated."},{"label":"6.","content":"Event free survival (EFS) for B-LLy patients[ Time Frame: 5 years ]EFS is calculated as the Time from study enrollment to first event (induction failure, relapse, second malignancy, remission death) or date of last contact. The 5-year EFS and 95% confidence interval for these patients will be estimated."}],"first_posted":"June 23, 2020","completion_date":"March 31, 2028","primary_completion_date":"March 31, 2019","start_date":"August 9, 2010","last_update_posted":"July 12, 2022"},{"nctid":"NCT01190930","version_a":132,"version_b":133,"version_a_date":"2020-01-22","version_b_date":"2020-02-05","pom_a":[{"label":"1.","content":"Disease free survival (DFS) in average risk (AR) patients based on the methotrexate dose randomization[ Time Frame: 5.7 years ]DFS is calculated as the time from randomization at the end of interim maintenance II to first event (relapse, second malignancy, remission death) or date of last contact. Five year DFS estimates will be calculated from the point of randomization for both groups. Two-sided 95% confidence intervals will be calculated."},{"label":"2.","content":"DFS in average risk (AR) patients based on the pulse frequency randomization[ Time Frame: 5.7 years ]DFS is calculated as the time from randomization at the end of interim maintenance II to first event (relapse, second malignancy, remission death) or date of last contact. Five year DFS estimates will be calculated from the point of randomization for both groups. Two-sided 95% confidence intervals will be calculated."},{"label":"3.","content":"DFS in low risk (LR) patients based on randomization to 1 of 2 low-intensity regimens[ Time Frame: 5.1 years ]DFS is calculated as the time from randomization at the end of Induction to first event (relapse, second malignancy, remission death) or date of last contact. Five year DFS estimates will be calculated from the point of randomization for both groups. Two-sided 95% confidence intervals will be calculated."},{"label":"4.","content":"DFS for SR Down syndrome patients with standardized treatment and enhanced supportive care[ Time Frame: 5.1 years ]DFS is calculated as the time from end of Induction to first event (relapse, second malignancy, remission death) or date of last contact. The 5-year DFS and 95% confidence interval for these patients will be estimated."},{"label":"5.","content":"Sample collection of central path review slides in B-LLy patients event free survival (EFS) for B-LLy patients[ Time Frame: 5 years ]EFS is calculated as the Time from study enrollment to first event (induction failure, relapse, second malignancy, remission death) or date of last contact. The 5-year EFS and 95% confidence interval for these patients will be estimated."},{"label":"6.","content":"Event free survival (EFS) for B-LLy patients[ Time Frame: 5 years ]EFS is calculated as the Time from study enrollment to first event (induction failure, relapse, second malignancy, remission death) or date of last contact. The 5-year EFS and 95% confidence interval for these patients will be estimated."}],"pom_b":[{"label":"1.","content":"Disease free survival (DFS) in average risk (AR) patients based on the methotrexate dose randomization[ Time Frame: 5.7 years ]DFS is calculated as the time from randomization at the end of interim maintenance II to first event (relapse, second malignancy, remission death) or date of last contact. Five year DFS estimates will be calculated from the point of randomization for both groups. Two-sided 95% confidence intervals will be calculated."},{"label":"2.","content":"DFS in average risk (AR) patients based on the pulse frequency randomization[ Time Frame: 5.7 years ]DFS is calculated as the time from randomization at the end of interim maintenance II to first event (relapse, second malignancy, remission death) or date of last contact. Five year DFS estimates will be calculated from the point of randomization for both groups. Two-sided 95% confidence intervals will be calculated."},{"label":"3.","content":"DFS in low risk (LR) patients based on randomization to 1 of 2 low-intensity regimens[ Time Frame: 5.1 years ]DFS is calculated as the time from randomization at the end of Induction to first event (relapse, second malignancy, remission death) or date of last contact. Five year DFS estimates will be calculated from the point of randomization for both groups. Two-sided 95% confidence intervals will be calculated."},{"label":"4.","content":"DFS for SR Down syndrome patients with standardized treatment and enhanced supportive care[ Time Frame: 5.1 years ]DFS is calculated as the time from end of Induction to first event (relapse, second malignancy, remission death) or date of last contact. The 5-year DFS and 95% confidence interval for these patients will be estimated."},{"label":"5.","content":"Sample collection of central path review slides in B-LLy patients[ Time Frame: Up to 1 month ]Percent of B-LLy patients who had adequate/usable samples of samples collected will be reported."},{"label":"6.","content":"Event free survival (EFS) for B-LLy patients[ Time Frame: 5 years ]EFS is calculated as the Time from study enrollment to first event (induction failure, relapse, second malignancy, remission death) or date of last contact. The 5-year EFS and 95% confidence interval for these patients will be estimated."}],"first_posted":"June 23, 2020","completion_date":"March 31, 2028","primary_completion_date":"March 31, 2019","start_date":"August 9, 2010","last_update_posted":"July 12, 2022"},{"nctid":"NCT01190930","version_a":133,"version_b":134,"version_a_date":"2020-02-05","version_b_date":"2020-02-10","pom_a":[{"label":"1.","content":"Disease free survival (DFS) in average risk (AR) patients based on the methotrexate dose randomization[ Time Frame: 5.7 years ]DFS is calculated as the time from randomization at the end of interim maintenance II to first event (relapse, second malignancy, remission death) or date of last contact. Five year DFS estimates will be calculated from the point of randomization for both groups. Two-sided 95% confidence intervals will be calculated."},{"label":"2.","content":"DFS in average risk (AR) patients based on the pulse frequency randomization[ Time Frame: 5.7 years ]DFS is calculated as the time from randomization at the end of interim maintenance II to first event (relapse, second malignancy, remission death) or date of last contact. Five year DFS estimates will be calculated from the point of randomization for both groups. Two-sided 95% confidence intervals will be calculated."},{"label":"3.","content":"DFS in low risk (LR) patients based on randomization to 1 of 2 low-intensity regimens[ Time Frame: 5.1 years ]DFS is calculated as the time from randomization at the end of Induction to first event (relapse, second malignancy, remission death) or date of last contact. Five year DFS estimates will be calculated from the point of randomization for both groups. Two-sided 95% confidence intervals will be calculated."},{"label":"4.","content":"DFS for SR Down syndrome patients with standardized treatment and enhanced supportive care[ Time Frame: 5.1 years ]DFS is calculated as the time from end of Induction to first event (relapse, second malignancy, remission death) or date of last contact. The 5-year DFS and 95% confidence interval for these patients will be estimated."},{"label":"5.","content":"Sample collection of central path review slides in B-LLy patients[ Time Frame: Up to 1 month ]Percent of B-LLy patients who had adequate/usable samples of samples collected will be reported."},{"label":"6.","content":"Event free survival (EFS) for B-LLy patients[ Time Frame: 5 years ]EFS is calculated as the Time from study enrollment to first event (induction failure, relapse, second malignancy, remission death) or date of last contact. The 5-year EFS and 95% confidence interval for these patients will be estimated."}],"pom_b":[{"label":"1.","content":"Disease free survival (DFS) in average risk (AR) patients based on the methotrexate dose randomization[ Time Frame: 5.7 years ]DFS is calculated as the time from randomization at the end of interim maintenance II to first event (relapse, second malignancy, remission death) or date of last contact. Five year DFS estimates will be calculated from the point of randomization for both groups. Two-sided 95% confidence intervals will be calculated."},{"label":"2.","content":"DFS in average risk (AR) patients based on the pulse frequency randomization[ Time Frame: 5.7 years ]DFS is calculated as the time from randomization at the end of interim maintenance II to first event (relapse, second malignancy, remission death) or date of last contact. Five year DFS estimates will be calculated from the point of randomization for both groups. Two-sided 95% confidence intervals will be calculated."},{"label":"3.","content":"DFS in low risk (LR) patients based on randomization to 1 of 2 low-intensity regimens[ Time Frame: 5.1 years ]DFS is calculated as the time from randomization at the end of Induction to first event (relapse, second malignancy, remission death) or date of last contact. Five year DFS estimates will be calculated from the point of randomization for both groups. Two-sided 95% confidence intervals will be calculated."},{"label":"4.","content":"DFS for SR Down syndrome patients with standardized treatment and enhanced supportive care[ Time Frame: 5.1 years ]DFS is calculated as the time from end of Induction to first event (relapse, second malignancy, remission death) or date of last contact. The 5-year DFS and 95% confidence interval for these patients will be estimated."},{"label":"5.","content":"Sample collection of central path review slides in B-LLy patients[ Time Frame: Up to 1 month ]Percent of B-LLy patients who had adequate/usable samples of samples collected will be reported."},{"label":"6.","content":"Event free survival (EFS) for B-LLy patients[ Time Frame: 5 years ]EFS is calculated as the Time from study enrollment to first event (induction failure, relapse, second malignancy, remission death) or date of last contact. The 5-year EFS and 95% confidence interval for these patients will be estimated."},{"label":"7.","content":"Overall survival (OS) for B-LLy patients[ Time Frame: 5 years ]OS is calculated as the time from study enrollment to death or date of last contact. The 5-year OS and 95% confidence interval for these patients will be estimated."}],"first_posted":"June 23, 2020","completion_date":"March 31, 2028","primary_completion_date":"March 31, 2019","start_date":"August 9, 2010","last_update_posted":"July 12, 2022"},{"nctid":"NCT01190930","version_a":134,"version_b":135,"version_a_date":"2020-02-10","version_b_date":"2020-06-05","pom_a":[{"label":"1.","content":"Disease free survival (DFS) in average risk (AR) patients based on the methotrexate dose randomization[ Time Frame: 5.7 years ]DFS is calculated as the time from randomization at the end of interim maintenance II to first event (relapse, second malignancy, remission death) or date of last contact. Five year DFS estimates will be calculated from the point of randomization for both groups. Two-sided 95% confidence intervals will be calculated."},{"label":"2.","content":"DFS in average risk (AR) patients based on the pulse frequency randomization[ Time Frame: 5.7 years ]DFS is calculated as the time from randomization at the end of interim maintenance II to first event (relapse, second malignancy, remission death) or date of last contact. Five year DFS estimates will be calculated from the point of randomization for both groups. Two-sided 95% confidence intervals will be calculated."},{"label":"3.","content":"DFS in low risk (LR) patients based on randomization to 1 of 2 low-intensity regimens[ Time Frame: 5.1 years ]DFS is calculated as the time from randomization at the end of Induction to first event (relapse, second malignancy, remission death) or date of last contact. Five year DFS estimates will be calculated from the point of randomization for both groups. Two-sided 95% confidence intervals will be calculated."},{"label":"4.","content":"DFS for SR Down syndrome patients with standardized treatment and enhanced supportive care[ Time Frame: 5.1 years ]DFS is calculated as the time from end of Induction to first event (relapse, second malignancy, remission death) or date of last contact. The 5-year DFS and 95% confidence interval for these patients will be estimated."},{"label":"5.","content":"Sample collection of central path review slides in B-LLy patients[ Time Frame: Up to 1 month ]Percent of B-LLy patients who had adequate/usable samples of samples collected will be reported."},{"label":"6.","content":"Event free survival (EFS) for B-LLy patients[ Time Frame: 5 years ]EFS is calculated as the Time from study enrollment to first event (induction failure, relapse, second malignancy, remission death) or date of last contact. The 5-year EFS and 95% confidence interval for these patients will be estimated."},{"label":"7.","content":"Overall survival (OS) for B-LLy patients[ Time Frame: 5 years ]OS is calculated as the time from study enrollment to death or date of last contact. The 5-year OS and 95% confidence interval for these patients will be estimated."}],"pom_b":[{"label":"1.","content":"Disease Free Survival (DFS) in Average Risk (AR) Patients Based on the Methotrexate Dose Randomization[ Time Frame: 5.7 years ]DFS is calculated as the time from randomization at the end of interim maintenance II to first event (relapse, second malignancy, remission death) or date of last contact. Five year DFS estimates will be calculated from the point of randomization for both groups. Two-sided 95% confidence intervals will be calculated."},{"label":"2.","content":"DFS in Average Risk (AR) Patients Based on the Pulse Frequency Randomization[ Time Frame: 5.7 years ]DFS is calculated as the time from randomization at the end of interim maintenance II to first event (relapse, second malignancy, remission death) or date of last contact. Five year DFS estimates will be calculated from the point of randomization for both groups. Two-sided 95% confidence intervals will be calculated."},{"label":"3.","content":"DFS in Low Risk (LR) Patients Based on Randomization to 1 of 2 Low-intensity Regimens[ Time Frame: 5.1 years ]DFS is calculated as the time from randomization at the end of Induction to first event (relapse, second malignancy, remission death) or date of last contact. Five year DFS estimates will be calculated from the point of randomization for both groups. Two-sided 95% confidence intervals will be calculated."},{"label":"4.","content":"DFS for SR Down Syndrome Patients With Standardized Treatment and Enhanced Supportive Care[ Time Frame: 5.1 years ]DFS is calculated as the time from end of Induction to first event (relapse, second malignancy, remission death) or date of last contact. The 5-year DFS and 95% confidence interval for these patients will be estimated."},{"label":"5.","content":"Sample Collection of Central Path Review Slides in B-LLy Patients[ Time Frame: Up to 1 month ]Percent of B-LLy patients who had adequate/usable samples of samples collected will be reported."},{"label":"6.","content":"Event Free Survival (EFS) for B-LLy Patients[ Time Frame: 5 years ]EFS is calculated as the Time from study enrollment to first event (induction failure, relapse, second malignancy, remission death) or date of last contact. The 5-year EFS and 95% confidence interval for these patients will be estimated."},{"label":"7.","content":"Overall Survival (OS) for B-LLy Patients[ Time Frame: 5 years ]OS is calculated as the time from study enrollment to death or date of last contact. The 5-year OS and 95% confidence interval for these patients will be estimated."}],"first_posted":"June 23, 2020","completion_date":"March 31, 2028","primary_completion_date":"March 31, 2019","start_date":"August 9, 2010","last_update_posted":"July 12, 2022"},{"nctid":"NCT00812240","version_a":4,"version_b":5,"version_a_date":"2012-09-25","version_b_date":"2018-12-12","pom_a":[{"label":"1.","content":"Progression Free Survival[ Time Frame: 24 months ]"}],"pom_b":[{"label":"1.","content":"Progression Free Survival (PFS)[ Time Frame: From day of randomization to disease progression or death, assessed for a maximum of 96 months] ]Progression Free Survival is defined as the time from randomization to first documentation of objective tumor progression (date of tumor assessment documenting progressive disease assessed by CT Scan according to RECIST 1.1 and based on central review) or to death due to any cause (whichever comes first)."}],"first_posted":"No date provided","completion_date":"July 2018","primary_completion_date":"July 2018","start_date":"January 2009","last_update_posted":"December 4, 2019"},{"nctid":"NCT02057666","version_a":8,"version_b":9,"version_a_date":"2015-06-29","version_b_date":"2021-03-24","pom_a":[{"label":"1.","content":"Time to Radiological Progression-Free Survival [PFS][ Time Frame: Every 3 months, up to 3 years ]PFS is defined as the time from the date of randomisation to the date of radiological progression (confirmed by the central imaging assessment) or death due to any cause."}],"pom_b":[{"label":"1.","content":"Time to Radiological Progression-Free Survival (PFS)[ Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years ]PFS was defined as the time from the date of randomisation to the date of radiological progression (confirmed by the central imaging assessment) or death due to any cause. Radiological progression was defined by any of the following criteria: progression of soft tissue lesions evaluated by computed tomography (CT) or magnetic resonance imaging (MRI) scan according to Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1 criteria; progression of bone lesions detected with bone scan according to Prostate Cancer Clinical Trials Working Group 2 (PCWG2) criteria; or radiologically confirmed spinal cord compression or pathological fracture due to malignant progression.The primary endpoint was centrally and independently evaluated."}],"first_posted":"April 23, 2021","completion_date":"May 2015","primary_completion_date":"May 2015","start_date":"January 2014","last_update_posted":"April 23, 2021"},{"nctid":"NCT00089479","version_a":9,"version_b":10,"version_a_date":"2006-01-18","version_b_date":"2006-02-20","pom_a":[],"pom_b":[{"label":"1.","content":"Efficacy: Superiority of Xeloda + Taxotere vs Taxotere in disease-free survival"}],"first_posted":"June 23, 2011","completion_date":"May 2012","primary_completion_date":"June 2010","start_date":"August 2002","last_update_posted":"December 21, 2012"},{"nctid":"NCT00089479","version_a":32,"version_b":33,"version_a_date":"2007-12-18","version_b_date":"2008-01-18","pom_a":[{"label":"1.","content":"Efficacy: Superiority of Xeloda + Taxotere vs Taxotere in disease-free survival"}],"pom_b":[{"label":"1.","content":"Disease free survival[ Time Frame: Event driven ]"}],"first_posted":"June 23, 2011","completion_date":"May 2012","primary_completion_date":"June 2010","start_date":"August 2002","last_update_posted":"December 21, 2012"},{"nctid":"NCT00089479","version_a":66,"version_b":67,"version_a_date":"2011-03-15","version_b_date":"2011-05-24","pom_a":[{"label":"1.","content":"Disease free survival[ Time Frame: Event driven ]"}],"pom_b":[{"label":"1.","content":"Disease Free Survival [Number of Events][ Time Frame: Time from the date of randomization until the date of first event, or date last known to be event free if no event was reported. Patients were followed for an average of 5 years. ]Number of patients with/without recurrence of breast cancer, or death due to any cause."},{"label":"2.","content":"Disease Free Survival [Time to Event][ Time Frame: Time from the date of randomization until the date of first event, or date last known to be event free if no event was reported. Patients were followed for an average of 5 years. ]Disease free survival was measured as the time from the date of randomization until the date of first event (recurrence of breast cancer, or death due to any cause). Patients without event at the time of the analysis were censored using the date they were last known to be recurrent disease free."}],"first_posted":"June 23, 2011","completion_date":"May 2012","primary_completion_date":"June 2010","start_date":"August 2002","last_update_posted":"December 21, 2012"},{"nctid":"NCT00544765","version_a":1,"version_b":2,"version_a_date":"2007-10-15","version_b_date":"2016-02-09","pom_a":[{"label":"1.","content":"Determination of pCR rates[ Time Frame: 2005 ]"}],"pom_b":[{"label":"1.","content":"Determination of pCR rates[ Time Frame: 2010 ]To determine the iRR rate of 4 cycles of docetaxel, doxorubicin and cyclophosphamide (TAC) and of 4 cycles of vinorelbine and capecitabine (NX) (TAC-NX) as a salvage treatment"}],"first_posted":"No date provided","completion_date":"February 2008","primary_completion_date":"February 2008","start_date":"September 2002","last_update_posted":"February 4, 2021"},{"nctid":"NCT00194571","version_a":1,"version_b":2,"version_a_date":"2005-09-13","version_b_date":"2006-01-13","pom_a":[{"label":"1.","content":"-Enhanced cognitive-behavioral adjustments of school age children."},{"label":"2.","content":"-Increased parenting skills and confidence by diagnosed mothers."}],"pom_b":[{"label":"1.","content":"Enhanced cognitive-behavioral adjustments of school age children"},{"label":"2.","content":"Increased parenting skills and confidence by diagnosed mothers"}],"first_posted":"No date provided","completion_date":"May 2007","primary_completion_date":"May 2007","start_date":"June 1999","last_update_posted":"May 20, 2016"},{"nctid":"NCT00194571","version_a":4,"version_b":5,"version_a_date":"2006-09-06","version_b_date":"2008-01-02","pom_a":[{"label":"1.","content":"Enhanced cognitive-behavioral adjustments of school age children"},{"label":"2.","content":"Increased parenting skills and confidence by diagnosed mothers"}],"pom_b":[{"label":"1.","content":"Increased parenting skills and confidence by diagnosed mothers[ Time Frame: 1-year ]"}],"first_posted":"No date provided","completion_date":"May 2007","primary_completion_date":"May 2007","start_date":"June 1999","last_update_posted":"May 20, 2016"},{"nctid":"NCT00156156","version_a":6,"version_b":7,"version_a_date":"2007-04-10","version_b_date":"2007-06-29","pom_a":[{"label":"1.","content":"The percent of subjects who demonstrate a clinically meaningful improvement in bleeding and do not have surgical/invasive intervention during the treatment period or who discontinue treatment because of planned surgical/invasive intervention"}],"pom_b":[{"label":"1.","content":"Change from baseline in mean monthly bleeding score.[ Time Frame: Monthly for up to 2 years ]"},{"label":"2.","content":"Change from baseline in number of days with bleeding.[ Time Frame: Monthly for up to 2 years ]"}],"first_posted":"No date provided","completion_date":"February 2007","primary_completion_date":"February 2007","start_date":"November 2004","last_update_posted":"May 28, 2008"},{"nctid":"NCT00156156","version_a":9,"version_b":10,"version_a_date":"2008-01-03","version_b_date":"2008-04-08","pom_a":[{"label":"1.","content":"Change from baseline in mean monthly bleeding score.[ Time Frame: Monthly for up to 2 years ]"},{"label":"2.","content":"Change from baseline in number of days with bleeding.[ Time Frame: Monthly for up to 2 years ]"}],"pom_b":[{"label":"1.","content":"Long-term Safety.[ Time Frame: Throughout 2 year treatment period ]"}],"first_posted":"No date provided","completion_date":"February 2007","primary_completion_date":"February 2007","start_date":"November 2004","last_update_posted":"May 28, 2008"},{"nctid":"NCT01200992","version_a":58,"version_b":59,"version_a_date":"2013-12-18","version_b_date":"2014-09-10","pom_a":[{"label":"1.","content":"The primary objective of this study is to evaluate the efficacy of intravesical EN3348 as compared with mitomycin C in the treatment of subjects with recurrent or refractory NMIBC.[ Time Frame: 1 year ]"}],"pom_b":[{"label":"1.","content":"Comparison of Event-free Survival of Intravesical EN3348 With Mitomycin C.[ Time Frame: 1 year ]Primary efficacy endpoint will be event-free survival - the interval from randomization to an event. An event is defined as tumor recurrence, tumor progression to muscle invasive bladder cancer or death, whichever occurs first. Tumor recurrence or progression must be documented by bladder biopsy."}],"first_posted":"September 11, 2014","completion_date":"December 2013","primary_completion_date":"April 2013","start_date":"November 2010","last_update_posted":"August 24, 2017"},{"nctid":"NCT00699374","version_a":79,"version_b":80,"version_a_date":"2012-01-26","version_b_date":"2012-12-07","pom_a":[{"label":"1.","content":"Overall Survival[ Time Frame: From screening/baseline to patient death ]"}],"pom_b":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: Baseline, every 4 weeks during treatment, every 8 weeks posttreatment up to Week 150 ]Overall survival is the duration from randomization to death. For participants who are alive, overall survival was censored at the last contact."}],"first_posted":"January 14, 2013","completion_date":"December 2011","primary_completion_date":"December 2011","start_date":"July 2008","last_update_posted":"January 14, 2013"},{"nctid":"NCT00268892","version_a":1,"version_b":2,"version_a_date":"2005-12-21","version_b_date":"2007-02-27","pom_a":[{"label":"1.","content":"\u2022 Changes in clinical safety parameters (adverse events including death from any cause, local tolerability, physical examination, vital signs, ECG and body weight)"},{"label":"2.","content":"\u2022 Clinically significant changes in laboratory safety parameters (biochemistry and haematology)"}],"pom_b":[{"label":"1.","content":"Changes in clinical safety parameters (adverse events including death from any cause, local tolerability, physical examination, vital signs, ECG and body weight)"},{"label":"2.","content":"Clinically significant changes in laboratory safety parameters (biochemistry and haematology)"}],"first_posted":"December 6, 2010","completion_date":"December 2009","primary_completion_date":"September 2009","start_date":"January 2006","last_update_posted":"December 24, 2010"},{"nctid":"NCT00268892","version_a":3,"version_b":4,"version_a_date":"2008-07-10","version_b_date":"2009-03-13","pom_a":[{"label":"1.","content":"Changes in clinical safety parameters (adverse events including death from any cause, local tolerability, physical examination, vital signs, ECG and body weight)"},{"label":"2.","content":"Clinically significant changes in laboratory safety parameters (biochemistry and haematology)"}],"pom_b":[{"label":"1.","content":"Changes in clinical safety parameters (adverse events including death from any cause, local tolerability, physical examination, vital signs, ECG and body weight)[ Time Frame: Up to 45 months ]"}],"first_posted":"December 6, 2010","completion_date":"December 2009","primary_completion_date":"September 2009","start_date":"January 2006","last_update_posted":"December 24, 2010"},{"nctid":"NCT00268892","version_a":4,"version_b":5,"version_a_date":"2009-03-13","version_b_date":"2009-08-24","pom_a":[{"label":"1.","content":"Changes in clinical safety parameters (adverse events including death from any cause, local tolerability, physical examination, vital signs, ECG and body weight)[ Time Frame: Up to 45 months ]"}],"pom_b":[{"label":"1.","content":"Changes in clinical safety parameters (adverse events including death from any cause, local tolerability, physical examination, vital signs, ECG and body weight)[ Time Frame: Up to 45 months ]"},{"label":"2.","content":"Clinically significant changes in laboratory safety parameters (biochemistry and haematology)[ Time Frame: Over the entire treatment period ]"}],"first_posted":"December 6, 2010","completion_date":"December 2009","primary_completion_date":"September 2009","start_date":"January 2006","last_update_posted":"December 24, 2010"},{"nctid":"NCT00268892","version_a":6,"version_b":7,"version_a_date":"2009-12-18","version_b_date":"2010-01-05","pom_a":[{"label":"1.","content":"Changes in clinical safety parameters (adverse events including death from any cause, local tolerability, physical examination, vital signs, ECG and body weight)[ Time Frame: Up to 45 months ]"},{"label":"2.","content":"Clinically significant changes in laboratory safety parameters (biochemistry and haematology)[ Time Frame: Over the entire treatment period ]"}],"pom_b":[{"label":"1.","content":"Changes in clinical safety parameters (adverse events including death from any cause, local tolerability, physical examination, vital signs, ECG and body weight)[ Time Frame: Up to 45 months ]"},{"label":"2.","content":"Clinically significant changes in laboratory safety parameters (biochemistry and haematology)[ Time Frame: Up to 45 months ]"}],"first_posted":"December 6, 2010","completion_date":"December 2009","primary_completion_date":"September 2009","start_date":"January 2006","last_update_posted":"December 24, 2010"},{"nctid":"NCT00268892","version_a":7,"version_b":8,"version_a_date":"2010-01-05","version_b_date":"2010-11-17","pom_a":[{"label":"1.","content":"Changes in clinical safety parameters (adverse events including death from any cause, local tolerability, physical examination, vital signs, ECG and body weight)[ Time Frame: Up to 45 months ]"},{"label":"2.","content":"Clinically significant changes in laboratory safety parameters (biochemistry and haematology)[ Time Frame: Up to 45 months ]"}],"pom_b":[{"label":"1.","content":"Number of Participants With Markedly Abnormal Change in Vital Signs and Body Weight as Compared to Baseline[ Time Frame: 4.5 years ]This outcome measure included incidence of markedly abnormal changes in blood pressure (systolic and diastolic), pulse, and body weight. The table presents the number of participants with normal baseline and at least one post-baseline markedly abnormal value."},{"label":"2.","content":"Liver Function Tests[ Time Frame: 4.5 years ]The figures present the number of participants who had abnormal (defined as above upper limit of normal range (ULN)) alanine aminotransferase (ALT) levels, aspartate aminotransferase levels, and bilirubin levels plus the number of participants who had ALT increases >3x ULN and ALT increases >3x ULN with concurrently increased bilirubin >1.5 ULN."}],"first_posted":"December 6, 2010","completion_date":"December 2009","primary_completion_date":"September 2009","start_date":"January 2006","last_update_posted":"December 24, 2010"},{"nctid":"NCT00268892","version_a":8,"version_b":9,"version_a_date":"2010-11-17","version_b_date":"2010-12-08","pom_a":[{"label":"1.","content":"Number of Participants With Markedly Abnormal Change in Vital Signs and Body Weight as Compared to Baseline[ Time Frame: 4.5 years ]This outcome measure included incidence of markedly abnormal changes in blood pressure (systolic and diastolic), pulse, and body weight. The table presents the number of participants with normal baseline and at least one post-baseline markedly abnormal value."},{"label":"2.","content":"Liver Function Tests[ Time Frame: 4.5 years ]The figures present the number of participants who had abnormal (defined as above upper limit of normal range (ULN)) alanine aminotransferase (ALT) levels, aspartate aminotransferase levels, and bilirubin levels plus the number of participants who had ALT increases >3x ULN and ALT increases >3x ULN with concurrently increased bilirubin >1.5 ULN."}],"pom_b":[{"label":"1.","content":"Number of Participants With Markedly Abnormal Values in Vital Signs and Body Weight[ Time Frame: Baseline and up to 4.5 years ]This outcome measure included incidence of markedly abnormal values in blood pressure (systolic and diastolic), pulse, and body weight during the trial. The table presents the number of participants with a normal baseline value and at least one post-baseline markedly abnormal value."},{"label":"2.","content":"Liver Function Tests[ Time Frame: 4.5 years ]The figures present the number of participants who had abnormal (defined as above upper limit of normal range (ULN)) alanine aminotransferase (ALT) levels, aspartate aminotransferase levels, and bilirubin levels plus the number of participants who had ALT increases >3x ULN and ALT increases >3x ULN with concurrently increased bilirubin >1.5 ULN."}],"first_posted":"December 6, 2010","completion_date":"December 2009","primary_completion_date":"September 2009","start_date":"January 2006","last_update_posted":"December 24, 2010"},{"nctid":"NCT02972840","version_a":14,"version_b":15,"version_a_date":"2020-07-21","version_b_date":"2021-02-08","pom_a":[{"label":"1.","content":"Progression-free survival per the Lugano Classification for NHL in Arm 1 compared to Arm 2[ Time Frame: 48 months ]"}],"pom_b":[{"label":"1.","content":"Progression-free survival per the Lugano Classification for NHL in Arm 1 compared to Arm 2[ Time Frame: Up to 6 years ]Defined as the time from the date of randomization until disease progression (assessed by the IRC per the Lugano Classification for NHL) or death from any cause, whichever occurs first."}],"first_posted":"No date provided","completion_date":"April 30, 2023","primary_completion_date":"April 30, 2023","start_date":"April 5, 2017","last_update_posted":"August 9, 2022"},{"nctid":"NCT01272037","version_a":180,"version_b":181,"version_a_date":"2012-02-07","version_b_date":"2012-12-04","pom_a":[{"label":"1.","content":"Invasive disease-free survival (DFS) of women with node-positive breast cancer treated with endocrine therapy with vs without chemotherapy"}],"pom_b":[{"label":"1.","content":"Invasive disease-free survival (DFS) of women with node-positive breast cancer treated with endocrine therapy with vs without chemotherapy[ Time Frame: Up to 15 years ]"}],"first_posted":"No date provided","completion_date":"February 1, 2023","primary_completion_date":"February 1, 2023","start_date":"January 15, 2011","last_update_posted":"September 9, 2022"},{"nctid":"NCT01272037","version_a":181,"version_b":182,"version_a_date":"2012-12-04","version_b_date":"2013-04-01","pom_a":[{"label":"1.","content":"Invasive disease-free survival (DFS) of women with node-positive breast cancer treated with endocrine therapy with vs without chemotherapy[ Time Frame: Up to 15 years ]"}],"pom_b":[{"label":"1.","content":"Invasive disease-free survival (DFS) of women with node-positive breast cancer treated with endocrine therapy with vs without chemotherapy[ Time Frame: Up to 15 years ]Defined as the time from the second registration (randomization) to local, regional, or distant recurrence, new invasive primary, or death due to any cause. The STEEP definition of invasive disease-free survival (IDFS) is used, although it is referred to here by the more common acronym DFS. Survival times are censored at time of last follow-up for individuals who did not have any event meeting the above definition."}],"first_posted":"No date provided","completion_date":"February 1, 2023","primary_completion_date":"February 1, 2023","start_date":"January 15, 2011","last_update_posted":"September 9, 2022"},{"nctid":"NCT01272037","version_a":184,"version_b":185,"version_a_date":"2014-01-15","version_b_date":"2014-03-19","pom_a":[{"label":"1.","content":"Invasive disease-free survival (DFS) of women with node-positive breast cancer treated with endocrine therapy with vs without chemotherapy[ Time Frame: Up to 15 years ]Defined as the time from the second registration (randomization) to local, regional, or distant recurrence, new invasive primary, or death due to any cause. The STEEP definition of invasive disease-free survival (IDFS) is used, although it is referred to here by the more common acronym DFS. Survival times are censored at time of last follow-up for individuals who did not have any event meeting the above definition."}],"pom_b":[{"label":"1.","content":"RS, as measured by Oncotype DX[ Time Frame: Up to 15 years ]The interaction of the linear RS term and chemotherapy benefit will be tested in a Cox regression model of DFS. If the interaction is statistically significant and there is a point of equivalence between the two randomized treatments for some RS value in the range 0-25, a clinical cutpoint for recommending chemotherapy will be estimated. This estimated cutpoint is the upper bound of the 95% confidence interval on the point of equivalence. Kaplan-Meier curves comparing randomized arms generated separately for RS values below and above this cutpoint and tested with stratified log-rank tests."}],"first_posted":"No date provided","completion_date":"February 1, 2023","primary_completion_date":"February 1, 2023","start_date":"January 15, 2011","last_update_posted":"September 9, 2022"},{"nctid":"NCT01272037","version_a":1089,"version_b":1090,"version_a_date":"2018-12-14","version_b_date":"2019-01-03","pom_a":[{"label":"1.","content":"RS, as measured by Oncotype DX[ Time Frame: Up to 15 years ]The interaction of the linear RS term and chemotherapy benefit will be tested in a Cox regression model of DFS. If the interaction is statistically significant and there is a point of equivalence between the two randomized treatments for some RS value in the range 0-25, a clinical cutpoint for recommending chemotherapy will be estimated. This estimated cutpoint is the upper bound of the 95% confidence interval on the point of equivalence. Kaplan-Meier curves comparing randomized arms generated separately for RS values below and above this cutpoint and tested with stratified log-rank tests."}],"pom_b":[{"label":"1.","content":"Recurrence scores (RS), as measured by Oncotype DX[ Time Frame: Up to 15 years ]The interaction of the linear RS term and chemotherapy benefit will be tested in a Cox regression model of disease-free survival (DFS). If the interaction is statistically significant and there is a point of equivalence between the two randomized treatments for some RS value in the range 0-25, a clinical cutpoint for recommending chemotherapy will be estimated. This estimated cutpoint is the upper bound of the 95% confidence interval on the point of equivalence. Kaplan-Meier curves comparing randomized arms generated separately for RS values below and above this cutpoint and tested with stratified log-rank tests."}],"first_posted":"No date provided","completion_date":"February 1, 2023","primary_completion_date":"February 1, 2023","start_date":"January 15, 2011","last_update_posted":"September 9, 2022"},{"nctid":"NCT02454517","version_a":7,"version_b":8,"version_a_date":"2017-02-15","version_b_date":"2017-10-25","pom_a":[{"label":"1.","content":"Change in expression of insulin receptor (IR), IGF-1R, and protein kinase B (AKT) on prostate cancer epithelial cells[ Time Frame: Baseline (6 months prior to randomization) to follow-up surveillance biopsy (6 months post-randomization) ]Global assessment of intervention effects will be evaluated using a two-sided t-test (or Wilcoxon rank sum test). Linear regression will be used to assess associations of IR, IGF-1R, and AKT expression with systemic measures of glycemic control at 6 months. Exploratory analyses will also evaluate associations between adverse pathology, biomarkers of glycemic control and IR/IGF-1R/AKT expression."},{"label":"2.","content":"Change in fasting C-peptide, insulin, IGF-1, IGF-BP3, and adiponectin levels relative to baseline between the intervention and control arms[ Time Frame: Baseline to up to 12 months ]Global and subgroup effects based on intention-to-treat analyses will be compared."},{"label":"3.","content":"Change in fasting glucose levels relative to baseline between the intervention and control arms[ Time Frame: Baseline to up to 12 months ]Global assessment of intervention effects will be evaluated using a two-sided t-test or Wilcoxon rank sum test if normality of the measurement is questionable (as determined by QQ-normal plots). Further analysis will quantify effects of patient age, BMI and other body composition measures on change in fasting glucose using linear regression. Differential effects between intervention and control arms will be quantified using interaction terms. All analyses will compare effects based on intention-to-treat."},{"label":"4.","content":"Sustainability of beneficial changes in weight and glucose regulation[ Time Frame: 6 months after active intervention ]The DPP research group will be followed for characterization of sustained weight loss as maintenance of a 7% reduction in weight and sustained glucose regulation as maintenance within 5% of 6-month levels. The subset of participants who did and did not achieve this goal both separately and combined will be evaluated. A one-sample test of proportions will be used to determine whether the proportion of participants that are able to sustain lifestyle changes differs from zero."}],"pom_b":[{"label":"1.","content":"Change in expression of insulin receptor (IR), IGF-1R, and protein kinase B (AKT) on prostate cancer epithelial cells[ Time Frame: Baseline (6 months prior to randomization) to follow-up surveillance biopsy (6 months post-randomization) ]Global assessment of intervention effects will be evaluated using a two-sided t-test (or Wilcoxon rank sum test). Linear regression will be used to assess associations of IR, IGF-1R, and AKT expression with systemic measures of glycemic control at 6 months. Exploratory analyses will also evaluate associations between adverse pathology, biomarkers of glycemic control and IR/IGF-1R/AKT expression."},{"label":"2.","content":"Change in fasting C-peptide, insulin, IGF-1, IGF-BP3, and adiponectin levels relative to baseline between the intervention and control arms[ Time Frame: Baseline to up to 12 months ]Global and subgroup effects based on intention-to-treat analyses will be compared."},{"label":"3.","content":"Change in fasting glucose levels relative to baseline between the intervention and control arms[ Time Frame: Baseline to up to 12 months ]Global assessment of intervention effects will be evaluated using a two-sided t-test or Wilcoxon rank sum test if normality of the measurement is questionable (as determined by QQ-normal plots). Further analysis will quantify effects of patient age, body mass index (BMI) and other body composition measures on change in fasting glucose using linear regression. Differential effects between intervention and control arms will be quantified using interaction terms. All analyses will compare effects based on intention-to-treat."},{"label":"4.","content":"Sustainability of beneficial changes in weight and glucose regulation[ Time Frame: 6 months after active intervention ]The Diabetes Prevention Program (DPP) research group will be followed for characterization of sustained weight loss as maintenance of a 7% reduction in weight and sustained glucose regulation as maintenance within 5% of 6-month levels. The subset of participants who did and did not achieve this goal both separately and combined will be evaluated. A one-sample test of proportions will be used to determine whether the proportion of participants that are able to sustain lifestyle changes differs from zero."}],"first_posted":"No date provided","completion_date":"September 30, 2021","primary_completion_date":"September 30, 2021","start_date":"May 19, 2016","last_update_posted":"October 18, 2021"},{"nctid":"NCT02454517","version_a":12,"version_b":13,"version_a_date":"2019-10-18","version_b_date":"2020-04-17","pom_a":[{"label":"1.","content":"Change in expression of insulin receptor (IR), IGF-1R, and protein kinase B (AKT) on prostate cancer epithelial cells[ Time Frame: Baseline (6 months prior to randomization) to follow-up surveillance biopsy (6 months post-randomization) ]Global assessment of intervention effects will be evaluated using a two-sided t-test (or Wilcoxon rank sum test). Linear regression will be used to assess associations of IR, IGF-1R, and AKT expression with systemic measures of glycemic control at 6 months. Exploratory analyses will also evaluate associations between adverse pathology, biomarkers of glycemic control and IR/IGF-1R/AKT expression."},{"label":"2.","content":"Change in fasting C-peptide, insulin, IGF-1, IGF-BP3, and adiponectin levels relative to baseline between the intervention and control arms[ Time Frame: Baseline to up to 12 months ]Global and subgroup effects based on intention-to-treat analyses will be compared."},{"label":"3.","content":"Change in fasting glucose levels relative to baseline between the intervention and control arms[ Time Frame: Baseline to up to 12 months ]Global assessment of intervention effects will be evaluated using a two-sided t-test or Wilcoxon rank sum test if normality of the measurement is questionable (as determined by QQ-normal plots). Further analysis will quantify effects of patient age, body mass index (BMI) and other body composition measures on change in fasting glucose using linear regression. Differential effects between intervention and control arms will be quantified using interaction terms. All analyses will compare effects based on intention-to-treat."},{"label":"4.","content":"Sustainability of beneficial changes in weight and glucose regulation[ Time Frame: 6 months after active intervention ]The Diabetes Prevention Program (DPP) research group will be followed for characterization of sustained weight loss as maintenance of a 7% reduction in weight and sustained glucose regulation as maintenance within 5% of 6-month levels. The subset of participants who did and did not achieve this goal both separately and combined will be evaluated. A one-sample test of proportions will be used to determine whether the proportion of participants that are able to sustain lifestyle changes differs from zero."}],"pom_b":[{"label":"1.","content":"Change in fasting glucose levels relative to baseline between the intervention and control arms[ Time Frame: Baseline to up to 12 months ]Global assessment of intervention effects will be evaluated using a two-sided t-test or Wilcoxon rank sum test if normality of the measurement is questionable (as determined by QQ-normal plots). Further analysis will quantify effects of patient age, body mass index (BMI) and other body composition measures on change in fasting glucose using linear regression. Differential effects between intervention and control arms will be quantified using interaction terms. All analyses will compare effects based on intention-to-treat."},{"label":"2.","content":"Change in fasting C-peptide, insulin, IGF-1, IGF-BP3, and adiponectin levels relative to baseline between the intervention and control arms[ Time Frame: Baseline to up to 12 months ]Global and subgroup effects based on intention-to-treat analyses will be compared."},{"label":"3.","content":"Change in expression of insulin receptor (IR), IGF-1R, and protein kinase B (AKT) on prostate cancer epithelial cells[ Time Frame: Baseline (6 months prior to randomization) to follow-up surveillance biopsy (6 months post-randomization) ]Global assessment of intervention effects will be evaluated using a two-sided t-test (or Wilcoxon rank sum test). Linear regression will be used to assess associations of IR, IGF-1R, and AKT expression with systemic measures of glycemic control at 6 months. Exploratory analyses will also evaluate associations between adverse pathology, biomarkers of glycemic control and IR/IGF-1R/AKT expression."},{"label":"4.","content":"Sustainability of beneficial changes in weight and glucose regulation[ Time Frame: 6 months after active intervention ]The Diabetes Prevention Program (DPP) research group will be followed for characterization of sustained weight loss as maintenance of a 7% reduction in weight and sustained glucose regulation as maintenance within 5% of 6-month levels. The subset of participants who did and did not achieve this goal both separately and combined will be evaluated. A one-sample test of proportions will be used to determine whether the proportion of participants that are able to sustain lifestyle changes differs from zero."}],"first_posted":"No date provided","completion_date":"September 30, 2021","primary_completion_date":"September 30, 2021","start_date":"May 19, 2016","last_update_posted":"October 18, 2021"},{"nctid":"NCT02611960","version_a":27,"version_b":28,"version_a_date":"2018-05-31","version_b_date":"2019-06-21","pom_a":[{"label":"1.","content":"Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)[ Time Frame: Up to approximately 2 years ]"},{"label":"2.","content":"Overall Survival (OS)[ Time Frame: Up to approximately 2 years ]"}],"pom_b":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: Up to approximately 2 years ]"}],"first_posted":"December 15, 2021","completion_date":"October 3, 2022","primary_completion_date":"November 30, 2020","start_date":"April 18, 2016","last_update_posted":"June 15, 2022"},{"nctid":"NCT02611960","version_a":32,"version_b":33,"version_a_date":"2020-12-09","version_b_date":"2021-11-16","pom_a":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: Up to approximately 2 years ]"}],"pom_b":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: Up to approximately 53 months (through analysis cut-off date of 30-Nov-2020) ]Overall Survival was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last known contact. OS was reported for each treatment arm. Per protocol, analysis for this outcome measure was performed for the first pembrolizumab course and for the standard treatment arm, with a protocol-specified analysis data cut-off date of 30-Nov-2020."}],"first_posted":"December 15, 2021","completion_date":"October 3, 2022","primary_completion_date":"November 30, 2020","start_date":"April 18, 2016","last_update_posted":"June 15, 2022"},{"nctid":"NCT00003414","version_a":15,"version_b":16,"version_a_date":"2014-05-01","version_b_date":"2015-07-16","pom_a":[],"pom_b":[{"label":"1.","content":"Relapse rate for lymphoma after autologous transplant[ Time Frame: 2 years ]"}],"first_posted":"No date provided","completion_date":"May 2004","primary_completion_date":"May 2004","start_date":"October 1997","last_update_posted":"July 20, 2015"},{"nctid":"NCT02136069","version_a":15,"version_b":16,"version_a_date":"2014-10-20","version_b_date":"2014-10-23","pom_a":[{"label":"1.","content":"Proportion of patients in sustained clinical remission as determined by Mayo Clinic Score (MCS). Clinical remission is defined as MCS </=2 with individual subscores </=1.[ Time Frame: Week 10 ]"},{"label":"2.","content":"Proportion of patients in sustained clinical remission as determined by Mayo Clinic Score (MCS). Clinical remission is defined as MCS </=2 with individual subscores </=1.[ Time Frame: Week 54 ]"},{"label":"3.","content":"Proportion of patients in sustained clinical remission as determined by Mayo Clinic Score (MCS). Clinical remission is defined as MCS </=2 with individual subscores </=1.[ Time Frame: Week 30 ]"}],"pom_b":[{"label":"1.","content":"Sustained remission as determined by Mayo clinic score (MCS)[ Time Frame: At Weeks 10, 30, and 54 ]"}],"first_posted":"August 13, 2021","completion_date":"June 23, 2020","primary_completion_date":"June 23, 2020","start_date":"December 24, 2014","last_update_posted":"December 3, 2021"},{"nctid":"NCT02136069","version_a":16,"version_b":17,"version_a_date":"2014-10-23","version_b_date":"2014-10-27","pom_a":[{"label":"1.","content":"Sustained remission as determined by Mayo clinic score (MCS)[ Time Frame: At Weeks 10, 30, and 54 ]"}],"pom_b":[{"label":"1.","content":"Proportion of patients in sustained clinical remission as determined by Mayo Clinic Score (MCS). Clinical remission is defined as MCS </=2 with individual subscores </=1.[ Time Frame: Week 10 ]"},{"label":"2.","content":"Proportion of patients in sustained clinical remission as determined by Mayo Clinic Score (MCS). Clinical remission is defined as MCS </=2 with individual subscores </=1.[ Time Frame: Week 54 ]"},{"label":"3.","content":"Proportion of patients in sustained clinical remission as determined by Mayo Clinic Score (MCS). Clinical remission is defined as MCS </=2 with individual subscores </=1.[ Time Frame: Week 30 ]"}],"first_posted":"August 13, 2021","completion_date":"June 23, 2020","primary_completion_date":"June 23, 2020","start_date":"December 24, 2014","last_update_posted":"December 3, 2021"},{"nctid":"NCT02136069","version_a":17,"version_b":18,"version_a_date":"2014-10-27","version_b_date":"2014-11-04","pom_a":[{"label":"1.","content":"Proportion of patients in sustained clinical remission as determined by Mayo Clinic Score (MCS). Clinical remission is defined as MCS </=2 with individual subscores </=1.[ Time Frame: Week 10 ]"},{"label":"2.","content":"Proportion of patients in sustained clinical remission as determined by Mayo Clinic Score (MCS). Clinical remission is defined as MCS </=2 with individual subscores </=1.[ Time Frame: Week 54 ]"},{"label":"3.","content":"Proportion of patients in sustained clinical remission as determined by Mayo Clinic Score (MCS). Clinical remission is defined as MCS </=2 with individual subscores </=1.[ Time Frame: Week 30 ]"}],"pom_b":[{"label":"1.","content":"Proportion of patients in sustained remission as determined by Mayo Clinic Score (MCS). Sustained remission is defined as MCS </=2 with individual subscores </=1 and a rectal bleeding subscore of 0 sustained at each of the Week 10, 30, and 54 assessments[ Time Frame: Weeks 10, 30, and 54 ]"}],"first_posted":"August 13, 2021","completion_date":"June 23, 2020","primary_completion_date":"June 23, 2020","start_date":"December 24, 2014","last_update_posted":"December 3, 2021"},{"nctid":"NCT02136069","version_a":50,"version_b":51,"version_a_date":"2016-10-03","version_b_date":"2017-03-31","pom_a":[{"label":"1.","content":"Proportion of patients in sustained remission as determined by Mayo Clinic Score (MCS). Sustained remission is defined as MCS </=2 with individual subscores </=1 and a rectal bleeding subscore of 0 sustained at each of the Week 10, 30, and 54 assessments[ Time Frame: Weeks 10, 30, and 54 ]"}],"pom_b":[{"label":"1.","content":"Outcome Measure: Percentage of Participants in sustained remission determined by Mayo Clinic Score (MCS). Sustained remission is defined as MCS </=2 with individual sub scores </=1, a rectal bleeding sub score of 0 sustained at each of the Week 10[ Time Frame: Week 10 ]"},{"label":"2.","content":"Percentage of Participants With sustained remission determined by Mayo Clinic Score (MCS). Sustained remission is defined as MCS </=2 with individual sub scores </=1, a rectal bleeding sub score of 0 sustained at Week 10[ Time Frame: Week 30 ]"},{"label":"3.","content":"Percentage of Participants With sustained remission determined by Mayo Clinic Score (MCS). Sustained remission is defined as MCS </=2 with individual sub scores </=1, a rectal bleeding sub score of 0 sustained at Week 54[ Time Frame: Week 30 ]"}],"first_posted":"August 13, 2021","completion_date":"June 23, 2020","primary_completion_date":"June 23, 2020","start_date":"December 24, 2014","last_update_posted":"December 3, 2021"},{"nctid":"NCT02136069","version_a":57,"version_b":58,"version_a_date":"2018-04-07","version_b_date":"2018-07-24","pom_a":[{"label":"1.","content":"Outcome Measure: Percentage of Participants in sustained remission determined by Mayo Clinic Score (MCS). Sustained remission is defined as MCS </=2 with individual sub scores </=1, a rectal bleeding sub score of 0 sustained at each of the Week 10[ Time Frame: Week 10 ]"},{"label":"2.","content":"Percentage of Participants With sustained remission determined by Mayo Clinic Score (MCS). Sustained remission is defined as MCS </=2 with individual sub scores </=1, a rectal bleeding sub score of 0 sustained at Week 10[ Time Frame: Week 30 ]"},{"label":"3.","content":"Percentage of Participants With sustained remission determined by Mayo Clinic Score (MCS). Sustained remission is defined as MCS </=2 with individual sub scores </=1, a rectal bleeding sub score of 0 sustained at Week 54[ Time Frame: Week 30 ]"}],"pom_b":[{"label":"1.","content":"Percentage of Participants with both Clinical Response at Week 10 and Clinical Remission at Week 54[ Time Frame: Week 10, Week 54 ]"}],"first_posted":"August 13, 2021","completion_date":"June 23, 2020","primary_completion_date":"June 23, 2020","start_date":"December 24, 2014","last_update_posted":"December 3, 2021"},{"nctid":"NCT02136069","version_a":70,"version_b":71,"version_a_date":"2020-05-14","version_b_date":"2020-07-28","pom_a":[{"label":"1.","content":"Percentage of Participants with both Clinical Response at Week 10 and Clinical Remission at Week 54[ Time Frame: Week 10, Week 54 ]"}],"pom_b":[{"label":"1.","content":"Percentage of Participants with Both Clinical Response at Week 10 and Clinical Remission at Week 54[ Time Frame: Week 10, Week 54 ]"}],"first_posted":"August 13, 2021","completion_date":"June 23, 2020","primary_completion_date":"June 23, 2020","start_date":"December 24, 2014","last_update_posted":"December 3, 2021"},{"nctid":"NCT02136069","version_a":72,"version_b":73,"version_a_date":"2020-12-07","version_b_date":"2021-07-21","pom_a":[{"label":"1.","content":"Percentage of Participants with Both Clinical Response at Week 10 and Clinical Remission at Week 54[ Time Frame: Week 10, Week 54 ]"}],"pom_b":[{"label":"1.","content":"Percentage of Participants With Both Clinical Response at Week 10 and Clinical Remission at Week 54, as Determined by the Mayo Clinic Score (MCS)[ Time Frame: Week 10, Week 54 ]Mayo Clinic Score (MCS) is a composite of 4 assessments, each rated from 0-3: stool frequency, rectal bleeding, endoscopy, and physician\'s global assessment. Higher scores indicate more severe disease.Clinical Response is MCS with \u22653-point decrease and 30% reduction from baseline as well as \u22651-point decrease in rectal bleeding subscore or an absolute rectal bleeding score of 0 or 1.Clinical Remission is MCS \u22642 with individual subscores \u22641."}],"first_posted":"August 13, 2021","completion_date":"June 23, 2020","primary_completion_date":"June 23, 2020","start_date":"December 24, 2014","last_update_posted":"December 3, 2021"},{"nctid":"NCT02319837","version_a":45,"version_b":46,"version_a_date":"2018-07-11","version_b_date":"2018-09-13","pom_a":[{"label":"1.","content":"Metastasis-free survival (MFS)[ Time Frame: During Study Period up to 56 months ]"}],"pom_b":[{"label":"1.","content":"Metastasis-free survival (MFS)[ Time Frame: Up to approximatey 67 months ]Compared between enzalutamide plus leuprolide and placebo plus leuprolide."}],"first_posted":"No date provided","completion_date":"September 19, 2026","primary_completion_date":"December 31, 2022","start_date":"December 17, 2014","last_update_posted":"August 30, 2022"},{"nctid":"NCT02319837","version_a":61,"version_b":62,"version_a_date":"2021-10-12","version_b_date":"2021-11-19","pom_a":[{"label":"1.","content":"Metastasis-free survival (MFS)[ Time Frame: Up to approximatey 67 months ]Compared between enzalutamide plus leuprolide and placebo plus leuprolide."}],"pom_b":[{"label":"1.","content":"Metastasis-free survival (MFS)[ Time Frame: Up to approximately 90 months ]Compared between enzalutamide plus leuprolide and placebo plus leuprolide."}],"first_posted":"No date provided","completion_date":"September 19, 2026","primary_completion_date":"December 31, 2022","start_date":"December 17, 2014","last_update_posted":"August 30, 2022"},{"nctid":"NCT00301886","version_a":5,"version_b":6,"version_a_date":"2006-08-07","version_b_date":"2007-02-20","pom_a":[],"pom_b":[{"label":"1.","content":"Skeletal-related events (SRE)"}],"first_posted":"No date provided","completion_date":"May 2006","primary_completion_date":"May 2006","start_date":"May 2006","last_update_posted":"November 13, 2013"},{"nctid":"NCT00423683","version_a":2,"version_b":3,"version_a_date":"2007-10-18","version_b_date":"2008-06-16","pom_a":[{"label":"1.","content":"Death due to any cause, event free survival."}],"pom_b":[{"label":"1.","content":"Death due to any cause, event free survival.[ Time Frame: One year ]"}],"first_posted":"May 3, 2016","completion_date":"November 2010","primary_completion_date":"November 2010","start_date":"January 2007","last_update_posted":"June 8, 2016"},{"nctid":"NCT00423683","version_a":8,"version_b":9,"version_a_date":"2012-06-29","version_b_date":"2016-03-30","pom_a":[{"label":"1.","content":"Death due to any cause, event free survival.[ Time Frame: One year ]"}],"pom_b":[{"label":"1.","content":"Adverse Outcomes[ Time Frame: 3 years or until death ]Rates of VCF complications, bleeding, and recurrent or residual DVTs or PEs"}],"first_posted":"May 3, 2016","completion_date":"November 2010","primary_completion_date":"November 2010","start_date":"January 2007","last_update_posted":"June 8, 2016"},{"nctid":"NCT04148911","version_a":20,"version_b":21,"version_a_date":"2021-02-04","version_b_date":"2021-02-25","pom_a":[{"label":"1.","content":"Percentage of Participants with treatment-emergent Grade\u22653 AEs[ Time Frame: From baseline to up to 3 years ]"},{"label":"2.","content":"Percentage of Participants with treatment-emergent Grade\u22652 imAEs[ Time Frame: From baseline to up to 3 years FU ]"}],"pom_b":[{"label":"1.","content":"Percentage of Participants with treatment-emergent Grade\u22653 AEs[ Time Frame: From baseline to up to 4.5 years ]"},{"label":"2.","content":"Percentage of Participants with treatment-emergent Grade\u22652 imAEs[ Time Frame: From baseline to up to 4.5 years ]"}],"first_posted":"No date provided","completion_date":"December 15, 2024","primary_completion_date":"December 15, 2024","start_date":"December 17, 2019","last_update_posted":"August 25, 2022"},{"nctid":"NCT01728805","version_a":19,"version_b":20,"version_a_date":"2018-08-06","version_b_date":"2019-03-20","pom_a":[{"label":"1.","content":"Progression free survival[ Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months ]"}],"pom_b":[{"label":"1.","content":"Progression Free Survival[ Time Frame: From date of randomization at every visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months ]Progression was defined as follows, based on Olsen (2011):Lymph nodes: \u2265 50% increase in SPD from baseline of lymph nodes, any new node > 1.5 cm in the long axis or > 1 cm in the short axis if 1-1.5 cm in the long axis that is proven to be N3 histologically, or > 50% increase from nadir in SPD of lymph nodes in those with PRSkin: \u2265 25% increase in skin disease from baseline, new tumors (T3) in patients with T1, T2 or T4 only skin disease, or in those with CR or PR, increase of skin score of greater than the sum of nadir plus 50% baseline scoreBlood: B0 to B2, > 50% increase from baseline and at least 5,000 neoplastic cells/\u03bcL36, or > 50% increase from nadir and at least 5,000 neoplastic cells/\u03bcLViscera: > 50% increase in size (SPD) of any organs involved at baseline, new organ involvement, or > 50% increase from nadir in the size (SPD) of any previous organ involvement in those with PR"}],"first_posted":"April 11, 2019","completion_date":"February 17, 2021","primary_completion_date":"March 2017","start_date":"November 2012","last_update_posted":"July 28, 2022"},{"nctid":"NCT01067976","version_a":22,"version_b":23,"version_a_date":"2013-09-29","version_b_date":"2014-11-10","pom_a":[{"label":"1.","content":"The determination of the extent of malignant disease assessed for each breast region for unenhanced Magnetic Resonance Mammography (MRM) versus combined unenhanced and gadobutrol enhanced MRM[ Time Frame: Within 6 weeks after MRM ]"},{"label":"2.","content":"The determination of the extent of malignant disease assessed for each breast region for unenhanced MRM versus combined unenhanced and gadobutrol-enhanced MRM plus X-Ray Mammography (XRM) versus unenhanced MRM plus XRM[ Time Frame: Within 6 weeks after MRM ]"}],"pom_b":[{"label":"1.","content":"Difference for Sensitivity for Detection of Full Extent of Malignant Breast Disease Using CMRM vs UMRM Per Reader[ Time Frame: Immediately before injection and after injection ]For a single participant the sensitivity was defined as the proportion of malignant breast regions that were recognized by the clinical investigators and the 3 blinded readers using the respective imaging modality as malignant. Subsequently the sensitivity percentage was calculated based on the mean of the sensitivities across all participants. The difference was calculated as CMRM value minus UMRM value. For ease of expression, the following abbreviations will be used: Magnetic Resonance Mammography (MRM), Unenhanced MRM (UMRM), combined unenhanced and contrast (gadobutrol)-enhanced MRM (CMRM), X-ray mammography (XRM)."},{"label":"2.","content":"Sensitivity for Detection of Full Extent of Malignant Breast Disease Using CMRM vs UMRM Per Reader[ Time Frame: Immediately before injection and after injection ]For a single participant the sensitivity was defined as the proportion of malignant breast regions that were recognized by the clinical investigators and the 3 blinded readers using the respective imaging modality as malignant. Subsequently the sensitivity percentage was calculated based on the mean of the sensitivities across all participants."},{"label":"3.","content":"Breast Level Specificity of CMRM for Non-malignant Breasts by Reader[ Time Frame: Immediately before injection and after injection ]A non-malignant breast was defined as false positive (FP), when the reader assessed at least one breast region as malignant. When all breast regions were assessed as non-malignant, the breast was defined as true negative (TN). Breast level specificity was first defined in participant as number of TN-breasts in participant divided by number of non-malignant breasts in participant. Subsequently the specificity percentage was calculated based on the mean of the specificities across all participants who contributed with at least one non-malignant breast."}],"first_posted":"November 11, 2014","completion_date":"January 2012","primary_completion_date":"July 2011","start_date":"February 2010","last_update_posted":"November 11, 2014"},{"nctid":"NCT00088166","version_a":1,"version_b":2,"version_a_date":"2005-06-23","version_b_date":"2005-09-29","pom_a":[],"pom_b":[{"label":"1.","content":"The primary efficacy endpoint is the proportion of reponders, i.e. patients in each treatment group who show improvement at the end of Week 2."}],"first_posted":"August 13, 2014","completion_date":"March 2008","primary_completion_date":"March 2008","start_date":"May 2004","last_update_posted":"August 13, 2014"},{"nctid":"NCT00088166","version_a":4,"version_b":5,"version_a_date":"2006-08-25","version_b_date":"2006-09-12","pom_a":[{"label":"1.","content":"The primary efficacy endpoint is the proportion of reponders, i.e. patients in each treatment group who show improvement at the end of Week 2."}],"pom_b":[{"label":"1.","content":"The primary efficacy endpoint is the proportion of responders, i.e. patients in each treatment group who show improvement at the end of Week 2."}],"first_posted":"August 13, 2014","completion_date":"March 2008","primary_completion_date":"March 2008","start_date":"May 2004","last_update_posted":"August 13, 2014"},{"nctid":"NCT00088166","version_a":9,"version_b":10,"version_a_date":"2007-03-26","version_b_date":"2007-09-07","pom_a":[{"label":"1.","content":"The primary efficacy endpoint is the proportion of responders, i.e. patients in each treatment group who show improvement at the end of Week 2."}],"pom_b":[{"label":"1.","content":"The proportion of patients in each treatment group who are Responders at Week 2 and continue at Week 5[ Time Frame: Prospective ]"}],"first_posted":"August 13, 2014","completion_date":"March 2008","primary_completion_date":"March 2008","start_date":"May 2004","last_update_posted":"August 13, 2014"},{"nctid":"NCT00088166","version_a":13,"version_b":14,"version_a_date":"2008-03-07","version_b_date":"2014-07-22","pom_a":[{"label":"1.","content":"The proportion of patients in each treatment group who are Responders at Week 2 and continue at Week 5[ Time Frame: Prospective ]"}],"pom_b":[{"label":"1.","content":"The Proportion of Patients in Each Treatment Group Who Are Responders at Week 2 and Continue to be Responders at Week 5[ Time Frame: Prospective ]The primary efficacy endpoint was the proportion of patients in each treatment group who were Responders at Week 2 and who continued to be Responders at Week 5. Responders were defined as study patients who demonstrated the following:50% or greater reduction in dexamethasone dose relative to BaselineOverall 10-Item Neurological Examination Score unchanged or lower compared to BaselineKarnofsky Score unchanged or increased relative to Baseline"}],"first_posted":"August 13, 2014","completion_date":"March 2008","primary_completion_date":"March 2008","start_date":"May 2004","last_update_posted":"August 13, 2014"},{"nctid":"NCT03021486","version_a":12,"version_b":13,"version_a_date":"2018-08-08","version_b_date":"2019-07-26","pom_a":[{"label":"1.","content":"Agitation Intensity in Participants Admitted to an Acute Palliative Care Unit Who Did Not Experience a Response to Low-Dose Haloperidol[ Time Frame: 24 hours ]Agitation intensity measured by Richmond Agitation Sedation Scale (RASS)."}],"pom_b":[{"label":"1.","content":"Richmond Agitation Sedation Scale (RASS)[ Time Frame: 24 hours after study medication administration ]A validated 10-point numeric rating scale that ranges from -5 (unarousable) to +4 (very agitated), where 0 denotes a calm and alert patient."}],"first_posted":"September 1, 2022","completion_date":"June 5, 2023","primary_completion_date":"June 5, 2021","start_date":"June 5, 2017","last_update_posted":"September 1, 2022"},{"nctid":"NCT03021486","version_a":15,"version_b":16,"version_a_date":"2020-11-27","version_b_date":"2022-04-19","pom_a":[{"label":"1.","content":"Richmond Agitation Sedation Scale (RASS)[ Time Frame: 24 hours after study medication administration ]A validated 10-point numeric rating scale that ranges from -5 (unarousable) to +4 (very agitated), where 0 denotes a calm and alert patient."}],"pom_b":[{"label":"1.","content":"Change in Richmond Agitation Sedation Score (RASS) (0-24h)[ Time Frame: Time 0 or Baseline and 24 hours after study medication administration ]RASS score is a 10-point scale with scores ranging from +4 (very combative, violent) to -5 (unarousable). The primary outcome was mean change in RASS score between time 0 (immediately before initiation of masked treatment) and 24 h later. The Richmond Agitation-Sedation Scale (RASS) was developed by a multidisciplinary team at Virginia Commonwealth University in Richmond; it is a validated method used to avoid oversedation in the Intensive Care Unit."}],"first_posted":"September 1, 2022","completion_date":"June 5, 2023","primary_completion_date":"June 5, 2021","start_date":"June 5, 2017","last_update_posted":"September 1, 2022"},{"nctid":"NCT01132547","version_a":12,"version_b":13,"version_a_date":"2011-12-20","version_b_date":"2012-07-26","pom_a":[{"label":"1.","content":"Incidence rate at the end of 16 weeks"},{"label":"2.","content":"Severity of weight loss"}],"pom_b":[{"label":"1.","content":"Efficacy of cyproheptadine HCl in the prevention of cancer/treatment-related weight loss, defined as weight loss \u2265 5% at the 4 or 8- week assessment when compared to baseline"},{"label":"2.","content":"Severity of weight loss"}],"first_posted":"July 2, 2015","completion_date":"January 2014","primary_completion_date":"January 2014","start_date":"June 2010","last_update_posted":"July 2, 2015"},{"nctid":"NCT01132547","version_a":13,"version_b":14,"version_a_date":"2012-07-26","version_b_date":"2013-05-20","pom_a":[{"label":"1.","content":"Efficacy of cyproheptadine HCl in the prevention of cancer/treatment-related weight loss, defined as weight loss \u2265 5% at the 4 or 8- week assessment when compared to baseline"},{"label":"2.","content":"Severity of weight loss"}],"pom_b":[{"label":"1.","content":"Efficacy of cyproheptadine HCl in the prevention of cancer/treatment-related weight loss, defined as weight loss \u2265 5% at the 4 or 8- week assessment when compared to baseline[ Time Frame: 8 weeks ]"},{"label":"2.","content":"Severity of weight loss[ Time Frame: 8 weeks ]"}],"first_posted":"July 2, 2015","completion_date":"January 2014","primary_completion_date":"January 2014","start_date":"June 2010","last_update_posted":"July 2, 2015"},{"nctid":"NCT01132547","version_a":21,"version_b":22,"version_a_date":"2014-01-31","version_b_date":"2015-06-04","pom_a":[{"label":"1.","content":"Efficacy of cyproheptadine HCl in the prevention of cancer/treatment-related weight loss, defined as weight loss \u2265 5% at the 4 or 8- week assessment when compared to baseline[ Time Frame: 8 weeks ]"},{"label":"2.","content":"Severity of weight loss[ Time Frame: 8 weeks ]"}],"pom_b":[{"label":"1.","content":"Participant With Weight Loss \u2265 5% at the 8- Week Assessment When Compared to Baseline[ Time Frame: 8 weeks ]"},{"label":"2.","content":"Severity of Weight Loss[ Time Frame: Baseline and 8 weeks ]Change from Baseline in Weight Z score"}],"first_posted":"July 2, 2015","completion_date":"January 2014","primary_completion_date":"January 2014","start_date":"June 2010","last_update_posted":"July 2, 2015"},{"nctid":"NCT00045032","version_a":17,"version_b":18,"version_a_date":"2007-02-20","version_b_date":"2007-04-09","pom_a":[],"pom_b":[{"label":"1.","content":"Disease-free survival"},{"label":"2.","content":"Relapse-free survival"},{"label":"3.","content":"Distant disease-free survival"},{"label":"4.","content":"Incidence of cardiac dysfunction"},{"label":"5.","content":"Safety and tolerability"}],"first_posted":"April 27, 2017","completion_date":"June 2015","primary_completion_date":"March 2005","start_date":"November 2001","last_update_posted":"April 27, 2017"},{"nctid":"NCT00045032","version_a":35,"version_b":36,"version_a_date":"2012-06-04","version_b_date":"2017-03-17","pom_a":[{"label":"1.","content":"Disease-free survival"},{"label":"2.","content":"Relapse-free survival"},{"label":"3.","content":"Distant disease-free survival"},{"label":"4.","content":"Incidence of cardiac dysfunction"},{"label":"5.","content":"Safety and tolerability"}],"pom_b":[{"label":"1.","content":"Percentage of Participants With Disease-Free Survival (DFS) Events in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up[ Time Frame: From Baseline until time of event (median of 1 year) ]DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants with at least one DFS event was reported. The analysis of the Herceptin 1-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed by the Sponsor in 2006 following database cleaning. The analysis of the Herceptin 2-Year Arm against the Observation Arm was performed for an Independent Data Monitoring Committee (IDMC) in 2005 at a time the Sponsor was blinded. Therefore, these data are reported under a separate Outcome Measure."},{"label":"2.","content":"Percentage of Participants With DFS Events in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up[ Time Frame: From Baseline until time of event (median of 1 year) ]DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants with at least one DFS event was reported. The analysis of the Herceptin 2-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed for an IDMC in 2005 at a time the Sponsor was blinded. The analysis of the Herceptin 1-Year Arm against the Observation Arm was performed by the Sponsor in 2006 following database cleaning. Therefore, these data are reported under a separate Outcome Measure."},{"label":"3.","content":"DFS Rate According to Kaplan-Meier Analysis in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up[ Time Frame: Year 2 ]DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95 percent (%) confidence interval (CI) were estimated by Kaplan-Meier analysis based on available data at the time of the 1-year median follow-up analysis. The analysis of the Herceptin 1-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed by the Sponsor in 2006 following database cleaning. The analysis of the Herceptin 2-Year Arm against the Observation Arm was performed for an IDMC in 2005 at a time the Sponsor was blinded. Therefore, these data are reported under a separate Outcome Measure."},{"label":"4.","content":"DFS Rate According to Kaplan-Meier Analysis in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up[ Time Frame: Year 2 ]DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 1-year median follow-up analysis. The analysis of the Herceptin 2-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed for an IDMC in 2005 at a time the Sponsor was blinded. The analysis of the Herceptin 1-Year Arm against the Observation Arm was performed by the Sponsor in 2006 following database cleaning. Therefore, these data are reported under a separate Outcome Measure."},{"label":"5.","content":"Percentage of Participants With DFS Events Compared to Observation: 8-Year Median Follow-Up[ Time Frame: From Baseline until time of event (median of 8 years) ]DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants with at least one DFS event was reported."},{"label":"6.","content":"DFS Rate at Year 3 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up[ Time Frame: Year 3 ]DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis."},{"label":"7.","content":"DFS Rate at Year 5 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up[ Time Frame: Year 5 ]DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis."},{"label":"8.","content":"DFS Rate at Year 7 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up[ Time Frame: Year 7 ]DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis."},{"label":"9.","content":"DFS Rate at Year 8 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up[ Time Frame: Year 8 ]DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis."},{"label":"10.","content":"Percentage of Participants With DFS Events Compared to Observation: 10-Year Maximum Follow-Up[ Time Frame: From Baseline until time of event (maximum of 10 years) ]DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants with at least one DFS event was reported."},{"label":"11.","content":"DFS Rate at Year 3 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up[ Time Frame: Year 3 ]DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events."},{"label":"12.","content":"DFS Rate at Year 5 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up[ Time Frame: Year 5 ]DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events."},{"label":"13.","content":"DFS Rate at Year 7 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up[ Time Frame: Year 7 ]DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events."},{"label":"14.","content":"DFS Rate at Year 8 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up[ Time Frame: Year 8 ]DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events."},{"label":"15.","content":"DFS Rate at Year 9 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up[ Time Frame: Year 9 ]DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events."},{"label":"16.","content":"DFS Rate at Year 10 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up[ Time Frame: Year 10 ]DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events."}],"first_posted":"April 27, 2017","completion_date":"June 2015","primary_completion_date":"March 2005","start_date":"November 2001","last_update_posted":"April 27, 2017"},{"nctid":"NCT00439751","version_a":1,"version_b":2,"version_a_date":"2007-02-22","version_b_date":"2007-04-26","pom_a":[{"label":"1.","content":"Primary Outcome: Time to androgen-independent disease."},{"label":"2.","content":"Follow-up data will be collected on all patients until the date of death, regardless of the status of any of the other outcomesdisease"}],"pom_b":[{"label":"1.","content":"Time to androgen independent disease (AID). AID is defined as the time from randomization to AID or last follow-up.[ Time Frame: Indefinetly ]"}],"first_posted":"No date provided","completion_date":"June 2016","primary_completion_date":"December 2015","start_date":"April 2007","last_update_posted":"July 12, 2016"},{"nctid":"NCT00439751","version_a":9,"version_b":10,"version_a_date":"2008-03-06","version_b_date":"2008-05-27","pom_a":[{"label":"1.","content":"Time to androgen independent disease (AID). AID is defined as the time from randomization to AID or last follow-up.[ Time Frame: Indefinetly ]"}],"pom_b":[{"label":"1.","content":"Time to androgen independent disease (AID). AID is defined as the time from randomization to AID or last follow-up.[ Time Frame: Indefinitely ]"}],"first_posted":"No date provided","completion_date":"June 2016","primary_completion_date":"December 2015","start_date":"April 2007","last_update_posted":"July 12, 2016"},{"nctid":"NCT00439751","version_a":23,"version_b":24,"version_a_date":"2014-11-10","version_b_date":"2015-06-03","pom_a":[{"label":"1.","content":"Time to androgen independent disease (AID). AID is defined as the time from randomization to AID or last follow-up.[ Time Frame: Indefinitely ]"}],"pom_b":[{"label":"1.","content":"Time to androgen independent disease (AID). AID is defined as the time from randomization to AID or last follow-up.[ Time Frame: Every 6 months ]"}],"first_posted":"No date provided","completion_date":"June 2016","primary_completion_date":"December 2015","start_date":"April 2007","last_update_posted":"July 12, 2016"},{"nctid":"NCT04294810","version_a":4,"version_b":5,"version_a_date":"2020-04-27","version_b_date":"2020-06-02","pom_a":[{"label":"1.","content":"Progression-Free Survival (PFS)[ Time Frame: From randomization up to disease progression or relapse or death (whichever occurs first), up to 59 months ]"},{"label":"2.","content":"Overall Survival (OS)[ Time Frame: From randomization up to death of any cause, up to 59 months ]"}],"pom_b":[{"label":"1.","content":"Investigator-Assessed Progression-Free Survival (PFS)[ Time Frame: From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 59 months) ]"},{"label":"2.","content":"Overall Survival (OS)[ Time Frame: From randomization to death from any cause (up to approximately 59 months) ]"}],"first_posted":"No date provided","completion_date":"February 21, 2025","primary_completion_date":"August 25, 2022","start_date":"March 4, 2020","last_update_posted":"December 7, 2021"},{"nctid":"NCT04294810","version_a":9,"version_b":10,"version_a_date":"2020-10-29","version_b_date":"2020-11-23","pom_a":[{"label":"1.","content":"Investigator-Assessed Progression-Free Survival (PFS)[ Time Frame: From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 59 months) ]"},{"label":"2.","content":"Overall Survival (OS)[ Time Frame: From randomization to death from any cause (up to approximately 59 months) ]"}],"pom_b":[{"label":"1.","content":"Investigator-Assessed Progression-Free Survival (PFS) in the Primary Population[ Time Frame: From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 59 months) ]"},{"label":"2.","content":"Overall Survival (OS) in the Primary Population[ Time Frame: From randomization to death from any cause (up to approximately 59 months) ]"}],"first_posted":"No date provided","completion_date":"February 21, 2025","primary_completion_date":"August 25, 2022","start_date":"March 4, 2020","last_update_posted":"December 7, 2021"},{"nctid":"NCT04294810","version_a":20,"version_b":21,"version_a_date":"2021-11-04","version_b_date":"2021-11-23","pom_a":[{"label":"1.","content":"Investigator-Assessed Progression-Free Survival (PFS) in the Primary Population[ Time Frame: From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 59 months) ]"},{"label":"2.","content":"Overall Survival (OS) in the Primary Population[ Time Frame: From randomization to death from any cause (up to approximately 59 months) ]"}],"pom_b":[{"label":"1.","content":"Investigator-Assessed Progression-Free Survival (PFS) in the Primary Analysis Set[ Time Frame: From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 59 months) ]"},{"label":"2.","content":"Overall Survival (OS) in the Primary Analysis Set[ Time Frame: From randomization to death from any cause (up to approximately 59 months) ]"}],"first_posted":"No date provided","completion_date":"February 21, 2025","primary_completion_date":"August 25, 2022","start_date":"March 4, 2020","last_update_posted":"December 7, 2021"},{"nctid":"NCT01125566","version_a":57,"version_b":58,"version_a_date":"2013-09-18","version_b_date":"2013-10-09","pom_a":[{"label":"1.","content":"The primary endpoint of this study is progression-free survival, defined as the time from the date of randomisation to the date of disease progression, or to the date of death if a patient died earlier[ Time Frame: 25 months ]"}],"pom_b":[{"label":"1.","content":"The primary endpoint of this study is progression-free survival, defined as the time from the date of randomisation to the date of disease progression, or to the date of death if a patient died earlier[ Time Frame: 34 months ]"}],"first_posted":"August 21, 2014","completion_date":"July 6, 2018","primary_completion_date":"June 8, 2013","start_date":"June 22, 2010","last_update_posted":"July 18, 2019"},{"nctid":"NCT01125566","version_a":73,"version_b":74,"version_a_date":"2014-04-30","version_b_date":"2014-08-05","pom_a":[{"label":"1.","content":"The primary endpoint of this study is progression-free survival, defined as the time from the date of randomisation to the date of disease progression, or to the date of death if a patient died earlier[ Time Frame: 34 months ]"}],"pom_b":[{"label":"1.","content":"Progression-free Survival (PFS)[ Time Frame: From randomization until disease progression, death or data cut-off (08Jun2013); Up to 34 months ]PFS is defined as time from randomisation to disease progression or death whichever occurs first. Assessed by investigator according to the Response Evaluation Criteria in Solid Tumours (RECIST 1.1).Only data collected until the cut-off date for RECIST 1.1 based endpoints (08Jun2013) were considered.Progression of disease was determined if at least 1 of the following criteria applied:At least a 20% increase in the sum of the diameters (SoD) of target lesions taking as reference the smallest SoD recorded since the treatment started, together with an absolute increase in the SoD of at least 5 mmAppearance of 1 or more new lesionsUnequivocal progression of existing non-target lesions"}],"first_posted":"August 21, 2014","completion_date":"July 6, 2018","primary_completion_date":"June 8, 2013","start_date":"June 22, 2010","last_update_posted":"July 18, 2019"},{"nctid":"NCT01125566","version_a":84,"version_b":85,"version_a_date":"2018-07-03","version_b_date":"2019-07-04","pom_a":[{"label":"1.","content":"Progression-free Survival (PFS)[ Time Frame: From randomization until disease progression, death or data cut-off (08Jun2013); Up to 34 months ]PFS is defined as time from randomisation to disease progression or death whichever occurs first. Assessed by investigator according to the Response Evaluation Criteria in Solid Tumours (RECIST 1.1).Only data collected until the cut-off date for RECIST 1.1 based endpoints (08Jun2013) were considered.Progression of disease was determined if at least 1 of the following criteria applied:At least a 20% increase in the sum of the diameters (SoD) of target lesions taking as reference the smallest SoD recorded since the treatment started, together with an absolute increase in the SoD of at least 5 mmAppearance of 1 or more new lesionsUnequivocal progression of existing non-target lesions"}],"pom_b":[{"label":"1.","content":"Progression-free Survival (PFS)[ Time Frame: From randomization (07Sep2010) until disease progression, death or data cut-off (08Jun2013); Up to 34 months ]PFS is defined as time from randomisation to disease progression or death whichever occurs first. Assessed by investigator according to the Response Evaluation Criteria in Solid Tumours (RECIST 1.1). RECIST is a set of published rules that define when tumors in cancer patients improve (\\"respond\\"), stay the same (\\"stabilize\\") or worsen (\\"progress\\") during treatment.Only data collected until the cut-off date for RECIST 1.1 based endpoints (08Jun2013) were considered.Progression of disease was determined if at least 1 of the following criteria applied:At least a 20% increase in the sum of the diameters (SoD) of target lesions taking as reference the smallest SoD recorded since the treatment started, together with an absolute increase in the SoD of at least 5 mmAppearance of 1 or more new lesionsUnequivocal progression of existing non-target lesions"}],"first_posted":"August 21, 2014","completion_date":"July 6, 2018","primary_completion_date":"June 8, 2013","start_date":"June 22, 2010","last_update_posted":"July 18, 2019"},{"nctid":"NCT02409342","version_a":22,"version_b":23,"version_a_date":"2016-08-01","version_b_date":"2016-08-18","pom_a":[{"label":"1.","content":"Progression-free survival (PFS) time as determined by the investigator using RECIST v1.1[ Time Frame: Up to approximately 3.7 years ]"}],"pom_b":[{"label":"1.","content":"Progression-free Survival (PFS) Time as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)[ Time Frame: Every 6 weeks for 48 weeks following Cycle 1, Day 1, thereafter every 9 weeks after completion of the Week 48 tumor assessment, regardless of treatment delays, until radiographic disease progression (up to approximately 33 months) ]"},{"label":"2.","content":"Overall Survival (OS)[ Time Frame: Every 6 weeks for 48 weeks following Cycle 1, Day 1, thereafter every 9 weeks after completion of the Week 48 tumor assessment, regardless of treatment delays, until radiographic disease progression (up to approximately 33 months) ]"}],"first_posted":"February 18, 2021","completion_date":"March 8, 2022","primary_completion_date":"February 4, 2020","start_date":"July 20, 2015","last_update_posted":"May 10, 2022"},{"nctid":"NCT02409342","version_a":23,"version_b":24,"version_a_date":"2016-08-18","version_b_date":"2016-08-26","pom_a":[{"label":"1.","content":"Progression-free Survival (PFS) Time as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)[ Time Frame: Every 6 weeks for 48 weeks following Cycle 1, Day 1, thereafter every 9 weeks after completion of the Week 48 tumor assessment, regardless of treatment delays, until radiographic disease progression (up to approximately 33 months) ]"},{"label":"2.","content":"Overall Survival (OS)[ Time Frame: Every 6 weeks for 48 weeks following Cycle 1, Day 1, thereafter every 9 weeks after completion of the Week 48 tumor assessment, regardless of treatment delays, until radiographic disease progression (up to approximately 33 months) ]"}],"pom_b":[{"label":"1.","content":"Progression-free survival (PFS) time as determined by the investigator using RECIST v1.1[ Time Frame: Up to approximately 3.7 years ]"}],"first_posted":"February 18, 2021","completion_date":"March 8, 2022","primary_completion_date":"February 4, 2020","start_date":"July 20, 2015","last_update_posted":"May 10, 2022"},{"nctid":"NCT02409342","version_a":24,"version_b":25,"version_a_date":"2016-08-26","version_b_date":"2016-09-12","pom_a":[{"label":"1.","content":"Progression-free survival (PFS) time as determined by the investigator using RECIST v1.1[ Time Frame: Up to approximately 3.7 years ]"}],"pom_b":[{"label":"1.","content":"Progression-free Survival (PFS) Time as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)[ Time Frame: Every 6 weeks for 48 weeks following Cycle 1, Day 1, thereafter every 9 weeks after completion of the Week 48 tumor assessment, regardless of treatment delays, until radiographic disease progression (up to approximately 33 months) ]"},{"label":"2.","content":"Overall Survival (OS)[ Time Frame: Up to approximately 33 months ]"}],"first_posted":"February 18, 2021","completion_date":"March 8, 2022","primary_completion_date":"February 4, 2020","start_date":"July 20, 2015","last_update_posted":"May 10, 2022"},{"nctid":"NCT02409342","version_a":33,"version_b":34,"version_a_date":"2017-05-22","version_b_date":"2017-06-16","pom_a":[{"label":"1.","content":"Progression-free Survival (PFS) Time as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)[ Time Frame: Every 6 weeks for 48 weeks following Cycle 1, Day 1, thereafter every 9 weeks after completion of the Week 48 tumor assessment, regardless of treatment delays, until radiographic disease progression (up to approximately 33 months) ]"},{"label":"2.","content":"Overall Survival (OS)[ Time Frame: Up to approximately 33 months ]"}],"pom_b":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: From randomization to death from any cause (maximum up to approximately 58 months) ]"}],"first_posted":"February 18, 2021","completion_date":"March 8, 2022","primary_completion_date":"February 4, 2020","start_date":"July 20, 2015","last_update_posted":"May 10, 2022"},{"nctid":"NCT02409342","version_a":56,"version_b":57,"version_a_date":"2020-11-03","version_b_date":"2021-01-26","pom_a":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: From randomization to death from any cause (maximum up to approximately 58 months) ]"}],"pom_b":[{"label":"1.","content":"Overall Survival (OS) in the TC3 or IC3-WT Populations[ Time Frame: From randomization to death from any cause until data cut-off on 10 September 2018 (up to approximately 38 months) ]OS is defined as the time from randomization to death from any cause."},{"label":"2.","content":"Overall Survival (OS) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations[ Time Frame: From randomization to death from any cause until data cut-off on 4 February 2020 (up to approximately 54.5 months) ]OS is defined as the time from randomization to death from any cause."}],"first_posted":"February 18, 2021","completion_date":"March 8, 2022","primary_completion_date":"February 4, 2020","start_date":"July 20, 2015","last_update_posted":"May 10, 2022"},{"nctid":"NCT00853567","version_a":4,"version_b":5,"version_a_date":"2014-06-23","version_b_date":"2014-08-05","pom_a":[{"label":"1.","content":"To determine the efficacy of 50 mg Proellex\xae versus placebo in the treatment of subjects with symptomatic uterine fibroids from Baseline to Month 4 as determined by scoring changes in the Pictorial Blood Loss Assessment Chart (PBAC)[ Time Frame: 4 months ]"},{"label":"2.","content":"To determine the efficacy of 50 mg Proellex\xae versus placebo in the treatment of subjects with symptomatic uterine fibroids from Baseline to Month 4 as determined by scoring changes in the Uterine Fibroid Symptom Quality of Life (UFS-QOL) severity score.[ Time Frame: 4 months ]"}],"pom_b":[{"label":"1.","content":"To Determine the Efficacy of 50 mg Proellex\xae Versus Placebo in the Treatment of Subjects With Symptomatic Uterine Fibroids From Baseline to Month 4 as Determined by Scoring Changes in the Pictorial Blood Loss Assessment Chart (PBAC)[ Time Frame: 4 months ]"}],"first_posted":"August 21, 2014","completion_date":"August 2009","primary_completion_date":"August 2009","start_date":"February 2009","last_update_posted":"August 21, 2014"},{"nctid":"NCT03785964","version_a":62,"version_b":63,"version_a_date":"2021-01-21","version_b_date":"2021-04-29","pom_a":[{"label":"1.","content":"Number of progression free survival (PFS) events as defined as the time from randomization until date of assessment of progression or death by any cause using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 Criteria.[ Time Frame: On the first day of every 3 cycles (each cycle is 28 days) until disease progression is observed or death, whichever comes first, assessed up to approximately 2 years ]The documented date of progression will be determined by an independent, blinded, central radiologic review."}],"pom_b":[{"label":"1.","content":"Number of progression free survival (PFS) events as defined as the time from randomization until date of assessment of progression or death by any cause.[ Time Frame: On the first day of every 3 cycles (each cycle is 28 days) until disease progression is observed or death, whichever comes first, assessed up to approximately 2 years ]Progression will be determined radiographically using RECIST v1.1 criteria by an independent, blinded, central radiologic review, or clinically as assessed by the Investigator."}],"first_posted":"No date provided","completion_date":"December 31, 2023","primary_completion_date":"April 7, 2022","start_date":"May 15, 2019","last_update_posted":"September 6, 2022"},{"nctid":"NCT01343277","version_a":6,"version_b":7,"version_a_date":"2011-09-09","version_b_date":"2011-12-06","pom_a":[{"label":"1.","content":"Evaluation of overall survival[ Time Frame: Approximately 3 years ]"}],"pom_b":[{"label":"1.","content":"Overall survival[ Time Frame: Approximately 3 years ]"}],"first_posted":"January 28, 2016","completion_date":"April 2016","primary_completion_date":"January 2015","start_date":"June 2011","last_update_posted":"August 26, 2016"},{"nctid":"NCT01343277","version_a":49,"version_b":50,"version_a_date":"2015-12-11","version_b_date":"2015-12-22","pom_a":[{"label":"1.","content":"Overall survival[ Time Frame: Approximately 3 years ]"}],"pom_b":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: approximately 3 years 8 months (From Study start date [27 May 2011] up to final analysis data cut-off [05 January 2015] ]The OS is defined as the time from the date of first dose of study drug to date of death from any cause. If the participant is alive or the vital status is unknown, the participant will be censored at the date the participant will be last known to be alive."}],"first_posted":"January 28, 2016","completion_date":"April 2016","primary_completion_date":"January 2015","start_date":"June 2011","last_update_posted":"August 26, 2016"},{"nctid":"NCT05100862","version_a":4,"version_b":5,"version_a_date":"2022-10-05","version_b_date":"2022-11-14","pom_a":[{"label":"1.","content":"Progression-free Survival As Determined By An Independent Review Committee[ Time Frame: Approximately 73 months ]"}],"pom_b":[{"label":"1.","content":"Progression-free Survival As Determined By An Independent Review Committee[ Time Frame: Approximately 78 months ]"}],"first_posted":"No date provided","completion_date":"May 2028","primary_completion_date":"May 2028","start_date":"March 10, 2022","last_update_posted":"March 31, 2022"},{"nctid":"NCT02838420","version_a":15,"version_b":16,"version_a_date":"2019-03-19","version_b_date":"2019-07-09","pom_a":[{"label":"1.","content":"PFS as determined by Investigator using RECIST v1.1[ Time Frame: Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) ]"}],"pom_b":[{"label":"1.","content":"Progression-Free Survival (PFS) as Determined by Investigator Using Response Evaluation Criteria in Solid Tumor (RECIST) v1.1[ Time Frame: From the date of randomization to the date of the first documented disease progression or death, whichever occurred first (up to overall period of approximately 40 months) ]PFS was defined as the time (in months) from randomization to the first documentation of disease progression, as determined by the investigators, or to death from any cause, whichever occurred first."}],"first_posted":"July 11, 2019","completion_date":"December 6, 2019","primary_completion_date":"May 31, 2018","start_date":"August 3, 2016","last_update_posted":"September 10, 2019"},{"nctid":"NCT00132301","version_a":8,"version_b":9,"version_a_date":"2007-06-05","version_b_date":"2008-08-12","pom_a":[],"pom_b":[{"label":"1.","content":"Progression-Free Survival[ Time Frame: 5 years ]"}],"first_posted":"June 25, 2018","completion_date":"September 2016","primary_completion_date":"October 2015","start_date":"June 2006","last_update_posted":"June 25, 2018"},{"nctid":"NCT00132301","version_a":28,"version_b":29,"version_a_date":"2016-06-22","version_b_date":"2018-05-25","pom_a":[{"label":"1.","content":"Progression-Free Survival[ Time Frame: 5 years ]"}],"pom_b":[{"label":"1.","content":"Number of Participants With Progression-Free Survival[ Time Frame: Up to 100 months (centralized follow-up) ]The primary objective of this study is to determine whether adding early chemotherapy based on docetaxel plus prednisone compared to standard of care alone reduces disease progression as evidenced by detectable PSA in high risk patients with prostate cancer who have undergone radical prostatectomy."}],"first_posted":"June 25, 2018","completion_date":"September 2016","primary_completion_date":"October 2015","start_date":"June 2006","last_update_posted":"June 25, 2018"},{"nctid":"NCT00995293","version_a":9,"version_b":10,"version_a_date":"2013-10-08","version_b_date":"2013-11-22","pom_a":[{"label":"1.","content":"Progression-free survival[ Time Frame: From randomization to any progression event or patient death followed-up every 3 months ]"}],"pom_b":[{"label":"1.","content":"Progression-free survival[ Time Frame: From randomization to any progression event or patient death (follow-up every 3 months 1st year, then every 6 months) ]"}],"first_posted":"No date provided","completion_date":"January 26, 2018","primary_completion_date":"January 26, 2018","start_date":"August 27, 2009","last_update_posted":"March 2, 2018"},{"nctid":"NCT01178281","version_a":21,"version_b":22,"version_a_date":"2012-11-13","version_b_date":"2013-11-01","pom_a":[{"label":"1.","content":"Proportion of subjects achieving RBC-transfusion-independence[ Time Frame: 6 months ]"}],"pom_b":[{"label":"1.","content":"Red blood cell (RBC)-transfusion-independence[ Time Frame: Up to 6 months ]Number of subjects achieving greater than or equal to 84 days without a RBC transfusion"}],"first_posted":"March 14, 2014","completion_date":"May 15, 2018","primary_completion_date":"January 1, 2013","start_date":"September 8, 2010","last_update_posted":"July 17, 2019"},{"nctid":"NCT01178281","version_a":22,"version_b":23,"version_a_date":"2013-11-01","version_b_date":"2014-01-31","pom_a":[{"label":"1.","content":"Red blood cell (RBC)-transfusion-independence[ Time Frame: Up to 6 months ]Number of subjects achieving greater than or equal to 84 days without a RBC transfusion"}],"pom_b":[{"label":"1.","content":"Percentage of Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence[ Time Frame: 168 days ]Defined as the absence of intravenous RBC transfusions for any consecutive \\"rolling\\" 84 day interval (i.e. days 1 to 84, days 2 to 85 etc) before Day 169 visit. A responder is: a. One who received at least two RBC transfusions on/after the first dose of study drug, and at least one \u2265 84 days between two consecutive RBC-transfusions; b. One who received at least one RBC transfusion after the first dose of study drug and no RBC transfusion at the first study drug day, and the time interval between the first dose of study drug and the RBC transfusion date is \u2265 84 days; c. One who received at least one RBC transfusion on/after the first dose of study drug and the time interval between the last RBC transfusion and the last transfusion assessment date is \u2265 84 days; d. One who did not receive any RBC transfusions on and after the first dose of study drug, and the time interval between the first dose of study drug and the date of the last transfusion assessment is \u2265 84 days"}],"first_posted":"March 14, 2014","completion_date":"May 15, 2018","primary_completion_date":"January 1, 2013","start_date":"September 8, 2010","last_update_posted":"July 17, 2019"},{"nctid":"NCT01178281","version_a":28,"version_b":29,"version_a_date":"2019-01-17","version_b_date":"2019-06-24","pom_a":[{"label":"1.","content":"Percentage of Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence[ Time Frame: 168 days ]Defined as the absence of intravenous RBC transfusions for any consecutive \\"rolling\\" 84 day interval (i.e. days 1 to 84, days 2 to 85 etc) before Day 169 visit. A responder is: a. One who received at least two RBC transfusions on/after the first dose of study drug, and at least one \u2265 84 days between two consecutive RBC-transfusions; b. One who received at least one RBC transfusion after the first dose of study drug and no RBC transfusion at the first study drug day, and the time interval between the first dose of study drug and the RBC transfusion date is \u2265 84 days; c. One who received at least one RBC transfusion on/after the first dose of study drug and the time interval between the last RBC transfusion and the last transfusion assessment date is \u2265 84 days; d. One who did not receive any RBC transfusions on and after the first dose of study drug, and the time interval between the first dose of study drug and the date of the last transfusion assessment is \u2265 84 days"}],"pom_b":[{"label":"1.","content":"Percentage of Participants Who Achieved RBC-Transfusion Independence[ Time Frame: 168 days ]RBC-transfusion independence was defined as the absence of RBC transfusions for any consecutive 84-day interval."},{"label":"2.","content":"China Extension: Number of Participants Achieving a Hemoglobin Increase of \u2265 15 g/L Compared to Baseline for \u2265 84 Consecutive Days[ Time Frame: From the first dose of study drug until treatment discontinuation; median treatment duration was 24.0 weeks. ]A response in the China extension study was defined as an increase in hemoglobin \u2265 15 g/L above baseline value (in the absence of RBC transfusion) for \u2265 84 consecutive days."}],"first_posted":"March 14, 2014","completion_date":"May 15, 2018","primary_completion_date":"January 1, 2013","start_date":"September 8, 2010","last_update_posted":"July 17, 2019"},{"nctid":"NCT03728556","version_a":1,"version_b":2,"version_a_date":"2018-11-01","version_b_date":"2018-11-05","pom_a":[{"label":"1.","content":"Progress Free Survival (PFS)[ Time Frame: from the date of randomization to the first date of recorded progression or all-cause death, whichever comes first, assessed up to 24 months ]The primary endpoint is the PFS of CS1001 versus placebo (evaluated by investigators according to response evaluation criteria in solid tumors RECIST v1.1)"}],"pom_b":[{"label":"1.","content":"Progress Free Survival (PFS)[ Time Frame: from the date of randomization to the first date of recorded progression or all-cause death, whichever comes first, assessed up to 30 months ]The primary endpoint is the PFS of CS1001 versus placebo (evaluated by investigators according to response evaluation criteria in solid tumors RECIST v1.1)"}],"first_posted":"No date provided","completion_date":"June 2024","primary_completion_date":"March 31, 2023","start_date":"October 26, 2018","last_update_posted":"January 21, 2022"},{"nctid":"NCT03728556","version_a":3,"version_b":4,"version_a_date":"2020-01-20","version_b_date":"2021-02-25","pom_a":[{"label":"1.","content":"Progress Free Survival (PFS)[ Time Frame: from the date of randomization to the first date of recorded progression or all-cause death, whichever comes first, assessed up to 30 months ]The primary endpoint is the PFS of CS1001 versus placebo (evaluated by investigators according to response evaluation criteria in solid tumors RECIST v1.1)"}],"pom_b":[{"label":"1.","content":"Progress Free Survival (PFS)[ Time Frame: from the date of randomization to the first date of recorded progression or all-cause death, whichever comes first, assessed up to 30 months. ]The primary endpoint is the PFS of CS1001 versus placebo (evaluated by blinded independent central review(BICR) according to response evaluation criteria in solid tumors RECIST v1.1)."}],"first_posted":"No date provided","completion_date":"June 2024","primary_completion_date":"March 31, 2023","start_date":"October 26, 2018","last_update_posted":"January 21, 2022"},{"nctid":"NCT01938001","version_a":38,"version_b":39,"version_a_date":"2018-10-29","version_b_date":"2019-07-19","pom_a":[{"label":"1.","content":"Progression free survival (PFS) for indolent lymphoma (Follicular lymphoma and Marginal zone lymphoma[ Time Frame: Up to 8 years ]Progression-free survival is defined as the time from date of randomization to the first observation of disease progression or death due to any cause as assessed by an independent review committee."}],"pom_b":[{"label":"1.","content":"Kaplan Meier Estimate of Progression Free Survival Assessed by the Independent Review Committee (IRC) According to the 2007 International Working Group Response Criteria (IWGRC)[ Time Frame: From randomization of study drug up to disease progression or death, which occurred first; up to the data cut-off date of 22 June 2018; overall median follow-up time for all participants was 28.30 months (range: 0.1 to 51.3 months). ]Progression-free survival (PFS) was defined as the time from date of randomization into the study to the first observation of documented disease progression or death due to any cause, whichever occurred first. PFS was based on the data from the IRC review using the modified 2007 International Working Group Response Criteria (IWGRC) using FDA censoring rules."}],"first_posted":"August 13, 2019","completion_date":"January 26, 2022","primary_completion_date":"June 22, 2018","start_date":"November 21, 2013","last_update_posted":"June 24, 2022"},{"nctid":"NCT02394834","version_a":8,"version_b":9,"version_a_date":"2018-07-20","version_b_date":"2019-07-31","pom_a":[{"label":"1.","content":"Relationship between overall survival (OS) and mutation of each gene[ Time Frame: Up to 60 months ]Evaluation of the relationship between overall survival (OS) of the main study and mutation of each gene in tumor samples from baseline of the main study. OS is the period from the day of randomization until death by all causes."}],"pom_b":[{"label":"1.","content":"Overall survival (OS)[ Time Frame: Up to approximately 63 months ]OS obtained in the main study will be stratified by the presence or absence of mutation of tumor-associated genes in tumor tissues at the baseline of the main study to evaluate the relationship between OS and gene mutations. OS will be measured as the time from the date of randomization to the date of death due to any causes."}],"first_posted":"No date provided","completion_date":"January 14, 2022","primary_completion_date":"January 14, 2022","start_date":"May 29, 2015","last_update_posted":"February 18, 2022"},{"nctid":"NCT00540514","version_a":4,"version_b":5,"version_a_date":"2007-12-10","version_b_date":"2008-06-06","pom_a":[],"pom_b":[{"label":"1.","content":"Response rate[ Time Frame: none specified ]"}],"first_posted":"August 19, 2013","completion_date":"February 1, 2013","primary_completion_date":"October 1, 2009","start_date":"November 1, 2007","last_update_posted":"October 29, 2019"},{"nctid":"NCT00540514","version_a":27,"version_b":28,"version_a_date":"2011-10-06","version_b_date":"2012-05-10","pom_a":[{"label":"1.","content":"Response rate[ Time Frame: none specified ]"}],"pom_b":[{"label":"1.","content":"Response rate[ Time Frame: Up to 23 months ]The percent of patients who achieved an objective confirmed complete response or partial response based on blinded radiological review using RECIST response guidelines"}],"first_posted":"August 19, 2013","completion_date":"February 1, 2013","primary_completion_date":"October 1, 2009","start_date":"November 1, 2007","last_update_posted":"October 29, 2019"},{"nctid":"NCT00540514","version_a":28,"version_b":29,"version_a_date":"2012-05-10","version_b_date":"2013-08-16","pom_a":[{"label":"1.","content":"Response rate[ Time Frame: Up to 23 months ]The percent of patients who achieved an objective confirmed complete response or partial response based on blinded radiological review using RECIST response guidelines"}],"pom_b":[{"label":"1.","content":"Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment[ Time Frame: Objective response was evaluated every 6 weeks until progression or new anti-cancer therapy initiation, up to 22 months. ]Antitumor response was defined as the percentage of participants who achieved an objective response (Confirmed Response [CR] or Partial Response [PR]), confirmed by repeat assessments performed no less than 4 weeks after the criteria for response were first met. Response was based on the blinded radiological review using Response Evaluation Criteria in Solid Tumors (RECIST) response guidelines, Version 1.0.A complete response was defined as a disappearance of all target and non-target lesions and no new lesions.Partial response was defined as \u2265 30% decrease in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline SLD, and the persistence of one or more non-target lesions not qualifying for CR or Progressive Disease (the \\"unequivocal progression\\" of existing non-target lesion(s) or appearance of one or more new lesions)."}],"first_posted":"August 19, 2013","completion_date":"February 1, 2013","primary_completion_date":"October 1, 2009","start_date":"November 1, 2007","last_update_posted":"October 29, 2019"},{"nctid":"NCT01767467","version_a":117,"version_b":118,"version_a_date":"2016-12-01","version_b_date":"2017-04-21","pom_a":[{"label":"1.","content":"Occurrence of solicited local and general symptoms[ Time Frame: Up to 7 days (Days 0-6) after each vaccination ]"},{"label":"2.","content":"Occurrence of unsolicited adverse events (AEs)[ Time Frame: Up to 30 days (Days 0-29) after each vaccination ]"},{"label":"3.","content":"Occurrence of serious adverse events (SAEs)[ Time Frame: Up to 30 days post last vaccination ]"},{"label":"4.","content":"Occurrence of AEs of specific interest[ Time Frame: Up to 30 days post last vaccination ]"},{"label":"5.","content":"Anti gE humoral immunogenicity in all vaccinated subjects excluding subjects with Non-Hodgkin B-cell Lymphoma and Chronic Lymphocytic Leukaemia[ Time Frame: At Month 2 ]"}],"pom_b":[{"label":"1.","content":"Vaccine Response Rates (VRR) for Anti-gE Antibody ELISA Concentrations[ Time Frame: At Month 2 ]Vaccine response rate was the number of subjects with a vaccine response. Vaccine response was defined as:For initially seronegative subjects, antibody concentration at Month 2 \u2265 4 fold the cut-off for Anti-gE (4x97 mIU/mL) For initially seropositive subjects, antibody concentration at Month 2 \u2265 4 fold the pre-vaccination antibody concentration This analysis was performed in subjects with haematologic malignancies excluding subjects with Non-Hodgkin B-cell Lymphoma and Chronic Lymphocytic Leukaemia."},{"label":"2.","content":"Adjusted Geometric Mean Concentration of Anti-gE Antibodies[ Time Frame: At Month 2 ]The Adjusted geometric mean concentration was measured in all subjects excluding those with Non-Hodgkin B-cell Lymphoma and Chronic Lymphocytic Leukaemia."},{"label":"3.","content":"Number of Subjects With Any and Grade 3 Solicited Local Symptoms.[ Time Frame: Up to 7 days (Days 0-6) after each vaccination ]Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. Since the study is ongoing, results for the individual groups are blinded. Hence results were presented per the total number of subjects."},{"label":"4.","content":"Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms.[ Time Frame: during the 7-day (Days 0-6) post-vaccination period ]Assessed solicited general symptoms were arthralgia, fatigue, fever [defined as axillary temperature equal to or above 37.5 degrees Celsius (\xb0C)], headache, myalgia, shivering and sweating. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever > 39.0 \xb0C. Related = symptom assessed by the investigator as related to the vaccination."},{"label":"5.","content":"Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs).[ Time Frame: Up to 30 days (Days 0-29) after each vaccination ]An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination."},{"label":"6.","content":"Number of Subjects With Serious Adverse Events (SAEs).[ Time Frame: From first vaccination up to 30 days post last vaccination ]Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity."},{"label":"7.","content":"Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs)[ Time Frame: Up to 30 days post last vaccination ]Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology."},{"label":"8.","content":"Number of Days With Solicited Local Symptoms[ Time Frame: within 7 days (Days 0-6) after each vaccination ]"},{"label":"9.","content":"Number of Days With Solicited General Symptoms[ Time Frame: within the 7 days (Day 0-6) after each vaccination ]"}],"first_posted":"May 25, 2017","completion_date":"January 6, 2017","primary_completion_date":"January 7, 2016","start_date":"March 1, 2013","last_update_posted":"June 6, 2018"},{"nctid":"NCT01767467","version_a":118,"version_b":119,"version_a_date":"2017-04-21","version_b_date":"2018-02-27","pom_a":[{"label":"1.","content":"Vaccine Response Rates (VRR) for Anti-gE Antibody ELISA Concentrations[ Time Frame: At Month 2 ]Vaccine response rate was the number of subjects with a vaccine response. Vaccine response was defined as:For initially seronegative subjects, antibody concentration at Month 2 \u2265 4 fold the cut-off for Anti-gE (4x97 mIU/mL) For initially seropositive subjects, antibody concentration at Month 2 \u2265 4 fold the pre-vaccination antibody concentration This analysis was performed in subjects with haematologic malignancies excluding subjects with Non-Hodgkin B-cell Lymphoma and Chronic Lymphocytic Leukaemia."},{"label":"2.","content":"Adjusted Geometric Mean Concentration of Anti-gE Antibodies[ Time Frame: At Month 2 ]The Adjusted geometric mean concentration was measured in all subjects excluding those with Non-Hodgkin B-cell Lymphoma and Chronic Lymphocytic Leukaemia."},{"label":"3.","content":"Number of Subjects With Any and Grade 3 Solicited Local Symptoms.[ Time Frame: Up to 7 days (Days 0-6) after each vaccination ]Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. Since the study is ongoing, results for the individual groups are blinded. Hence results were presented per the total number of subjects."},{"label":"4.","content":"Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms.[ Time Frame: during the 7-day (Days 0-6) post-vaccination period ]Assessed solicited general symptoms were arthralgia, fatigue, fever [defined as axillary temperature equal to or above 37.5 degrees Celsius (\xb0C)], headache, myalgia, shivering and sweating. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever > 39.0 \xb0C. Related = symptom assessed by the investigator as related to the vaccination."},{"label":"5.","content":"Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs).[ Time Frame: Up to 30 days (Days 0-29) after each vaccination ]An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination."},{"label":"6.","content":"Number of Subjects With Serious Adverse Events (SAEs).[ Time Frame: From first vaccination up to 30 days post last vaccination ]Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity."},{"label":"7.","content":"Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs)[ Time Frame: Up to 30 days post last vaccination ]Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology."},{"label":"8.","content":"Number of Days With Solicited Local Symptoms[ Time Frame: within 7 days (Days 0-6) after each vaccination ]"},{"label":"9.","content":"Number of Days With Solicited General Symptoms[ Time Frame: within the 7 days (Day 0-6) after each vaccination ]"}],"pom_b":[{"label":"1.","content":"Vaccine Response Rates (VRR) for Anti-glycoprotein E (Anti-gE) Antibody Concentrations[ Time Frame: At Month 2 ]Vaccine response rate refers to the percentage of subjects with a vaccine response, as determined by Enzyme-Linked Immunosorbent Assay (ELISA). Vaccine response was defined as: For initially seronegative subjects, antibody concentration at Month 2 greater than or equal to (\u2265) 4 fold the cut-off for Anti-gE [4x97 milli-international units per milliliter (mIU/mL)]. For initially seropositive subjects, antibody concentration at Month 2 \u2265 4 fold the pre-vaccination antibody concentration.This analysis was performed on subjects with haematologic malignancies excluding subjects with Non-Hodgkin B-cell Lymphoma and Chronic Lymphocytic Leukaemia."},{"label":"2.","content":"Adjusted Geometric Mean Concentration of Anti-gE Antibodies[ Time Frame: At Month 2 ]The Adjusted geometric mean concentration was measured in all subjects excluding those with Non-Hodgkin B-cell Lymphoma and Chronic Lymphocytic Leukaemia."},{"label":"3.","content":"Number of Subjects With Any and Grade 3 Solicited Local Symptoms[ Time Frame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses ]Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site."},{"label":"4.","content":"Number of Days With Solicited Local Symptoms[ Time Frame: Within the 7-day (Days 0-6) post-vaccination period ]Solicited local symptoms: pain, redness, swelling and their number of days were recorded after each vaccination dose."},{"label":"5.","content":"Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms[ Time Frame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses ]Assessed solicited general symptoms were fatigue, gastrointestinal symptoms (included nausea, vomiting, diarrhoea and/or abdominal pain), headache, myalgia, shivering and fever [defined as oral, axillary or tympanic route measured temperature equal to or above 37.5 degrees Celsius (\xb0C)]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever > 39.0 \xb0C. Related = symptom assessed by the investigator as related to the vaccination."},{"label":"6.","content":"Number of Days With Solicited General Symptoms[ Time Frame: Withing the 7-day (Day 0-6) post-vaccination period ]Solicited general symptoms: fatigue, gastrointestinal symptoms, headache, myalgia, shivering, temperature and their number of days were recorded after each vaccination dose."},{"label":"7.","content":"Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)[ Time Frame: Within the 30-day (Days 0-29) post-vaccination period ]An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study. It also included any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination."},{"label":"8.","content":"Number of Subjects With Serious Adverse Events (SAEs)[ Time Frame: From first vaccination up to 30 days post last vaccination ]A Serious adverse event (SAE) is any untoward medical occurrence that result in death, is life threatening, requires hospitalisation or prolongation of existing hospitalisation, results in disability/incapacity, or is a congenital anomaly/birth defect in the offspring of a study subject. Related = SAEs assessed by the investigator as causally related to the study vaccination"},{"label":"9.","content":"Number of Subjects Reporting Any and Related Potential Immune-mediated Diseases (pIMDs)[ Time Frame: From first vaccination up to 30 days post last vaccination ]Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Related = pIMds assessed by the investigator as causally related to the study vaccination"}],"first_posted":"May 25, 2017","completion_date":"January 6, 2017","primary_completion_date":"January 7, 2016","start_date":"March 1, 2013","last_update_posted":"June 6, 2018"},{"nctid":"NCT01830621","version_a":24,"version_b":25,"version_a_date":"2018-02-06","version_b_date":"2018-11-14","pom_a":[{"label":"1.","content":"Overall Survival[ Time Frame: 38 month ]The primary objective of this study is to assess the effect of orally administered BBI608 plus best supportive care (BSC), in comparison to placebo plus best supportive care on the Overall Survival of patients with advanced histopathologically confirmed colorectal carcinoma who have exhausted all standard treatment options"}],"pom_b":[{"label":"1.","content":"Overall Survival[ Time Frame: 38 month ]Time from the day of randomization to death. For alive patients, overall survival was censored at the last day the patient was known alive (LKA)."}],"first_posted":"March 11, 2019","completion_date":"May 16, 2016","primary_completion_date":"December 21, 2015","start_date":"April 15, 2013","last_update_posted":"April 14, 2020"},{"nctid":"NCT00773747","version_a":1,"version_b":2,"version_a_date":"2008-10-15","version_b_date":"2008-10-17","pom_a":[{"label":"1.","content":"Determine the TTP (time-to-progression) in patients with multiple myeloma, treated with bortezomib and vorinostat compared to patients treated with bortezomib and placebo[ Time Frame: 33 months ]"}],"pom_b":[{"label":"1.","content":"Determine the PFS (progression free survival) in patients with multiple myeloma, treated with bortezomib and vorinostat compared to patients treated with bortezomib and placebo.[ Time Frame: 33 months ]"}],"first_posted":"April 30, 2021","completion_date":"June 30, 2015","primary_completion_date":"September 8, 2011","start_date":"December 1, 2008","last_update_posted":"April 30, 2021"},{"nctid":"NCT00773747","version_a":2,"version_b":3,"version_a_date":"2008-10-17","version_b_date":"2008-10-29","pom_a":[{"label":"1.","content":"Determine the PFS (progression free survival) in patients with multiple myeloma, treated with bortezomib and vorinostat compared to patients treated with bortezomib and placebo.[ Time Frame: 33 months ]"}],"pom_b":[{"label":"1.","content":"Determine the PFS (progression free survival) in patients with multiple myeloma, treated with bortezomib and vorinostat compared to patients treated with bortezomib and placebo[ Time Frame: 33 months ]"}],"first_posted":"April 30, 2021","completion_date":"June 30, 2015","primary_completion_date":"September 8, 2011","start_date":"December 1, 2008","last_update_posted":"April 30, 2021"},{"nctid":"NCT00773747","version_a":21,"version_b":22,"version_a_date":"2009-10-30","version_b_date":"2009-11-05","pom_a":[{"label":"1.","content":"Determine the PFS (progression free survival) in patients with multiple myeloma, treated with bortezomib and vorinostat compared to patients treated with bortezomib and placebo[ Time Frame: 33 months ]"}],"pom_b":[{"label":"1.","content":"Determine the PFS (progression free survival)[ Time Frame: every 21 days ]"}],"first_posted":"April 30, 2021","completion_date":"June 30, 2015","primary_completion_date":"September 8, 2011","start_date":"December 1, 2008","last_update_posted":"April 30, 2021"},{"nctid":"NCT00773747","version_a":33,"version_b":34,"version_a_date":"2011-01-14","version_b_date":"2011-02-24","pom_a":[{"label":"1.","content":"Determine the PFS (progression free survival)[ Time Frame: every 21 days ]"}],"pom_b":[{"label":"1.","content":"Duration of progression-free survival (PFS) in participants treated with vorinostat + bortezomib versus placebo + bortezomib[ Time Frame: From randomization to event of disease progression or death ]"}],"first_posted":"April 30, 2021","completion_date":"June 30, 2015","primary_completion_date":"September 8, 2011","start_date":"December 1, 2008","last_update_posted":"April 30, 2021"},{"nctid":"NCT00773747","version_a":50,"version_b":51,"version_a_date":"2015-08-20","version_b_date":"2021-04-29","pom_a":[{"label":"1.","content":"Duration of progression-free survival (PFS) in participants treated with vorinostat + bortezomib versus placebo + bortezomib[ Time Frame: From randomization to event of disease progression or death ]"}],"pom_b":[{"label":"1.","content":"Progression-Free Survival (PFS)[ Time Frame: From randomization to event of disease progression or death assessed up to 32 months (final study analysis) ]Progression-free survival was measured from the start of the treatment to the time when the criteria for progression was met or death due to any cause (whichever is first recorded). Response to study therapy was assessed using European Blood and Marrow Transplantation Group (EBMT) Criteria. A stratified Cox proportional hazards model was used with Efron\'s likelihood approximation to account for ties in event times."}],"first_posted":"April 30, 2021","completion_date":"June 30, 2015","primary_completion_date":"September 8, 2011","start_date":"December 1, 2008","last_update_posted":"April 30, 2021"},{"nctid":"NCT01202747","version_a":2,"version_b":3,"version_a_date":"2011-02-09","version_b_date":"2011-11-01","pom_a":[],"pom_b":[{"label":"1.","content":"Association Between Screening Methods (Meibomian Gland Expression) and Treatment Effectiveness Outcomes (Total Meibomian Gland Score)[ Time Frame: Baseline and 4 Weeks ]Analysis of association between Baseline Meibomian Gland Expression Score and Total Meibomian Gland Score at 4 Weeks. Success was defined by demonstration of a statistically significant (p<0.05) association between the screening method and outcome.Meibomian gland expression sum scores range from 0 to 60 with a higher score reflecting less meibomian gland dysfunction. Total meibomian gland scores range from 0 to 45 with a higher score reflecting less meibomian gland dysfunction."}],"first_posted":"December 6, 2011","completion_date":"January 2011","primary_completion_date":"January 2011","start_date":"September 2010","last_update_posted":"December 6, 2011"},{"nctid":"NCT00638690","version_a":55,"version_b":56,"version_a_date":"2011-07-27","version_b_date":"2011-08-19","pom_a":[{"label":"1.","content":"Overall Survival[ Time Frame: During the Study ]"}],"pom_b":[{"label":"1.","content":"Overall Survival[ Time Frame: During study period. ]Difference between abiraterone acetate and placebo groups."}],"first_posted":"May 16, 2013","completion_date":"October 2012","primary_completion_date":"August 2010","start_date":"May 2008","last_update_posted":"April 30, 2014"},{"nctid":"NCT00638690","version_a":56,"version_b":57,"version_a_date":"2011-08-19","version_b_date":"2013-04-05","pom_a":[{"label":"1.","content":"Overall Survival[ Time Frame: During study period. ]Difference between abiraterone acetate and placebo groups."}],"pom_b":[{"label":"1.","content":"Overall Survival[ Time Frame: Up to 60 months ]Overall survival is defined as the time interval from the date of randomization to the date of death from any cause."}],"first_posted":"May 16, 2013","completion_date":"October 2012","primary_completion_date":"August 2010","start_date":"May 2008","last_update_posted":"April 30, 2014"},{"nctid":"NCT01188187","version_a":33,"version_b":34,"version_a_date":"2016-10-11","version_b_date":"2016-10-13","pom_a":[{"label":"1.","content":"Overall Survival[ Time Frame: 31 months ]To ascertain whether the survival time distribution for patients randomized to the investigational arm is consistent with longer survival as compared to patients randomized to the control arm."}],"pom_b":[{"label":"1.","content":"Kaplan-Meier Estimates for Time to Death (Overall Survival)[ Time Frame: Randomization (approximately Day -12) to longest survival follow-up (Day 971). ]Time from the date of randomization to death from any cause. After stopping treatment, patients were followed every 4 weeks until disease progression and then followed every 12 weeks until death."}],"first_posted":"No date provided","completion_date":"June 2014","primary_completion_date":"February 2014","start_date":"November 2010","last_update_posted":"October 14, 2016"},{"nctid":"NCT02040935","version_a":18,"version_b":19,"version_a_date":"2016-11-01","version_b_date":"2017-05-02","pom_a":[{"label":"1.","content":"Safety: Incidence and severity of adverse events and serious adverse events by NCI CTAE version 4-0[ Time Frame: approximately 1 year ]"}],"pom_b":[{"label":"1.","content":"Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs)[ Time Frame: From Baseline up to approximately 4 years ]"}],"first_posted":"No date provided","completion_date":"September 14, 2018","primary_completion_date":"September 14, 2018","start_date":"February 21, 2014","last_update_posted":"August 22, 2019"},{"nctid":"NCT02322320","version_a":12,"version_b":13,"version_a_date":"2019-09-10","version_b_date":"2020-04-27","pom_a":[{"label":"1.","content":"Compare the PFS as a time to event analysis from randomization on the BMT CTN 0702 protocol between the three randomized treatment arms as a pairwise comparison.[ Time Frame: 5 years post randomization on BMT CTN 0702 ]The primary analysis will include all randomized subjects from the BMT CTN 0702 protocol, classified according to their randomized treatment allocation, irrespective of treatment actually received [intent-to-treat]. The time to this event is the time from randomization on the BMT CTN 0702 protocol to progression, initiation of non-protocol anti-myeloma therapy, or death from any cause. Patients will be censored at loss to follow-up or end of 2018, whichever comes first. Deaths without progression are treated as failures no matter when they occur. The analysis will be conducted once all living patients have been followed for 5-years post randomization on the BMT CTN 0702 protocol."}],"pom_b":[{"label":"1.","content":"Percentage of Participants With Progression-free Survival (PFS)[ Time Frame: 5 years post-randomization in BMT CTN 0702 ]This analysis includes all randomized subjects from the BMT CTN 0702 protocol classified according to their randomized treatment assignment (intention-to-treat). Progression-free survival is defined as survival without disease progression or initiation of non-protocol anti-myeloma therapy. To account for loss to follow-up, the Kaplan-Meier estimator was used to estimate progression-free survival during the 5 year post-randomization follow-up period."}],"first_posted":"May 11, 2020","completion_date":"June 7, 2019","primary_completion_date":"June 7, 2019","start_date":"March 2015","last_update_posted":"May 11, 2020"}]}'),Q=n(1184);var X=e.createContext(),ee=n(5878);function te(e){return(0,T.Z)("MuiGrid",e)}var ne=["auto",!0,1,2,3,4,5,6,7,8,9,10,11,12],re=(0,ee.Z)("MuiGrid",["root","container","item","zeroMinWidth"].concat((0,j.Z)([0,1,2,3,4,5,6,7,8,9,10].map((function(e){return"spacing-xs-".concat(e)}))),(0,j.Z)(["column-reverse","column","row-reverse","row"].map((function(e){return"direction-xs-".concat(e)}))),(0,j.Z)(["nowrap","wrap-reverse","wrap"].map((function(e){return"wrap-xs-".concat(e)}))),(0,j.Z)(ne.map((function(e){return"grid-xs-".concat(e)}))),(0,j.Z)(ne.map((function(e){return"grid-sm-".concat(e)}))),(0,j.Z)(ne.map((function(e){return"grid-md-".concat(e)}))),(0,j.Z)(ne.map((function(e){return"grid-lg-".concat(e)}))),(0,j.Z)(ne.map((function(e){return"grid-xl-".concat(e)}))))),ae=re,oe=["className","columns","columnSpacing","component","container","direction","item","rowSpacing","spacing","wrap","zeroMinWidth"];function ie(e){var t=parseFloat(e);return"".concat(t).concat(String(e).replace(String(t),"")||"px")}function se(e){var t=e.breakpoints,n=e.values,r="";Object.keys(n).forEach((function(e){""===r&&0!==n[e]&&(r=e)}));var a=Object.keys(t).sort((function(e,n){return t[e]-t[n]}));return a.slice(0,a.indexOf(r))}var le=(0,O.ZP)("div",{name:"MuiGrid",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState,r=n.container,a=n.direction,o=n.item,i=n.spacing,s=n.wrap,l=n.zeroMinWidth,c=n.breakpoints,u=[];r&&(u=function(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:{};if(!e||e<=0)return[];if("string"===typeof e&&!Number.isNaN(Number(e))||"number"===typeof e)return[n["spacing-xs-".concat(String(e))]];var r=[];return t.forEach((function(t){var a=e[t];Number(a)>0&&r.push(n["spacing-".concat(t,"-").concat(String(a))])})),r}(i,c,t));var d=[];return c.forEach((function(e){var r=n[e];r&&d.push(t["grid-".concat(e,"-").concat(String(r))])})),[t.root,r&&t.container,o&&t.item,l&&t.zeroMinWidth].concat((0,j.Z)(u),["row"!==a&&t["direction-xs-".concat(String(a))],"wrap"!==s&&t["wrap-xs-".concat(String(s))]],d)}})((function(e){var t=e.ownerState;return(0,r.Z)({boxSizing:"border-box"},t.container&&{display:"flex",flexWrap:"wrap",width:"100%"},t.item&&{margin:0},t.zeroMinWidth&&{minWidth:0},"wrap"!==t.wrap&&{flexWrap:t.wrap})}),(function(e){var t=e.theme,n=e.ownerState,r=(0,Q.P$)({values:n.direction,breakpoints:t.breakpoints.values});return(0,Q.k9)({theme:t},r,(function(e){var t={flexDirection:e};return 0===e.indexOf("column")&&(t["& > .".concat(ae.item)]={maxWidth:"none"}),t}))}),(function(e){var t=e.theme,n=e.ownerState,r=n.container,a=n.rowSpacing,o={};if(r&&0!==a){var i,s=(0,Q.P$)({values:a,breakpoints:t.breakpoints.values});"object"===typeof s&&(i=se({breakpoints:t.breakpoints.values,values:s})),o=(0,Q.k9)({theme:t},s,(function(e,n){var r,a=t.spacing(e);return"0px"!==a?(0,_.Z)({marginTop:"-".concat(ie(a))},"& > .".concat(ae.item),{paddingTop:ie(a)}):null!=(r=i)&&r.includes(n)?{}:(0,_.Z)({marginTop:0},"& > .".concat(ae.item),{paddingTop:0})}))}return o}),(function(e){var t=e.theme,n=e.ownerState,r=n.container,a=n.columnSpacing,o={};if(r&&0!==a){var i,s=(0,Q.P$)({values:a,breakpoints:t.breakpoints.values});"object"===typeof s&&(i=se({breakpoints:t.breakpoints.values,values:s})),o=(0,Q.k9)({theme:t},s,(function(e,n){var r,a=t.spacing(e);return"0px"!==a?(0,_.Z)({width:"calc(100% + ".concat(ie(a),")"),marginLeft:"-".concat(ie(a))},"& > .".concat(ae.item),{paddingLeft:ie(a)}):null!=(r=i)&&r.includes(n)?{}:(0,_.Z)({width:"100%",marginLeft:0},"& > .".concat(ae.item),{paddingLeft:0})}))}return o}),(function(e){var t,n=e.theme,a=e.ownerState;return n.breakpoints.keys.reduce((function(e,o){var i={};if(a[o]&&(t=a[o]),!t)return e;if(!0===t)i={flexBasis:0,flexGrow:1,maxWidth:"100%"};else if("auto"===t)i={flexBasis:"auto",flexGrow:0,flexShrink:0,maxWidth:"none",width:"auto"};else{var s=(0,Q.P$)({values:a.columns,breakpoints:n.breakpoints.values}),l="object"===typeof s?s[o]:s;if(void 0===l||null===l)return e;var c="".concat(Math.round(t/l*1e8)/1e6,"%"),u={};if(a.container&&a.item&&0!==a.columnSpacing){var d=n.spacing(a.columnSpacing);if("0px"!==d){var f="calc(".concat(c," + ").concat(ie(d),")");u={flexBasis:f,maxWidth:f}}}i=(0,r.Z)({flexBasis:c,flexGrow:0,maxWidth:c},u)}return 0===n.breakpoints.values[o]?Object.assign(e,i):e[n.breakpoints.up(o)]=i,e}),{})}));var ce=function(e){var t=e.classes,n=e.container,r=e.direction,a=e.item,o=e.spacing,i=e.wrap,s=e.zeroMinWidth,l=e.breakpoints,c=[];n&&(c=function(e,t){if(!e||e<=0)return[];if("string"===typeof e&&!Number.isNaN(Number(e))||"number"===typeof e)return["spacing-xs-".concat(String(e))];var n=[];return t.forEach((function(t){var r=e[t];if(Number(r)>0){var a="spacing-".concat(t,"-").concat(String(r));n.push(a)}})),n}(o,l));var u=[];l.forEach((function(t){var n=e[t];n&&u.push("grid-".concat(t,"-").concat(String(n)))}));var d={root:["root",n&&"container",a&&"item",s&&"zeroMinWidth"].concat((0,j.Z)(c),["row"!==r&&"direction-xs-".concat(String(r)),"wrap"!==i&&"wrap-xs-".concat(String(i))],u)};return(0,F.Z)(d,te,t)},ue=e.forwardRef((function(t,n){var o=(0,a.Z)({props:t,name:"MuiGrid"}),i=(0,G.Z)(m.Z).breakpoints,s=V(o),l=s.className,c=s.columns,u=s.columnSpacing,d=s.component,p=void 0===d?"div":d,h=s.container,v=void 0!==h&&h,y=s.direction,b=void 0===y?"row":y,g=s.item,_=void 0!==g&&g,k=s.rowSpacing,T=s.spacing,F=void 0===T?0:T,C=s.wrap,x=void 0===C?"wrap":C,A=s.zeroMinWidth,E=void 0!==A&&A,D=(0,w.Z)(s,oe),P=k||F,R=u||F,M=e.useContext(X),N=v?c||12:M,O={},z=(0,r.Z)({},D);i.keys.forEach((function(e){null!=D[e]&&(O[e]=D[e],delete z[e])}));var I=(0,r.Z)({},s,{columns:N,container:v,direction:b,item:_,rowSpacing:P,columnSpacing:R,wrap:x,zeroMinWidth:E,spacing:F},O,{breakpoints:i.keys}),L=ce(I);return(0,f.jsx)(X.Provider,{value:N,children:(0,f.jsx)(le,(0,r.Z)({ownerState:I,className:(0,S.Z)(L.root,l),as:p,ref:n},z))})})),de=ue,fe=n(2065);function pe(e){return(0,T.Z)("MuiPaper",e)}(0,ee.Z)("MuiPaper",["root","rounded","outlined","elevation","elevation0","elevation1","elevation2","elevation3","elevation4","elevation5","elevation6","elevation7","elevation8","elevation9","elevation10","elevation11","elevation12","elevation13","elevation14","elevation15","elevation16","elevation17","elevation18","elevation19","elevation20","elevation21","elevation22","elevation23","elevation24"]);var me=["className","component","elevation","square","variant"],he=function(e){return((e<1?5.11916*Math.pow(e,2):4.5*Math.log(e+1)+2)/100).toFixed(2)},ve=(0,O.ZP)("div",{name:"MuiPaper",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,t[n.variant],!n.square&&t.rounded,"elevation"===n.variant&&t["elevation".concat(n.elevation)]]}})((function(e){var t,n=e.theme,a=e.ownerState;return(0,r.Z)({backgroundColor:(n.vars||n).palette.background.paper,color:(n.vars||n).palette.text.primary,transition:n.transitions.create("box-shadow")},!a.square&&{borderRadius:n.shape.borderRadius},"outlined"===a.variant&&{border:"1px solid ".concat((n.vars||n).palette.divider)},"elevation"===a.variant&&(0,r.Z)({boxShadow:(n.vars||n).shadows[a.elevation]},!n.vars&&"dark"===n.palette.mode&&{backgroundImage:"linear-gradient(".concat((0,fe.Fq)("#fff",he(a.elevation)),", ").concat((0,fe.Fq)("#fff",he(a.elevation)),")")},n.vars&&{backgroundImage:null==(t=n.vars.overlays)?void 0:t[a.elevation]}))})),ye=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiPaper"}),o=n.className,i=n.component,s=void 0===i?"div":i,l=n.elevation,c=void 0===l?1:l,u=n.square,d=void 0!==u&&u,p=n.variant,m=void 0===p?"elevation":p,h=(0,w.Z)(n,me),v=(0,r.Z)({},n,{component:s,elevation:c,square:d,variant:m}),y=function(e){var t=e.square,n=e.elevation,r=e.variant,a=e.classes,o={root:["root",r,!t&&"rounded","elevation"===r&&"elevation".concat(n)]};return(0,F.Z)(o,pe,a)}(v);return(0,f.jsx)(ve,(0,r.Z)({as:s,ownerState:v,className:(0,S.Z)(y.root,o),ref:t},h))}));function be(e){return(0,T.Z)("MuiCard",e)}(0,ee.Z)("MuiCard",["root"]);var ge=["className","raised"],_e=(0,O.ZP)(ye,{name:"MuiCard",slot:"Root",overridesResolver:function(e,t){return t.root}})((function(){return{overflow:"hidden"}})),we=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiCard"}),o=n.className,i=n.raised,s=void 0!==i&&i,l=(0,w.Z)(n,ge),c=(0,r.Z)({},n,{raised:s}),u=function(e){var t=e.classes;return(0,F.Z)({root:["root"]},be,t)}(c);return(0,f.jsx)(_e,(0,r.Z)({className:(0,S.Z)(u.root,o),elevation:s?8:void 0,ref:t,ownerState:c},l))}));function Se(e){return(0,T.Z)("MuiCardContent",e)}(0,ee.Z)("MuiCardContent",["root"]);var ke=["className","component"],Te=(0,O.ZP)("div",{name:"MuiCardContent",slot:"Root",overridesResolver:function(e,t){return t.root}})((function(){return{padding:16,"&:last-child":{paddingBottom:24}}})),Fe=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiCardContent"}),o=n.className,i=n.component,s=void 0===i?"div":i,l=(0,w.Z)(n,ke),c=(0,r.Z)({},n,{component:s}),u=function(e){var t=e.classes;return(0,F.Z)({root:["root"]},Se,t)}(c);return(0,f.jsx)(Te,(0,r.Z)({as:s,className:(0,S.Z)(u.root,o),ownerState:c,ref:t},l))}));function Ce(e){return(0,T.Z)("MuiTypography",e)}(0,ee.Z)("MuiTypography",["root","h1","h2","h3","h4","h5","h6","subtitle1","subtitle2","body1","body2","inherit","button","caption","overline","alignLeft","alignRight","alignCenter","alignJustify","noWrap","gutterBottom","paragraph"]);var xe=["align","className","component","gutterBottom","noWrap","paragraph","variant","variantMapping"],Ae=(0,O.ZP)("span",{name:"MuiTypography",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,n.variant&&t[n.variant],"inherit"!==n.align&&t["align".concat((0,N.Z)(n.align))],n.noWrap&&t.noWrap,n.gutterBottom&&t.gutterBottom,n.paragraph&&t.paragraph]}})((function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({margin:0},n.variant&&t.typography[n.variant],"inherit"!==n.align&&{textAlign:n.align},n.noWrap&&{overflow:"hidden",textOverflow:"ellipsis",whiteSpace:"nowrap"},n.gutterBottom&&{marginBottom:"0.35em"},n.paragraph&&{marginBottom:16})})),Ee={h1:"h1",h2:"h2",h3:"h3",h4:"h4",h5:"h5",h6:"h6",subtitle1:"h6",subtitle2:"h6",body1:"p",body2:"p",inherit:"p"},De={primary:"primary.main",textPrimary:"text.primary",secondary:"secondary.main",textSecondary:"text.secondary",error:"error.main"},Pe=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiTypography"}),o=function(e){return De[e]||e}(n.color),i=V((0,r.Z)({},n,{color:o})),s=i.align,l=void 0===s?"inherit":s,c=i.className,u=i.component,d=i.gutterBottom,p=void 0!==d&&d,m=i.noWrap,h=void 0!==m&&m,v=i.paragraph,y=void 0!==v&&v,b=i.variant,g=void 0===b?"body1":b,_=i.variantMapping,k=void 0===_?Ee:_,T=(0,w.Z)(i,xe),C=(0,r.Z)({},i,{align:l,color:o,className:c,component:u,gutterBottom:p,noWrap:h,paragraph:y,variant:g,variantMapping:k}),x=u||(y?"p":k[g]||Ee[g])||"span",A=function(e){var t=e.align,n=e.gutterBottom,r=e.noWrap,a=e.paragraph,o=e.variant,i=e.classes,s={root:["root",o,"inherit"!==e.align&&"align".concat((0,N.Z)(t)),n&&"gutterBottom",r&&"noWrap",a&&"paragraph"]};return(0,F.Z)(s,Ce,i)}(C);return(0,f.jsx)(Ae,(0,r.Z)({as:x,ref:t,ownerState:C,className:(0,S.Z)(A.root,c)},T))})),Re=n(5682),Me=["component","direction","spacing","divider","children"];function Ne(t,n){var r=e.Children.toArray(t).filter(Boolean);return r.reduce((function(t,a,o){return t.push(a),o<r.length-1&&t.push(e.cloneElement(n,{key:"separator-".concat(o)})),t}),[])}var Oe=(0,O.ZP)("div",{name:"MuiStack",slot:"Root",overridesResolver:function(e,t){return[t.root]}})((function(e){var t=e.ownerState,n=e.theme,a=(0,r.Z)({display:"flex",flexDirection:"column"},(0,Q.k9)({theme:n},(0,Q.P$)({values:t.direction,breakpoints:n.breakpoints.values}),(function(e){return{flexDirection:e}})));if(t.spacing){var o=(0,Re.hB)(n),i=Object.keys(n.breakpoints.values).reduce((function(e,n){return("object"===typeof t.spacing&&null!=t.spacing[n]||"object"===typeof t.direction&&null!=t.direction[n])&&(e[n]=!0),e}),{}),s=(0,Q.P$)({values:t.direction,base:i}),l=(0,Q.P$)({values:t.spacing,base:i});"object"===typeof s&&Object.keys(s).forEach((function(e,t,n){if(!s[e]){var r=t>0?s[n[t-1]]:"column";s[e]=r}}));a=(0,B.Z)(a,(0,Q.k9)({theme:n},l,(function(e,n){return{"& > :not(style) + :not(style)":(0,_.Z)({margin:0},"margin".concat((r=n?s[n]:t.direction,{row:"Left","row-reverse":"Right",column:"Top","column-reverse":"Bottom"}[r])),(0,Re.NA)(o,e))};var r})))}return a=(0,Q.dt)(n.breakpoints,a)})),ze=e.forwardRef((function(e,t){var n=V((0,a.Z)({props:e,name:"MuiStack"})),o=n.component,i=void 0===o?"div":o,s=n.direction,l=void 0===s?"column":s,c=n.spacing,u=void 0===c?0:c,d=n.divider,p=n.children,m=(0,w.Z)(n,Me),h={direction:l,spacing:u};return(0,f.jsx)(Oe,(0,r.Z)({as:i,ownerState:h,ref:t},m,{children:d?Ne(p,d):p}))})),Ie=ze,Le=n(1774),Ze=n.n(Le);var je=function(e){var t=e.datum,n=e.datumNumber,r=e.results,a=(e.setResults,t.pom_a),o=t.pom_b,i=t.version_a_date,s=t.version_b_date;console.log({datum:t});var l=function(e,t){return e.map((function(e){return(0,f.jsx)(we,{children:(0,f.jsx)(Fe,{children:(0,f.jsxs)(Pe,{children:[(0,f.jsx)("b",{children:e.label})," ",e.content]})})},e.content)}))};return(0,f.jsxs)(de,{container:!0,spacing:2,children:[(0,f.jsx)(de,{item:!0,xs:12,children:(0,f.jsx)(we,{children:(0,f.jsx)(Fe,{children:(0,f.jsxs)(de,{container:!0,children:[(0,f.jsxs)(de,{item:!0,xs:4,children:[(0,f.jsxs)(Pe,{variant:"h6",children:["Comparison Number ",n+1," of ",r.length]}),(0,f.jsxs)(Pe,{variant:"h4",children:["Trial ",t.nctid]})]}),(0,f.jsxs)(de,{item:!0,xs:4,children:[t.first_posted?(0,f.jsxs)(Pe,{children:["First Posted: ",t.first_posted]}):null,t.start_date?(0,f.jsxs)(Pe,{children:["Start Date: ",t.start_date]}):null]}),(0,f.jsxs)(de,{item:!0,xs:4,children:[t.primary_completion_date?(0,f.jsxs)(Pe,{children:["Primary Completion Date: ",t.primary_completion_date]}):null,t.last_update_posted?(0,f.jsxs)(Pe,{children:["Last Update Posted : ",t.last_update_posted]}):null]})]})})})}),(0,f.jsx)(de,{item:!0,xs:6,children:(0,f.jsx)(we,{children:(0,f.jsxs)(Fe,{children:[(0,f.jsxs)(Pe,{variant:"h6",children:["Primary Outcomes for Version ",t.version_a,": ",i]}),(0,f.jsx)(Pe,{variant:"caption"}),(0,f.jsx)(Ie,{spacing:1,children:l(t.pom_a)})]})})}),(0,f.jsx)(de,{item:!0,xs:6,children:(0,f.jsx)(we,{children:(0,f.jsxs)(Fe,{children:[(0,f.jsxs)(Pe,{variant:"h6",children:["Primary Outcomes for Version ",t.version_b,": ",s]}),(0,f.jsx)(Ie,{spacing:1,children:l(t.pom_b)})]})})}),(0,f.jsx)(de,{item:!0,xs:12,children:(0,f.jsx)(we,{children:(0,f.jsxs)(Fe,{children:[(0,f.jsx)(Pe,{variant:"h6",children:"Compare the Raw Text"}),(0,f.jsx)(Ze(),{oldValue:JSON.stringify(a,void 0,4),newValue:JSON.stringify(o,void 0,4),splitView:!0,compareMethod:Le.DiffMethod.WORDS,styles:{variables:{light:{codeFoldGutterBackground:"#6F767E",codeFoldBackground:"#E2E4E5"}}},leftTitle:"Version ".concat(t.version_a),rightTitle:"Version ".concat(t.version_b)})]})})})]})};function Be(e){return(0,T.Z)("MuiAppBar",e)}(0,ee.Z)("MuiAppBar",["root","positionFixed","positionAbsolute","positionSticky","positionStatic","positionRelative","colorDefault","colorPrimary","colorSecondary","colorInherit","colorTransparent"]);var We=["className","color","enableColorOnDark","position"],Ue=function(e,t){return"".concat(null==e?void 0:e.replace(")",""),", ").concat(t,")")},Ve=(0,O.ZP)(ye,{name:"MuiAppBar",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,t["position".concat((0,N.Z)(n.position))],t["color".concat((0,N.Z)(n.color))]]}})((function(e){var t=e.theme,n=e.ownerState,a="light"===t.palette.mode?t.palette.grey[100]:t.palette.grey[900];return(0,r.Z)({display:"flex",flexDirection:"column",width:"100%",boxSizing:"border-box",flexShrink:0},"fixed"===n.position&&{position:"fixed",zIndex:(t.vars||t).zIndex.appBar,top:0,left:"auto",right:0,"@media print":{position:"absolute"}},"absolute"===n.position&&{position:"absolute",zIndex:(t.vars||t).zIndex.appBar,top:0,left:"auto",right:0},"sticky"===n.position&&{position:"sticky",zIndex:(t.vars||t).zIndex.appBar,top:0,left:"auto",right:0},"static"===n.position&&{position:"static"},"relative"===n.position&&{position:"relative"},!t.vars&&(0,r.Z)({},"default"===n.color&&{backgroundColor:a,color:t.palette.getContrastText(a)},n.color&&"default"!==n.color&&"inherit"!==n.color&&"transparent"!==n.color&&{backgroundColor:t.palette[n.color].main,color:t.palette[n.color].contrastText},"inherit"===n.color&&{color:"inherit"},"dark"===t.palette.mode&&!n.enableColorOnDark&&{backgroundColor:null,color:null},"transparent"===n.color&&(0,r.Z)({backgroundColor:"transparent",color:"inherit"},"dark"===t.palette.mode&&{backgroundImage:"none"})),t.vars&&(0,r.Z)({},"default"===n.color&&{"--AppBar-background":n.enableColorOnDark?t.vars.palette.AppBar.defaultBg:Ue(t.vars.palette.AppBar.darkBg,t.vars.palette.AppBar.defaultBg),"--AppBar-color":n.enableColorOnDark?t.vars.palette.text.primary:Ue(t.vars.palette.AppBar.darkColor,t.vars.palette.text.primary)},n.color&&!n.color.match(/^(default|inherit|transparent)$/)&&{"--AppBar-background":n.enableColorOnDark?t.vars.palette[n.color].main:Ue(t.vars.palette.AppBar.darkBg,t.vars.palette[n.color].main),"--AppBar-color":n.enableColorOnDark?t.vars.palette[n.color].contrastText:Ue(t.vars.palette.AppBar.darkColor,t.vars.palette[n.color].contrastText)},{backgroundColor:"var(--AppBar-background)",color:"inherit"===n.color?"inherit":"var(--AppBar-color)"},"transparent"===n.color&&{backgroundImage:"none",backgroundColor:"transparent",color:"inherit"}))})),Ge=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiAppBar"}),o=n.className,i=n.color,s=void 0===i?"primary":i,l=n.enableColorOnDark,c=void 0!==l&&l,u=n.position,d=void 0===u?"fixed":u,p=(0,w.Z)(n,We),m=(0,r.Z)({},n,{color:s,position:d,enableColorOnDark:c}),h=function(e){var t=e.color,n=e.position,r=e.classes,a={root:["root","color".concat((0,N.Z)(t)),"position".concat((0,N.Z)(n))]};return(0,F.Z)(a,Be,r)}(m);return(0,f.jsx)(Ve,(0,r.Z)({square:!0,component:"header",ownerState:m,elevation:4,className:(0,S.Z)(h.root,o,"fixed"===d&&"mui-fixed"),ref:t},p))}));function Je(e){return(0,T.Z)("MuiToolbar",e)}(0,ee.Z)("MuiToolbar",["root","gutters","regular","dense"]);var $e=["className","component","disableGutters","variant"],He=(0,O.ZP)("div",{name:"MuiToolbar",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,!n.disableGutters&&t.gutters,t[n.variant]]}})((function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({position:"relative",display:"flex",alignItems:"center"},!n.disableGutters&&(0,_.Z)({paddingLeft:t.spacing(2),paddingRight:t.spacing(2)},t.breakpoints.up("sm"),{paddingLeft:t.spacing(3),paddingRight:t.spacing(3)}),"dense"===n.variant&&{minHeight:48})}),(function(e){var t=e.theme;return"regular"===e.ownerState.variant&&t.mixins.toolbar})),qe=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiToolbar"}),o=n.className,i=n.component,s=void 0===i?"div":i,l=n.disableGutters,c=void 0!==l&&l,u=n.variant,d=void 0===u?"regular":u,p=(0,w.Z)(n,$e),m=(0,r.Z)({},n,{component:s,disableGutters:c,variant:d}),h=function(e){var t=e.classes,n={root:["root",!e.disableGutters&&"gutters",e.variant]};return(0,F.Z)(n,Je,t)}(m);return(0,f.jsx)(He,(0,r.Z)({as:s,className:(0,S.Z)(h.root,o),ref:t,ownerState:m},p))})),Ke=n(792),Ye=n(6702),Qe=n(2763);function Xe(e,t){return t||(t=e.slice(0)),Object.freeze(Object.defineProperties(e,{raw:{value:Object.freeze(t)}}))}function et(e,t){return et=Object.setPrototypeOf?Object.setPrototypeOf.bind():function(e,t){return e.__proto__=t,e},et(e,t)}var tt=e.createContext(null);function nt(t,n){var r=Object.create(null);return t&&e.Children.map(t,(function(e){return e})).forEach((function(t){r[t.key]=function(t){return n&&(0,e.isValidElement)(t)?n(t):t}(t)})),r}function rt(e,t,n){return null!=n[t]?n[t]:e.props[t]}function at(t,n,r){var a=nt(t.children),o=function(e,t){function n(n){return n in t?t[n]:e[n]}e=e||{},t=t||{};var r,a=Object.create(null),o=[];for(var i in e)i in t?o.length&&(a[i]=o,o=[]):o.push(i);var s={};for(var l in t){if(a[l])for(r=0;r<a[l].length;r++){var c=a[l][r];s[a[l][r]]=n(c)}s[l]=n(l)}for(r=0;r<o.length;r++)s[o[r]]=n(o[r]);return s}(n,a);return Object.keys(o).forEach((function(i){var s=o[i];if((0,e.isValidElement)(s)){var l=i in n,c=i in a,u=n[i],d=(0,e.isValidElement)(u)&&!u.props.in;!c||l&&!d?c||!l||d?c&&l&&(0,e.isValidElement)(u)&&(o[i]=(0,e.cloneElement)(s,{onExited:r.bind(null,s),in:u.props.in,exit:rt(s,"exit",t),enter:rt(s,"enter",t)})):o[i]=(0,e.cloneElement)(s,{in:!1}):o[i]=(0,e.cloneElement)(s,{onExited:r.bind(null,s),in:!0,exit:rt(s,"exit",t),enter:rt(s,"enter",t)})}})),o}var ot=Object.values||function(e){return Object.keys(e).map((function(t){return e[t]}))},it=function(t){var n,a;function o(e,n){var r,a=(r=t.call(this,e,n)||this).handleExited.bind(function(e){if(void 0===e)throw new ReferenceError("this hasn't been initialised - super() hasn't been called");return e}(r));return r.state={contextValue:{isMounting:!0},handleExited:a,firstRender:!0},r}a=t,(n=o).prototype=Object.create(a.prototype),n.prototype.constructor=n,et(n,a);var i=o.prototype;return i.componentDidMount=function(){this.mounted=!0,this.setState({contextValue:{isMounting:!1}})},i.componentWillUnmount=function(){this.mounted=!1},o.getDerivedStateFromProps=function(t,n){var r,a,o=n.children,i=n.handleExited;return{children:n.firstRender?(r=t,a=i,nt(r.children,(function(t){return(0,e.cloneElement)(t,{onExited:a.bind(null,t),in:!0,appear:rt(t,"appear",r),enter:rt(t,"enter",r),exit:rt(t,"exit",r)})}))):at(t,o,i),firstRender:!1}},i.handleExited=function(e,t){var n=nt(this.props.children);e.key in n||(e.props.onExited&&e.props.onExited(t),this.mounted&&this.setState((function(t){var n=(0,r.Z)({},t.children);return delete n[e.key],{children:n}})))},i.render=function(){var t=this.props,n=t.component,r=t.childFactory,a=(0,w.Z)(t,["component","childFactory"]),o=this.state.contextValue,i=ot(this.state.children).map(r);return delete a.appear,delete a.enter,delete a.exit,null===n?e.createElement(tt.Provider,{value:o},i):e.createElement(tt.Provider,{value:o},e.createElement(n,a,i))},o}(e.Component);it.propTypes={},it.defaultProps={component:"div",childFactory:function(e){return e}};var st=it;var lt=function(t){var n=t.className,r=t.classes,a=t.pulsate,o=void 0!==a&&a,i=t.rippleX,s=t.rippleY,l=t.rippleSize,c=t.in,u=t.onExited,d=t.timeout,p=e.useState(!1),m=(0,g.Z)(p,2),h=m[0],v=m[1],y=(0,S.Z)(n,r.ripple,r.rippleVisible,o&&r.ripplePulsate),b={width:l,height:l,top:-l/2+s,left:-l/2+i},_=(0,S.Z)(r.child,h&&r.childLeaving,o&&r.childPulsate);return c||h||v(!0),e.useEffect((function(){if(!c&&null!=u){var e=setTimeout(u,d);return function(){clearTimeout(e)}}}),[u,c,d]),(0,f.jsx)("span",{className:y,style:b,children:(0,f.jsx)("span",{className:_})})};var ct,ut,dt,ft,pt,mt,ht,vt,yt=(0,ee.Z)("MuiTouchRipple",["root","ripple","rippleVisible","ripplePulsate","child","childLeaving","childPulsate"]),bt=["center","classes","className"],gt=d(pt||(pt=ct||(ct=Xe(["\n  0% {\n    transform: scale(0);\n    opacity: 0.1;\n  }\n\n  100% {\n    transform: scale(1);\n    opacity: 0.3;\n  }\n"])))),_t=d(mt||(mt=ut||(ut=Xe(["\n  0% {\n    opacity: 1;\n  }\n\n  100% {\n    opacity: 0;\n  }\n"])))),wt=d(ht||(ht=dt||(dt=Xe(["\n  0% {\n    transform: scale(1);\n  }\n\n  50% {\n    transform: scale(0.92);\n  }\n\n  100% {\n    transform: scale(1);\n  }\n"])))),St=(0,O.ZP)("span",{name:"MuiTouchRipple",slot:"Root"})({overflow:"hidden",pointerEvents:"none",position:"absolute",zIndex:0,top:0,right:0,bottom:0,left:0,borderRadius:"inherit"}),kt=(0,O.ZP)(lt,{name:"MuiTouchRipple",slot:"Ripple"})(vt||(vt=ft||(ft=Xe(["\n  opacity: 0;\n  position: absolute;\n\n  &."," {\n    opacity: 0.3;\n    transform: scale(1);\n    animation-name: ",";\n    animation-duration: ","ms;\n    animation-timing-function: ",";\n  }\n\n  &."," {\n    animation-duration: ","ms;\n  }\n\n  & ."," {\n    opacity: 1;\n    display: block;\n    width: 100%;\n    height: 100%;\n    border-radius: 50%;\n    background-color: currentColor;\n  }\n\n  & ."," {\n    opacity: 0;\n    animation-name: ",";\n    animation-duration: ","ms;\n    animation-timing-function: ",";\n  }\n\n  & ."," {\n    position: absolute;\n    /* @noflip */\n    left: 0px;\n    top: 0;\n    animation-name: ",";\n    animation-duration: 2500ms;\n    animation-timing-function: ",";\n    animation-iteration-count: infinite;\n    animation-delay: 200ms;\n  }\n"]))),yt.rippleVisible,gt,550,(function(e){return e.theme.transitions.easing.easeInOut}),yt.ripplePulsate,(function(e){return e.theme.transitions.duration.shorter}),yt.child,yt.childLeaving,_t,550,(function(e){return e.theme.transitions.easing.easeInOut}),yt.childPulsate,wt,(function(e){return e.theme.transitions.easing.easeInOut})),Tt=e.forwardRef((function(t,n){var o=(0,a.Z)({props:t,name:"MuiTouchRipple"}),i=o.center,s=void 0!==i&&i,l=o.classes,c=void 0===l?{}:l,u=o.className,d=(0,w.Z)(o,bt),p=e.useState([]),m=(0,g.Z)(p,2),h=m[0],v=m[1],y=e.useRef(0),b=e.useRef(null);e.useEffect((function(){b.current&&(b.current(),b.current=null)}),[h]);var _=e.useRef(!1),k=e.useRef(null),T=e.useRef(null),F=e.useRef(null);e.useEffect((function(){return function(){clearTimeout(k.current)}}),[]);var C=e.useCallback((function(e){var t=e.pulsate,n=e.rippleX,r=e.rippleY,a=e.rippleSize,o=e.cb;v((function(e){return[].concat((0,j.Z)(e),[(0,f.jsx)(kt,{classes:{ripple:(0,S.Z)(c.ripple,yt.ripple),rippleVisible:(0,S.Z)(c.rippleVisible,yt.rippleVisible),ripplePulsate:(0,S.Z)(c.ripplePulsate,yt.ripplePulsate),child:(0,S.Z)(c.child,yt.child),childLeaving:(0,S.Z)(c.childLeaving,yt.childLeaving),childPulsate:(0,S.Z)(c.childPulsate,yt.childPulsate)},timeout:550,pulsate:t,rippleX:n,rippleY:r,rippleSize:a},y.current)])})),y.current+=1,b.current=o}),[c]),x=e.useCallback((function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},n=arguments.length>2?arguments[2]:void 0,r=t.pulsate,a=void 0!==r&&r,o=t.center,i=void 0===o?s||t.pulsate:o,l=t.fakeElement,c=void 0!==l&&l;if("mousedown"===(null==e?void 0:e.type)&&_.current)_.current=!1;else{"touchstart"===(null==e?void 0:e.type)&&(_.current=!0);var u,d,f,p=c?null:F.current,m=p?p.getBoundingClientRect():{width:0,height:0,left:0,top:0};if(i||void 0===e||0===e.clientX&&0===e.clientY||!e.clientX&&!e.touches)u=Math.round(m.width/2),d=Math.round(m.height/2);else{var h=e.touches&&e.touches.length>0?e.touches[0]:e,v=h.clientX,y=h.clientY;u=Math.round(v-m.left),d=Math.round(y-m.top)}if(i)(f=Math.sqrt((2*Math.pow(m.width,2)+Math.pow(m.height,2))/3))%2===0&&(f+=1);else{var b=2*Math.max(Math.abs((p?p.clientWidth:0)-u),u)+2,g=2*Math.max(Math.abs((p?p.clientHeight:0)-d),d)+2;f=Math.sqrt(Math.pow(b,2)+Math.pow(g,2))}null!=e&&e.touches?null===T.current&&(T.current=function(){C({pulsate:a,rippleX:u,rippleY:d,rippleSize:f,cb:n})},k.current=setTimeout((function(){T.current&&(T.current(),T.current=null)}),80)):C({pulsate:a,rippleX:u,rippleY:d,rippleSize:f,cb:n})}}),[s,C]),A=e.useCallback((function(){x({},{pulsate:!0})}),[x]),E=e.useCallback((function(e,t){if(clearTimeout(k.current),"touchend"===(null==e?void 0:e.type)&&T.current)return T.current(),T.current=null,void(k.current=setTimeout((function(){E(e,t)})));T.current=null,v((function(e){return e.length>0?e.slice(1):e})),b.current=t}),[]);return e.useImperativeHandle(n,(function(){return{pulsate:A,start:x,stop:E}}),[A,x,E]),(0,f.jsx)(St,(0,r.Z)({className:(0,S.Z)(yt.root,c.root,u),ref:F},d,{children:(0,f.jsx)(st,{component:null,exit:!0,children:h})}))})),Ft=Tt;function Ct(e){return(0,T.Z)("MuiButtonBase",e)}var xt,At=(0,ee.Z)("MuiButtonBase",["root","disabled","focusVisible"]),Et=["action","centerRipple","children","className","component","disabled","disableRipple","disableTouchRipple","focusRipple","focusVisibleClassName","LinkComponent","onBlur","onClick","onContextMenu","onDragLeave","onFocus","onFocusVisible","onKeyDown","onKeyUp","onMouseDown","onMouseLeave","onMouseUp","onTouchEnd","onTouchMove","onTouchStart","tabIndex","TouchRippleProps","touchRippleRef","type"],Dt=(0,O.ZP)("button",{name:"MuiButtonBase",slot:"Root",overridesResolver:function(e,t){return t.root}})((xt={display:"inline-flex",alignItems:"center",justifyContent:"center",position:"relative",boxSizing:"border-box",WebkitTapHighlightColor:"transparent",backgroundColor:"transparent",outline:0,border:0,margin:0,borderRadius:0,padding:0,cursor:"pointer",userSelect:"none",verticalAlign:"middle",MozAppearance:"none",WebkitAppearance:"none",textDecoration:"none",color:"inherit","&::-moz-focus-inner":{borderStyle:"none"}},(0,_.Z)(xt,"&.".concat(At.disabled),{pointerEvents:"none",cursor:"default"}),(0,_.Z)(xt,"@media print",{colorAdjust:"exact"}),xt)),Pt=e.forwardRef((function(t,n){var o=(0,a.Z)({props:t,name:"MuiButtonBase"}),i=o.action,s=o.centerRipple,l=void 0!==s&&s,c=o.children,u=o.className,d=o.component,p=void 0===d?"button":d,m=o.disabled,h=void 0!==m&&m,v=o.disableRipple,y=void 0!==v&&v,b=o.disableTouchRipple,_=void 0!==b&&b,k=o.focusRipple,T=void 0!==k&&k,C=o.LinkComponent,x=void 0===C?"a":C,A=o.onBlur,E=o.onClick,D=o.onContextMenu,P=o.onDragLeave,R=o.onFocus,M=o.onFocusVisible,N=o.onKeyDown,O=o.onKeyUp,z=o.onMouseDown,I=o.onMouseLeave,L=o.onMouseUp,Z=o.onTouchEnd,j=o.onTouchMove,B=o.onTouchStart,W=o.tabIndex,U=void 0===W?0:W,V=o.TouchRippleProps,G=o.touchRippleRef,J=o.type,$=(0,w.Z)(o,Et),H=e.useRef(null),q=e.useRef(null),K=(0,Ke.Z)(q,G),Y=(0,Qe.Z)(),Q=Y.isFocusVisibleRef,X=Y.onFocus,ee=Y.onBlur,te=Y.ref,ne=e.useState(!1),re=(0,g.Z)(ne,2),ae=re[0],oe=re[1];h&&ae&&oe(!1),e.useImperativeHandle(i,(function(){return{focusVisible:function(){oe(!0),H.current.focus()}}}),[]);var ie=e.useState(!1),se=(0,g.Z)(ie,2),le=se[0],ce=se[1];e.useEffect((function(){ce(!0)}),[]);var ue=le&&!y&&!h;function de(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:_;return(0,Ye.Z)((function(r){return t&&t(r),!n&&q.current&&q.current[e](r),!0}))}e.useEffect((function(){ae&&T&&!y&&le&&q.current.pulsate()}),[y,T,ae,le]);var fe=de("start",z),pe=de("stop",D),me=de("stop",P),he=de("stop",L),ve=de("stop",(function(e){ae&&e.preventDefault(),I&&I(e)})),ye=de("start",B),be=de("stop",Z),ge=de("stop",j),_e=de("stop",(function(e){ee(e),!1===Q.current&&oe(!1),A&&A(e)}),!1),we=(0,Ye.Z)((function(e){H.current||(H.current=e.currentTarget),X(e),!0===Q.current&&(oe(!0),M&&M(e)),R&&R(e)})),Se=function(){var e=H.current;return p&&"button"!==p&&!("A"===e.tagName&&e.href)},ke=e.useRef(!1),Te=(0,Ye.Z)((function(e){T&&!ke.current&&ae&&q.current&&" "===e.key&&(ke.current=!0,q.current.stop(e,(function(){q.current.start(e)}))),e.target===e.currentTarget&&Se()&&" "===e.key&&e.preventDefault(),N&&N(e),e.target===e.currentTarget&&Se()&&"Enter"===e.key&&!h&&(e.preventDefault(),E&&E(e))})),Fe=(0,Ye.Z)((function(e){T&&" "===e.key&&q.current&&ae&&!e.defaultPrevented&&(ke.current=!1,q.current.stop(e,(function(){q.current.pulsate(e)}))),O&&O(e),E&&e.target===e.currentTarget&&Se()&&" "===e.key&&!e.defaultPrevented&&E(e)})),Ce=p;"button"===Ce&&($.href||$.to)&&(Ce=x);var xe={};"button"===Ce?(xe.type=void 0===J?"button":J,xe.disabled=h):($.href||$.to||(xe.role="button"),h&&(xe["aria-disabled"]=h));var Ae=(0,Ke.Z)(te,H),Ee=(0,Ke.Z)(n,Ae);var De=(0,r.Z)({},o,{centerRipple:l,component:p,disabled:h,disableRipple:y,disableTouchRipple:_,focusRipple:T,tabIndex:U,focusVisible:ae}),Pe=function(e){var t=e.disabled,n=e.focusVisible,r=e.focusVisibleClassName,a=e.classes,o={root:["root",t&&"disabled",n&&"focusVisible"]},i=(0,F.Z)(o,Ct,a);return n&&r&&(i.root+=" ".concat(r)),i}(De);return(0,f.jsxs)(Dt,(0,r.Z)({as:Ce,className:(0,S.Z)(Pe.root,u),ownerState:De,onBlur:_e,onClick:E,onContextMenu:pe,onFocus:we,onKeyDown:Te,onKeyUp:Fe,onMouseDown:fe,onMouseLeave:ve,onMouseUp:he,onDragLeave:me,onTouchEnd:be,onTouchMove:ge,onTouchStart:ye,ref:Ee,tabIndex:h?-1:U,type:J},xe,$,{children:[c,ue?(0,f.jsx)(Ft,(0,r.Z)({ref:K,center:l},V)):null]}))})),Rt=Pt;function Mt(e){return(0,T.Z)("MuiIconButton",e)}var Nt=(0,ee.Z)("MuiIconButton",["root","disabled","colorInherit","colorPrimary","colorSecondary","edgeStart","edgeEnd","sizeSmall","sizeMedium","sizeLarge"]),Ot=["edge","children","className","color","disabled","disableFocusRipple","size"],zt=(0,O.ZP)(Rt,{name:"MuiIconButton",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,"default"!==n.color&&t["color".concat((0,N.Z)(n.color))],n.edge&&t["edge".concat((0,N.Z)(n.edge))],t["size".concat((0,N.Z)(n.size))]]}})((function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({textAlign:"center",flex:"0 0 auto",fontSize:t.typography.pxToRem(24),padding:8,borderRadius:"50%",overflow:"visible",color:(t.vars||t).palette.action.active,transition:t.transitions.create("background-color",{duration:t.transitions.duration.shortest})},!n.disableRipple&&{"&:hover":{backgroundColor:t.vars?"rgba(".concat(t.vars.palette.action.activeChannel," / ").concat(t.vars.palette.action.hoverOpacity,")"):(0,fe.Fq)(t.palette.action.active,t.palette.action.hoverOpacity),"@media (hover: none)":{backgroundColor:"transparent"}}},"start"===n.edge&&{marginLeft:"small"===n.size?-3:-12},"end"===n.edge&&{marginRight:"small"===n.size?-3:-12})}),(function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({},"inherit"===n.color&&{color:"inherit"},"inherit"!==n.color&&"default"!==n.color&&(0,r.Z)({color:(t.vars||t).palette[n.color].main},!n.disableRipple&&{"&:hover":{backgroundColor:t.vars?"rgba(".concat(t.vars.palette[n.color].mainChannel," / ").concat(t.vars.palette.action.hoverOpacity,")"):(0,fe.Fq)(t.palette[n.color].main,t.palette.action.hoverOpacity),"@media (hover: none)":{backgroundColor:"transparent"}}}),"small"===n.size&&{padding:5,fontSize:t.typography.pxToRem(18)},"large"===n.size&&{padding:12,fontSize:t.typography.pxToRem(28)},(0,_.Z)({},"&.".concat(Nt.disabled),{backgroundColor:"transparent",color:(t.vars||t).palette.action.disabled}))})),It=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiIconButton"}),o=n.edge,i=void 0!==o&&o,s=n.children,l=n.className,c=n.color,u=void 0===c?"default":c,d=n.disabled,p=void 0!==d&&d,m=n.disableFocusRipple,h=void 0!==m&&m,v=n.size,y=void 0===v?"medium":v,b=(0,w.Z)(n,Ot),g=(0,r.Z)({},n,{edge:i,color:u,disabled:p,disableFocusRipple:h,size:y}),_=function(e){var t=e.classes,n=e.disabled,r=e.color,a=e.edge,o=e.size,i={root:["root",n&&"disabled","default"!==r&&"color".concat((0,N.Z)(r)),a&&"edge".concat((0,N.Z)(a)),"size".concat((0,N.Z)(o))]};return(0,F.Z)(i,Mt,t)}(g);return(0,f.jsx)(zt,(0,r.Z)({className:(0,S.Z)(_.root,l),centerRipple:!0,focusRipple:!h,disabled:p,ref:t,ownerState:g},b,{children:s}))})),Lt=n(2156),Zt=n(5129);n(8472),(0,H.Z)({palette:{neutral:{main:"#fff",contrastText:"#000"}}});function jt(e){var t=e.datumNumber,n=e.setDatumNumber,r=e.numComparisons,a=(e.outputData,e.batchNum),o=function(){n(t-1)},i=function(){n(t+1)};return(0,f.jsx)(K,{sx:{flexGrow:1},children:(0,f.jsx)(Ge,{position:"static",children:(0,f.jsxs)(qe,{children:[(0,f.jsxs)(Pe,{component:"div",variant:"h6",sx:{flexGrow:1},children:["Compare Trial Versions for Batch ",a]}),(0,f.jsxs)(Pe,{component:"div",children:[t>0?(0,f.jsx)(It,{color:"inherit",variant:"text",onClick:o,children:(0,f.jsx)(Lt.Z,{})}):null,t<r-1?(0,f.jsx)(It,{color:"inherit",variant:"text",onClick:i,children:(0,f.jsx)(Zt.Z,{})}):null]})]})})})}for(var Bt=JSON.parse('{"1":"Add endpoint to composite endpoint","2":"Add endpoint","3":"Change endpoint","4":"Change endpoint, add endpoint","5":"Change in endpoint in a composite endpoint","6":"Change method of analysis","7":"Change number of events","8":"Change population","9":"Change readers","10":"Change timepoint","11":"Error","12":"From nothing to something","13":"Refine definition","14":"Remove endpoint","15":"Shuffle Endpoints","16":"Syntax","":""}'),Wt=[],Ut=Y.e,Vt=Y.C,Gt=Vt.length,Jt=0;Jt<Gt;Jt++)Wt.push("");var $t=function(){var t=(0,e.useState)(0),n=(0,g.Z)(t,2),r=n[0],a=n[1],o=(0,e.useState)(Vt[r]),i=(0,g.Z)(o,2),s=i[0],l=i[1],c=(0,e.useState)(Wt),u=(0,g.Z)(c,2),d=u[0],p=u[1],m=(0,e.useState)([]),h=(0,g.Z)(m,2),v=h[0],y=h[1];return(0,e.useEffect)((function(){l(Vt[r])}),[r]),(0,e.useEffect)((function(){for(var e=[],t=0;t<Gt;t++){var n={};n.nctid=Vt[t].nctid,n.version_a=Vt[t].version_a,n.version_b=Vt[t].version_b,n.classification_number=d[t],n.classification_meaning=Bt[d[t]],e.push(n)}y(e)}),[d]),(0,f.jsxs)(e.Fragment,{children:[(0,f.jsx)(jt,{datumNumber:r,setDatumNumber:a,numComparisons:Gt,outputData:v,batchNum:Ut}),(0,f.jsx)(I,{children:(0,f.jsx)(K,{sx:{flexGrow:1,m:1},children:(0,f.jsx)(je,{datum:s,datumNumber:r,results:d,setResults:p})})})]})};t.createRoot(document.getElementById("root")).render((0,f.jsxs)(e.StrictMode,{children:[(0,f.jsx)(b,{}),(0,f.jsx)($t,{})]}))}()}();
//# sourceMappingURL=main.bac5b26c.js.map